acetylcysteine profile

N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Products

ID Source	ID
PubMed CID	12035
CHEMBL ID	600
CHEBI ID	28939
CHEBI ID	22198
SCHEMBL ID	5292
MeSH ID	M0000171
PubMed CID	581
CHEMBL ID	145615
SCHEMBL ID	5291
MeSH ID	M0000171

Synonym
AC-16071
n-acetyl-cysteine
unii-wyq7n0bpyc
neo-fluimucil
acetylcysteine [usan:usp:inn:ban:jan]
wyq7n0bpyc ,
cetylev
flumil
MLS001076125
n-acetyl-l-cysteine hydrochloride
AKOS015841009
acetilcisteina
l-alpha-acetamido-beta-mercaptopropionic acid
(r)-2-acetylamino-3-mercaptopropanoic acid
n-acetyl-l-(+)-cysteine
acetylcysteinum
CHEBI:28939 ,
(2r)-2-acetylamino-3-sulfanylpropanoic acid
(r)-mercapturic acid
nac & tnf
n-acetyl-l-cysteine & tumor necrosis factor (tnf)
l-cysteine, n-acetyl- & tumor necrosis factor
acetadote
mucolator
ilube
rk-0202
mucosil
exomuc
einecs 210-498-3
n-acetyl-3-mercaptoalanine
nsc 111180
hsdb 3003
mucosil-10
fluimicil infantil
n-acetyl cysteine
mucosil-20
mucofilin
inspir
lysomucil
cysteine, n-acetyl-, l-
fluprowit
acetilcisteina [inn-spanish]
ccris 3764
acetylcysteinum [inn-latin]
EU-0100081
n-acetyl-l-cysteine, sigma grade, >=99% (tlc), powder
D00221
SPECTRUM5_000764
LOPAC0_000081
BSPBIO_001794
fluimucil
l-acetylcysteine
mucolyticum lappe
flumucetin
mercapturic acid, (r)-
nsc111180
nac-tb
component of naxid
nsc-111180
n-acetyl-l-cysteine
616-91-1
fluimucetin
mucolyticum-lappe
mucolytikum lappe
acetein
n-acetylcysteine
airbron
mucosolvin
acetylcysteine ,
broncholysin
mercapturic acid
NAC ,
l-cysteine, n-acetyl-
mucomyst
respaire
parvolex
tixair
fluatox
fabrol
brunac
mucret
mucolyticum
(2r)-2-acetamido-3-sulfanyl-propanoic acid
SC2 ,
C06809
n-acetyl-l-cysteine, cell culture tested, bioreagent
n-acetyl-l-cysteine, bioxtra, >=99% (tlc)
mucomyst (tn)
acetylcysteine (jp17/usp/inn)
lnac
NCGC00022304-05
smr000058377
MLS000028419 ,
KBIO3_001294
KBIOGR_000554
SPBIO_000012
SPECTRUM4_000137
SPECTRUM2_000086
SPECTRUM3_000287
SPECTRUM1500105
NCGC00022304-03
NCGC00022304-06
NCGC00022304-04
acid, mercapturic
n acetylcysteine
muco sanigen
n acetyl l cysteine
A-1100
A 7250
HMS2091G11
CABC898A-E48B-4E13-9F72-98D0609A1854
ac-cys-oh
A0905
NCGC00022304-07
n-acetyl-n-cysteine
DB06151
(2r)-2-acetamido-3-sulfanylpropanoic acid
fluimicil
oristar nalc
n-acetyi-l-cysteine
acetyl cysteine
CHEMBL600
syntemucol
HMS1920A11
NCGC00022304-08
HMS3260A04
n-acetylcystein
EN300-72028
NCGC00258631-01
tox21_201078
dtxcid4021
tox21_110877
cas-616-91-1
dtxsid5020021 ,
CCG-204176
HMS2234J22
CCG-38902
bdbm50420190
BP-12854
AM20100502
LP00081
acetylcysteine [inn]
acetylcysteine [mi]
acetylcysteine [jan]
acetylcysteine [who-dd]
n-acetyl-(r)-cysteine
acetylcysteine [orange book]
acetylcysteine [ii]
acetylcysteine [usan]
acetylcysteine [mart.]
acetylcysteine [usp-rs]
(r)-n-acetylcysteine
acetylcysteine [usp monograph]
acetylcysteine [hsdb]
acetyl cysteine [inci]
acetylcysteine [ep monograph]
acetylcysteine [vandf]
S1623
HY-B0215
MLS006011563
SCHEMBL5292
tox21_110877_1
NCGC00015086-04
AB00382974-12
naxid (salt/mix)
l-.alpha.-acetamido-.beta.-mercaptopropionic acid
mucocedyl
NCGC00260766-01
tox21_500081
(2r)-2-acetylamino-3-mercapto-propionic acid
(r)-2-acetamido-3-mercaptopropanoic acid
n-acetyl-l-cystein
accys
acetylcysteine, british pharmacopoeia (bp) reference standard
AC-24117
AB00051908_02
OPERA_ID_452
AB00382974_13
J-507685
acetylcysteine, european pharmacopoeia (ep) reference standard
GS-3121
SR-01000075439-1
sr-01000075439
acetyl-l-cysteine
acetylcysteine, united states pharmacopeia (usp) reference standard
n-acetyl-l-cysteine, saj special grade, 98.0-102.0%
HMS3655G11
2-acetylamino-3-mercapto-propionate
n-acetyl-l-cysteine, usp grade
acetylcysteine ph. eur.
n-acetyl-l-cysteine, pharmaceutical secondary standard; certified reference material
n-acetyl-l-cysteine, vetec(tm) reagent grade, 98%
acetylcysteine (n-acetyl-l-cysteine)
SR-01000075439-5
SR-01000075439-3
SBI-0051272.P003
n-acetyl-l-cys
HMS3715D03
SW199597-2
F1905-7178
Q375613
acetyl cysteine,(s)
n-acety-l-cysteine
BRD-K59058747-001-20-9
SDCCGSBI-0050069.P002
HMS3884E04
NCGC00022304-17
gtpl10945
ilube (eye drops)
n-a-c sustain
NCGC00022304-23
n-acetyl-l-cysteine 100 microg/ml in acetonitrile
acetylcysteine(n-acetylcysteine)
(r)-2-acetamido-3-mercaptopropanoicacid
dtxcid6028076
v03ab23
s01xa08
chebi:22198
acetylcysteine (usp-rs)
acetylcysteine (usan:usp:inn:ban:jan)
acetylcysteine (usp monograph)
acetylcysteine injection
r05cb01
acetylcysteinum (inn-latin)
acetylcysteine (ep monograph)
acetilcisteina (inn-spanish)
broncholysin (mucolytic)
tris-nac
acetylcysteine (mart.)
acetylcysteine (ii)
Z1143441555
c5h9no3s
flumicil
l-cysteine,
wln: sh1yvqmv1 -l
sodium 2-acetamido-3-mercaptopropionate
NCI60_000255
45F1315B-9604-4E8C-8048-902731179704
cysteine, n-acetyl-
AKOS002434507
FT-0661198
2-acetamido-3-sulfanylpropanoic acid
STL135991
CHEMBL145615
2sph1imo2v ,
7218-04-4
dl-acetylcysteine
n-acetyl-dl-cysteine
einecs 230-609-9
unii-2sph1imo2v
dl-cysteine, n-acetyl-
FT-0629832
NCGC00015086-03
AKOS017342892
(z)-n-(1-hydroxyethylidene)cysteine
STL454996
2-acetylamino-3-mercapto propionic acid
2-acetylamino-3-mercapto-propionic acid
hsch2ch(nhcoch3)co2h
PWKSKIMOESPYIA-UHFFFAOYSA-N
SCHEMBL5291
DTXSID8048105 ,
2-acetamido-3-mercaptopropanoic acid
mfcd00004880
F2173-0391
SY009511
2-acetamido-3-sulfanyl-propanoic acid
mfcd00269768
cysteine, n-acetyl-, dl-
EN300-136669
acetylcysteine isomer impurity
mfcd00151956
2-chloro-3-methoxythiophene-4-carboxylic acid
ac-dl-cys-oh
ac-d-cys-oh
AS-57272
CS-0071230
(s)-n-acetylcysteine
SY317365
2-acetamido-3-mercaptopropanoicacid
bdbm610685
us10624871, compound 21

Excerpt	Reference	Relevance
" Toxicity is likely to occur after a minimum ingestion of 140 mg/kg, but the toxic dose may vary as a function of individual glutathione levels."	( Toxicity of acetaminophen overdose. Peterson, RG; Rumack, BH, 1978)	0.26
"Acetaldehyde is a toxic substance common to heavy drinking of alcohol and heavy smoking of cigarettes."	( Protective action of ascorbic acid and sulfur compounds against acetaldehyde toxicity: implications in alcoholism and smoking. Gonzales, LJ; Parker, CM; Smith, GG; Sprince, H, 1975)	0.25
" Diabetics and persons who drink alcohol may have an increased risk of adverse effects following exposure to carbon tetrachloride."	( Carbon tetrachloride toxicity. Agency for Toxic Substances and Disease Registry. , 1992)	0.28
"1 The ability of iloprost (ZK36374) to protect hamster isolated hepatocytes from the toxic effects of paracetamol and its reactive metabolite N-acetyl-p-benzoquinoneimine (NABQI) was investigated."	( Cytoprotection by iloprost against paracetamol-induced toxicity in hamster isolated hepatocytes. Boobis, AR; Davies, DS; Fawthrop, DJ; Nasseri-Sina, P; Wilson, J, 1992)	0.28
"Acetaminophen is eliminated primarily by glucuronidation, thereby avoiding cytochrome P450-catalyzed bioactivation to a toxic reactive intermediate."	( Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Chow, SY; de Morais, SM; Wells, PG, 1992)	0.28
" Fifty-five patients (18%) had toxic paracetamol levels, 51% received treatment with NAC, including 40% of those with non-toxic levels, and 11% of those treated with NAC experienced side effects."	( Hepatotoxicity from paracetamol self-poisoning in western Sydney: a continuing challenge. Batey, RG; Brotodihardjo, AE; Byth, K; Farrell, GC, 1992)	0.28
"N-Acetylcysteine (NAC) is protective against acetaminophen-induced hepatotoxicity primarily by providing precursor for the glutathione synthetase pathway, while cysteamine has been demonstrated to alter the cytochrome P-450 dependent formation of toxic acetaminophen metabolite."	( Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity. Brown, IR; Peterson, TC, 1992)	0.28
" Four hours following injection of a toxic dose of [ring-14C]dichlobenil (12 mg/kg) the covalent binding in the olfactory mucosa was 26 times higher than that in the liver."	( Effects of glutathione-modulating agents on the covalent binding and toxicity of dichlobenil in the mouse olfactory mucosa. Brandt, I; Brittebo, EB; Eriksson, C, 1992)	0.28
" The role of metabolites in sulphasalazine-mediated toxicity has been investigated in vitro by the use of human red blood cells and mononuclear leucocytes as target cells, with methaemoglobin formation and cytotoxicity respectively, being the defined toxic end-points."	( Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Breckenridge, AM; Coleman, MD; Hussain, F; Park, BK; Pirmohamed, M, 1991)	0.28
"A potential side effect of paracetamol is its hepatotoxicity."	( [Paracetamol hepatotoxicity]. Lubec, G, 1990)	0.28
" Inhibition of cellular respiration as well as a lowering of cellular ATP contents and ATP/ADP ratios was associated with exposure to toxic concentrations of paracetamol."	( Mitochondrial dysfunction in paracetamol hepatotoxicity: in vitro studies in isolated mouse hepatocytes. Burcham, PC; Harman, AW, 1990)	0.28
" The cytotoxicity of the cysteine-S-conjugates and mercapturates of TFE and CTFE was similar, but the cysteine-S-conjugates of DCDFE and DBDFE were more toxic than their mercapturates."	( Toxicity of the cysteine-S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney. Uptake of the conjugates and activation to toxic metabolites. Boogaard, PJ; Commandeur, JN; Mulder, GJ; Nagelkerke, JF; Vermeulen, NP, 1989)	0.28
" When used adjunctively with oxygen radical generating chemotherapeutic agents in mice, however, WR2721 produces synergistic toxicity rather than attenuation of the toxic effects of such agents."	( Mechanisms of synergistic toxicity of the radioprotective agent, WR2721, and 6-hydroxydopamine. Schor, NF, 1988)	0.27
"Hymenoxon and helenalin are toxic sesquiterpene lactones present in the toxic range plants Hymenoxys odorata and Helenium microcephalum."	( Role of glutathione in the toxicity of the sesquiterpene lactones hymenoxon and helenalin. Hayes, MA; Kim, HL; Merrill, JC; Murray, CA; Safe, S, 1988)	0.27
" In contrast apical treatment with PCBD-NAC was only toxic at high concentrations (greater than 850 microM), and this effect could hardly be inhibited by AOAA."	( Differential toxicity as a result of apical and basolateral treatment of LLC-PK1 monolayers with S-(1,2,3,4,4-pentachlorobutadienyl)glutathione and N-acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine. Mertens, JJ; Spenkelink, B; Temmink, JH; van Bladeren, PJ; van Doorn, WJ; Weijnen, JG, 1988)	0.27
" To study the mechanism of this toxicity, suspensions of mouse hepatocytes were tested as an in vitro model system suitable for the study of the relationship between (i) the toxic potential of formamides, (ii) their metabolism to N-alkylcarbamoylating species, and (iii) their ability to deplete hepatic glutathione pools."	( Cytotoxicity and metabolism of the hepatotoxin N-methylformamide and related formamides in mouse hepatocytes. Gescher, A; Mráz, J; Shaw, AJ, 1988)	0.27
" This allowed potentially toxic elevations in calcium concentration to be detected as early as 2 hr after acetaminophen overdose."	( Early sustained rise in total liver calcium during acetaminophen hepatotoxicity in mice. Corcoran, GB; Neese, BL; Wong, BK, 1987)	0.27
" Elevated glutathione may be responsible for inhibiting covalent binding but above-normal concentrations have never been demonstrated in vivo after N-acetyl-L-cysteine treatment or separated adequately from other possible hepatoprotective actions including direct reduction of the toxic acetaminophen metabolite by the antidote."	( Role of glutathione in prevention of acetaminophen-induced hepatotoxicity by N-acetyl-L-cysteine in vivo: studies with N-acetyl-D-cysteine in mice. Corcoran, GB; Wong, BK, 1986)	0.27
" As well as its effect in reducing the formation of the reactive metabolite, DTT has a potent protective effect against the toxic processes initiated by the APAP reactive metabolite."	( Comparison of the protective effects of N-acetylcysteine, 2-mercaptopropionylglycine and dithiothreitol against acetaminophen toxicity in mouse hepatocytes. Harman, AW; Self, G, 1986)	0.27
" S-(1,2-Dichlorovinyl)-L-glutathione is not toxic when the cells are pretreated with AT-125, an inhibitor of gamma-glutamyl transpeptidase."	( The role of glutathione conjugate metabolism and cysteine conjugate beta-lyase in the mechanism of S-cysteine conjugate toxicity in LLC-PK1 cells. Hayden, P; Stevens, J; Taylor, G, 1986)	0.27
" HCBD was about four times more toxic to female rats than males."	( Nephrotoxicity of hexachlorobutadiene and its glutathione-derived conjugates. Ishmael, J; Lock, EA, 1986)	0.27
" Species differences in sensitivity to paracetamol toxicity were shown to be due to differences in the rate of oxidation of the drug to its toxic metabolite."	( Freshly isolated hepatocytes as a model for studying the toxicity of paracetamol. Boobis, AR; Davies, DS; Hampden, CE; Tee, LB, )	0.13
" All three smoke condensate fractions were toxic to isolated rat hepatocytes and lung cells and caused a loss of cell membrane integrity."	( N-acetylcysteine protection against the toxicity of cigarette smoke and cigarette smoke condensates in various tissues and cells in vitro. Berggren, M; Grafström, R; Moldéus, P, 1985)	0.27
" An increase in extracellular and/or intracellular resistance to toxic oxygen metabolites by NAC may be one approach to the prevention of in vivo lung oxidant injury."	( Lung cell oxidant injury: decrease in oxidant mediated cytotoxicity by N-acetylcysteine. Simon, LM; Suttorp, N, 1985)	0.27
"2 ml per animal of 19% alcohol, given at 3 - 4 hours after an LD50 dose of acetaminophen, produced a 24 hour survival of 92%."	( The effect of alcohol on the toxicity of acetaminophen in mice. Banda, PW; Quart, BD, 1984)	0.27
" N-acetylcysteine pretreatment also ablated electron microscopic evidence of doxorubicin cardiomyopathy without alleviating morphological features of its toxic effects on the liver or small intestinal mucosa."	( Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. Doroshow, JH; Ifrim, I; Locker, GY; Myers, CE, 1981)	0.26
" No significant adverse events occurred."	( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995)	0.29
"NAC in combination with NTG and streptokinase appeared to be safe for the treatment of evolving AMI and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion, and better preservation of left ventricular function."	( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995)	0.29
" The reactive N-hydroxylamine metabolites N-hydroxy-IQ and N-hydroxy-PhIP are toxic to isolated rat cardiomyocytes."	( Protective effect of N-acetylcysteine against heterocyclic amine-induced cardiotoxicity in cultured myocytes and in rats. Davis, CD; Snyderwine, EG, 1995)	0.29
" We interpret the results as follows: ara-C kills cells in two ways: first, directly, by incorporation into DNA and chain termination; second, indirectly, by inducing the production of toxic radicals."	( Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Hu, ZB; Li, M; McCulloch, EA; Minden, MD; Miyamoto, N; Yang, GS, 1995)	0.29
"0 mM thiol, but is not seen at higher or lower drug concentrations; N-acetylcysteine (NAC) is toxic only at concentrations > or = 2 mM and shows no biphasic pattern; and glutathione (GSH) and penicillamine are only minimally toxic at all concentrations."	( Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Biaglow, JE; Held, KD, 1994)	0.29
" Serious sulphasalazine-related adverse reactions are rare and their outcome is generally favourable within a few weeks after drug withdrawal."	( Sulphasalazine-related life-threatening side effects: is N-acetylcysteine of therapeutic value? De Bandt, M; Gabay, C; Palazzo, E, )	0.13
" An in vitro endothelial model of injury was developed to assess the direct toxic effects of CP, CP derivatives and CP metabolites on cultured endothelial cells."	( Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. Kachel, DL; Martin, WJ, 1994)	0.29
"N-Acetyl-L-cysteine (NAC) has been widely used in the protection against the toxic effects produced by several chemicals because of its radical scavenger properties and because NAC is a precursor of glutathione, one of the most important intracellular defenses against oxidants."	( The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. Ferrini, S; Giavini, E; Ornaghi, F; Prati, M, 1993)	0.29
" The five L-cysteine conjugates tested: S-(1,2-dichlorovinyl)-L-cysteine (1,2-DCVC), S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC), S-(1-chloro-1,2,2-trifluoroethyl)-L-cysteine (CTFEC), S-(1,1-dichloro-2,2-difluoroethyl)-L-cysteine (DCDFEC) and S-(1,1-dibromo-2,2-difluoroethyl)-L-cysteine (DBDFEC) were more toxic compared to the corresponding mercapturic acids."	( Examination of the structure-toxicity relationships of L-cysteine-S-conjugates of halogenated alkenes and their corresponding mercapturic acids in rat renal tissue slices. Commandeur, JN; Gandolfi, AJ; McGuinness, S; Stijntjes, GJ; te Koppele, JM; Vermeulen, NP, 1993)	0.29
" Hepatocellular damage is probably caused by accumulation of the toxic intermediate metabolite N-acetyl-p-benzoquinoneimine when hepatic glutathione stores are depleted."	( Management of acetaminophen toxicity. Fuller, SH; Larsen, LC, 1996)	0.29
" One patient died, one received N-acetylcysteine, and two ingested minimally toxic amounts of pennyroyal and were not treated with N-acetylcysteine."	( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996)	0.29
" Data on human metabolites may provide new insights into the toxic mechanisms and treatment of pennyroyal poisoning, including the potential role of N-acetylcysteine."	( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996)	0.29
" OxoPrGSH was toxic when present for 24 hr, and this toxicity was also enhanced by pretreatment with DEM."	( Studies on the basis for the toxicity of acrolein mercapturates. Ahmed, T; Kehrer, JP; Pakenham, G; Perry, CS; Ramu, K, 1996)	0.29
" These results demonstrate that (a) reduction in the availability of glucose and intracellular glutathione renders the cells more vulnerable to the cytotoxic effects of NO donors, (b) in this model of cytotoxicity, long-lived NO donors were more cytotoxic than short-lived NO donors, (c) the differential effects of N-acetylcysteine on S-nitroso-N-acetylpenicillamine-induced and bacterial lipopolysaccharide-mediated cytotoxicity support the existence of other toxic species different from NO or NO-related compounds with a potent cytotoxic activity in immunostimulated macrophages, and (d) other non-protein thiols like N-acetylcysteine may substitute for glutathione as a major component of the cellular antioxidant defense system."	( The protective role of thiols against nitric oxide-mediated cytotoxicity in murine macrophage J774 cells. Herman, AG; Matthys, KE; Zamora, R, 1997)	0.3
" These data together with histopathological results, clearly showed that the inducible GSH system in weanling rat liver act as a safe guard against APAP toxicity."	( Role of glutathione conjugation in protection of weanling rat liver against acetaminophen-induced hepatotoxicity. Allameh, A; Vansoun, EY; Zarghi, A, 1997)	0.3
" No adverse sequelae developed in the three viable infants."	( Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity. Bearer, CF; Dart, RC; Gupta, U; Horowitz, RS; Jarvie, DR, 1997)	0.3
" Administration of deferoxamine (75 mg/kg) 1 h after a toxic dose of acetaminophen (300 mg/kg) significantly delayed the development of the toxicity without altering covalent binding."	( Deferoxamine delays the development of the hepatotoxicity of acetaminophen in mice. Bucci, TJ; Hinson, JA; Kusewitt, DF; Pumford, NR; Schnellmann, JG, 1999)	0.3
" In the first instance, NO released from S-nitrosocysteine, a compound not related to cyanide, has no toxic effect on the hair cells of the cochlea."	( Ototoxicity of sodium nitroprusside is not due to nitric oxide. Leong, SK; Ruan, RS; Yeoh, KH, 1999)	0.3
"Chronic exposure of pancreatic islets to supraphysiologic concentrations of glucose causes adverse alterations in beta cell function, a phenomenon termed glucose toxicity and one that may play a secondary pathogenic role in type 2 diabetes."	( Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Gleason, CE; Harmon, JS; Robertson, RP; Tanaka, Y; Tran, PO, 1999)	0.3
"Amino acids (AA) which were proposed as an alternative osmotically active agents in dialysates are toxic to human peritoneal mesothelial cells (HPMC) due to disturbance of the antioxidant-oxidant balance in cells by reducing level of glutathione."	( In vitro effect of glutathione precursors on cytotoxicity of amino acids to human mesothelial cells. Grzybowski, AE, 1999)	0.3
" Our results indicate that infection with Ad-p53 (50-100 viral particles per cell) resulted in pronounced cytotoxicity, whereas infection with 10 viral particles per cell, which was weakly toxic for the MCF7/Adr cells, sensitized these cells to TNF-induced cell death."	( Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. Ameyar, M; Bouquet, C; Cai, Z; Chouaib, S; Haddada, H; Shatrov, VA; Stancou, R, 2000)	0.31
" HC alone was slightly toxic to HepG2 cells."	( Enhanced hydroxychavicol-induced cytotoxic effects in glutathione-depleted HepG2 cells. Chen, CL; Chi, CW; Liu, TY, 2000)	0.31
" Valproic acid alone was not toxic to hepatocytes even at ten times higher concentrations (10 mmol/l), suggesting that cell damage was not a mere additive effect."	( Evidence for a trigger function of valproic acid in xenobiotic-induced hepatotoxicity. Johanssen, S; Klee, S; Ungemach, FR, 2000)	0.31
" We concluded that management of acetaminophen toxicity can be optimized by early identification, obtaining a complete drug screen, starting N-acetylcysteine early or whenever toxic acetaminophen levels or elevated transaminases are identified, and referring patients with acetaminophen toxicity to a liver center."	( Acetaminophen hepatoxicity. Broughan, TA; Soloway, RD, 2000)	0.31
" Here we examine the effects of N-acetyl-L-cysteine (NAC) on beta-amyloid (A beta) secretion and tau phosphorylation in SHSY5Y neuroblastoma cells after exposure to oxidative stress inducing/cytotoxic compounds (H(2)O(2), UV light and toxic A beta peptides)."	( N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. Baysang, G; Brack, C; Brockhaus, M; Meier, F; Müller-Spahn, F; Olivieri, G; Stähelin, HB, 2001)	0.31
" These data suggest that NAC and U-83836E mitigate the toxic effects of methanol on the antioxidant system of the rat brain."	( N-acetylcysteine or trolox derivative mitigate the toxic effects of methanol on the antioxidant system of rat brain. Farbiszewski, R; Skrzydlewska, E; Witek, A, 2000)	0.31
" We concluded that NAC/OLZ modulates some end points related to GSH but is too toxic for chemoprevention at the doses used."	( Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Bolanowska-Higdon, W; Creaven, PJ; Hitt, S; Lawrence, D; Murphy, M; Pendyala, L; Schwartz, G; Zdanowicz, J, 2001)	0.31
" Catalase or vitamin E showed no protective effect against betaA25-35 Dithiothreitol (DTT), N-acetylcysteine (NAC) and cyclosporine A significantly prevented the toxic effects of both betaA25-35 and peroxide, while inhibition of peroxide detoxifying enzymes enhanced toxicity."	( beta-Amyloid-induced cytotoxicity, peroxide generation and blockade of glutamate uptake in cultured astrocytes. Brera, B; de Ceballos, ML; Fernández-Tomé, MP, 2001)	0.31
" These findings underscore that moderate accumulation of excitotoxins at concentrations that alone do not appear to initiate adverse events may enhance the effects of other factors known to cause neurodegeneration such as Abeta."	( Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. Ashline, D; Collins, SC; Dhitavat, S; Ho, PI; Ortiz, D; Rogers, E; Shea, TB, 2001)	0.31
"The toxic effect of thiram, a widely used dithiocarbamate fungicide, was investigated in cultured human skin fibroblasts."	( Thiram-induced cytotoxicity is accompanied by a rapid and drastic oxidation of reduced glutathione with consecutive lipid peroxidation and cell death. Boget, S; Cereser, C; Parvaz, P; Revol, A, 2001)	0.31
"The aim of this study is to determine the efficacy of L-N-acetyl-cysteine (L-NAC) as a protectant for inner ear auditory sensory cells against the toxic effects of cisplatin."	( L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Feghali, JG; Liu, W; Van De Water, TR, 2001)	0.31
" Their rate of survival was studied after exposure to toxic levels of cisplatin."	( L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Feghali, JG; Liu, W; Van De Water, TR, 2001)	0.31
"Pretreatment of cultures with L-NAC protected both auditory neurons and hair cells from the effects of exposure to toxic levels of cisplatin."	( L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Feghali, JG; Liu, W; Van De Water, TR, 2001)	0.31
"Our in vitro studies have demonstrated that L-NAC protected both auditory neurons and hair cells from the toxic effects of cisplatin."	( L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Feghali, JG; Liu, W; Van De Water, TR, 2001)	0.31
" To elucidate direct toxic effects of isothiocyanates (ITCs), BITC, AITC, or BITC-metabolites conjugated either with glutathione, cysteinylglycine, cysteine, or mercapturic acid were intravesically instilled into female F344 rats."	( Toxic effects of benzyl and allyl isothiocyanates and benzyl-isoform specific metabolites in the urinary bladder after a single intravesical application to rats. Hirose, M; Masutomi, N; Niho, N; Shibutani, M; Takahashi, N; Toyoda, K; Uneyama, C, )	0.13
" Immediately after this, a toxic dose of acetaminophen (500 mg/kg orally) was administered followed by another administration one hour later (500 mg/kg orally)."	( The protective effect of garlic oil on hepatotoxicity induced by acetaminophen in mice and comparison with N-acetylcysteine. Kalantari, H; Salehi, M, 2001)	0.31
" Therefore it protects the liver from toxic doses of acetaminophen."	( The protective effect of garlic oil on hepatotoxicity induced by acetaminophen in mice and comparison with N-acetylcysteine. Kalantari, H; Salehi, M, 2001)	0.31
" The detoxification effect of antioxidants showed cooperation with Bcl-2, suggesting that Cd(2+)-treatment causes diversified toxic signals including oxidative stress."	( Cellular toxicity of cadmium ions and their detoxification by heavy metal-specific plant peptides, phytochelatins, expressed in Mammalian cells. Amano, S; Eguchi, Y; Fukui, K; Hirata, K; Imanaka, T; Miyamoto, K; Mizuno, H; Satofuka, H; Takagi, M, 2002)	0.31
" N-acetylcysteine (NAC), an antioxidant, could not only reduce adverse effect of lead on GSH, but also antagonize its toxicity to cell survival and differentiation."	( [Toxicity to neural cell development of lead and its relation to glutathione]. Fu, S; Li, H, 2000)	0.31
" No adverse effects were observed."	( Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. App, EM; Baran, D; Coffiner, M; Dab, I; King, M; Malfroot, A; Vanderbist, F, 2002)	0.31
" In conclusion, the administration of 4-MP and/or NAC after 4 h of administering toxic dose of acetaminophen, inhibits hepatotoxicity in rats."	( Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats. Acar, HV; Cankir, Z; Cermik, H; Cinan, U; Danaci, M; Küçükardali, Y; Nalbant, S; Ozkan, S; Top, C, 2002)	0.31
" Both treatments were well tolerated with fewer than 5% of patients experiencing an adverse event."	( Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. De Benedetto, F; Grassi, C, 2002)	0.31
" A relationship between exposure to busulphan, expressed as an area under the plasma concentration time curve (AUC), and effect and/or adverse effects, such as veno-occlusive disease (VOD), was reported."	( The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Alsadi, S; Edgren, M; Hägglund, H; Hassan, M; Hassan, Z; Hellström-Lindberg, E, 2002)	0.31
"Antioxidant drugs have been reported to protect pancreatic islets from the adverse effects of chronic exposure to supraphysiological glucose concentrations."	( A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Harmon, J; Robertson, RP; Tanaka, Y; Tran, PO, 2002)	0.31
"Paraquat, a quarternary nitrogen herbicide, is a highly toxic compound for humans and animals and many cases of acute poisoning and death have been reported over the past few decades."	( Role of antioxidants in paraquat toxicity. Suntres, ZE, 2002)	0.31
" These results suggest an innovative therapeutic approach for treating the adverse effects of acetaminophen and potentially other hepatotoxic agents."	( Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Chua, SS; Huang, W; Moore, DD; Wei, P; Zhang, J, 2002)	0.31
" Since VOCs are used in industrial, commercial and military applications, concern is mounting with respect to VOC safe exposure limits."	( The effect of m-xylene on cytotoxicity and cellular antioxidant status in rat dermal equivalents. Coleman, CA; Hull, BE; McDougal, JN; Rogers, JV, 2003)	0.32
" It has been reported that the toxic effects of AA are the result of oxidative reactions that take place during its metabolism."	( Protective effects of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. Ayanoğlu-Dülger, G; Sehirli, AO; Sener, G, 2003)	0.32
" To determine the importance of reversible versus toxic events, N-acetylcysteine (NAC) was administered to mice either before APAP or 1, 2, or 4 h after APAP."	( Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Hinson, JA; James, LP; Lamps, LW; McCullough, SS, 2003)	0.32
"Acetaminophen, a safe analgesic when dosed properly but hepatotoxic at overdoses, has been reported to induce DNA strand breaks but it is unclear whether this event preceeds hepatocyte toxicity or is only obvious in case of overt cytotoxicity."	( Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity. El-Bahay, C; Hanelt, S; Kahl, R; Lewerenz, V; Nastevska, C; Röhrdanz, E, 2003)	0.32
" Recent data have shown that nitrated tyrosine residues as well as acetaminophen adducts occur in the necrotic cells following toxic doses of acetaminophen."	( Acetaminophen-induced hepatotoxicity. Hinson, JA; James, LP; Mayeux, PR, 2003)	0.32
"We conduct a study to determine the rate of adverse events (anaphylactoid and cardiorespiratory) associated with the use of oral N-acetylcysteine by the intravenous route for the treatment of suspected acetaminophen poisoning and to examine specific variables that may be associated with adverse events."	( What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning? Brizendine, EJ; Furbee, RB; Kao, LW; Kirk, MA; Mehta, NH; Skinner, JR, 2003)	0.32
" Adverse events were divided into categories of cutaneous, systemic, or life threatening."	( What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning? Brizendine, EJ; Furbee, RB; Kao, LW; Kirk, MA; Mehta, NH; Skinner, JR, 2003)	0.32
"There were 7 adverse events identified in 187 patients (3."	( What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning? Brizendine, EJ; Furbee, RB; Kao, LW; Kirk, MA; Mehta, NH; Skinner, JR, 2003)	0.32
"Intravenous administration of an oral solution of N-acetylcysteine is associated with a low rate of adverse events and should be considered for selected patients with suspected acetaminophen poisoning."	( What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning? Brizendine, EJ; Furbee, RB; Kao, LW; Kirk, MA; Mehta, NH; Skinner, JR, 2003)	0.32
" At 80 microM, the compound was significantly toxic to cells, but the resulting QR inhibition was dose-dependently overcome by NAC."	( Augmented gene expression of quinone reductase by 6-(methylsulfinyl)hexyl isothiocyanate through avoiding its cytotoxicity. Fuke, Y; Kidachi, Y; Mori, N; Nara, M; Ryoyama, K; Umetsu, H; Yamaguchi, H, )	0.13
"Arsenic, a common environmental pollutant, is toxic to many mammalian cells."	( Comparison of the cytotoxicity induced by different exposure to sodium arsenite in two fish cell lines. Chaung, RH; Tung, LC; Wang, YC, 2004)	0.32
" The aims of the present in vitro study were: (1) to evaluate and compare the hepatotoxic effects of MDMA and one of its main metabolites, N-methyl-alpha-methyldopamine (N-Me-alpha-MeDA) and (2) to investigate the ability of antioxidants, namely ascorbic acid and N-acetyl-L-cysteine (NAC), to prevent N-Me-alpha-MeDA-induced toxic injury, using freshly isolated rat hepatocytes."	( The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Bastos, ML; Borges, F; Carvalho, F; Carvalho, M; Fernandes, E; Milhazes, N; Remião, F, 2004)	0.32
"Cochlear ototoxicity is a well-known side effect of cisplatin administration, with the mechanism of injury thought to rest in oxidative damage to the outer hair cells."	( Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Chang, KW; Chinosornvatana, N; Choe, WT, 2004)	0.32
"Acetaminophen poisoning accounts for a disproportionate percentage of all toxic ingestions, and can be life-threatening."	( An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Marzullo, L, 2005)	0.33
" This review summarizes this controversy, and offers a framework to develop a safe treatment plan that has the optimal outcome for the patient, as well as reflecting knowledge of the potential caveats at work."	( An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Marzullo, L, 2005)	0.33
" Recently, attention has focused on the estrogen-like and carcinogenic adverse effects of BPA and HQ."	( Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells. Fujisawa, S; Kadoma, Y; Sakagami, H; Terasaka, H, )	0.13
"Diesel exhaust particles (DEP) are known to induce adverse biological responses such as inflammation of the airway."	( Oxidative ability and toxicity of n-hexane insoluble fraction of diesel exhaust particles. Kobayashi, T; Koike, E; Shima, H; Shinohara, R, 2006)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Cytotoxicity and cell proliferation assays were performed to elucidate the toxic effects of eugenol on the human osteoblastic cell line U2OS."	( Mechanisms of cytotoxicity of eugenol in human osteoblastic cells in vitro. Chang, YC; Ho, YC; Huang, FM, 2006)	0.33
" The data suggest that CYP2E1 played a major role in metabolizing AA to more toxic GA."	( Metabolism of acrylamide to glycidamide and their cytotoxicity in isolated rat hepatocytes: protective effects of GSH precursors. Kurebayashi, H; Ohno, Y, 2006)	0.33
"Styrene has been found to be toxic to the respiratory system, and the toxicity of styrene is metabolism-dependent."	( Investigation of bioactivation and toxicity of styrene in CYP2E1 transgenic cells. Chung, JK; Liu, G; Yuan, W; Zheng, J, 2006)	0.33
"3-Butene-1,2-diol (butenediol), a major metabolite of 1,3-butadiene (butadiene), can undergo either detoxification or biotransformation to potentially toxic metabolites, including 3,4-epoxy-1,2-butanediol and hydroxymethylvinyl ketone (HMVK)."	( Effect of n-hexane on the disposition and toxicity of the 1,3-butadiene metabolite 3-butene-1,2-diol. Bird, MG; Iba, MM, 2007)	0.34
" Considering that the oxidation of DCFH diminishes ROS generated by various stressors, our findings provide a potential strategy for protection of cells from toxic insults using DCFH-like molecules."	( The antioxidant role of a reagent, 2',7'-dichlorodihydrofluorescin diacetate, detecting reactive-oxygen species and blocking the induction of heme oxygenase-1 and preventing cytotoxicity. Adachi, Y; Andoh, Y; Ikehara, S; Ishii, T; Kojo, S; Mizutani, A; Ohashi, T; Taketani, S, 2006)	0.33
" The aim of this study was to evaluate the ability of OTA to produce single-strand DNA breaks and oxidative DNA damage in the human renal proximal tubular epithelial cell line (HK-2), due to the fact that there is no study on human kidney cells as the toxic target."	( Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity. Arbillaga, L; Azqueta, A; Ezpeleta, O; López de Cerain, A, 2007)	0.34
" In conclusion, CsA induced liver injury and NAC treatment prevented the toxic side effects induced by CsA administration through the antioxidant and radical scavenging effects of NAC."	( The protective effect of N-acetylcysteine against cyclosporine A-induced hepatotoxicity in rats. Durgut, R; Duru, M; Kaya, H; Koc, A; Sogut, S; Uz, E; Yilmaz, HR, 2008)	0.35
"Ifosfamide (IF) nephrotoxicity is a serious adverse effect in children undergoing chemotherapy."	( The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2007)	0.34
" Our results indicate that ACN is toxic to rat primary glial cells as evidenced by induction of oxidative stress and generation of CN(-) with subsequent energy depletion."	( Toxicity and oxidative stress of acrylonitrile in rat primary glial cells: preventive effects of N-acetylcysteine. Abdel-Naim, AB; El-Demerdash, E; El-Mesallamy, H; Esmat, A, 2007)	0.34
" We hypothesized that oxidative stress plays a role in lead-induced cytotoxicity, and that NAC affords protection against this adverse effect."	( N-acetyl-l-cysteine affords protection against lead-induced cytotoxicity and oxidative stress in human liver carcinoma (HepG2) cells. Tchounwou, PB; Yedjou, CG, 2007)	0.34
" Primary safety/tolerability endpoints included the mortality rate and incidence of adverse drug reactions, while efficacy endpoints included alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels."	( Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. Dawson, AH; Francis, B; Whyte, IM, 2007)	0.34
"3%) had an adverse drug reaction to IV-NAC, of which seven (1."	( Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. Dawson, AH; Francis, B; Whyte, IM, 2007)	0.34
" The molecular mechanisms responsible for the glucose toxic effect on beta cell function involves disappearance of two important regulators of insulin promoter activity, PDX-1 and MafA."	( Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Harmon, JS; Robertson, R; Zhang, T; Zhou, H, 2007)	0.34
" It is safe when taken at therapeutic doses; however, overdose can lead to serious and even fatal hepatotoxicity."	( Acetaminophen hepatotoxicity. Larson, AM, 2007)	0.34
" Exogenously administrated NAC might reduce toxic effects of Cd on the kidney without any reduction in tissue Cd level."	( Influence of N-acetylcysteine on renal toxicity of cadmium in rats. Aktoz, T; Atakan, IH; Aydoğdu, N; Inci, O; Kaplan, M; Ozpuyan, F; Seren, G; Tokuç, B, 2008)	0.35
" In conclusion, NAC is safe in non-acetaminophen-induced ALF."	( Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Bansal, S; Cheeseman, P; Dhawan, A; Kortsalioudaki, C; Mieli-Vergani, G; Taylor, RM, 2008)	0.35
"Ifosfamide nephrotoxicity is a serious adverse effect for children undergoing cancer chemotherapy."	( N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2008)	0.35
"Several adverse health effects, including irritant and allergic contact dermatitis, have been reported among workers who are occupationally exposed to chromium-containing compounds."	( Heme-oxygenase 1 gene expression is a marker for hexavalent chromium-induced stress and toxicity in human dermal fibroblasts. He, Q; Joseph, P; Umbright, C, 2008)	0.35
" Administration of tetracycline caused a reduction in the epididymal sperm motility, percentage of live spermatozoa, sperm count, and an increase in abnormal sperm morphology, as well as induction of adverse histopathologic changes in the testes."	( Tetracycline-induced reproductive toxicity in male rats: effects of vitamin C and N-acetylcysteine. Ekor, M; Ezenwadu, TT; Farombi, EO; Oyeyemi, MO; Ugwuezunmba, MC, 2008)	0.35
" However, it is undetectable in cultured hepatocyte monolayers in vitro at the equivalent toxic concentration in vivo."	( Investigation of rifampicin-induced hepatotoxicity in rat hepatocytes maintained in gel entrapment culture. Cheng, X; Li, D; Meng, Q; Shen, C, 2009)	0.35
"In patients with massive acetaminophen ingestion, erratic absorption may occur, and toxic serum concentrations may persist beyond a standard 21-hour course of intravenous NAC therapy."	( Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW, 2008)	0.35
"Several heavy metals have been shown to have toxic effects on the peripheral and central auditory system."	( The protective mechanism of antioxidants in cadmium-induced ototoxicity in vitro and in vivo. Hong, SH; Jeong, HJ; Kim, HM; Kim, MC; Kim, SJ; Lee, JH; Myung, NY; Park, RK; So, HS; Um, JY, 2008)	0.35
" However, ROS generation may be the cause of the toxicity, and application of antioxidants can prevent the toxic effect."	( The protective mechanism of antioxidants in cadmium-induced ototoxicity in vitro and in vivo. Hong, SH; Jeong, HJ; Kim, HM; Kim, MC; Kim, SJ; Lee, JH; Myung, NY; Park, RK; So, HS; Um, JY, 2008)	0.35
" The aim of this study was to address the toxic effects of MnCl2 and MnSO4 on the immortalized rat brain microvessel endothelial cell line (RBE4) and to characterize toxic mechanism associated with exposure to Mn."	( Antioxidants prevent the cytotoxicity of manganese in RBE4 cells. Aschner, M; Au, C; Batoréu, MC; Marreilha dos Santos, AP; Milatovic, D; Santos, D, 2008)	0.35
" When dosed at quantities limited by toxicity, allyl acetate and allyl alcohol produce higher levels of urinary mercapturic acids than the minimally toxic dose of acrolein."	( A comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein. Auerbach, SS; Irwin, RD; Mahler, J; Travlos, GS, 2008)	0.35
" These results suggest that ER stress mediates polyglutamine toxicity prior to UPS impairment during the initial stages of these toxic effects."	( ER stress is the initial response to polyglutamine toxicity in PC12 cells. Fujikake, N; Hamada, M; Hatano, O; Ikeuchi, T; Isosaki, M; Nagai, Y; Nakayama, H; Shimoke, K; Yoshizumi, M; Zhao, J, 2008)	0.35
"Intravenous acetylcysteine seemed to be a safe and effective formulation of N-acetylcysteine."	( Safety and effectiveness of acetadote for acetaminophen toxicity. Brooks, DE; Katz, KD; Kehrl, T; Sokolowski, D; Whyte, AJ, 2010)	0.36
" The enhancement was highly synergistic because MeHg and L-Glu alone had little toxic effect in the conditions used."	( L-glutamate enhances methylmercury toxicity by synergistically increasing oxidative stress. Amonpatumrat, S; Kanai, Y; Khunweeraphong, N; Nagamori, S; Piyachaturawat, P; Sakurai, H; Tanaka, H; Wiriyasermkul, P, 2008)	0.35
" Cyanide is predominantly a neurotoxin but its toxic manifestations in non-neuronal cells are also documented."	( Oxidative stress mediated cytotoxicity of cyanide in LLC-MK2 cells and its attenuation by alpha-ketoglutarate and N-acetyl cysteine. Bhattacharya, R; Hariharakrishnan, J; Prasad, GB; Satpute, RM, 2009)	0.35
" N-acetylcysteine offers promising therapeutic value to inhibit ethanol-induced adverse effects."	( Effects of N-acetylcysteine on alcohol abstinence and alcohol-induced adverse effects in rats. Amauchi, JF; Burneiko, RM; Ebaid, GX; Ferreira Seiva, FR; Novelli, EL; Ribeiro Rocha, KK; Souza, GA, 2009)	0.35
" Furthermore, the use of antidotes that reduced the toxic insult was also recorded using this technique."	( Acute liver acetaminophen toxicity in rabbits and the use of antidotes: a metabonomic approach in serum. Galanopoulou, P; Giannioti, K; Liapi, C; Mikros, E; Papalois, A; Theocharis, S; Zira, A, 2009)	0.35
" The toxic metabolite of IFO thought to be responsible for IFO-induced kidney damage is chloroacetaldehyde (CAA)."	( Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Chen, N; Hanly, L; Koren, G; Rieder, M, 2009)	0.35
"It is well known that antioxidants containing sulfhydryl (-SH) groups are protective against the toxic effects of mercury."	( The role of intracellular glutathione in inorganic mercury-induced toxicity in neuroblastoma cells. Becker, A; Soliman, KF, 2009)	0.35
" Administration of studied antidotes without alpha-AMA, was not associated with any adverse effects in hepatocytes."	( Failure of benzylpenicillin, N-acetylcysteine and silibinin to reduce alpha-amanitin hepatotoxicity. Dziegiel, P; Izykowska, I; Magdalan, J; Nowak, M; Ostrowska, A; Piotrowska, A; Szelag, A, )	0.13
" Using the murine mesencephalic cell line MN9D, we have shown that DAC [50-250 microM] leads to cell death in a concentration-dependent manner, whereas oxidized l-dopa, dopachrome [50-250 microM], is only toxic at the highest concentration used."	( Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Linsenbardt, AJ; Macarthur, H; Westfall, TC; Wilken, GH, 2009)	0.35
"High-dose NAC was a well-tolerated and safe medication."	( A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Aulbach, B; Bargon, J; Dauletbaev, N; Fischer, P; Gross, J; Kusche, W; Thyroff-Friesinger, U; Wagner, TO, 2009)	0.35
"High-dose NAC is a well-tolerated and safe medication for a prolonged therapy of patients with CF with a potential to increase extracellular glutathione in CF airways."	( A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Aulbach, B; Bargon, J; Dauletbaev, N; Fischer, P; Gross, J; Kusche, W; Thyroff-Friesinger, U; Wagner, TO, 2009)	0.35
"Acetaminophen overdose causes hepatotoxicity mediated by toxic metabolites generated through the cytochrome P450 enzyme."	( Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Czauderna, P; Fuchs, J; Knap, N; Losin, M; Neuwelt, AJ; Neuwelt, EA; Pagel, MA; Warmann, S; Wozniak, M; Wu, YJ, 2009)	0.35
"Our results suggest that a chemotherapeutic regimen containing both AAP and CDDP with delayed NAC rescue has the potential to enhance chemotherapeutic efficacy while decreasing adverse effects."	( Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Czauderna, P; Fuchs, J; Knap, N; Losin, M; Neuwelt, AJ; Neuwelt, EA; Pagel, MA; Warmann, S; Wozniak, M; Wu, YJ, 2009)	0.35
" The secondary endpoints are absolute and relative increases in sCr of at least 50%, thrombolysis in myocardial infarction (TIMI) perfusion grade, and major adverse cardiac events at 1, 6, and 12 months."	( The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study. Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Limbruno, U; Picchi, A; Pierli, C, 2010)	0.36
" Today's oncologists must be fully aware of cardiovascular risks to avoid or prevent adverse cardiovascular effects, and cardiologists must now be ready to assist oncologists by performing evaluations relevant to the choice of therapy."	( Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Albini, A; Cammarota, R; De Flora, S; Donatelli, F; Noonan, DM; Pennesi, G, 2010)	0.36
"1 to 180 mg/kg and reduced the production of a potential toxic metabolite chloroacetaldehyde (CAA) in animal plasma."	( Protective effects of fomepizole on 2-chloroethanol toxicity. Chen, YT; Hung, DZ; Liao, JW, 2010)	0.36
" Adverse biological events around biomaterials may be associated with oxidative stress."	( N-acetyl cysteine alleviates cytotoxicity of bone substitute. Hori, N; Iwasa, F; Minamikawa, H; Ogawa, T; Sato, N; Ueno, T; Yamada, M, 2010)	0.36
" However, reports of severe NVP-induced hepatotoxicity and serious adverse cutaneous effects have raised concerns about its use."	( Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity. Antunes, AM; Beland, FA; Godinho, AL; Justino, GC; Marques, MM; Martins, IL, 2010)	0.36
" The primary safety outcome was the percentage of patients with NAC-related adverse events."	( A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Aguilera, E; Al-Helial, M; Arnold, T; Bebarta, VS; Bogdan, G; Buchanan, J; Clark, RF; Dart, R; Delgado, J; Froberg, B; Haur, W; Heard, K; Hoppe, J; Kao, L; Kokko, J; Lares, C; Lavonas, E; McDonagh, J; Mendoza, C; Mlynarchek, S; O'Malley, G; Odujebe, O; Qi, M; Rhyee, S; Stanford, C; Tan, HH; Tran, NN; Varney, S; Zosel, A, 2010)	0.36
" There were no serious adverse events related to NAC for either route."	( A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Aguilera, E; Al-Helial, M; Arnold, T; Bebarta, VS; Bogdan, G; Buchanan, J; Clark, RF; Dart, R; Delgado, J; Froberg, B; Haur, W; Heard, K; Hoppe, J; Kao, L; Kokko, J; Lares, C; Lavonas, E; McDonagh, J; Mendoza, C; Mlynarchek, S; O'Malley, G; Odujebe, O; Qi, M; Rhyee, S; Stanford, C; Tan, HH; Tran, NN; Varney, S; Zosel, A, 2010)	0.36
"IV and oral NAC are generally mild adverse drug reactions."	( A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Aguilera, E; Al-Helial, M; Arnold, T; Bebarta, VS; Bogdan, G; Buchanan, J; Clark, RF; Dart, R; Delgado, J; Froberg, B; Haur, W; Heard, K; Hoppe, J; Kao, L; Kokko, J; Lares, C; Lavonas, E; McDonagh, J; Mendoza, C; Mlynarchek, S; O'Malley, G; Odujebe, O; Qi, M; Rhyee, S; Stanford, C; Tan, HH; Tran, NN; Varney, S; Zosel, A, 2010)	0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Reconstitution of SIRT3 levels and/or treatment with N-acetylcysteine ameliorates these adverse effects."	( SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Bao, J; Dimond, CC; Gius, D; Lu, Z; Pang, L; Sack, MN; Scott, I, 2010)	0.36
" These benefits, however, can be offset by adverse iatrogenic muscle pain."	( N-acetylcysteine protects against bupivacaine-induced myotoxicity caused by oxidative and sarcoplasmic reticulum stress in human skeletal myotubes. Bourret, A; Capdevila, X; Galbes, O; Matecki, S; Mercier, J; Nouette-Gaulain, K; Philips, A; Pillard, F; Py, G, 2010)	0.36
"The authors used primary cell cultures of human skeletal muscle myoblasts to study local anesthetic adverse effects."	( N-acetylcysteine protects against bupivacaine-induced myotoxicity caused by oxidative and sarcoplasmic reticulum stress in human skeletal myotubes. Bourret, A; Capdevila, X; Galbes, O; Matecki, S; Mercier, J; Nouette-Gaulain, K; Philips, A; Pillard, F; Py, G, 2010)	0.36
"2,3,5-Tris(glutathion-S-yl)-hydroquinone (TGHQ), a metabolite of hydroquinone, is toxic to renal proximal tubule epithelial cells."	( The cytoprotective effect of N-acetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis. Lau, SS; Monks, TJ; Zhang, F, 2011)	0.37
" These results indicate that low-dose MeHg toxicity may be related to an induction of tau phosphorylation through an oxidative stress-dependent mechanism and that blockade of this pathway may attenuate the toxic effects of MeHg."	( Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Agrawal, K; George, W; Mondal, D; Petroni, D; Tsai, J, 2012)	0.38
" Mammalian auditory cells are unable to regenerate when affected by several toxic agents."	( Protective effect of L-N-acetylcysteine against gentamycin ototoxicity in the organ cultures of the rat cochlea. Cosgarea, M; Maniu, A; Perde-Schrepler, M, 2011)	0.37
"Natural products from plants are expected to play significant roles in creating new, safe and improved chemopreventive and therapeutic antitumor agents."	( Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione. Akitaya, T; Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yoshida, K; Yu, T, 2011)	0.37
" No adverse outcomes were associated with medication errors."	( Evaluation of a simplified N-acetylcysteine dosing regimen for the treatment of acetaminophen toxicity. Halcomb, SE; Johnson, MT; McCammon, CA; Mullins, ME, 2011)	0.37
" Nephrotoxicity is an adverse effect that limits their successful use."	( Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. Essig, M; Gastinel, LN; Lamoureux, F; Marquet, P; Mestre, E; Sauvage, FL, 2011)	0.37
"Ototoxicity is a common and irreversible adverse effect of cisplatin treatment with great impact on the patients' quality of life."	( Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Amarantidis, K; Chamalidou, E; Chelis, L; Danielides, V; Dimopoulos, P; Kakolyris, S; Papadopoulos, S; Riga, MG; Stathakidou, S; Xenidis, N, 2013)	0.39
" An acute pain starting shortly after the injection and lasting for a few minutes seemed to be the only significant adverse effect."	( Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Amarantidis, K; Chamalidou, E; Chelis, L; Danielides, V; Dimopoulos, P; Kakolyris, S; Papadopoulos, S; Riga, MG; Stathakidou, S; Xenidis, N, 2013)	0.39
"Nickel and cobalt are heavy metals found in land, water, and air that can enter the body primarily through the respiratory tract and accumulate to toxic levels."	( Co-exposure to nickel and cobalt chloride enhances cytotoxicity and oxidative stress in human lung epithelial cells. Lynch, C; Patel, E; Reynolds, M; Ruff, V, 2012)	0.38
"Nickel compounds are known to be toxic and carcinogenic in kidney and lung."	( Nickel (II)-induced cytotoxicity and apoptosis in human proximal tubule cells through a ROS- and mitochondria-mediated pathway. Chang, YC; Chen, CY; Chou, MC; Huang, YL; Lin, KH; Liu, HL; Shyu, HW; Tseng, WC; Wang, YF, 2012)	0.38
" We investigated the protective effect of SFN against the toxic response of copper oxide (CuO) NPs in mouse embryonic fibroblasts (BALB 3T3)."	( Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3. Ahamed, M; Akhtar, MJ; Alrokayan, SA; Fareed, M; Kumar, S, 2012)	0.38
" No adverse effects were observed during chelation therapy."	( Case series of mercury toxicity among children in a hot, closed environment. Akyildiz, BN; Kondolot, M; Konuşkan, B; Kurtoğlu, S, 2012)	0.38
"01-1000μM) did not show neurotoxicity, 2'-OH- and 4'-OH-deltamethrin (10-1000μM) were more toxic than deltamethrin (10-1000μM)."	( Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. Anadón, A; Ares, I; Castellano, V; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Ramos, E; Romero, A, 2012)	0.38
" The most commonly administered drug used in treatment and prophylaxis is amiodarone which has several toxic effects on major organ functions."	( May toxicity of amiodarone be prevented by antioxidants? A cell-culture study. Durukan, AB; Durukan, E; Erdem, B; Gurbuz, HA; Gurpinar, A; Karaduman, T; Sevim, H; Yorgancioglu, C, 2012)	0.38
" Data obtained with the prophylactic protocol of treatment might indicate that individuals under treatment with ACE inhibitors are less susceptible to the toxic effects of APAP."	( Effects of treatment with enalapril on hepatotoxicity induced by acetaminophen in mice. Betto, MR; Campos, MM; Driemeier, D; Lazarotto, LF; Leite, CE; Watanabe, TT, 2012)	0.38
" Prior work has shown that the efficiency of the GSH-dependent renal detoxification of haloalkene derived mercapturates is significantly decreased upon their deacetylation because of rapid transformation of the deacetylated products into toxic compounds mediated by β-lyase."	( Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal. Abuladze, N; Bragin, A; Cascio, D; Damoiseaux, R; Faull, K; Pushkin, A; Schibler, MJ; Tsirulnikov, K, 2012)	0.38
" While the hepatotoxic effects of the drug have been well recognized in cases of acute overdose and chronic supratherapeutic doses, the toxic effects of acetaminophen are rarely documented in cases where therapeutic guidelines are followed."	( Acute liver failure following cleft palate repair: a case of therapeutic acetaminophen toxicity. Boyajian, M; Cheerharan, M; Iorio, ML; Kaufman, SS; Reece-Stremtan, S, 2013)	0.39
" The authors conclude that As(2) O(3) -induced DNA damage and apoptosis are mediated by oxidative stress and selenium and that, although toxic at higher concentrations, selenium provides significant protection against As(2) O(3) effects in PLHC-1 cells."	( Protective and antioxidant role of selenium on arsenic trioxide-induced oxidative stress and genotoxicity in the fish hepatoma cell line PLHC-1. Murray, E; Selvaraj, V; Yeager-Armstead, M, 2012)	0.38
" In addition, NAC could almost completely reverse the adverse effects of OTA at the protein level."	( An iTRAQ-based mitoproteomics approach for profiling the nephrotoxicity mechanisms of ochratoxin A in HEK 293 cells. Huang, K; Liang, R; Luo, Y; Shen, XL; Wang, Y; Xu, W; Zhang, Y; Zheng, J, 2013)	0.39
" No C4-related adverse clinical signs or organ toxicity were observed."	( A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment. Borne, A; Carmazzi, Y; Frank, SJ; Gagea, M; Johansen, MJ; Madden, T; Martirosyan, KS; Van Pelt, CS, 2013)	0.39
" Our data here showed that acute TiO(2)-NPs exposure in the range of μg/L had no obviously adverse effects on nematodes, but the chronic toxicities of large sizes (60 nm and 90 nm) of TiO(2)-NPs in the range of μg/L were detected in nematodes in a modified chronic toxicity assay system."	( Small sizes of TiO2-NPs exhibit adverse effects at predicted environmental relevant concentrations on nematodes in a modified chronic toxicity assay system. Li, Y; Tang, M; Wang, D; Wang, W; Wu, Q; Ye, B, 2012)	0.38
" The protein α-synuclein (αSyn), the principle toxic effector in PD, has been shown to interfere with neuronal Ca(2+) fluxes, arguing for an involvement of deregulated Ca(2+) homeostasis in this neuronal demise."	( The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models. Benke, S; Broeskamp, F; Büttner, S; Callewaert, G; Carmona-Gutierrez, D; D'hooge, P; Eisenberg, T; Faes, L; Franssens, V; Freudenberger, P; Ghillebert, R; Habernig, L; Harger, A; Kourtis, N; Kroemer, G; Madeo, F; Pieber, TR; Reichelt, WN; Ruli, D; Sigrist, SJ; Tavernarakis, N; Winderickx, J, 2013)	0.39
" In conclusion, MDMA catechol metabolites promote differential toxic effects to differentiated dopaminergic human SH-SY5Y cells."	( Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells. Bastos, ML; Branco, PS; Capela, JP; Carvalho, F; Costa, VM; Fernandes, E; Ferreira, LM; Ferreira, PS; Meisel, A; Nogueira, TB, 2013)	0.39
" However, its use is limited due to its serious side effect on kidneys."	( Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity. El-Desoky, KI; El-Sisi, Ael-D; El-Syaad, ME; Moussa, EA, 2015)	0.42
" This lack of observed toxic effects from PEG-coated Qdots may be due to the fact that PEG-coating can inhibit ROS generation induced by U-Qdots."	( Quantum dot-related genotoxicity perturbation can be attenuated by PEG encapsulation. Chen, FF; Duerksen-Hughes, PJ; Jiang, Y; Ju, L; Sun, L; Yan, C; Yang, J; Zhang, C; Zhang, G; Zhang, X; Zhu, X, 2013)	0.39
"Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes."	( Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Brophy, MT; Cass, A; Chertow, GM; Conner, TA; Fine, MJ; Gallagher, M; Huang, GD; Kaufman, J; Lee, J; Lew, RA; McCullough, PA; Mor, MK; Palevsky, PM; Parikh, CR; Shunk, KA; Soliva, S; Weisbord, SD, 2013)	0.39
" A 5-point (1-5 mM) dose-response curve of NAC clearly indicated no adverse effect on astroglial cell viability."	( Attenuating effect of N-acetyl-L-cysteine against acute cocaine toxicity in rat C6 astroglial cells. Badisa, RB; Fitch-Pye, CA; Goodman, CB, 2013)	0.39
" Oxidative stress mediated by GO might explain the reason of its toxic effect."	( Role of surface charge and oxidative stress in cytotoxicity and genotoxicity of graphene oxide towards human lung fibroblast cells. Dong, B; Duan, W; Liu, Y; Pu, K; Wang, A; Zhang, L; Zhang, Z; Zhu, Y, 2013)	0.39
"Nephrotoxicity is a serious side effect associated with ifosfamide use."	( N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. Hanly, L; Huang, SH; Koren, G; Regueira, O; Rieder, MJ; Shah, RK; Vasylyeva, TL, 2013)	0.39
" The aim of this study was to establish the protective effects of taurine against cytotoxicity induced by isoniazid and its suspected toxic metabolite hydrazine in isolated rat hepatocytes by measuring reactive oxygen species (ROS) formation, lipid peroxidation, mitochondrial depolarisation, reduced glutathione (GSH), and oxidised glutathione (GSSG)."	( Cytoprotective effects of taurine against toxicity induced by isoniazid and hydrazine in isolated rat hepatocytes. Babaei, H; Eghbal, MA; Heidari, R, 2013)	0.39
" Taken collectively, these results indicate that pretreatment with NAC ameliorates (a) mitochondrial dysfunction linked to the depletion of ATP, MMP, and mitochondrial GSH level and (b) induction of oxidative stress assessed by reactive oxygen species generation, losses of intracellular GSH and protein thiol levels, and MDA formation caused by C60(OH)24, suggesting that the onset of toxic effects is at least partially attributable to a thiol redox-state imbalance as well as mitochondrial dysfunction related to oxidative phosphorylation."	( Effects of N-acetyl-L-cysteine on target sites of hydroxylated fullerene-induced cytotoxicity in isolated rat hepatocytes. Inomata, A; Nakae, D; Nakagawa, Y; Nakajima, K; Ogata, A; Suzuki, T, 2014)	0.4
" NAC reduced the adverse effects of α-CYP on lung tissues and improved the histological architecture of lung since it showed antioxidant, anti-inflammatory and antifibrotic effects on lung tissues."	( Ameliorative effect of N-acetyl cysteine on alpha-cypermethrin-induced pulmonary toxicity in male rats. Arafa, MH; Atteia, HH; Mohamed, DA, 2015)	0.42
"The aims of this study were to evaluate the effects of N-acetylcysteine (NAC) on cardiac remodeling and major adverse events following acute myocardial infarction (AMI)."	( Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. Broumand, MA; Darabi, F; Fahimi, F; Jenab, Y; Khalili, H; Salarifar, M; Talasaz, AH, 2014)	0.4
" Also, the patients were followed up for a 1-year period for major adverse cardiac events (MACE), including the occurrence of recurrent myocardial infarction, death, and need for target vessel revascularization."	( Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. Broumand, MA; Darabi, F; Fahimi, F; Jenab, Y; Khalili, H; Salarifar, M; Talasaz, AH, 2014)	0.4
"The toxic effect of urethane dimethacrylate (UDMA), a major dental resin monomer, on human dental pulp is not fully clear."	( Urethane dimethacrylate induces cytotoxicity and regulates cyclooxygenase-2, hemeoxygenase and carboxylesterase expression in human dental pulp cells. Chan, CP; Chang, HH; Chang, MC; Huang, GF; Jeng, JH; Lee, YL; Tseng, SK; Wang, HH; Wang, YL; Yeung, SY, 2014)	0.4
" We showed that MDMA metabolites exhibited toxicity to SH-SY5Y differentiated cells, being the GSH and NAC conjugates more toxic than their catecholic precursors and MDMA."	( "Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites. Barbosa, DJ; Bastos, ML; Branco, PS; Capela, JP; Carvalho, F; Fernandes, E; Ferreira, LM; Silva, R, 2014)	0.4
" The results indicated that the toxic effect produced by ACN on hUC‑MSCs is based on a redox mechanism."	( Cytotoxic effects of acrylonitrile on human umbilical cord mesenchymal stem cells in vitro. Lu, R; Ma, R; Sun, M; Sun, X; Xie, Y; Xu, W; Zhai, W; Zhu, W, 2014)	0.4
" No adverse drug effects were noted in either group."	( Hepatotoxicity in Obese Versus Nonobese Patients With Acetaminophen Poisoning Who Are Treated With Intravenous N-Acetylcysteine. Erstad, BL; Patanwala, AE; Radosevich, JJ, )	0.13
" It is treated with intravenous acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to concentration, which can cause treatment interruption."	( Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014)	0.4
" Specific and sensitive detection of liver injury is important for the prompt and safe treatment of patients with the antidote N-acetylcysteine (NAC) and for the determination of NAC efficacy."	( Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Antoine, DJ; Dear, JW, 2014)	0.4
"Ambient particulate matter (PM) is associated with adverse health effects."	( Airborne quinones induce cytotoxicity and DNA damage in human lung epithelial A549 cells: the role of reactive oxygen species. Jiang, Y; Li, Y; Lu, P; Shang, Y; Zhang, L, 2014)	0.4
" The NCP-cultured HepG2 cells showed higher expression of mRNA and protein levels of cytochrome P450 2E1, which metabolizes APAP to a toxic metabolite, APAP-cysteine adduct formation, and higher sensitivity against APAP-induced cell injury compared with conventionally cultured cells."	( Evaluation of three-dimensional cultured HepG2 cells in a nano culture plate system: an in vitro human model of acetaminophen hepatotoxicity. Abe, N; Aritomi, K; Irie, T; Irikura, M; Ishitsuka, Y; Kai, H; Shimizu, D; Shuto, T; Tomishima, Y, 2014)	0.4
" In the following study, the relationship of acylcarnitines with other known indicators of APAP toxicity was examined in children receiving low-dose (therapeutic) and high-dose ('overdose' or toxic ingestion) exposure to APAP."	( Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Beger, RD; Bhattacharyya, S; Gill, P; James, LP; Kearns, GL; Letzig, LG; Marshall, JD; Pence, L; Reed, MD; Simpson, PM; Sullivan, JE; Van Den Anker, JN; Yan, K, 2014)	0.4
" Some authors do not recommend treatment with N-acetylcysteine at low paracetamol plasma concentrations since unnecessary adverse effects may be induced."	( Recommendations for the paracetamol treatment nomogram and side effects of N-acetylcysteine. de Vries, I; Koppen, A; Meulenbelt, J; van Riel, A, 2014)	0.4
" NAC is found to be safe and effective in amikacin-related ototoxicity in patients with PD-related peritonitis."	( Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Aydemir, S; İlhan Sahin, M; Kocyigit, I; Oymak, O; Sipahioglu, MH; Tokgoz, B; Unal, A; Vural, A; Yazici, C; Yucel, HE, 2015)	0.42
" Taken together, our findings suggest that at the studied conditions NAC protects against 2,5-HD neurotoxicity and DMPN may be proposed as a new sensitive and specific biomarker of 2,5-HD neurotoxicity in animals treated with a toxic amount of 2,5-hexanedione."	( Role of N-acetylcysteine in protecting against 2,5-hexanedione neurotoxicity in a rat model: changes in urinary pyrroles levels and motor activity performance. Andrade, V; Batoréu, MC; dos Santos, AP; Gonçalves, LL; Mateus, ML; Torres, ME, 2014)	0.4
"Cisplatin is commonly used as a therapeutic agent, despite its known adverse side effects and the occurrence of drug resistance."	( Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells. Li, D; Li, Z; Liu, S; Wang, C; Wang, Y; Xu, Y; Yu, Y; Zeng, L; Zhang, L, 2015)	0.42
"Perfluorooctane sulfonate (PFOS) is an emerging persistent pollutant which shows multiple adverse health effects."	( Chronic exposure to perfluorooctane sulfonate induces behavior defects and neurotoxicity through oxidative damages, in vivo and in vitro. Chen, N; He, D; Li, D; Li, J; Yang, Y, 2014)	0.4
" This study examined the toxic effects of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and decabromodiphenyl ether (BDE-209) on the immune system by using peritoneal macrophages as the model."	( In vitro immune toxicity of polybrominated diphenyl ethers on murine peritoneal macrophages: apoptosis and immune cell dysfunction. Guo, LH; Lv, QY; Wan, B; Yang, Y; Zhao, L, 2015)	0.42
" These findings, coupled with the fact that astrocytes maintain neuronal integrity, suggest that compounds which target and mitigate these early toxic changes in astrocytes could have a potentially broad therapeutic role in cocaine-induced CNS damage."	( N-acetyl cysteine mitigates the acute effects of cocaine-induced toxicity in astroglia-like cells. Allen, JR; Badisa, RB; Davidson, MW; Fitch-Pye, CA; Goodman, CB; Haughbrook, RD; Kumar, SS; Mazzio, E, 2015)	0.42
" For more than a decade, a number of laboratories have investigated the use of antioxidants as a safe and effective adjunct to hearing conservation programs."	( Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing loss: a randomized clinical trial. Balough, B; Dreisbach, L; Fausti, S; Hammill, T; Jackson, R; Kopke, R; Lonsbury-Martin, B; Rabinowitz, P; Sanderson, A; Slade, MD; Torre, P, 2015)	0.42
" The present study evaluated the toxic effects and the possible underlying mechanism of Ag NPs on Pseudomonas putida."	( Toxic effect of environmentally relevant concentration of silver nanoparticles on environmentally beneficial bacterium Pseudomonas putida. Chandran, P; Ghouse, SS; Khan, SS, 2015)	0.42
" The results demonstrate that EUK-134 and NAC protect PMNs from the toxic effects of Zn and PQ in rats and also suggest that metallothioneins I/II might contribute to antioxidant defense under GSH depleted conditions."	( The manganese-salen compound EUK-134 and N-acetyl cysteine rescue from zinc- and paraquat-induced toxicity in rat polymorphonuclear leukocytes. Chauhan, AK; Kumar, A; Pandey, HP; Shukla, S; Singh, C; Singh, D, 2015)	0.42
"NAC is safe for NAI-ALF."	( Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials. Hu, J; Quan, Q; Ren, X; Sun, Z; Zhang, Q, 2015)	0.42
" These experimental results strongly indicate the protective effect of NAC alone with Se against toxic effects of lead on liver tissue."	( Lead acetate-induced hepatoxicity in Wistar rats: possible protective role of combination therapy. Jaswal, A; Raghuvanshi, S; Sharma, S; Shrivastava, S; Shukla, S, 2015)	0.42
" Taken collectively, these results indicate that incubation of rat hepatocytes with C60 (OH)24 elicits DNA damage, suggesting that nuclei as well as mitochondria are target sites of the hydroxylated fullerene; and induction of DNA damage and oxidative stress is ameliorated by an increase in cellular GSH levels, suggesting that the onset of toxic effects may be partially attributable to a thiol redox-state imbalance caused by C60 (OH)24 ."	( Comparative effects of sulfhydryl compounds on target organellae, nuclei and mitochondria, of hydroxylated fullerene-induced cytotoxicity in isolated rat hepatocytes. Inomata, A; Nakae, D; Nakagawa, Y; Ogata, A, 2015)	0.42
" However, significantly higher adverse reactions developed in the patients who were treated with NAC."	( A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Farsaei, S; Karimzadeh, I; Khalili, H; Sagheb, MM, 2015)	0.42
"Silver nanoparticles are toxic both in vitro and in vivo."	( Silver nanoparticles-induced cytotoxicity requires ERK activation in human bladder carcinoma cells. Castiglioni, S; Cazzaniga, A; Maier, JA; Perrotta, C, 2015)	0.42
" One notable exception is acetaminophen (APAP, paracetamol), which is a safe drug at therapeutic doses but can cause severe liver injury and acute liver failure after intentional and unintentional overdoses."	( Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients. Jaeschke, H, 2015)	0.42
" Occupational exposure to 1-BP is associated with adverse peripheral sensory, motor, and central nervous system (CNS) effects."	( Neurotoxicity associated with exposure to 1-bromopropane in golf-club cleansing workers. Deng, JF; Lin, KP; Tsai, WJ; Wang, CL; Wang, TH; Wu, ML; Wu, YH; Yang, CC, 2015)	0.42
" Occupational exposure to 1-BP may result in peripheral neuropathy as well as adverse CNS effects."	( Neurotoxicity associated with exposure to 1-bromopropane in golf-club cleansing workers. Deng, JF; Lin, KP; Tsai, WJ; Wang, CL; Wang, TH; Wu, ML; Wu, YH; Yang, CC, 2015)	0.42
"Treatment with the combination of GA and NAC was safe and well tolerated."	( Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis. Arnold, D; Constantin, M; Godin, J; GrandʼMaison, F; Levental, M; Melmed, C; Moore, F; Schipper, HM; Stril, JL; Su, H, )	0.13
" However, the individual toxic dynamics of diversified OPCs should not be overlooked and further studies with different OPCs are suggested."	( Efficacy of N-Acetylcysteine, Glutathione, and Ascorbic Acid in Acute Toxicity of Paraoxon to Wistar Rats: Survival Study. Adem, A; Kalasz, H; Nurulain, SM; Ojha, S; Shafiullah, M; Tekes, K, 2015)	0.42
" Its main side-effect is nephrotoxicity."	( Organic Anion Transporter 5 (Oat5) Urinary Excretion Is a Specific Biomarker of Kidney Injury: Evaluation of Urinary Excretion of Exosomal Oat5 after N-Acetylcysteine Prevention of Cisplatin Induced Nephrotoxicity. Anzai, N; Bulacio, RP; Ouchi, M; Torres, AM, 2015)	0.42
" Thus, toxic oral APAP doses sufficient to cause severe widespread liver damage do not cause significant damage when administered concurrently with equal amounts of NAC, that is, in the NAC-APAP treated animals, hepatic transaminases increase only marginally and liver architecture remains fully intact."	( Co-administration of N-Acetylcysteine and Acetaminophen Efficiently Blocks Acetaminophen Toxicity. Andrus, JP; Herzenberg, LA; Owumi, SE, 2015)	0.42
"Ototoxicity is a severe side effect of aminoglycoside antibiotics."	( A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Cox, H; Drobniewski, F; Elamin, WF; Ford, N; Kranzer, K; Seddon, JA, 2015)	0.42
" GSH and NAC treatment can reduce SM-induced toxic effects."	( Protective effects of the thiol compounds GSH and NAC against sulfur mustard toxicity in a human keratinocyte cell line. Balszuweit, F; Kehe, K; Menacher, G; Popp, T; Schmidt, A; Steinritz, D; Thiermann, H; Worek, F, 2016)	0.43
" It is safe at therapeutic doses, but its overdose can result in severe hepatotoxicity, a leading cause of drug-induced acute liver failure in the USA."	( N-acetylcysteine amide, a promising antidote for acetaminophen toxicity. Ercal, N; Hart, M; Khayyat, A; Tobwala, S, 2016)	0.43
"Oxidative stress (OS) is thought to play an important role in the pharmacological and toxic effects of various drugs of abuse."	( Cardiovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of Modulators of Oxidative Stress. Antonilli, L; Badiani, A; Grassi, MC; Graziani, M; Saso, L; Togna, AR, 2016)	0.43
" However, during disinfection, toxic disinfection byproducts (DBPs) are formed."	( Energy of the Lowest Unoccupied Molecular Orbital, Thiol Reactivity, and Toxicity of Three Monobrominated Water Disinfection Byproducts. Pals, JA; Plewa, MJ; Wagner, ED, 2016)	0.43
" It is considered to be safe when administered within its therapeutic range, but in cases of acute intoxication, hepatotoxicity can occur."	( Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity. Ghanem, CI; Manautou, JE; Mottino, AD; Pérez, MJ, 2016)	0.43
" In a cellular model, tamoxifen resistance was associated with increased sensitivity towards toxic dicarbonyls and reduced free sulfhydryl group content."	( Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative. Ignatov, A; Kalinski, T; Nass, N; Roessner, A; Sel, S, 2016)	0.43
"Under the conditions of this experiment, ACR may induce hepatic toxicity through the activation of NF-κB signaling pathway, and NAC could antagonize the hepatic toxicity of ACR by inhibiting the NF-κB signaling pathway, whereas the toxic effect of ACR on kidney needs to be further studied."	( [The antagonistic effect and mechanism of N-acetylcysteine on acrylamide-induced hepatic and renal toxicity]. Pan, X; Qi, J; Wang, D; Yan, D; Yan, H, 2016)	0.43
" The primary endpoint was assessment of adverse events, which were collected at each visit and for 28 days after the last dose of study drug."	( Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Albera, C; Beck, J; Behr, J; Bendstrup, E; Crestani, B; Günther, A; Koschel, D; Kreuter, M; Lin, CY; Olschewski, H; Sköld, CM; Wallaert, B; Wells, A; Wuyts, W, 2016)	0.43
" The occurrence of at least one adverse event (46 [77%] patients receiving acetylcysteine vs 50 [81%] receiving placebo), adverse events related to study treatment (17 [28%] vs 16 [26%]), and the number of patients experiencing severe adverse events (three [5%] vs two [3%]), life-threatening adverse events (one [2%] vs one [2%]), or death (one [2%] vs three [5%]) was similar between treatment groups."	( Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Albera, C; Beck, J; Behr, J; Bendstrup, E; Crestani, B; Günther, A; Koschel, D; Kreuter, M; Lin, CY; Olschewski, H; Sköld, CM; Wallaert, B; Wells, A; Wuyts, W, 2016)	0.43
"Zinc is both an essential and potentially toxic metal."	( Mechanistic studies of the toxicity of zinc gluconate in the olfactory neuronal cell line Odora. Choubey, D; Deepe, GS; Genter, MB; Hsieh, H; Shertzer, HG; Vignesh, KS, 2016)	0.43
" Cytotoxicity parameters, such as [3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT), neutral red uptake (NRU), and lactate dehydrogenase (LDH) release suggested that cobalt NPs were toxic to MCF-7 cells in a dose-dependent manner (50-200μg/ml)."	( Nanotoxicity of cobalt induced by oxidant generation and glutathione depletion in MCF-7 cells. Ahamed, M; Akhtar, MJ; Alhadlaq, HA; Alshamsan, A, 2017)	0.46
"To review the current literature and evaluate the effects of NAC supplementation on sport performance and the risk of adverse effects."	( Performance and Side Effects of Supplementation with N-Acetylcysteine: A Systematic Review and Meta-Analysis. Braakhuis, A; Rhodes, K, 2017)	0.46
"Diclofenac (DCF) adverse reactions involve diverse mechanisms in different models."	( N-acetylcysteine potentiates diclofenac toxicity in Saccharomyces cerevisiae: stronger potentiation in ABC transporter mutant strains. Abdel-Razzak, Z; Al-Attrache, H; Chamieh, H; Hamzé, M; Morel, I; Taha, S, 2018)	0.48
" On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin."	( TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC. Choi, YJ; Lee, J; Lee, YS; Park, WY; Seo, SW; Shim, DM, 2017)	0.46
"The dose-limiting toxic effect of cyclophosphamide (CY) is cardiotoxicity."	( Role of metabolites of cyclophosphamide in cardiotoxicity. Kawano, Y; Kurauchi, K; Miyahara, E; Nishikawa, T; Okamoto, Y, 2017)	0.46
" The antioxidant N-acetylcysteine (NAC) has been proposed as a therapeutic intervention for DMD boys, but potential adverse effects of NAC have not been widely investigated."	( Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy. Arthur, PG; Assan, EB; Grounds, MD; Pinniger, GJ; Terrill, JR, 2017)	0.46
" The toxic effects of 5-MAPB were greater than those of MDMA."	( Preventive effects of fructose and N-acetyl-L-cysteine against cytotoxicity induced by the psychoactive compounds N-methyl-5-(2-aminopropyl)benzofuran and 3,4-methylenedioxy-N-methamphetamine in isolated rat hepatocytes. Inomata, A; Nakagawa, Y; Suzuki, T, 2018)	0.48
" The blood-labyrinth barrier is somewhat permeable to cisplatin, and sensory hair cells and cochlear supporting cells are highly sensitive to this toxic drug."	( Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. Doolittle, ND; Dósa, E; Fu, R; Heltai, K; Kapocsi, J; Merkely, B; Molnár, G; Neuwelt, EA; Radovits, T; Tóth, GB; Urdang, Z, 2017)	0.46
"The toxic effect of CIPN might be attributed to either oxidative or severe inflammatory stress."	( N-acetylcysteine versus progesterone on the cisplatin-induced peripheral neurotoxicity. Abdel Fattah, S; Mohamed, EA; Motawie, AG; Zaki, SM, 2018)	0.48
" These investigations revealed that a highly toxic CP-derived hydrolysis product - the highly toxic monoaqua hydrolysis complex (MHC) - is formed within 5min."	( Improving the safety of metal-based drugs by tuning their metabolism with chemoprotective agents. Gailer, J, 2018)	0.48
"Acetylcysteine (NAC), an effective antidote for paracetamol poisoning, is commonly associated with adverse reactions."	( Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. Chandru, P; Gunja, N; Lim, JME; McNulty, R, 2018)	0.48
" We compared adverse reactions in patients receiving the modified two-bag protocol with a historical control (traditional three-bag regimen with initial bolus of 150 mg/kg/h)."	( Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. Chandru, P; Gunja, N; Lim, JME; McNulty, R, 2018)	0.48
" These results add to the accumulating evidence that reducing the initial NAC infusion rate reduces the risk of adverse reactions."	( Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. Chandru, P; Gunja, N; Lim, JME; McNulty, R, 2018)	0.48
" In conclusion, these results suggested that NAC combined with FA can ameliorate the toxic effect of ASP on the rat's cerebral cortex."	( The possible protective effect of N-acetyl-L-cysteine and folic acid in combination against aspartame-induced cerebral cortex neurotoxicity in adult male rats: a light and transmission electron microscopic study. Abd-Ellah, HF; Abou-Zeid, NRA; Nasr, NM, )	0.13
" Protective strategies aiming at counteracting this important side effect have a crucial clinical impact."	( Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma. Berruti, A; Bianchi, S; Consoli, F; Cosentini, D; Ferrari, VD; Grisanti, S; Lazzari, B; Roca, E; Tovazzi, V, 2018)	0.48
" N-acetylcysteine prevented the toxic effects of its on fetal brain (p < 0."	( Acrylamide applied during pregnancy causes the neurotoxic effect by lowering BDNF levels in the fetal brain. Altinoz, E; Arif Aladag, M; Bag, HG; Demirtas, S; Erdemli, ME; Turkoz, Y; Yigitcan, B, )	0.13
"Our study indicated that acrylamide has toxic effects in the fetal brain and N-acetylcysteine prevents its toxic effect."	( Acrylamide applied during pregnancy causes the neurotoxic effect by lowering BDNF levels in the fetal brain. Altinoz, E; Arif Aladag, M; Bag, HG; Demirtas, S; Erdemli, ME; Turkoz, Y; Yigitcan, B, )	0.13
" Our results help to elucidate the development mechanisms of RD-induced leukoderma and provide information for innovation of safe skin-whitening compounds."	( 4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress. Goto, N; Ito, S; Masaki, T; Nagai, H; Nishigori, C; Tsujimoto, M; Wakamatsu, K, 2018)	0.48
" Here, we show that N-acetylcysteine prevents ketamine's adverse effects on development and monoaminergic neurons in zebrafish embryos."	( N-acetylcysteine prevents ketamine-induced adverse effects on development, heart rate and monoaminergic neurons in zebrafish. Dumas, M; Gu, Q; Kanungo, J; Robinson, B, 2018)	0.48
" Although CYP has been shown to pose toxic effects in some immune cells, as of now the immunotoxicity of CYP on immune progenitor cells has not been well studied."	( β-Cypermethrin and its metabolite 3-phenoxybenzoic acid induce cytotoxicity and block granulocytic cell differentiation in HL-60 cells. Fu, Z; He, B; Jin, Y; Kong, B; Wang, X; Wei, L; Xie, X, 2018)	0.48
" The most common side effect of cisplatin is ototoxicity."	( Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial. Ahmadi, A; Daneshi, A; Sarafraz, Z, 2018)	0.48
"Transtympanic injections of N-acetylcysteineas a safe and inexpensive antioxidant agent seem to be an effective otoprotective strategy for the prevention of cisplatin-induced ototoxicity and for increasing the quality of life, especially in children."	( Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial. Ahmadi, A; Daneshi, A; Sarafraz, Z, 2018)	0.48
"Toxicity arising from toxic disinfection byproducts is an unintended result of disinfection during water reclamation."	( The impact of disinfection Ct values on cytotoxicity of agricultural wastewaters: Ozonation vs. chlorination. Dong, S; Massalha, N; Nguyen, TH; Plewa, MJ, 2018)	0.48
" This study provides important implications for understanding the potential toxic effects of GW1, RW1 and RCF2 exposure; it also indicates that NAC may prevent respiratory diseases induced by exposure to MMMFs."	( N-acetylcysteine prevents cytotoxic effects induced by man-made mineral fibers in a human bronchial epithelial cell line. Chen, J; Chen, K; Ju, L; Xia, H; Xiao, Y; Yu, M; Zhang, M; Zhao, J; Zhu, L, 2018)	0.48
"This study aimed at determining the toxic potential of rGO-Ag nanocomposite on human liver normal (CHANG) and cancer (HepG2) cells."	( Silver-doped graphene oxide nanocomposite triggers cytotoxicity and apoptosis in human hepatic normal and carcinoma cells. Alarifi, S; Ali, D; Alkahtani, S; Almeer, RS, 2018)	0.48
"This result provides a basic comparative toxic effect of rGO-Ag nanocomposite on hepatic normal and cancerous liver cells."	( Silver-doped graphene oxide nanocomposite triggers cytotoxicity and apoptosis in human hepatic normal and carcinoma cells. Alarifi, S; Ali, D; Alkahtani, S; Almeer, RS, 2018)	0.48
"Although antibiotics are generally well tolerated, their toxic effects on the central nervous system have been gained attention."	( Different influences on mitochondrial function, oxidative stress and cytotoxicity of antibiotics on primary human neuron and cell lines. Meng, X; Song, L; Xiao, Y; Xiao, Z; Xiong, T; Yu, D, 2019)	0.51
" This regimen was introduced in the 1970s and has remained largely unchanged even though the initial NAC infusion is frequently associated with adverse reactions, in particular nausea, vomiting, and anaphylactoid reactions."	( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi Dear, J, 2019)	0.51
" This study will provide valuable data regarding the incidence of adverse events caused by the 12-h NAC plus PP100-01 regimen and may provide evidence of PP100-01 efficacy in the treatment of paracetamol-induced liver injury."	( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi Dear, J, 2019)	0.51
"Mercury (Hg) and cadmium (Cd) are the major toxic heavy metals and are known to induce neurotoxicity."	( Comparative analysis of in vitro neurotoxicity of methylmercury, mercury, cadmium, and hydrogen peroxide on SH-SY5Y cells. Miyamoto, A; Shiraishi, M; Sudo, K; VAN Dao, C, 2019)	0.51
" Moreover, cotreatment with an autophagy agonist, rapamycin (RAPA), partially blocked mitochondrial dysfunction and oxidative stress in the two cell types, whereas cotreatment with an autophagy inhibitor, 3-methyladenine (3-MA), augmented the abovementioned toxic effects."	( Autophagy protects murine macrophages from β-cypermethrin-induced mitochondrial dysfunction and cytotoxicity via the reduction of oxidation stress. Fu, Z; He, B; Jin, Y; Kong, B; Wang, X; Wei, L; Zhu, J, 2019)	0.51
" The frequency of adverse events (AEs) was also investigated."	( Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Calzetta, L; Cazzola, M; Matera, MG; Page, C; Puxeddu, E; Rogliani, P, 2019)	0.51
" Adverse events are monitored at each weekly assessment."	( A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence. Arunogiri, S; Baker, AL; Bathish, R; Berk, M; Carter, G; Cordaro, F; Dean, OM; Dietze, P; Higgs, P; Hill, H; Kelly, PJ; Kent, M; Liang, W; Lubman, DI; Manning, V; McKetin, R; Quinn, B; Raftery, D; Reid, D; Sinclair, B; Te Pas, N; Thomas, T; Turner, A, 2019)	0.51
" Primary endpoints: all participants experienced ≥1 adverse event (AE), most commonly gastrointestinal."	( Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). Black, P; Dear, JW; Gallagher, B; Grahamslaw, J; Henriksen, D; Lee, RJ; Morrison, EE; O'Brien, R; Oatey, K; Oosthuyzen, W; Weir, CJ, 2019)	0.51
"Acetaminophen-protein adducts are specific biomarkers of toxic acetaminophen (paracetamol) metabolite exposure."	( Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5). Buckley, NA; Chan, BSH; Chiew, AL; Isbister, GK; James, LP; McArdle, K; Pickering, JW, 2020)	0.56
" This study examined a new biomarker of acetaminophen toxicity, which measures the amount of toxic metabolite exposure called acetaminophen-protein adduct."	( Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5). Buckley, NA; Chan, BSH; Chiew, AL; Isbister, GK; James, LP; McArdle, K; Pickering, JW, 2020)	0.56
"Cryptococcosis is a life-threatening fungal infection, and its current treatment is toxic and subject to resistance."	( N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis. Carmo, PHF; Carvalho, VSD; Costa, MC; de Brito, CB; de Resende-Stoianoff, MA; de Souza, DG; Emídio, ECP; Ferreira, GF; Freitas, GJC; Holanda, RA; Magalhães, TFF; Paixão, TA; Ribeiro, NQ; Rocha, CEV; Santos, DA, 2020)	0.56
" The aim of this study was to investigate whether the Neo Acetamiprid (Ace) and one of its commercial formulations (Ace CF) display toxic features to a human first trimester trophoblast cell line."	( Trophoblast toxicity of the neonicotinoid insecticide acetamiprid and an acetamiprid-based formulation. Bustos, PS; Gomez, SD; Guiñazú, N; Ortega, MG; Sánchez, VG, 2020)	0.56
" In this article, we review recent pharmacological and toxicological findings about APAP from basic, clinical, and epidemiological studies, including spontaneous drug adverse events reporting system, especially focusing on drug-induced asthma and pre-and post-natal closure of ductus arteriosus."	( Toxicological Property of Acetaminophen: The Dark Side of a Safe Antipyretic/Analgesic Drug? Ishitsuka, Y; Kadowaki, D; Kondo, Y, 2020)	0.56
" Neuropathy severity was assessed after eight courses of chemotherapy based on National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE) criteria neuropathy grading scale and also sensory and motor electrophysiological assessment was performed by a neurologist."	( Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial. Allahyari, A; Barri, A; Bondad, N; Boostani, R; Elyasi, S, 2020)	0.56
" However, cyclophosphamide may lead to toxic side effects on the bladder, namely hemorrhagic cystitis, which can cause hematuria, and, potentially, bladder cancer."	( Quantification of 3-Hydroxypropyl Mercapturic Acid in the Urine of Patients with Breast Cancer to Monitor Cyclophosphamide Toxicity. Harahap, Y; Melhan, M; Muhammad, C; Purwanto, DJ; Yanuar, A, 2020)	0.56
" These adverse outcomes can be attenuated by the antioxidant N-acetyl-L-cysteine (NAC), suggesting that oxidative stress is involved in BPAF-induced cardiotoxicity."	( Oxidative stress in bisphenol AF-induced cardiotoxicity in zebrafish and the protective role of N-acetyl N-cysteine. Fan, D; Gu, A; Gu, J; Ji, G; Shi, L; Wang, H; Zhou, L, 2020)	0.56
" First and second groups served as normal and toxic control were given distilled water 6 ml/ kg while third, fourth and fifth experimental groups were given N-acetylcysteine (300 mg/ kg), prazosin (0."	( Hepatoprotective Effect Of Prazosin Is Comparable To N-Acetylcysteine In Acetaminophen Induced Hepatotoxicity In Mice. Chiragh, S; Hussain, M; Shad, MN; Sulaiman, S, )	0.13
" We hypothesized that administrating of N-acetylcysteine (NAC) prevents serious adverse events including cardiac complications in TDT patients by reducing systemic oxidative stress and balancing cardiac sympathovagal control."	( N-acetylcysteine Restored Heart Rate Variability and Prevented Serious Adverse Events in Transfusion-dependent Thalassemia Patients: a Double-blind Single Center Randomized Controlled Trial. Chattipakorn, N; Chattipakorn, SC; Pattanakuhar, S; Phrommintikul, A; Srichairattanakool, S; Tantiworawit, A, 2020)	0.56
" Adverse event rates were similar in the two arms."	( Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study). Amaral, EP; Andrade, BB; Beraldi-Magalhães, F; Cordeiro-Santos, M; Costa, AA; Gomes, RS; Jesus, JS; Lacerda, MVG; Monteiro, WM; Neves, CP; Praia Marins, AF; Printes, VS; Rebelo Rabelo, AL; Safe, IP; Sampaio, VS; Souza, AB; Tavares, MA, 2020)	0.56
"5 mM did not have any adverse effects on the expression of tyrosine hydroxylase in the noradrenergic neurons of the arch-associated cluster (AAC) located near the heart."	( N-acetylcysteine prevents verapamil-induced cardiotoxicity with no effect on the noradrenergic arch-associated neurons in zebrafish. Gu, Q; Kanungo, J; Robinson, B; Rodgers, J, 2020)	0.56
"Anaphylactoid reactions are well-documented adverse events associated with the intravenous administration of N-acetylcysteine (NAC) in patients with acetaminophen overdose."	( A Case Report of a Severe, Unusually Delayed Anaphylactoid Reaction to Intravenous N-Acetylcysteine During Treatment of Acute Acetaminophen Toxicity in an Adolescent. Cao, DJ; Epperson, LC; Weiss, ST, 2021)	0.62
"Fomepizole (4-methylpyrazole) is safe and has shown efficacy in preclinical models, human hepatocytes and in volunteers against APAP overdose."	( Novel strategies for the treatment of acetaminophen hepatotoxicity. Akakpo, JY; Jaeschke, H; Ramachandran, A, 2020)	0.56
" Adverse event (AE) data were collected throughout the study."	( Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. Di Stefano, AFD; Papi, A; Radicioni, M, 2021)	0.62
" Mechanisms behind these adverse effects are complex and not fully understood."	( Could N-acetylcysteine improve the safety of clozapine? Alexandre, J; Chrétien, B; Dolladille, C; Fedrizzi, S; Lelong-Boulouard, V; Sassier, M, 2021)	0.62
" The aim of this review was to evaluate the adverse effects profile of NAC at higher than the standard dose in chronic respiratory diseases to establish a risk-benefit ratio in increasing the daily dose; therefore, studies using NAC at a dose of at least 600 mg/day were selected."	( Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Calverley, P; Papi, A; Rogliani, P, 2021)	0.62
" Therefore, it is important to strengthen the antioxidant system in aquatic organisms and to protect the organisms against these toxic chemicals."	( Treatment of oxidative stress, apoptosis, and DNA injury with N-acetylcysteine at simulative pesticide toxicity in fish. Alak, G; Atamanalp, M; Çilingir Yeltekin, A; Keleş, MS; Özgeriş, FB; Parlak, V; Ucar, A, 2021)	0.62
" However, its clinical application is very limited due to its severe toxic effects."	( Possible protective activity of n-acetyl cysteine against cisplatin‑induced hepatotoxicity in rats. Büyük, B; Coşkun, Ö; Öztopuz, Ö, 2021)	0.62
" Due to adverse events being inconsistently reported, no conclusion could be made regarding safety of N-acetylcysteine in chronic pain."	( Efficacy and Safety of N-Acetylcysteine for the Management of Chronic Pain in Adults: A Systematic Review and Meta-Analysis. Gilron, I; Khan, JS; Mohiuddin, M; Pivetta, B, 2021)	0.62
"Exposure to the industrial solvent trichloroethylene (TCE) has been associated with adverse pregnancy outcomes in humans and decreased fetal weight in rats."	( N-Acetyl-L-cysteine and aminooxyacetic acid differentially modulate trichloroethylene reproductive toxicity via metabolism in Wistar rats. Bergin, IL; Bjork, F; Lash, LH; Loch-Caruso, R; Su, AL, 2021)	0.62
"Perfluorooctanoic acid is a synthetic perfluoroalkyl-persistent in the environment and toxic to humans."	( N-acetyl cysteine co-treatment abates perfluorooctanoic acid-induced reproductive toxicity in male rats. Akomolafe, AP; Imosemi, IO; Odunola, OA; Owumi, SE; Oyelere, AK, 2021)	0.62
"Acetaminophen is a commonly used analgesic and antipyretic, with the potential to cause significant injury when ingested in toxic amounts."	( Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used? Akpunonu, P; Bailey, AM; Baum, RA; Geraghty, L; Howell, MM; Mohan, S; Su, MK; Weant, KA; Webb, AN; Woolum, JA, 2021)	0.62
" Secondary endpoints included number of drug-related adverse events, occurrence of hepatotoxicity, cumulative NAC dose, regimen cost, length of hospital and intensive care unit stays, and in-hospital mortality."	( Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used? Akpunonu, P; Bailey, AM; Baum, RA; Geraghty, L; Howell, MM; Mohan, S; Su, MK; Weant, KA; Webb, AN; Woolum, JA, 2021)	0.62
"Treatment of hematologic malignancies is a formidable challenge for hematologists and there is an urgent need to identify safe and efficacious agents either via synthesis in the laboratory or isolation from natural products."	( Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway. Cabrera, EC; Chakrabarti, S; Dhillon, B; Dulay, RM; Kalaw, SP; Li, Y; Reyes, RG; Valdez, BC, 2021)	0.62
"Current available therapies for pancreatic ductal adenocarcinoma (PDAC) provide minimal overall survival benefits and cause severe adverse effects."	( Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK, 2021)	0.62
" Although cadmium exposure leads to the dysfunction of various organs, the underlying mechanisms of the toxic effects of cadmium in vivo are still largely unknown."	( N-acetylcysteine restores the cadmium toxicity of Caenorhabditis elegans. Hirota, K; Matsuoka, M, 2021)	0.62
" EMPA and NHD can constrain oxidative stress liberation, inflammatory mediators proliferation, and apoptotic reactions in the renal tissue, which may be promising for further clinical applications to protect against MTX-induced renal injury or at least to reduce its adverse effects."	( Empagliﬂozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats. Abo-Youssef, AM; Hassan, MIA; Hemeida, RAM; Osman, AT; Sharkawi, SMZ, 2021)	0.62
" Cisplatin is the most important and highly effective chemotherapeutic agent used for the treatment of various solid tumors; however, it is associated with dose-dependent adverse effects, particularly in the kidney where it can cause severe nephrotoxicity."	( Necrostatins regulate apoptosis, necroptosis, and inflammation in cisplatin-induced nephrotoxicity in LLC-PK1 cells. Kim, DW; Lee, D; Lee, H; Lim Lee, H; Sung Kang, K; Wook Lee, J; Yamabe, N, 2021)	0.62
" Safety outcomes included adverse events and standard laboratory assessments."	( Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. Baum, SJ; Chakravarthy, MV; Chera, H; Gunn, NT; Harrison, SA; Kohli, A; Koziel, MJ; Patil, R; Younes, ZH; Zhao, J, 2021)	0.62
" Study products were safe and well tolerated with stable lipid and weight profiles."	( Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. Baum, SJ; Chakravarthy, MV; Chera, H; Gunn, NT; Harrison, SA; Kohli, A; Koziel, MJ; Patil, R; Younes, ZH; Zhao, J, 2021)	0.62
" Safety was assessed by adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72
" DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5."	( Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Korolkiewicz, RP; Mallmann, P; Melichar, B; Minar, L; Novotny, Z; Pluta, M; Rob, L; Spacek, J; Spisek, R; Valha, P, 2022)	0.72
"Acetaminophen (APAP) is one of the popular and safe pain medications worldwide."	( Acetaminophen-Induced Nephrotoxicity: Suppression of Apoptosis and Endoplasmic Reticulum Stress Using Boric Acid. Aytuğ, H; Çoban, FK; Demirel, HH; İnce, S; İslam, İ, 2023)	0.91
" We identified a mechanism by which acetaminophen overdose causes an increase in bile acid concentrations (to above toxic thresholds) in hepatocytes."	( Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. Akakpo, JY; Begher-Tibbe, B; Brackhagen, L; Brecklinghaus, T; Canbay, A; Copple, IM; Curry, SC; Friebel, A; Ghallab, A; Goldring, C; González, D; Hassan, R; Hengstler, JG; Hobloss, Z; Hoehme, S; Hofmann, U; Jaeschke, H; Kappenberg, F; Longerich, T; Luedde, T; Marchan, R; Murad, W; Myllys, M; Olyaee, M; Overbeck, N; Rahnenführer, J; Reinders, J; Schreiter, T; Seddek, AL; Sezgin, S; Sowa, JP; Trauner, M; Urban, S; Vucur, M; Zühlke, S, 2022)	0.72
"Intratympanic NAC administration is an efficient and safe means of preventing cisplatin-induced ototoxicity."	( Optimal N-acetylcysteine concentration for intratympanic injection to prevent cisplatin-induced ototoxicity in guinea pigs. Chen, BC; Hsu, WC; Lee, CF; Lin, LJ; Lin, YC, 2022)	0.72
" The use of oral NAC and PTX added to the therapeutic efficacy of topical clobetasol in the treatment of LPP, suggesting that they might be beneficial and safe adjuvant therapies and add to the efficacy of topical treatment without any noticeable impact on the adverse effects experienced by patients."	( Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: A triple arm blinded randomized controlled trial. Ahmadi Kahjoogh, H; Behrangi, E; Goodarzi, A; Hejazi, P; Roohaninasab, M; Yazdanian, N, 2022)	0.72
"There is an urgent need for development of drugs that are able to reverse the adverse effects of opioids on breathing and arterial blood-gas (ABG) chemistry while preserving opioid analgesia."	( L-NAC reverses of the adverse effects of fentanyl infusion on ventilation and blood-gas chemistry. Baby, SM; Bates, JN; Gaston, B; Getsy, PM; Hsieh, YH; Lewis, SJ; Lewis, THJ; May, WJ, 2022)	0.72
"Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF)."	( Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. Aithal, GP; Alvarez-Alvarez, I; Andrade, RJ; Arikan, C; Atallah, E; Lucena, MI; Medina-Caliz, I; Niu, H, 2022)	0.72
"ZnO NPs had toxic effects on the ovary of female mice, which were due to oxidative stress, ER stress, and the eventual activation of apoptosis."	( Zinc Oxide Particles Can Cause Ovarian Toxicity by Oxidative Stress in Female Mice Model. Chen, L; Feng, Y; Fu, F; Liu, S; Lv, S; Wang, W; Xu, H; Xu, Y; Zhao, Y, 2022)	0.72
"Acetaminophen (APAP), a widely used antipyretic and analgesic drug in clinics, is relatively safe at therapeutic doses; however, APAP overdose may lead to fatal acute liver injury."	( The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets. Huang, L; Luo, G; Zhang, Z, 2023)	0.91
"Hexavalent chromium Cr (VI) is a primary human carcinogen with damaging toxic effects on multiple organs."	( Role of NF-κB signaling pathway in hexavalent chromium-induced hepatotoxicity. Fu, G; Gao, Y; Huang, H; Jin, L; Kom, MC; Shen, J; Tang, Y; Xie, Y; Yan, J, 2023)	0.91
" Secondary outcomes included the requirement of renal replacement therapy, all-cause mortality, serious adverse events, and length of hospital stay."	( Efficacy and safety of N-acetylcysteine for preventing post-intravenous contrast acute kidney injury in patients with kidney impairment: a systematic review and meta-analysis. Bacaicoa, MC; Erviti, J; Gómez, H; Gutiérrez-Valencia, M; Leache, L; Maestro, C; Saiz, LC, 2023)	0.91
"Paracetamol is widely available and yet is substantially more toxic than other analgesics available without prescription."	( Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease. Buckley, NA; Cairns, R; Chidiac, AS; Noghrehchi, F, )	0.13
"Cadmium is a major environmental pollutant and a highly toxic metal."	( Pomegranate peel extract, N-Acetylcysteine and their combination with Ornipural alleviate Cadmium-induced toxicity in rats. Demirbas, A; Dik, B; Gungor, H; Korkmaz, Y, 2023)	0.91
" S-(1,2-Dichlorovinyl)-L-cysteine (DCVC) is a metabolite of TCE formed downstream in TCE glutathione (GSH) conjugation and is upstream of several toxic metabolites."	( N-Acetyl-L-cysteine and aminooxyacetic acid differentially modulate toxicity of the trichloroethylene metabolite S-(1,2-dichlorovinyl)-L-cysteine in human placental villous trophoblast BeWo cells. Lash, LH; Loch-Caruso, R; Su, AL, 2023)	0.91
"Drug induced liver injury (DILI) is a serious adverse effect caused by first-line anti-TB (ATT) drugs, limiting the TB-treatment."	( A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Abid Ali, M; Paramjyothi, GK; Sireesha, K; Subbalaxmi, MVS; Sukumaran, D; Usharani, P, 2023)	0.91
" Adverse Drug Reactions (ADRs) were monitored at every visit."	( A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Abid Ali, M; Paramjyothi, GK; Sireesha, K; Subbalaxmi, MVS; Sukumaran, D; Usharani, P, 2023)	0.91
" No clinically problematic adverse events were observed at any AC concentration, and we recommended AC gel at a concentration of 10%."	( Efficacy and safety of topical acetylcysteine combined with the use of an overcurvature-correcting device in patients with pincer nail deformity: a randomized, vehicle-controlled, investigator-blinded study. Fujikawa, A; Ikoma, A; Saito, M; Tanaka, K, 2023)	0.91
"25% NAC with ciprofloxacin and dexamethasone is safe in guinea pigs and support its potential use in the treatment of chronically discharging ears."	( Otologic safety of intratympanic N-acetylcysteine in an animal model. Chan, CY; Conley, SF; Daniel, SJ; Grenier, K; Linn, DT; Partain, MP; Salameh, S; Sayegh, J; Wurzba, SDS, 2023)	0.91
" N-acetyl cysteine (NAC) is a safe and inexpensive antioxidant that has been studied as an otoprotective alternative."	( [Efficacy of intratympanic infiltration of N-acetyl cysteine in cisplatin ototoxicity]. Fernández-Hernández, JP; Olea-González, AI; Rosas-Gutiérrez, GDC, 2023)	0.91

Excerpt	Reference	Relevance
" The elimination half-life ranged from 70."	( Pharmacokinetics of loracarbef and interaction with acetylcysteine. Boeckh, M; Deppermann, KM; Koeppe, P; Lode, H; Roller, S; Stelzer, I, 1992)	0.28
" Pharmacokinetic information is not available as to whether or not N-acetylcysteine crosses the blood-brain barrier or placenta, or into breast milk."	( Clinical pharmacokinetics of N-acetylcysteine. Holdiness, MR, 1991)	0.28
" No differences in the pharmacokinetic parameters were observed in comparison with the single 600 mg dose."	( Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Borgström, L; Kågedal, B, 1990)	0.28
" As indexes of bioavailability Cmax' tmax and AUC of NAC plasma concentrations were considered and MRT was taken as an estimate of its persistence in plasma."	( Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Costa, R; De Caro, L; Ghizzi, A; Lodola, E; Longo, A; Ventresca, GP, 1989)	0.28
" Pharmacokinetic results on BIU conjugation are described in the accompanying paper."	( alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. I. (Bio-) synthesis, analysis and identification of diastereomeric glutathione conjugates and mercapturates. Brussee, J; Mulder, GJ; Olde Boerrigter, JC; te Koppele, JM; van der Gen, A; van der Greef, J; van der Mark, EJ, 1986)	0.27
"The effects of N-acetylcysteine (NAC) on the pharmacokinetic parameters of acetaminophen (AP) in adult female beagles were studied."	( Effect of antidotal N-acetylcysteine on the pharmacokinetics of acetaminophen in dogs. Mohammad, FK; St Omer, VE, 1984)	0.27
" The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr."	( Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Collins, JM; Greene, RF; Jenkins, JF; Myers, CE; Speyer, JL, 1983)	0.27
" Little is known of NAC's pharmacokinetic properties in patients with cirrhosis."	( Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Hayes, PC; Jarvie, DR; Jones, AL; Prescott, LF; Simpson, D, 1997)	0.3
" Pharmacokinetic parameters of DDTC following intravenous administration of AC-DDTC (20 mg/kg) were calculated."	( Metabolism and pharmacokinetics of S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine in rats. Lee, BH; Park, J; Ryu, JC; Song, YS, 1994)	0.29
"Although the in vitro activity of the tested drugs evaluated by time-kill curves seemed comparable, some pharmacokinetic and pharmacodynamic characteristics of TGA contribute to improving the resolution of the infective process."	( Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. De Vecchi, E; Drago, L; Fassina, MC; Gismondo, MR; Lombardi, A; Mombelli, B, )	0.13
" The objective was to study toxicity and the modulation of pharmacodynamic end points."	( Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Bolanowska-Higdon, W; Creaven, PJ; Hitt, S; Lawrence, D; Murphy, M; Pendyala, L; Schwartz, G; Zdanowicz, J, 2001)	0.31
" However, this in vitro concentration of NAC needed to be compared to those used in human pharmacokinetic studies since the in vitro pharmacological effect of a compound is achieved at concentrations exceeding those used in clinical."	( Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations. Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Pharmacokinetic analysis revealed significantly prolonged acetaminophen absorption and a second peak acetaminophen concentration of 228 microg/mL approximately 48 hours postingestion."	( Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW, 2008)	0.35
" The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure."	( Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Capparelli, E; Davern, TJ; Hinson, JA; James, LP; Lee, WM; Letzig, L; Roberts, DW; Simpson, PM, 2009)	0.35
" However, NAC clearance was reduced by 90% in ESRD, leading to a 7-fold larger AUC and 13-fold longer half-life compared with healthy control subjects."	( Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Himmelfarb, J; McMenamin, ME; Nolin, TD; Ouseph, R; Ward, RA, 2010)	0.36
" Pharmacokinetic analysis of ICG demonstrated that the total body clearance (Cl(T)) of ICG was significantly decreased and the mean residence time (MRT) was significantly increased in the APAP mice compared to the saline mice."	( Indocyanine green clearance varies as a function of N-acetylcysteine treatment in a murine model of acetaminophen toxicity. Abdel-Rahman, SM; Brown, A; Hinson, JA; James, LP; Letzig, L; McCullough, SS; Milesi-Hallé, A, 2011)	0.37
" Data were analyzed via compartmental and noncompartmental pharmacokinetic analysis."	( Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. Buur, JL; Diniz, PP; KuKanich, B; Roderick, KV; Tegzes, JH, 2013)	0.39
"The safety and pharmacokinetic profile of liposomal formulations containing combinations of the antioxidants α-tocopherol, γ-tocopherol or N-acetylcysteine in beagle dogs was examined."	( Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol or γ-tocopherol in beagle dogs. Alipour, M; Bolger, G; Mitsopoulos, P; Pucaj, K; Smith, MG; Suntres, ZE, 2013)	0.39
" The present study was to investigate the effects of giving N-acetylcysteine (NAC) alone and in combination with either glycyrrhizin (GL), silibinin (SIB) or spironolactone (SL) on the plasma pharmacokinetic (PK) profiles, hepatic exposure, biliary excretion and urinary excretion of acetaminophen (APAP) and its major metabolite, acetaminophen glucuronide (AG)."	( Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat. Liu, X; Wang, Q; Xu, R; Yang, J; Zang, M; Zhang, J, 2014)	0.4
" A model based on pharmacokinetic parameters was developed to predict 4-h acetaminophen concentration for this and other ingested doses."	( Four-hour acetaminophen concentration estimation after ingested dose based on pharmacokinetic models. Gosselin, S; Villeneuve, E; Whyte, I, 2014)	0.4
" A population pharmacokinetic-pharmacodynamic model describing the pharmacodynamic effects of paracetamol and NAC on the INR was developed in Phoenix NLME."	( Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. Buckley, NA; Medlicott, NJ; Owens, KH; Reith, DM; Whyte, IM; Zacharias, M, 2015)	0.42
" Pharmacokinetic analysis showed a rapid uptake and complete metabolism of AITC following oral administration to rats."	( Pharmacokinetics, Tissue Distribution, and Anti-Lipogenic/Adipogenic Effects of Allyl-Isothiocyanate Metabolites. Ahn, J; Chung, WJ; Ha, TY; Jang, YJ; Jung, CH; Kim, YJ; Lee, DH; Moon, JH; Seong, KS, 2015)	0.42
" Although antidote, acetylcysteine, is potentially extracted by renal replacement therapies, pharmacokinetic data are lacking to guide potential dosing alterations."	( The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Hernandez, SH; Hoffman, RS; Howland, M; Schiano, TD, 2015)	0.42
" Alterations in pharmacokinetics were determined by applying standard pharmacokinetic equations."	( The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Hernandez, SH; Hoffman, RS; Howland, M; Schiano, TD, 2015)	0.42
"This pharmacokinetic simulation study is an important step in determining plasma acetylcysteine concentrations that are likely to be achieved using various modified treatment regimens."	( Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning. Graudins, A; Landersdorfer, C; Wong, A, 2017)	0.46
" It has emerged as a promising thiol antioxidant for multiple indications; however, the pharmacokinetic property is yet unclear due to lack of an accurate quantification method."	( Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. Ginman, T; Hassan, M; He, R; Norgren, S; Ottosson, H; Zhao, Y; Zheng, W, 2020)	0.56
" After five days of maintenance on the target dose, subjects completed overnight inpatient experimental sessions in which the pharmacodynamic effects of alcohol were determined."	( Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol. Hays, LR; Lile, JA; Rayapati, AO; Rush, CR; Stoops, WW; Strickland, JC, 2020)	0.56
" Pharmacokinetic characteristics of NAC were similar in the two cohorts."	( Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. Di Stefano, AFD; Papi, A; Radicioni, M, 2021)	0.62
"The pharmacokinetic characteristics of NAC are similar in healthy Chinese and Caucasian individuals after single and repeated administration."	( Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. Di Stefano, AFD; Papi, A; Radicioni, M, 2021)	0.62
" However, an understanding of the pharmacokinetic characteristics of intravenous NAC dosing in these patients is limited."	( Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. Basso, LM; Brundage, RC; Cloyd, JC; Coles, LD; Kartha, RV; Mishra, U; Ng, M; Orchard, PJ; Sahasrabudhe, SA, 2021)	0.62
" However, Pinnatifolone A pharmacokinetic and metabolites analysis investigations in male and female rats, as well as its in vitro stability in male and female rat liver microsomes, have not been evaluated and compared."	( Gender differences pharmacokinetics, bioavailability, hepatic metabolism and metabolism studies of Pinnatifolone A, a sesquiterpenoid compound, in rats by LC-MS/MS and UHPLC-Q-TOF-MS/MS. Cai, D; Feng, Y; Li, Z; Ouyang, H; Peng, W; Yang, S; Yi, X; Yue Jeff Zhang, J; Zhong, G, 2023)	0.91
"To investigate preclinical pharmacokinetic and metabolite in both genders, confirm gender differences, and provide usable information for the development of clinical applications."	( Gender differences pharmacokinetics, bioavailability, hepatic metabolism and metabolism studies of Pinnatifolone A, a sesquiterpenoid compound, in rats by LC-MS/MS and UHPLC-Q-TOF-MS/MS. Cai, D; Feng, Y; Li, Z; Ouyang, H; Peng, W; Yang, S; Yi, X; Yue Jeff Zhang, J; Zhong, G, 2023)	0.91
" The findings provide a comprehensive overview for further understanding of the pharmacokinetic and metabolic characteristics of Pinnatifolone A and serve as a guide for its future development and utilization."	( Gender differences pharmacokinetics, bioavailability, hepatic metabolism and metabolism studies of Pinnatifolone A, a sesquiterpenoid compound, in rats by LC-MS/MS and UHPLC-Q-TOF-MS/MS. Cai, D; Feng, Y; Li, Z; Ouyang, H; Peng, W; Yang, S; Yi, X; Yue Jeff Zhang, J; Zhong, G, 2023)	0.91
"The study was designed to evaluate daily acrylamide exposure in US adults via hemoglobin adducts and urinary metabolites using a pharmacokinetic framework."	( Reconstructing population exposures to acrylamide from human monitoring data using a pharmacokinetic framework. Caffrey, JL; Chou, WC; Kadry, AR; Lin, YS; Morozov, V, 2023)	0.91
" Three acrylamide biomarkers including hemoglobin adducts of acrylamide in blood and two urine metabolites, N-Acetyl-S-(2-carbamoylethyl)cysteine (AAMA) and N-Acetyl-S-(2-carbamoyl-2-hydroxyethyl)-l-cysteine (GAMA) were used to estimate daily acrylamide exposure using validated pharmacokinetic prediction models."	( Reconstructing population exposures to acrylamide from human monitoring data using a pharmacokinetic framework. Caffrey, JL; Chou, WC; Kadry, AR; Lin, YS; Morozov, V, 2023)	0.91
" This study also highlights the value of integrating a pharmacokinetic approach into exposure assessments."	( Reconstructing population exposures to acrylamide from human monitoring data using a pharmacokinetic framework. Caffrey, JL; Chou, WC; Kadry, AR; Lin, YS; Morozov, V, 2023)	0.91
" A 2-compartment population NAC pharmacokinetic model was developed."	( Population Pharmacokinetic Model of N-Acetylcysteine During Periods of Recurrent Hypoglycemia in Healthy Volunteers. Brooks, J; Coles, LD; Eberly, L; Fayed, MS; Kumar, A; Mishra, U; Moheet, A; Seaquist, ER, 2023)	0.91

Excerpt	Reference	Relevance
" Neither decrease in plasma acetaminophen levels nor depression of cytochrome P-450 enzyme activity appears to be the mechanism of protection when these doses of NAC, cysteamine, or both drugs together are administered with a toxic dose of acetaminophen in mice."	( Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity. Brown, IR; Peterson, TC, 1992)	0.28
"The additional effect of N-acetylcysteine in combination with inhaled terbutaline was studied in a controlled randomized double-blind cross-over study of one week periods in 22 patients with stable reversible chronic obstructive pulmonary disease."	( Effects of inhaled N-acetylcysteine in combination with terbutaline. Melin, S; Nemcek, K; Stiksa, G, 1984)	0.27
"Patients with AMI received either 15 g NAC infused over 24 hours (n = 20) or no NAC (n = 7), combined with intravenous NTG and streptokinase."	( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995)	0.29
"NAC in combination with NTG and streptokinase appeared to be safe for the treatment of evolving AMI and was associated with significantly less oxidative stress, a trend toward more rapid reperfusion, and better preservation of left ventricular function."	( N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Arstall, MA; Betts, WH; Horowitz, JD; Stafford, I; Yang, J, 1995)	0.29
"The aim of this study was to functionally evaluate the decongestant effect of a topical intranasal drug (Rhinofluimucil consisting of tuaminoheptane sulphate (CAS 6411-75-2, THS), a vasoconstrictor, combined with N-acetyl-cysteine (CAS 616-91-1, NAC)."	( Efficacy of topical tuaminoheptane combined with N-acetyl-cysteine in reducing nasal resistance. A double-blind rhinomanometric study versus xylometazoline and placebo. Chieffo, A; Ciaccia, A; Cogo, A; Farinatti, M, 1996)	0.29
"To evaluate the efficacy of N-acetylcysteine (N-AC) alone or combined with multiple-dose activated charcoal (AC) in the treatment of acetaminophen (ACT) overdose."	( [Evaluation of the efficacy of N-acetylcysteine administered alone or in combination with activated charcoal in the treatment of acetaminophen overdoses]. Escalante-Galindo, P; Montoya-Cabrera, MA; Nava-Juárez, A; Terán-Hernández, JA; Terroba-Larios, VM, )	0.13
" Group A (n = 7) were treated only with N-AC and group B (n = 7) with N-AC combined with AC."	( [Evaluation of the efficacy of N-acetylcysteine administered alone or in combination with activated charcoal in the treatment of acetaminophen overdoses]. Escalante-Galindo, P; Montoya-Cabrera, MA; Nava-Juárez, A; Terán-Hernández, JA; Terroba-Larios, VM, )	0.13
"007-8 mg/ml) of NAC alone and in combination with fosfomycin on the formation or disruption of biofilms was assessed."	( Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Bozzolasco, M; Debbia, EA; Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2003)	0.32
" Treatment with AF in combination with ATRA markedly increased the number of cells with differentiated features, such as lobed or multiple nuclei and numerous granules and vacuoles."	( Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Jin, JY; Kim, IS; Lee, IH; Park, SJ, 2004)	0.32
" This study was designed to evaluate magnesium supplementation, alone or combined with NAC, on ischemic acute renal failure."	( Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure. Andrade, L; Coimbra, TM; de Araujo, M; Rodrigues, AC; Seguro, AC, 2005)	0.33
" To assess sensitivity, a multiple reaction monitoring (MRM) mode with 251 theoretical transitions using the CNL of 129 Da combined with a product ion scan (IDA thMRM) was compared with CNL combined with a product ion scan (IDA CNL)."	( Rapid detection and identification of N-acetyl-L-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced product-ion scans on a linear ion trap mass spectrometer. Dekant, W; Pähler, A; Scholz, K; Völkel, W, 2005)	0.33
"In the field of metabonomics, 1H NMR and full scan mass spectrometry methods have usually been combined with principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) to detect patterns in biofluids that correspond to specific effects, usually a toxic site effect of a compound."	( Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Burton, L; Donegan, M; Scholz, K; Völkel, W; Wagner, S; Wingate, J, 2006)	0.33
" This study assesses the dose-dependent effect of N-acetylcysteine (NAC), a chemopreventive agent, in combination with vitamin C (VC) on the activity of ODC in lung carcinoma cell line, NCI-H82."	( The effect of N-acetylcysteine in combination with vitamin C on the activity of ornithine decarboxylase of lung carcinoma cells--In vitro. Shyamaladevi, CS; Vanisree, AJ, 2006)	0.33
" The current work tests the hypothesis that 2-deoxy-d-glucose (2DG) combined with cisplatin [cis-diamminedichloroplatinum(II)] can enhance cytotoxicity in human head and neck cancer cells (FaDu) by mechanisms involving oxidative stress."	( 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Ahmad, IM; Dornfeld, KJ; Mattson, DM; Simons, AL; Spitz, DR, 2007)	0.34
"We studied the prooxidant and cytotoxic action of thiols N-acetylcystein (NAC) and glutathione (GSH) combined with vitamin Bl2b."	( [Prooxidant and cytotoxic action of N-acetylcysteine and glutathione combined with vitamin Bl2b]. Akatov, VS; Faskhutdinova, AA; Kudriavtsev, AA; Solov'ev, VV; Solov'eva, ME, 2007)	0.34
" We evaluated the efficacy of a new clinical therapy consisting of cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents."	( [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents]. Enomoto, S; Hoshino, A; Kawahito, H; Kurata, H; Nakahara, Y; Nakamura, T, 2007)	0.34
"Therapy for patients with renal failure consisting of cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents is effective to prevent CIN in the chronic phase."	( [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents]. Enomoto, S; Hoshino, A; Kawahito, H; Kurata, H; Nakahara, Y; Nakamura, T, 2007)	0.34
"In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8."	( N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. Arriaza, E; Castillejo, MS; Delgado, M; Gisbert, JP; Gonzalez Lara, V; Guijarro, LG; Marin-Jimenez, I; Mate, J; Olleros, T; Pena, AS; Perez-Calle, JL; Prieto-Merino, D, 2008)	0.35
" These findings provide a biochemical rationale for evaluating agents that induce mitochondrial dysfunction in combination with chemotherapy and inhibitors of glutathione metabolism in head and neck cancer."	( Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Ahmad, IM; Aykin-Burns, N; Dayal, D; Dornfeld, KJ; Li, L; Mattson, DM; Orcutt, KP; Parsons, AD; Simons, AL; Spitz, DR, 2009)	0.35
"The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells."	( Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009)	0.35
" In view of these developments, we investigated whether a HAART drug combination of 3'-azido-2',3'-deoxythymidine (AZT) and indinavir (IDV) can alter the functionality of the blood-brain barrier (BBB) endothelial cells, thereby exacerbating this condition."	( Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Banerjee, A; Banks, WA; Ercal, N; Manda, KR, 2011)	0.37
" In order to extend our previous work on KX1-004 with noise exposure, the current studies were undertaken with two goals: (1) to test the effectiveness of NAC and KX1-004 in combination with one another when given in a protection paradigm, and (2) to test the NAC+KX1-004 combination in a postexposure rescue paradigm."	( Postexposure treatment with a Src-PTK inhibitor in combination with N-l-acetyl cysteine to reduce noise-induced hearing loss. Bielefeld, EC; Henderson, D; Wantuck, R, )	0.13
" This study also demonstrated the effectiveness of LC/HR-MS(n) in combination with multiple post-acquisition data-mining methods and the online H/D exchange technique for the rapid identification of drug metabolites."	( Metabolite identification of triptolide by data-dependent accurate mass spectrometric analysis in combination with online hydrogen/deuterium exchange and multiple data-mining techniques. Du, F; Liu, T; Wan, Y; Wang, Y; Xing, J, 2011)	0.37
"Three schistosomiasis patients combined with acute hepatitis E were treated with N-acetylcysteine, ursodeoxycholic acid and traditional Chinese medicine."	( [Three schistosomiasis patients combined with acute hepatitis E]. Li, YC; Zhou, TF, 2011)	0.37
" Sevoflurane combined with ATP could increase the level of activated caspase-1, pyroptosis, and reactive oxygen species (ROS)."	( Sevoflurane combined with ATP activates caspase-1 and triggers caspase-1-dependent pyroptosis in murine J774 macrophages. Chen, S; Fang, X; Jin, Y; Li, H; Wu, S; Xie, G, 2013)	0.39
"The extensively used thiol antioxidants (dithiothreitol, glutathione, and N-acetylcysteine) in combination with hydroxycobalamine (vitamin B12) gain toxic activity in relation to human lymphocytic leukemia cell line HL60."	( Thiol antioxidants in combination with vitamin B12 induce apoptotic death of human lymphocytic leukemia cells by destabilization of lysosomes with the involvement of iron ions. Akatov, VS; Faskhutdinova, AA; Solovyev, VV; Solovyeva, ME, 2013)	0.39
"To observe the clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in the treatment of silicosis."	( [Clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in treatment of silicosis]. Fang, ZH; Ji, J; Miao, RM; Qian, GL; Sun, XF; Wu, W; Zhang, YY; Zhao, DK; Zhao, R, 2013)	0.39
" Both groups were given routine therapy including anti-inflammatory, antitussive, and antiasthmatic drugs, and the patients in treatment group were given tetrandrine combined with acetylcysteine effervescent tablets at the same time."	( [Clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in treatment of silicosis]. Fang, ZH; Ji, J; Miao, RM; Qian, GL; Sun, XF; Wu, W; Zhang, YY; Zhao, DK; Zhao, R, 2013)	0.39
"The pathophysiology of toxic epidermal necrolysis (TEN) is thought to be related to a drug-induced oxidative stress combined with TNFα overexpression by keratinocytes."	( Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Delvenne, P; Jennes, S; Libon, F; Paquet, P; Piérard, GE; Rousseau, AF, 2014)	0.4
"In this proof-to-concept attempt, NAC treatment or its combination with infliximab did not appear to reverse the evolving TEN process."	( Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Delvenne, P; Jennes, S; Libon, F; Paquet, P; Piérard, GE; Rousseau, AF, 2014)	0.4
"Metformin, a biguanide drug used in the treatment of type II diabetes, was evaluated alone and in combination with amifostine, captopril, MESNA or N-acetyl-cysteine (NAC) for its ability to protect when administered 24 h after irradiation."	( Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs. Grdina, DJ; Miller, RC; Murley, JS, 2014)	0.4
" A promising approach could be photodynamic inactivation (PDI) which uses light in combination with a photosensitizer to induce a phototoxic reaction."	( Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms. Djavid, GE; Karami, S; Kashef, N, 2015)	0.42
"5-4) results against the bacterium in combination with ampicillin, ciprofloxacin, tetracycline or metronidazole."	( In vitro effects of N-acetyl cysteine alone and in combination with antibiotics on Prevotella intermedia. Jang, EY; Lee, JY; Moon, JH; Shim, KS, 2015)	0.42
" We sought to verify brain exposure of the systemically administered antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probenecid, and identify adverse effects of this drug combination after severe TBI in children."	( Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. Au, AK; Bayır, H; Bell, MJ; Clark, RSB; Empey, PE; Horvat, CM; Kochanek, PM; Nolin, TD; Poloyac, SM; Rosario, BL; Wisniewski, SR, 2017)	0.46
"To investigate the potential synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii strains grown in planktonic phase or as biofilms."	( In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms. Aliberti, S; Blasi, F; Boncompagni, S; Di Maggio, T; Di Pilato, V; Fiori, B; Pallecchi, L; Pollini, S; Rossolini, GM; Sergio, F; Spanu, T, 2018)	0.48
" Synergism of colistin in combination with N-acetylcysteine was investigated by chequerboard assays."	( In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms. Aliberti, S; Blasi, F; Boncompagni, S; Di Maggio, T; Di Pilato, V; Fiori, B; Pallecchi, L; Pollini, S; Rossolini, GM; Sergio, F; Spanu, T, 2018)	0.48
" Therefore, we sought to determine if a low glucose environment (in vitro) or a ketogenic diet (in vivo) could inhibit anaplastic thyroid cancer tumor growth when combined with the antioxidant N-acetylcysteine."	( Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. Aggarwal, A; Barletta, JA; Lorch, JH; Nehs, MA; Yuan, Z, 2020)	0.56
" With bacterial resistance an ongoing concern, it would be ideal if non-ototoxic agents combined with antibiotics resulted in a synergistic effect, requiring lower antibiotic concentrations to treat infections."	( Antibacterial effect of N-acetylcysteine in combination with antimicrobials on common canine otitis externa bacterial isolates. Bemis, DA; May, ER; Ratliff, BE, 2019)	0.51
"To determine if NAC, an otoprotective and antimicrobial compound, has synergistic activity when combined with enrofloxacin or gentamicin in vitro against bacterial isolates causing canine otitis externa."	( Antibacterial effect of N-acetylcysteine in combination with antimicrobials on common canine otitis externa bacterial isolates. Bemis, DA; May, ER; Ratliff, BE, 2019)	0.51
" In this study, rat adipose stem cells (rASCs) were seeded into anti-oxidative N-acetylcysteine (NAC) grafted polyurethane (PU) scaffold and then combined with short dynamic compressive stimulation (24 h) to induce rASCs chondrogenesis differentiation in vitro."	( Studies of proliferation and chondrogenic differentiation of rat adipose stem cells using an anti-oxidative polyurethane scaffold combined with cyclic compression culture. Cheng, CH; Huang, ST; Lin, JC; Tseng, SJ; Wu, CC, 2020)	0.56
" Further NAC in combination with Celecoxib (CXB) inhibits tumor growth by altering antioxidant status and increasing autophagy in DON initiated Swiss mice."	( N-acetyl-cysteine in combination with celecoxib inhibits Deoxynivalenol induced skin tumor initiation via induction of autophagic pathways in swiss mice. Asthana, S; Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mishra, S; Rath, SK; Sharma, D; Srivastava, S; Wahajuddin, M, 2020)	0.56
" Our study aimed to investigate the clinical value of N-acetylcysteine (NAC) combined with terbutaline sulfate in the treatment of COPD in elderly people, and its effect on the apoptosis/anti-apoptosis mechanism."	( Clinical value of N-acetylcysteine combined with terbutaline sulfate in elderly patients with chronic obstructive pulmonary disease and its effect on apoptosis/anti-apoptosis mechanism. Lin, J; Sun, Y; Xie, M; Zhang, L; Zhou, Q, 2020)	0.56
" This study assessed the potential protective effects of coenzyme Q10 (CoQ10) alone or combined with N-acetyl cysteine (NAC) or atorvastatin against CIN in diabetic rats."	( Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats. Alshogran, OY; Alzoubi, KH; El-Elimat, T; Nusair, SD; Obeidat, A; Sweidan, M, 2021)	0.62
"Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72
" The purpose of this study is to investigate the effect of per os colchicine administration in combination with fenofibrate and NAC on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits."	( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021)	0.62
"Colchicine administration in combination with fenofibrate or NAC statistically significantly reduced the extent of atherosclerotic lesions in aortic preparations."	( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021)	0.62
"In an experimental rabbit model, it appears that colchicine statistically significantly reduces the development of atherosclerosis of the aorta, especially in combination with NAC."	( The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021)	0.62
"Chinese herbs for supplementing qi and activating blood circulation (CH) combined with N-acetylcysteine (NAC) is widely used for idiopathic pulmonary fibrosis (IPF) in China, but there is a lack of literature to evaluate its efficacy and clinical value."	( Clinical efficacy of Chinese herbs for supplementing qi and activating blood circulation combined with N-acetylcysteine in the treatment of idiopathic pulmonary fibrosis: A systematic review and network meta-analysis. Cao, F; Jiao, Y; Li, G; Liu, H; Pang, Q; Wei, W, 2022)	0.72
" However, data regarding the therapeutic outcomes of oral steroid combined with oral NAC for ISSNHL are still limited."	( Effects of oral N-acetylcysteine combined with oral prednisolone on idiopathic sudden sensorineural hearing loss. Chen, SL; Chin, SC; Ho, CY, 2022)	0.72
"This study demonstrated the effect of oral steroid combined with oral NAC for ISSNHL."	( Effects of oral N-acetylcysteine combined with oral prednisolone on idiopathic sudden sensorineural hearing loss. Chen, SL; Chin, SC; Ho, CY, 2022)	0.72
" A total of 40 beagles were randomly divided into 5 groups (control group, DM group, insulin monotherapy group, NAC combined with insulin group, and NAC monotherapy group) to explore the effects of NAC on alleviating the oxidative damage in cerebrum."	( N-acetylcysteine combined with insulin alleviates the oxidative damage of cerebrum via regulating redox homeostasis in type 1 diabetic mellitus canine. Guo, J; Han, Q; Hu, L; Huo, H; Li, X; Li, Y; Ma, F; Pan, J; Tang, Z; Wu, H; Zhang, H; Zhao, M, 2022)	0.72
" Following the intraperitoneal (IP) administration of AFB1 at dose of 2 mg/kg, minocycline (45 and 90 mg/kg, IP) and dexamethasone (5 and 20 mg/kg, IP) were administered alone and combined with NAC (200 mg/kg, IP) and vitamin E (600 mg/kg, IP)."	( The effects of dexamethasone and minocycline alone and combined with N-acetylcysteine and vitamin E on serum matrix metalloproteinase-9 and coenzyme Q10 levels in aflatoxin B1 administered rats. Bahcivan, E; Dik, B; Eser Faki, H; Ozdemir Kutahya, Z; Tras, B; Uney, K, 2022)	0.72
" This study aims to explore the therapeutic effect and mechanism of N-acetylcysteine (NAC) combined with insulin on type 1 DM."	( N-acetylcysteine combined with insulin attenuates myocardial injury in canines with type 1 diabetes mellitus by modulating TNF-α-mediated apoptotic pathways and affecting linear ubiquitination. Bai, Y; Huang, J; Liao, J; Pang, X; Qiu, W; Su, R; Tang, Z; Wang, R; Xie, W; Xiong, Z; Zhang, X; Zhou, S, 2023)	0.91
" Antioxidant N-acetylcysteine (NAC) in combination with surfactant may improve lung function."	( Efficiency of exogenous surfactant combined with intravenous N-acetylcysteine in two-hit rodent model of ARDS. Calkovska, A; Hanusrichterova, J; Kolomaznik, M; Kosutova, P; Mikolka, P; Mokra, D; Vatecha, M; Zila, I, 2023)	0.91
" We found that, after SCI, rats given GlyNAC alone showed an improvement in Basso-Beattie-Bresnahan (BBB) scores, gait symmetry, and results in the open field test, indicative of improved motor function, while GlyNAC combined with BWSTT was more effective than either treatment alone at ameliorating voluntary motor function in injured rats."	( Glycine and N-Acetylcysteine (GlyNAC) Combined with Body Weight Support Treadmill Training Improved Spinal Cord and Skeletal Muscle Structure and Function in Rats with Spinal Cord Injury. Du, HY; Du, LJ; Gao, F; Jing, YL; Li, JJ; Li, ZH; Liang, YX; Liu, WB; Talifu, Z; Xu, X; Xu, XL; Yang, DG; Yu, Y; Zhang, CJ; Zhang, JM, 2023)	0.91

Excerpt	Reference	Relevance
" The substance was well absorbed with a mean peak level of 19."	( Pharmacokinetics of loracarbef and interaction with acetylcysteine. Boeckh, M; Deppermann, KM; Koeppe, P; Lode, H; Roller, S; Stelzer, I, 1992)	0.28
" Regarding the bioavailability of cefadroxil, the free combination is bioequivalent to the individual component."	( [The biological availability of cefadroxil given simultaneously with N-acetylcysteine]. Barkworth, MF; Mangold, B; Rehm, KD; Rübartsch, C; Schmieder, G; Töberich, H; Vinchenzo, A; Weber, J, 1991)	0.28
"08 microM were measured in 10 volunteers participating in a crossover study to compare the bioavailability of two different formulations of N-acetylcysteine."	( Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method. Gabard, B; Mascher, H, 1991)	0.28
" Bioavailability of NAC significantly increased with increasing dose."	( Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Borgström, L; Kågedal, B, 1990)	0.28
" The increase in peak height was calculated relative to nasal administration of hGH alone without any enhancers and the relative bioavailability was calculated with reference to subcutaneous injection data."	( Nasal absorption enhancers for biosynthetic human growth hormone in rats. Critchley, H; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Johansen, BR; O'Hagan, DT, 1990)	0.28
" We conclude that deacetylation in the intestinal mucosa and possibly in the intestinal lumen is the major factor determining the low oral bioavailability of N-acetyl-L-cysteine."	( Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Hallberg, A; Nilsson, E; Sjödin, K; Tunek, A, 1989)	0.28
"The pharmacokinetics and bioavailability of suckable tablets and granules of N-acetylcysteine (NAC) have been compared after oral administration of 400 mg doses to 10 healthy volunteers."	( Bioavailability of suckable tablets of oral N-acetylcysteine in man. Barindelli, E; De Bernardi di Valserra, M; Feletti, F; Galmozzi, MR; Lualdi, P; Mautone, G, 1989)	0.28
"The plasma pharmacokinetics of oral acetylcysteine(N-acetylcysteine, NAC) after the administration of single 600 mg and repeated 200 mg doses and the relative bioavailability of the two regimens were studied in 12 adult subjects."	( Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Costa, R; De Caro, L; Ghizzi, A; Lodola, E; Longo, A; Ventresca, GP, 1989)	0.28
" EPAC showed a better bioavailability than ES with longer-lasting serum levels of active antibiotic."	( Human pharmacokinetics of erythromycin propionate-N-acetylcysteinate: comparative evaluation with erythromycin stearate and N-acetylcysteine. De Bernardi, M; Feletti, F; Fregnan, GB; Gazzani, G, 1988)	0.27
"The pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers."	( Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Bolme, P; Gabrielsson, J; Johansson, M; Olsson, B, 1988)	0.27
" We assessed the effect of simultaneous oral administration of NAC on the bioavailability of two antibiotics in ten healthy volunteers."	( No effect of oral N-acetylcysteine on the bioavailability of erythromycin and bacampicillin. Borgström, L; Kågedal, B; Paulsen, O; Walder, M, 1988)	0.27
" These results may provide an explanation for the apparent low bioavailability of N-acetylcysteine when administered orally in humans and are discussed in terms of the origins of the protective effect of the drug in cases of paracetamol intoxication in humans."	( Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Berggren, M; Cotgreave, IA; Dawson, J; Jones, TW; Moldéus, P, )	0.13
" In vivo studies, however, demonstrated that NAC when administered orally has very low bioavailability due to rapid metabolism to GSH among other metabolites."	( Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Berggren, M; Cotgreave, IA; Moldéus, P, 1986)	0.27
"01) in neutrophils incubated with both sodium nitroprusside (SNP), an exogenous source of nitric oxide, and N-acetylcysteine (NAC), which increases the bioavailability of nitric oxide; this increase indicates that neutrophils contain a nitric oxide-sensitive guanylate cyclase."	( Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. Cobb, JP; Corriveau, CC; Danner, RL; Madara, PJ; Tropea, MM; Van Dervort, AL; Wesley, RA; Yan, L, 1994)	0.29
" 30, 1891-1896) that this thiazolidine, D-glucose-L-cysteine (DGC), offered no significant protection against the hepatic injury caused by 5 mmol/kg of acetaminophen in mice, suggesting that the cysteine present as DGC is poorly bioavailable in vivo."	( Attenuation of acetaminophen hepatotoxicity in mice as evidence for the bioavailability of the cysteine in D-glucose-L-cysteine in vivo. Benzick, AE; Gomez, MR; Heird, WC; Rogers, LK; Smith, CV, 1994)	0.29
"To investigate the ability of a supranormal dose of N-acetylcysteine to overcome the effects of activated charcoal on N-acetylcysteine bioavailability and to determine the effects of activated charcoal on serum acetaminophen levels."	( Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine? Chamberlain, JM; Gorman, RL; Klein, BL; Klein-Schwartz, W; Oderda, GM, 1993)	0.29
" If N-acetylcysteine is needed because of a toxic serum acetaminophen level, bioavailability can be ensured by increasing the N-acetylcysteine loading dose from 140 mg/kg to 235 mg/kg."	( Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine? Chamberlain, JM; Gorman, RL; Klein, BL; Klein-Schwartz, W; Oderda, GM, 1993)	0.29
" AC-DDTC was well absorbed after oral administration."	( Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. Bertram, B; Lee, BH; Park, J; Ryu, JC; Wiessler, M, 1995)	0.29
" The narrow range of 90% confidence intervals for the quotient test/reference for Cmax and AUC indicate reliable bioavailability of cefpodoxime proxetil independent of co-administered acetylcysteine."	( Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine. Bröhl, K; Grobecker, H; Kees, F; Wellenhofer, M, 1996)	0.29
" However, when purified cells were preincubated with SNP in the presence of 5 mM N-acetylcysteine (NAC), increasing the bioavailability of NO, the downregulation was recovered."	( Exogenous nitric oxide regulates the degranulation of human basophils and rat peritoneal mast cells. Hirai, K; Iida, M; Iikura, M; Koshino, T; Morita, Y; Takaishi, T; Yamada, H, 1998)	0.3
" A shorter hospital stay, patient and doctor convenience, and the concerns over the reduction in bioavailability of oral N-acetylcysteine by charcoal and vomiting make intravenous N-acetylcysteine preferable for most patients with acetaminophen poisoning."	( Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? Buckley, NA; Dawson, AH; O'Connell, DL; Whyte, IM, 1999)	0.3
"Glucoconjugates of (+/-)-ibuprofen, (+/-)-alpha-tocopherol (vitamin E), gentisic acid, gallic acid, 2,6-bis(tert-butyl)-4-thiophenol, and N-acetyl-L-cysteine were prepared with the objective of increasing the bioavailability of such antioxidant and anti-inflammatory drugs."	( Synthesis of antioxidative and anti-inflammatory drugs glucoconjugates. Beyreuther, K; Picard, MA; Uhrig, RK; Wiessler, M, 2000)	0.31
" The effective combinations (L-TC + DOX, NAC + DOX, NAC + DMTU, NAC + HMT, NC + DOX) combined agents, reducing the bioavailability of the mustard with compounds possibly acting on the consequences of alkylation."	( Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations. Baeza-Squiban, A; Calvet, J; Marano, F; Rappeneau, S, 2000)	0.31
" The high percentage of cell death with SNP+NAC suggests that NAC forms S-nitrosothiols with NO, resulting in an increase in the bioavailability of NO."	( Nitric oxide induces apoptosis in the fat body cell line IPLB-LdFB from the insect Lymantria dispar. Barbieri, D; Franchini, A; Malagoli, D; Ottaviani, E, 2001)	0.31
"N-acetyl-L-cysteine exerts direct anti-aggregating effects through an increased bioavailability of platelet nitric oxide."	( N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Russo, I; Trovati, M, 2001)	0.31
" Thus to further improve the NAC bioavailability a single oral administration of 1200 mg NAC has been recently proposed."	( Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Allegra, L; Bovio, C; Braga, PC; Dal Sasso, M; Fonti, E; Massoni, C, 2002)	0.31
" In the oral studies, however, a wide range of formulations were used, and the bioavailability of each product was uncertain."	( N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Humphries, KH; Levin, A; Pate, GE; Shalansky, SJ; Vu, T; Webb, JG, 2005)	0.33
"The effect of co-administration of a mucolytic agent with a penetration enhancer was assessed on the intestinal absorption of poorly absorbed hydrophilic compounds."	( Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Horikiri, Y; Kitazawa, T; Morita, T; Takatsuka, S; Yoshino, H, 2006)	0.33
" The protective effects may be attributable to restoration of NO bioavailability in the circulation."	( Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats. Guo, Z; McNeill, JH; Nagareddy, PR; Xia, Z; Zhang, W, 2006)	0.33
" Increasing the dose seems to improve NAC bioavailability and may also consolidate some of its effects."	( Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. De Backer, WA; Manuel-Y-Keenoy, B; Sadowska, AM, 2007)	0.34
" Dosing solutions containing these agents were administered directly into the rat jejunum, and the bioavailability of SCT up to 2 h was determined."	( Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Horikiri, Y; Koguchi, A; Morita, T; Takatsuka, S; Yamahara, H; Yoshino, H, 2006)	0.33
" Although many studies described the use of OPG during the treatment of bone diseases, its bioavailability and the mechanism by which the cells control the extracellular OPG remains blurred."	( OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Couillaud-Battaglia, S; Fortun, Y; Heymann, D; Padrines, M; Redini, F; Tat, SK; Theoleyre, S, 2006)	0.33
" Also, nasal administration of this formulation gave a quicker absorption rate than subcutaneous administration of SCT."	( Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. Horikiri, Y; Matsuyama, T; Morita, T; Yamahara, H; Yoshino, H, 2006)	0.33
" Our previous toxicokinetic investigations of AA and its genotoxic metabolite, glycidamide (GA), in rodents showed that AA is highly bioavailable from oral routes of administration, is widely distributed to tissues, and that the dietary route, in particular, favors metabolism to GA."	( Urinary excretion of acrylamide and metabolites in Fischer 344 rats and B6C3F(1) mice administered a single dose of acrylamide. Angerer, J; Boettcher, MI; Doerge, DR; McDaniel, LP; Twaddle, NC, 2007)	0.34
"Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by co-administration of a mucolytic agent and a non-ionic surfactant was examined in rats."	( Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant. Horikiri, Y; Morita, T; Saji, H; Takatsuka, S; Yamahara, H, 2007)	0.34
"Relative bioavailability and toxicity of N-acetyl-l-Cys (NAC) were evaluated in 9-d chick growth assays."	( Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine. Baker, DH; Dilger, RN, 2007)	0.34
" An intranasal administration experiment revealed that the use of less wettable powders provided better nasal absorbability, and the highest absolute bioavailability (30."	( Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption. Horikiri, Y; Matsuyama, T; Morita, T; Yamahara, H; Yoshino, H, 2007)	0.34
"The absorption enhancing effects of various combinations of a mucolytic agent and a non-ionic surfactant on the intestinal absorption of poorly absorbed hydrophilic compounds were examined."	( Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds. Horikiri, Y; Morita, T; Saji, H; Takatsuka, S; Yamahara, H, 2008)	0.35
" These results demonstrate that the reduction in the bioavailability of NO as a result of elevated oxidative stress contributes to the increase in norepinephrine overflow from the SHR mesenteric sympathetic neuroeffector junction."	( Oxidative stress attenuates NO-induced modulation of sympathetic neurotransmission in the mesenteric arterial bed of spontaneously hypertensive rats. Macarthur, H; Westfall, TC; Wilken, GH, 2008)	0.35
" N-acetylcysteine (NAC) is a thiol molecule that has direct and indirect antioxidant effects which decrease reactive oxidant species and increase the bioavailability of the DDAH enzyme."	( Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Pranawa, W; Thaha, M; Tomino, Y; Yogiantoro, M, 2008)	0.35
" For this reason, we tested the effects of l-arginine (ARG) and N-acetylcysteine (NAC) administration in increasing NO bioavailability by reducing free radical formation."	( Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Berchio, A; Bergamini, S; Brocato, L; Della Casa, L; Gigliardi, VR; Iannone, A; Manzato, E; Martina, V; Masha, A; Massarenti, P; Settanni, F, 2008)	0.35
"NAC + ARG administration seems to be a potential well-tolerated antiatherogenic therapy because it improves endothelial function in hypertensive patients with type 2 diabetes by improving NO bioavailability via reduction of oxidative stress and increase of NO production."	( Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Berchio, A; Bergamini, S; Brocato, L; Della Casa, L; Gigliardi, VR; Iannone, A; Manzato, E; Martina, V; Masha, A; Massarenti, P; Settanni, F, 2008)	0.35
" Reduced bioavailability of physiological vasodilators, such as prostaglandins and nitric oxide, could predispose to acute renal damage."	( [Contrast-induced nephropathy. Current concepts and propositions for Italian guidelines]. Detrenis, S; Meschi, M; Savazzi, G, 2008)	0.35
" We hypothesized that treatment with N-acetyl cysteine (NAC), a safe, orally bioavailable precursor of glutathione, may improve the depressive component of bipolar disorder."	( N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Anderson-Hunt, M; Berk, M; Bush, AI; Copolov, DL; Dean, O; Jeavons, S; Lu, K; Schapkaitz, I, 2008)	0.35
"To verify if an experimental model of alloxan-diabetic rats promotes oxidative stress, reduces nitric oxide bioavailability and causes vascular dysfunction, and to evaluate the effect of N-acetylcysteine (NAC) on these parameters."	( Oxidative stress is not associated with vascular dysfunction in a model of alloxan-induced diabetic rats. Baldo, CF; Batalhão, ME; Capellini, VK; Cárnio, EC; Celotto, AC; Evora, PR; Rodrigues, AJ, 2010)	0.36
" We studied whether the food matrix modulates bioavailability and/or biotransformation and investigated kinetics and biological effectiveness of AA in rats."	( Biological effects of acrylamide after daily ingestion of various foods in comparison to water: a study in rats. Baum, M; Berger, FI; Bertow, D; Eisenbrand, G; Feld, J; Fricker, G; Gerhardt, N; Merz, KH; Richling, E, 2011)	0.37
" Altogether, no significant differences in bioavailability of AA from water and the different food matrices were observed."	( Biological effects of acrylamide after daily ingestion of various foods in comparison to water: a study in rats. Baum, M; Berger, FI; Bertow, D; Eisenbrand, G; Feld, J; Fricker, G; Gerhardt, N; Merz, KH; Richling, E, 2011)	0.37
"The purpose of this study was to compare the pharmacokinetics and relative bioavailability of a generic test formulation and a branded reference formulation of acetylcysteine in fasting healthy Chinese male volunteers."	( Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers. Jia, JY; Li, GX; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Wang, JY; Wang, W; Weng, LP; Yu, C, 2010)	0.36
" The slow HNO-donor 1 demonstrates weak thiol-insensitive vasorelaxation, indicating HNO release kinetics determine HNO bioavailability and activity."	( Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties. Brandon, A; Crawford, JH; DuMond, JF; Honovar, J; Isbell, TS; King, SB; Patel, RP; Shoman, ME; Vitturi, DA; White, CR, 2011)	0.37
" This may increase bioavailability of protective NO in a narrow therapeutic range."	( Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Barrett, F; Gibson, KR; MacRury, SM; Megson, IL; Sharma, S; Winterburn, TJ, 2011)	0.37
"Oxidative stress may cause a loss of tetrahydrobiopterin (BH4), a co-factor of nitric oxide synthase (NOS), decrease the bioavailability of NO and aggravate ischemia/reperfusion (I/R) injury in diabetic heart."	( Ascorbic acid and N-acetyl cysteine prevent uncoupling of nitric oxide synthase and increase tolerance to ischemia/reperfusion injury in diabetic rat heart. Fujita, M; Iwasaka, T; Okazaki, T; Otani, H; Shimazu, T; Yoshioka, K, 2011)	0.37
" We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants."	( Antioxidant therapy: current status and future prospects. Firuzi, O; Miri, R; Saso, L; Tavakkoli, M, 2011)	0.37
" In a previous study, biomarkers of SF bioavailability from a powder rich in GRP, but lacking myrosinase, were enhanced by co-consumption of a myrosinase-containing air-dried broccoli sprout powder."	( Enhancing sulforaphane absorption and excretion in healthy men through the combined consumption of fresh broccoli sprouts and a glucoraphanin-rich powder. Cramer, JM; Jeffery, EH; Teran-Garcia, M, 2012)	0.38
" In eight young sedentary (23 ± 1 years; Y), eight older lifelong sedentary (66 ± 2 years; OS) and eight older lifelong physically active subjects (62 ± 2 years; OA), we studied the effect of ROS on systemic and skeletal muscle NO bioavailability and leg blood flow by infusion of the antioxidant N-acetylcysteine (NAC)."	( Lifelong physical activity prevents an age-related reduction in arterial and skeletal muscle nitric oxide bioavailability in humans. Blackwell, JR; Damsgaard, R; Hellsten, Y; Jones, AM; Mortensen, SP; Nyberg, M, 2012)	0.38
" Mean bioavailability of NAC after oral administration was 19."	( Pharmacokinetics of N-acetylcysteine after oral and intravenous administration to healthy cats. Buur, JL; Diniz, PP; KuKanich, B; Roderick, KV; Tegzes, JH, 2013)	0.39
" Superior bioavailability of NACA is likely to fulfill the promises of NAC as well as a molecule to improve the endurance and resident time of bioscaffolds and biomaterials."	( N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine. Girish, KS; Hemshekhar, M; Kemparaju, K; Santhosh, MS; Sunitha, K; Thushara, RM; Yariswamy, M, 2013)	0.39
"In order to quantify the relative bioavailability of glycidol from glycidyl fatty acid esters in vivo, glycidyl palmitoyl ester and glycidol were orally applied to rats in equimolar doses."	( Relative oral bioavailability of glycidol from glycidyl fatty acid esters in rats. Abraham, K; Apel, E; Appel, KE; Bakhiya, N; Berger-Preiss, E; Creutzenberg, O; Hansen, T; Lampen, A; Schuchardt, S; Vogt, C, 2013)	0.39
"EMBASE and Medline were searched to obtain values for volume of distribution, absorption, and elimination constants and bioavailability for acetaminophen."	( Four-hour acetaminophen concentration estimation after ingested dose based on pharmacokinetic models. Gosselin, S; Villeneuve, E; Whyte, I, 2014)	0.4
" However, this approach has been hindered by the low CNS bioavailability of NAC."	( N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI. Goldstein, GA; Pandya, JD; Patel, SP; Pauly, JR; Rabchevsky, AG; Readnower, RD; Sullivan, PG; Yonutas, HM, 2014)	0.4
" Therefore, we studied the protective effects of N-acetylcysteineamide (NACA), a novel antioxidant, with higher bioavailability and compared it with NAC in APAP-induced hepatotoxicity in a human-relevant in vitro system, HepaRG."	( Comparative evaluation of N-acetylcysteine and N-acetylcysteineamide in acetaminophen-induced hepatotoxicity in human hepatoma HepaRG cells. Ercal, N; Fan, W; Khayyat, A; Tobwala, S, 2015)	0.42
" Repeated administration of flupirtine MR showed lower bioavailability (∼ 60%)."	( Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. Bednarski, PJ; Borlak, J; Keiser, M; Methling, K; Modess, C; Nassif, A; Rosskopf, D; Scheuch, E; Siegmund, W; Terhaag, B, 2015)	0.42
" NAC administration prevented the onset of the disturbed lipid profile, exhibiting decreased lipid peroxidation and alkaline phosphatase (ALP) levels, restored nitric oxide bioavailability and reduced hepatic damage, compared to non-supplemented groups."	( Impact of N-acetylcysteine and sesame oil on lipid metabolism and hypothalamic-pituitary-adrenal axis homeostasis in middle-aged hypercholesterolemic mice. Agrogiannis, G; Dimitroulis, D; Karatzas, T; Kitraki, E; Koros, C; Korou, LM; Pergialiotis, V; Perrea, DN; Tzanetakou, I; Vlachos, IS, 2014)	0.4
" Poor bioavailability is the main factor limiting the efficacy of chemopreventive agents."	( Nanoparticles increase the efficacy of cancer chemopreventive agents in cells exposed to cigarette smoke condensate. Fenoglio, D; Filaci, G; Izzotti, A; Lee, JL; Parodi, A; Pulliero, A; Romani, M; Sinkam, PN; Soares, CP; Wu, Y, 2015)	0.42
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."	( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. Bharate, SS; Vishwakarma, RA, 2015)	0.42
" N-acetylcysteine (NAC) has limited but well-documented neuroprotective effects after experimental central nervous system ischemia and TBI, but its bioavailability is very low."	( Neuroprotective effects of N-acetylcysteine amide on experimental focal penetrating brain injury in rats. Davidsson, J; Günther, M; Mathiesen, T; Norgren, S; Plantman, S; Risling, M, 2015)	0.42
" Its very low bioavailability limits the interest of a supplementation."	( Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. Denis, FM; Garrel, C; Schmitt, B; Vicenzi, M, 2015)	0.42
" Its major drawbacks are poor bioavailability due to extensive first pass effect, poor lipophilicity, high protein binding and offensive odor."	( Novel Thioester Prodrug of N-acetylcysteine for Odor Masking and Bioavailability Enhancement. Bhilare, NV; Bodhankar, SL; Dhaneshwar, SS; Kandhare, AD; Sinha, AJ, 2016)	0.43
" We propose that thioester prodrug using palmitic acid as a carrier is a promising strategy to enhance bioavailability of NAC by increasing its lipophilicity/ absorption and minimizing its first pass metabolism."	( Novel Thioester Prodrug of N-acetylcysteine for Odor Masking and Bioavailability Enhancement. Bhilare, NV; Bodhankar, SL; Dhaneshwar, SS; Kandhare, AD; Sinha, AJ, 2016)	0.43
" Anti-oxidant therapy may still play a role in the management of sarcoidosis but therapy with better bioavailability or potency is needed to suppress the lung inflammatory response."	( The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis. Barkes, B; Canono, B; Day, B; Gillespie, M; Hamzeh, N; Huang, J; Li, L; Maier, L, 2016)	0.43
" The rapid gastrointestinal digestion of quercetin is also a major obstacle for its clinical implementation due to low bioavailability and poor aqueous solubility."	( 3',5-dihydroxy-3,4',7-trimethoxyflavone-induces ER-stress-associated HCT-116 programmed cell death via redox signaling. Han, J; Kang, SC; Singh, MP, 2017)	0.46
" However, the clinical application of NAC is limited by its low bioavailability and short half-life."	( Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival. Markoutsa, E; Xu, P, 2017)	0.46
" NAC is well absorbed and safe for the body at doses up to 300 mg per kg of body weight."	( [The application of N-acetylcysteine in optimization of specific pharmacological therapies]. Hołyńska-Iwan, I; Olszewska-Słonina, D; Tyrakowski, T; Wróblewski, M, 2017)	0.46
" In vivo oral pharmacokinetic evaluation suggested that the bioavailability of Cur in rats was proportional to the degree of functionalization of NLCs with NAPG."	( N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Asghar, S; Chen, Z; Huang, L; Kambere Amerigos, D; Ping, Q; Tian, C; Wu, Y; Xiao, Y; Yin, L; Zhang, M, 2017)	0.46
" Although N-acetylcysteine crosses the blood-brain-barrier, low bioavailability is an obstacle."	( Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia. Dacks, PA; Fillit, HM; Hara, Y; McKeehan, N, 2017)	0.46
" However, NAC suffers from drawbacks such as poor oral bioavailability and suboptimal blood-brain-barrier (BBB) permeability limiting its clinical success."	( Pediatric oral formulation of dendrimer-N-acetyl-l-cysteine conjugates for the treatment of neuroinflammation. Ghandehari, H; Kambhampati, SP; Kannan, RM; Mishra, MK; Mohammadpour, R; Sayre, C; Yellepeddi, VK, 2018)	0.48
"N-acetylcysteine modified hyaluronic acid-paclitaxel (NAC-HA-PTX) conjugate was designed to improve the water solubility and oral bioavailability of PTX through mucosal bioadhesion ability."	( N-acetylcysteine modified hyaluronic acid-paclitaxel conjugate for efficient oral chemotherapy through mucosal bioadhesion ability. Asghar, S; Chen, Z; Huang, L; Jin, X; Ping, Q; Xiao, Y; Zhang, M, 2018)	0.48
" Taking into consideration that GSH conjugation is, in general, a detoxification pathway, these results suggest that under hyperoxia/oxidative stress conditions the bioavailability of the parent drug may be compromised."	( The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals. Antunes, AMM; Charneira, C; Marques, MM; Martins, IL; Morello, J; Nunes, J; Pereira, SA; Telo, JP, 2018)	0.48
" These observations suggest that ROS generation by MEHP leads to activation of HSL and increase in STAR which, together, result in increased free-cholesterol bioavailability and progesterone formation."	( Redox regulation of hormone sensitive lipase: Potential role in the mechanism of MEHP-induced stimulation of basal steroid synthesis in MA-10 Leydig cells. Li, Y; Martinez-Arguelles, DB; Papadopoulos, V; Traore, K; Zaman, N; Zhou, C; Zirkin, B, 2019)	0.51
" Due to the poor stability,low solubility,poor absorption and low bioavailability of curcumin,N-acetyl-L-cysteine( NAC) was used as an absorption enhancer and mixed with curcumin to improve the absorption of curcumin in the body."	( [Effect of N-acetyl-L-cysteine on bioavailability and brain distribution of curcumin by nasal delivery]. Chen, XY; Fu, TM; Jing, J; Meng, ZP; Su, WQ; Wei, TX; Wu, XX; Zhu, HX, 2019)	0.51
"A major obstacle to the clinical use of curcumin (CUR) is its reduced bioavailability because of the drug's hydrophobic nature, low intestinal absorption, and rapid metabolism."	( BSA Nanoparticles Modified with Asghar, S; Chen, Z; Hu, Z; Ping, Q; Shao, F; Xiao, Y; Yu, F; Zhang, S, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively)."	( Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. Ginman, T; Hassan, M; He, R; Norgren, S; Ottosson, H; Zhao, Y; Zheng, W, 2020)	0.56
" Nevertheless, NAC has low membrane permeability and poor bioavailability and its limited delivery to the brain may explain inconsistencies in the literature."	( Effects of N-acetylcysteine amide on anxiety and stress behavior in zebrafish. Benvenutti, R; Elisabetsky, E; Herrmann, AP; Marcon, M; Mocelin, R; Piato, A; Reis, CG; Sachett, A, 2020)	0.56
"To solve the low oral bioavailability of curcumin (CUR) due to the limits imposed by gastrointestinal (GI) barrier, we constructed a nano delivery system to evaluate the effect of N-acetyl-L-cysteine (NAC) on intestinal absorption and oral bioavailability of CUR."	( The enhancement of N-acetylcysteine on intestinal absorption and oral bioavailability of hydrophobic curcumin. Asghar, S; Chen, Z; Hu, Z; Ping, Q; Shao, F; Xiao, Y; Yu, F; Zhang, S, 2020)	0.56
"Curcumin presents a promising anti-inflammatory potential, but its low water-solubility and bioavailability hinder its application."	( Curcumin and n-acetylcysteine cocrystal produced with supercritical solvent: characterization, solubility, and preclinical evaluation of antinociceptive and anti-inflammatory activities. Aguiar, GPS; Alves, BO; Apel, MA; Danielli, LJ; Dos Santos, AE; Müller, LG; Oliveira, JV; Paulazzi, AR; Pedroso, J; Petry, F; Siebel, AM; Soares, KD; Zilli, GAL, 2022)	0.72
" Niosomes are bilayer vesicles that enhance the bioavailability of drugs."	( Protective Effects of N-acetylcysteine Niosome Nanoparticles on Paraquatinduced Nephrotoxicity in Male Rats. Firozian, F; Ganjirad, Z; Jouzdani, AF; Ranjbar, A; Soleimani-Asl, S, 2022)	0.72
" Nevertheless, there are still limitations with bioavailability and extended redox control with regard to antioxidant drug delivery."	( Extending the Bioavailability of Hydrophilic Antioxidants for Metal Ion Detoxification via Crystallization with Polysaccharide Dopamine. Flaherty, D; Han, HS; Kim, B; Kim, Y; Kim, YJ; Kong, H; Lee, J; Miller, R; Park, CG; Torres, C, 2022)	0.72
" Here, for the first time, the bioavailability and metabolism of longer-chain epithionitriles (C4-C5) is studied in a human intervention study."	( Metabolism and Recovery of Epithionitriles from Glucosinolates-A Human Intervention Study. Baldermann, S; Bergmann, MM; Grune, T; Hanschen, FS; Hoffmann, H; Wiesner-Reinhold, M, 2023)	0.91
" NAC has an excellent safety profile and better oral and topical bioavailability than GSH."	( Oxidative stress and viral Infections: rationale, experiences, and perspectives on N-acetylcysteine. Danzo, F; Pini, S; Radovanovic, D; Saad, M; Santus, P; Visconti, A; Zuffi, A, 2022)	0.72
" In the acetylcysteine + budesonide group, the absorption rate of lung imaging lesions and clinical efficacy were superior to those of the other two groups."	( Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation. Chen, C; Liu, K; Wang, Y; Zhang, C, 2023)	0.91
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The mercapturic acid was excreted in the urine of rats dosed with benzyl isothiocyanate or its GSH, cysteinyl-glycine or cysteine conjugate, and was isolated as the dicyclohexylamine salt."	( The metabolism of benzyl isothiocyanate and its cysteine conjugate. Brüsewitz, G; Cameron, BD; Chasseaud, LF; Görler, K; Hawkins, DR; Koch, H; Mennicke, WH, 1977)	0.26
" In addition to ENPP-MA, dosed rats under 13 days of age excreted the corresponding substituted cysteine."	( Glutathione conjugation and mercapturic acid formation in the developing rat, in vivo and in vitro. James, SP; Pheasant, AE, 1978)	0.26
"A sensitive, reproducible spectrophotometric procedure using Ellman's reagent for the determination of acetylcysteine in pharmaceutical dosage froms is presented."	( Estimation of acetylcysteine and its preparations. Kapoor, JN; Kim, MW; Murty, BS, 1977)	0.26
" Young female rats dosed with 1-bromo[1-14C]propane excrete the same metabolites as adult females but in different relative proportions."	( Mercapturic acid formation in the developing rat. Baines, PJ; Bray, HG; James, SP, 1977)	0.26
" Dose-response curves to nitroglycerin were constructed for 11 normotensive volunteers before and during treatment with a sustained-release formulation of isosorbide dinitrate, 80 mg, three times daily for 7 days and followed by concurrent treatment with NAC at a mean dose of 150 mg/kg/day, in divided doses, for 2 days."	( Desensitization of nitrate-induced venodilation: reversal with oral N-acetylcysteine in humans. Blaschke, TF; Hoffman, BB; Kongpatanakul, S; Vincent, J, 1992)	0.28
" This dosage of NAC could not increase reduced glutathione and did not affect the red blood cell PP content nor the excretion of PP in the feces."	( Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine. Baart de la Faille, H; Bijlmer-Iest, JC; Koningsberger, JC; Marx, JJ; van Asbeck, BS; van Hattum, J; van Weelden, H, )	0.13
" To explore the biosynthetic origin of the bromonohydroxyphenyl mercapturic acids, rats were separately dosed intraperitoneally with synthetic racemic 2-, 3-, or 4-bromophenyl mercapturic acid, or biosynthetic L-(-)-4-bromophenyl mercapturic acid, or a biosynthetic mixture of the 3,4- and 4,3-premercapturic acids from bromobenzene, and their urine (0-24 hr) analyzed by alkaline permethylation and GC/MS."	( Bromo(monohydroxy)phenyl mercapturic acids. A new class of mercapturic acids from bromobenzene-treated rats. Hanzlik, RP; Zheng, J, )	0.13
" Antimutagenicity is investigated through the analysis of respondents in dose-response assays, when two different molecules are administered separately and as a mixture to a respondent system."	( The analysis of the joint effect of substances on reversion systems and the assessment of antimutagenicity. Ambrosino, P; Barale, R; Barrai, I; Beretta, M; Loprieno, N; Micheletti, R; Sbrana, C; Scapoli, C, 1992)	0.28
" To search for them, phenobarbital-induced Sprague-Dawley rats were dosed (0."	( Dihydroxylated mercapturic acid metabolites of bromobenzene. Hanzlik, RP; Zheng, J, )	0.13
" The thioethers present in urine of animals dosed with thiophenes have been examined chromatographically."	( Thioethers as urinary metabolites of thiophene and monobromothiophenes. Christie, BJ; Guy, RW; Hickman, RJ; White, TJ, 1992)	0.28
" Pretreatment of the mice with a single dose of pyridostigmine prevented the development of jitter after subsequent dosing with an organophosphate."	( Protection against the effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Bamforth, JP; Das, SK; Ferry, CB; Kelly, SS, 1992)	0.28
" The co-prescription of intravenous N-acetylcysteine at a dosage of 10 g/24 hours in 10 of the 19 patients did not affect the blood pressure or the response to the GTN bolus compared with the 9 other patients who had received placebo after double-blind randomisation."	( [Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina]. Auclert, L; Blin, P; Guérin, C; Guérin, F; Pellois, A; Touiza, K; Weber, S, 1992)	0.28
"Twenty-four hours following injection of a single dose of the herbicide dichlobenil (2,6-dichlorobenzonitrile) in C57Bl/6 mice a steep dose-response curve for the histopathological toxicity in the olfactory mucosa was observed."	( Effects of glutathione-modulating agents on the covalent binding and toxicity of dichlobenil in the mouse olfactory mucosa. Brandt, I; Brittebo, EB; Eriksson, C, 1992)	0.28
" Myelosuppression and granulocytopenia correlated better with day 1 versus day 5 ifosfamide pharmacokinetics suggesting that the alteration of ifosfamide pharmacology with multiple dosing has a significant effect on drug activity."	( Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine. Ayele, W; Benvenuto, JA; Legha, SS; Newman, RA; Nicaise, C; Raber, MN, 1992)	0.28
"4-week treatment with N-acetylcystein administered three times a day 200 mg dissolved (n = 1734) or undissolved (n = 608) or at some other, usually lower, dosage (n = 173)."	( [Therapy of respiratory tract diseases with N-acetylcysteine. An open therapeutic observation study of 2,512 patients]. Schneider, B; Völkl, KP, 1992)	0.28
" Rats were dosed ip with 100 mg/kg of VPA, 4-ene-, or 2,4-diene-VPA, and methylated bile and urine extracts were analyzed by LC/MS/MS and GC/MS, respectively."	( Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Abbott, F; Farrell, K; Kassahun, K, )	0.13
" Three and 24 hr after the end of the infusion, each rabbit was anesthetized with pentobarbital and instrumented to monitor blood pressure, and dose-response curves were performed using SNAP or GTN."	( Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits. Chern, WH; Han, BJ; Lee, FW; Shaffer, JE, 1992)	0.28
"S-(N-Methylcarbamoyl)-N-acetylcysteine (AMCC), a chemically labile mercapturic acid conjugate, was identified by liquid chromatography-mass spectrometry (LC-MS) in the urine of rats dosed intraperitoneally with methyl isocyanate (MIC; 45."	( Biotransformation of methyl isocyanate in the rat. Evidence for glutathione conjugation as a major pathway of metabolism and implications for isocyanate-mediated toxicities. Baillie, TA; Han, DH; Pearson, PG; Rashed, MS; Slatter, JG, )	0.13
" N-Acetylcysteine given orally (600 mg/day) increases both plasma and bronchoalveolar lavage GSH in normal subjects, but a sustained increase in plasma GSH requires higher dosage regimens in patients with chronic obstructive pulmonary disease (600 mg three times daily)."	( The effects of N-acetylcysteine and glutathione on smoke-induced changes in lung phagocytes and epithelial cells. Bridgeman, MM; Donaldson, K; Drost, E; Lannan, S; MacNee, W; Marsden, M; Selby, C, 1991)	0.28
" None of the fetal animals attained serial plasma NAC levels that equalled those associated with therapeutic dosing or hepatoprotective effects in human beings."	( Transplacental transport of N-acetylcysteine in an ovine model. Clark, RF; Curry, SC; Johnson, BC; Meinhart, R; Pizziconi, VB; Selden, BS, 1991)	0.28
" The dosage dependent experiment stated above was repeated, adding alpha-tocopherol (vitamin E, 1 mM), reduced glutathione (GSH, 1 mM), N-acetylcysteine (0."	( Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. Barth, SA; Engemann, R; Heidemann, HT; Inselmann, G, 1991)	0.28
" All patients have been administered both products at a dosage of 200 mg."	( [Therapeutic efficacy and general tolerability of 4-carbomethoxythiazolidine chlorohydrate in a double-blind crossover experiment on chronic obstructive bronchopneumopathy]. Iaia, E, )	0.13
" This side effect can be found in excessive overdosages exceeding the therapeutical dosage significantly."	( [Paracetamol hepatotoxicity]. Lubec, G, 1990)	0.28
" Biliary metabolites from rats dosed with pentachlorothioanisole (PCTA) were characterized by fast atom bombardment mass spectrometry and electron impact mass spectrometry."	( Biliary excretion and intestinal metabolism in the intermediary metabolism of pentachlorothioanisole. Bakke, JE; Feil, VJ; Mulford, DJ, 1990)	0.28
" A 5-day-old calf dosed orally with 14C-propachlor excreted 70% dose in the urine as the cysteine conjugate; no mercapturic acid was detected."	( Evidence for the absence of cysteine S-conjugate N-acetyltransferase activity in the metabolism of propachlor, naphthalene, and dichlobanil in calves. Bakke, JE; Davison, KL; Larsen, GL, 1990)	0.28
" Both of these points strengthen the view that a low enzyme dosage is likely to have an effect on the incidence of MIE."	( The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of high-energy intake. Andersen, HO; Hjelt, K; Overgaard, K; Waever, E, 1990)	0.28
" This indicates that the beneficial clinical effects observed after repeated dosing can not be ascribed to an accumulation of NAC in plasma."	( Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Borgström, L; Kågedal, B, 1990)	0.28
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."	( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development. Holzmann, S; Kukovetz, WR, 1987)	0.27
"The S-(N-methylcarbamoyl) derivatives of glutathione, cysteine and N-acetylcysteine, the S-linked conjugates derived from a reactive metabolite of N-methylformamide (NMF), were studied in mice dosed with an equimolar mixture of NMF and deuterium-labelled NMF."	( The use of mass spectrometry in the study of chemically-reactive drug metabolites. Application of MS/MS and LC/MS to the analysis of glutathione- and related S-linked conjugates of N-methylformamide. Baillie, TA; Howald, WN; Pearson, PG; Rashed, MS, 1989)	0.28
" The effects of chronic dosing with N-acetylcysteine (NAC), on nitrate-induced haemodynamic changes during the acute and chronic treatment of healthy volunteers with glyceryl trinitrate (GTN) patches (Transiderm nitro) has been investigated."	( N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers. Henderson, AH; Hogan, JC; Lewis, MJ, 1989)	0.28
") did not alter the dose-response relation of GTN under tolerance."	( Nitrate action on epicardial coronary arteries and tolerance: new aspects based on longterm glyceryl trinitrate infusions in dogs. Bassenge, E; Holtz, J; Münzel, T; Stewart, DJ, 1989)	0.28
") had no dilator effect and did not alter the dose-response relations of nitroglycerin."	( Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Bassenge, E; Holtz, J; Mülsch, A; Münzel, T; Stewart, DJ, 1989)	0.28
" In a multiple dosing study of the same tablets in the same subjects, a high maintenance plasma level of NAC was revealed."	( Bioavailability of suckable tablets of oral N-acetylcysteine in man. Barindelli, E; De Bernardi di Valserra, M; Feletti, F; Galmozzi, MR; Lualdi, P; Mautone, G, 1989)	0.28
" The dosage schedule for intravenous N-acetylcysteine should probably be modified since adverse reactions invariably occur early when plasma concentrations are at their highest, and liver damage was prevented just as effectively at the lowest as at the highest Cmax."	( The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Donovan, JW; Jarvie, DR; Prescott, LF; Proudfoot, AT, 1989)	0.28
"A selective difference spectrophotometric procedure is described for the assay of ethacrynic acid (a diuretic drug) in pharmaceutical dosage forms."	( Determination of ethacrynic acid in pharmaceutical formulations by difference ultraviolet spectrophotometry after derivatisation with N-acetylcysteine. Bonazzi, D; Cavrini, V; Di Pietra, AM; Gatti, R, 1989)	0.28
" Nitrate tolerance can be avoided or minimized with dosing strategies that use intermittent administration of nitrates, using the smallest effective dose and providing a nitrate-free interval."	( [Tolerance of nitrate derivatives: pharmacologic and clinical aspects]. Berkenboom, G; Bethume, P; Degré, S; Unger, P, 1989)	0.28
"In a randomized, double-blind study, 38 patients undergoing elective pulmonary surgery were given N-acetylcysteine (Fabrol, Ciba-Geigy) in recommended dosage (200 mg X 3) or placebo."	( Peroral N-acetylcysteine as prophylaxis against bronchopulmonary complications of pulmonary surgery. Jepsen, S; Klaerke, A; Nielsen, PH; Nielsen, ST; Simonsen, O, 1989)	0.28
" All of the patients had received preliminary treatment with oral NAC in a dosage of 1,200 mg daily (Mucomyst Retard) or a placebo for 22 weeks in a double-blind design."	( [Steroid response after long-term treatment with oral N-acetylcysteine in patients with chronic obstructive bronchitis]. Balsløv, S; Brorson-Riis, L; Evald, T; Hansen, M; Hansen, NC; Maltbaek, N; Thorshauge, H, 1989)	0.28
"5 and 28 mg/kg), increased AF hepatotoxicity (10-fold shift in the dose-response effect on SGPT)."	( Mechanism of allyl formate-induced hepatotoxicity in rainbow trout. Davis, ME; Droy, BF; Hinton, DE, 1989)	0.28
"Various dosing strategies to determine therapeutic effects of nitroglycerin (NTG) preparations are reviewed."	( Hemodynamic attenuation and the nitrate-free interval: alternative dosing strategies for transdermal nitroglycerin. Flaherty, JT, 1985)	0.27
", N-acetyl-S-(1-cyano-2-hydroxyethyl)-L-cysteine (CHEMA) and N-acetyl-S-(2-hydroxyethyl)-L-cysteine (HEMA), were isolated from the urine of rats dosed with four successive doses of oxiranecarbonitrile (glycidonitrile, GN), 5 mg/kg, a reactive metabolic intermediate of acrylonitrile (AN)."	( N-acetyl-S-(1-cyano-2-hydroxyethyl)-L-cysteine, a new urinary metabolite of acrylonitrile and oxiranecarbonitrile. Linhart, I; Novák, J; Smejkal, J, 1988)	0.27
"A case of acetaminophen poisoning following the ingestion of 26 g of acetaminophen by incremental dosing over a 25-h period is reported."	( Subacute acetaminophen overdose after incremental dosing. Kuhns, DW; Mathis, RD; Walker, JS, )	0.13
"The hemodynamic and antianginal effects of 30 mg of isosorbide dinitrate (ISDN) were assessed in 12 patients with chronic stable angina after initial dosing and after 7 to 10 days of therapy four times daily."	( Nitrate tolerance: the lack of effect of N-acetylcysteine. Farrell, B; Lahey, KA; Parker, JO; Rose, BF, 1987)	0.27
" It is a process of limited capacity; the extent of sulfate conjugate formation and the metabolic clearance of drugs subject to conjugation with sulfate depend therefore on the dose, the dosage form, the route of administration, and the rate and duration of administration as well as on the pharmacokinetic parameters of competing processes."	( Sulfate conjugation in drug metabolism: role of inorganic sulfate. Levy, G, 1986)	0.27
" The excretion of Hg (after dosing with HgCl2) was not influenced by N-acetylcysteine."	( Differential effect of N-acetylcysteine on excretion of the metals Hg, Cd, Pb and Au. Ottenwälder, H; Simon, P, 1987)	0.27
" In group P a statistically significant, but transitory, rise in plasma ALAT level following dosage was seen."	( Efficacy of paracetamol-esterified methionine versus cysteine or methionine on paracetamol-induced hepatic GSH depletion and plasma ALAT level in mice. Aalen, O; Ingebrigtsen, K; Nafstad, I; Skoglund, LA, 1986)	0.27
" Male Fischer 344 rats were dosed by gavage with [methylene-14C]benzyl acetate (500 mg/kg) alone or together with pyrazole (200 mg/kg), pentachlorophenol (10 mg/kg) or both pentachlorophenol (10 mg/kg) and pyrazole (200 mg/kg), given in each case ip."	( Studies on benzyl acetate. II. Use of specific metabolic inhibitors to define the pathway leading to the formation of benzylmercapturic acid in the rat. Caldwell, J; Chidgey, MA; Kennedy, JF, 1986)	0.27
" Appreciable quantities of 1- and 2-naphthol (7-20% of dose) and 1,2-dihydro-1-hydroxy-2-methylthionaphthalene (1-35% of dose) were in urine from rats dosed orally or intracecally with 1,2-dihydro-1-hydroxy-2-S-cysteinylnaphthalene and 1,2-dihydro-1-hydroxy-2-S-(N-acetyl)cysteinylnaphthalene."	( Catabolism of premercapturic acid pathway metabolites of naphthalene to naphthols and methylthio-containing metabolites in rats. Bakke, J; Gustafsson, B; Gustafsson, JA; Struble, C, 1985)	0.27
" However, protection against formaldehyde lethality could be increased to 90% survivors by repeated dosing with L-ascorbic acid per se over a two day period prior to administration of formaldehyde."	( Protective action of sulfur compounds against aldehyde toxicants of cigarette smoke. Sprince, H, 1985)	0.27
" At the dosage regimen used in the present experiments, doxorubicin, NAC, or ICRF-187 alone or in combination did not cause alterations in lungs, liver, kidney, or small intestine."	( Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Ferrans, VJ; Herman, EH; Myers, CE; Van Vleet, JF, 1985)	0.27
" N-Acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate or the L- or D-isomers of 2-methylthiazolidine-4-carboxylate were administered to male mice immediately after a hepatotoxic dosage of acetaminophen (5."	( Effects of cysteine pro-drugs on acetaminophen-induced hepatotoxicity. Hazelton, GA; Hjelle, JJ; Klaassen, CD, 1986)	0.27
"This study was designed to investigate whether either of 2 dosage schedules of N-acetylcysteine (NAC) was effective in preventing chronic doxorubicin-induced heart failure in dogs."	( Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Balcerzak, SP; Hamlin, RL; Leier, CV; Unverferth, DV, 1985)	0.27
"Oral N-acetylcysteine (NAC), IV NAC, and IV sodium sulfate were evaluated as treatments for cats dosed orally with toxic sublethal doses of acetaminophen (APAP)."	( Effects of various antidotal treatments on acetaminophen toxicosis and biotransformation in cats. Leipold, HW; Oehme, FW; Savides, MC, 1985)	0.27
" S-(3-Hydroxypropyl)-l-cysteine was detected in the bile of a rat dosed with allyl acetate."	( Biosynthesis of mercapturic acids from allyl alcohol, allyl esters and acrolein. Kaye, CM, 1973)	0.25
"Rats dosed with cyclohexene oxide excreted only two of the four possible isomeric N-acetyl-S-2-hydroxycyclohexyl-L-cysteines, the two diastereoisomers of N-acetyl-S-(trans-2-hydroxycyclohexyl)-L-cysteine."	( Dose-dependent stereoselectivity in the formation of mercapturic acids from cyclohexene oxide by the rat. Breimer, DD; Cauvet, J; Seghers, CJ; van Bladeren, PJ; van der Gen, A; Vermeulen, NP, )	0.13
" Free 2,4,5- and 2,3,5-isomers of trichlorothiophenol amounted to 33% of the urinary metabolites in the po dosed rats and 28% in the iv dosed rats; free 2,4,5- and 2,3,5-TCP's amounted to 1% and 10%, respectively."	( Comparative metabolism of 1,2,4-trichlorobenzene in the rat and rhesus monkey. Cragg, S; Kaylor, WH; Kopfler, FC; Lingg, RD; Pyle, SM; Smith, CC; Wolfe, GF, )	0.13
" The most common feature of the anaphylactoid reaction to normal dosage was rash; other features reported included angioedema, hypotension, and bronchospasm; all the patients recovered."	( Adverse reactions to acetylcysteine and effects of overdose. Mant, TG; Talbot, JC; Tempowski, JH; Volans, GN, 1984)	0.27
" In the blood, urine and feces of rats dosed with m-DCB, 2,4- and 3,5-dichlorophenyl methyl sulfoxides and 3,5- and 2,4-dichlorophenyl methyl sulfones emerged, while their possible precursors, 3,5- and 2,4-dichlorophenyl methyl sulfides (Me' and Mf', respectively), were not detected in the blood, urine and feces."	( Identification of sulfur-containing metabolites of m-dichlorobenzene and their disposition and relationship with glutathione in rats. Itagaki, K; Kimura, R; Kogure, T; Murata, T; Sano, H; Sato, M, 1984)	0.27
"Rats dosed with cinnamic aldehyde (I) excreted two mercapturic acids in the urine."	( Isolation and identification of mercapturic acids of cinnamic aldehyde and cinnamyl alcohol from urine of female rats. Delbressine, LP; Klippert, PJ; Reuvers, JT; Seuttler-Berlage, F, 1981)	0.26
" Five of the cats were given antidotal treatment with acetylcysteine (140 mg/kg, per os) at the time of the second dosing with acetaminophen and at 8-hour intervals thereafter for a total of three treatments."	( Acetylcysteine for treatment of acetaminophen toxicosis in the cat. McKnight, ED; St Omer, VV, 1980)	0.26
" The mercapturic acid conjugate in rats was also studied by collection of urine of rats dosed with radioactive DNBB by intraperitoneal injection."	( Glutathione and mercapturic acid conjugations in the metabolism of 2,4-dinitrobromobenzene. Chen, KC; Dorough, HW, 1980)	0.26
" N-Acetylcysteine pretreatment also significantly reduced the percentage of cardiac cells with T-tubule dilation and myelin figures in adult rats dosed with IQ."	( Protective effect of N-acetylcysteine against heterocyclic amine-induced cardiotoxicity in cultured myocytes and in rats. Davis, CD; Snyderwine, EG, 1995)	0.29
"To verify and quantify lipidic peroxidation by means of tiobarbituric-acid reactive substance (TBARS) dosage in patients treated daily with HBO."	( [Assessment of lipid peroxidation in hyperbaric oxygen therapy: protective role of N-acetylcysteine]. Alampi, D; Araimo, FS; De Blasi, RA; Nicolucci, S; Pelaia, P; Rocco, M; Spadetta, G, 1995)	0.29
" Data are also presented for the isolation and analysis of this compound obtained from dosed rats."	( Quantitation of the tetrachloroethylene metabolite N-acetyl-S-(trichlorovinyl)cysteine in rat urine via negative ion chemical ionization gas chromatography/tandem mass spectrometry. Bartels, MJ, 1994)	0.29
" The excretion of urinary metabolites was studied in rat dosed intraperitoneally with ethyl acrylate and 1-butyl acrylate."	( Biotransformation of acrylates. Excretion of mercapturic acids and changes in urinary carboxylic acid profile in rat dosed with ethyl and 1-butyl acrylate. Linhart, I; Smejkal, J; Vosmanská, M, 1994)	0.29
" After establishing a dose-response relationship for single or fractionated light dose illumination of the skin, drugs known to scavenge radicals, quench singlet oxygen or interfere with histamine release were tested for their protective effect."	( Partial protection of photodynamic-induced skin reactions in mice by N-acetylcysteine: a preclinical study. Baas, P; Oppelaar, H; Stewart, FA; van der Valk, MA; van Zandwijk, N, 1994)	0.29
" The latter dosage regimen was also given to six patients before bronchoscopy and to 11 patients before lung resection."	( Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Bridgeman, MM; MacNee, W; Marsden, M; Morrison, D; Selby, C, 1994)	0.29
"A direct semimicro conductometric method is described for the determination of five pharmaceutically-important thiol compounds, namely: N-acetylcysteine, captopril, D-penicillamine, 6-mercaptopurine and thioguanine, in bulk and in dosage forms."	( Conductometric determination of some pharmaceutically important thiol compounds in dosage forms. Belal, F; Eid, MM; Rizk, MS, 1993)	0.29
" To obtain a virtually complete metabolic pattern, rats were dosed by a single intraperitoneal dose of 1 mmol/kg 1-butyl [3-13C]acrylate."	( Metabolic pathways of 1-butyl [3-13C]acrylate. Identification of urinary metabolites in rat using nuclear magnetic resonance and mass spectroscopy. Hrabal, R; Linhart, I; Mitera, J; Smejkal, J, )	0.13
" dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1."	( Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies. Mollace, V; Pistelli, A; Salvemini, D, 1993)	0.29
" This unusually high concentration of 5OXP in the urine and its prevention by methionine indicates that chronic high level paracetamol dosing leads to severe depletion of sulphur-containing amino acids including cysteine with consequent disruption of the glutathione cycle."	( Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4-aminophenol (paracetamol). Beales, D; Ghauri, FY; McLean, AE; Nicholson, JK; Wilson, ID, 1993)	0.29
" Repeated dosing with the lower dose level (3 mg/kg) resulted in either no change, or in some instances, a reduction in the above parameters, suggesting an accumulation of the xenobiotic and a masking of the induction phenomenon."	( Dose-dependent induction or depression of cysteine conjugate beta-lyase in rat kidney by N-acetyl-S-(1,2,3,4,4-pentachloro-1,3-butadienyl)-L-cysteine. David, M; Gibson, GG; Goldfarb, PS; King, LJ; Lock, EA; MacFarlane, M; Parker, N; Roelandt, L; Schofield, M, 1993)	0.29
" Our studies suggest a dose-response relationship for ifosfamide."	( Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)	0.29
" There was a dose-response relationship between the formation of CE adducts with rat blood proteins, urinary mercapturic acids when the poison was given in a dose of 1-50 mg/kg."	( [Biological monitoring of exposure to alkylating xenobiotics by determining them in complexes with plasma proteins, hemoglobin, mercapturic acids from urine of rats and industrial workers. I. Acrylonitrile]. Hashimoto, K; Inomata, K; Ivanov, VV; Kawai, T; Klimatskaia, LG; Mizunuma, K, )	0.13
" Follow-up by the certified Regional Poison Information Center at 1-3 w post-discharge determined dosing compliance to be 83%."	( Outpatient N-acetylcysteine treatment for acetaminophen poisoning: an ethical dilemma or a new financial mandate? Bricker, JD; Dean, BS; Krenzelok, EP, 1996)	0.29
" The dose-response relationship describing the effects of NAC on lymphocyte proliferation with Con A-induced responses were enhanced in a dose-dependent manner, whereas the corresponding LPS-induced responses increased to a maximum level followed by decline in responses at higher concentrations of NAC."	( Immunomodulatory and protective effects of N-acetylcysteine in mitogen-activated murine splenocytes in vitro. Bernier, J; Blakley, BR; Fournier, M; Omara, FO, 1997)	0.3
" Dose-response determinations were made for each drug before and after an intra-arterial infusion of the reduced thiol, N-acetylcysteine, at rates estimated to achieve a physiological concentration of 1 mmol/L."	( N-acetylcysteine does not influence the activity of endothelium-derived relaxing factor in vivo. Boles, K; Creager, MA; Roddy, MA; Stamler, JS, 1997)	0.3
" However, the high incidence of side effects limits the clinical applicability of this therapeutic strategy at least at the dosage used in the present study."	( Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Ardissino, D; Bertocchi, F; Demicheli, G; Falcone, C; Ghio, S; Marinoni, G; Merlini, PA; Montemartini, C; Mussini, A; Savonitto, S; Zanini, P, 1997)	0.3
" In our study, rats were dosed with either disulfiram (0."	( Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates. Baillie, TA; Hu, P; Jin, L, 1997)	0.3
" Further studies to determine the optimum dosage regimen in such patients are required."	( Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Hayes, PC; Jarvie, DR; Jones, AL; Prescott, LF; Simpson, D, 1997)	0.3
" Theophylline provides little additional benefit in patients who receive frequent doses of inhaled bronchodilators and an adequate dosage of a glucocorticoid."	( Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Ikeda, A; Izumi, T; Nishimura, K, 1998)	0.3
" The findings indicate that 1) SNAC does not influence contractile function of EDL muscle not subjected to ischemia-reperfusion, 2) SNAC significantly protects the contractile function of ischemic skeletal muscle against reperfusion injury in the early reperfusion period, and 3) the protective role of SNAC is critically dosage dependent; protection is lost at higher doses."	( Effects of S-nitroso-N-acetylcysteine on contractile function of reperfused skeletal muscle. Chen, LE; Nasser, RM; Seaber, AV; Stamler, JS; Urbaniak, JR, 1998)	0.3
"Urine of rats dosed with styrene (240 mg/kg), R-, S- and racemic styrene oxide (150 mg/kg) was analysed for mandelic acid enantiomers and for regioisomers and diastereomers of mercapturic acids by NMR spectrometry."	( Stereochemical aspects of styrene biotransformation. Linhart, I; Mládková, I; Smejkal, J, 1998)	0.3
"From the selected studies, information was obtained regarding patient population, dosing regimen, duration of study, and effects on splanchnic blood flow (SBF), splanchnic oxygenation, and pHi."	( Effects of vasoactive drugs on gastric intramucosal pH. Créteur, J; DeBacker, D; Silva, E; Vincent, JL, 1998)	0.3
" However, a higher gene dosage of the transgenic Bcl-2 was required for protection against Dex, compared to the PMA and/or ionomycin-induced apoptosis."	( Biochemical and kinetic characterization of the glucocorticoid-induced apoptosis of immature CD4+CD8+ thymocytes. Ivanov, VN; Nikolić-Zugić, J, 1998)	0.3
" The concentrations of the different antioxidants were: 1 mM for thioproline and N-acetylcysteine and 5 microM for ascorbic acid and alpha-tocopherol, which induced a maximum effect in our previous dose-response experiments."	( Effects in vitro of several antioxidants on the natural killer function of aging mice. Correa, R; De la Fuente, M; Del Rio, M; Ferrández, MD, 1999)	0.3
"120 consecutive patients affected by biopsy-proven chronic hepatitis C who had been non-responders to a previous course of alpha-interferon, administered at the dosage of 3-6 million units (MU) three times a week (tiw) for 6 months."	( Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Airoldi, A; Bellobuono, A; Benetti, G; Bissoli, F; Cestari, C; Colombo, E; Del Poggio, P; Fracassetti, O; Idéo, G; Lazzaroni, S; Marelli, A; Mondazzi, L; Paris, B; Prada, A; Rainer, E; Roffi, L; Tempini, S, 1999)	0.3
"The patients were randomly assigned to one of two groups of treatment: group A, natural interferon-alphaN3, 6 or 9 MU tiw, when the body weight was < 60 kg or > or = 60 kg, respectively; group B, the same dosage of natural interferon-alphaN3 in association with oral administration of N-acetyl cysteine 1200 mg/day and vitamin E 600 mg/day."	( Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Airoldi, A; Bellobuono, A; Benetti, G; Bissoli, F; Cestari, C; Colombo, E; Del Poggio, P; Fracassetti, O; Idéo, G; Lazzaroni, S; Marelli, A; Mondazzi, L; Paris, B; Prada, A; Rainer, E; Roffi, L; Tempini, S, 1999)	0.3
" In many clinical situations acetylcysteine is used empirically utilising modifications of dosage regimens employed for paracetamol poisoning."	( Utility of acetylcysteine in treating poisonings and adverse drug reactions. Butler, AY; Chyka, PA; Herman, MI; Holliman, BJ, 2000)	0.31
" As is true for most all potentially beneficial medicines used in pediatrics, awareness of the actual amount of drug received from all sources and caution to not exceed the age-appropriate dosing guidelines (i."	( Acetaminophen intoxication during treatment: what you don't know can hurt you. Kearns, GL; Leeder, JS; Wasserman, GS, 2000)	0.31
"The dose-response study showed that H(2)O(2) > or = 100 microM was severely cytotoxic."	( Adverse effects of oxidative stress on renal cells and its prevention by antioxidants. Davidson, SD; Eshghi, M; Konno, S; Mallouh, C; Nowzari, FB; Tazaki, H, 2000)	0.31
" Measurement of the rate of ROS production in the presence of varying concentrations of cysteine together with 20 microM ferrous iron revealed a dose-response relationship."	( Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Bondy, SC; Campbell, A; Yang, EY, 2000)	0.31
" ICG significantly decreased the bile flow rate and biliary concentration of APAP-glutathione, APAP-glucuronide and APAP-mercapturate within the first hour after dosing without affecting the biliary concentration of APAP."	( Effects of clofibrate and indocyanine green on the hepatobiliary disposition of acetaminophen and its metabolites in male CD-1 mice. Chen, C; Hennig, GE; Manautou, JE; McCann, DJ, 2000)	0.31
"Patients were randomly assigned to receive either NAC (n = 15) for 4 days in increasing dosages (day 1: 6 g; day 2: 12 g; days 3 and 4: 18 g) or a mucolytic basis dosage of NAC (3 x 300 mg/day [control]; n = 15), respectively."	( N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. Breitkreutz, R; Groth, G; Heller, AR; Heller, SC; Koch, T; Nebe, T; Quintel, M, 2001)	0.31
" immediately after paracetamol overdose (T0) and 6 h after dosing (T6) and those administered S-adenosyl-L-methionine at doses of 20 mg/kg (0."	( Effect of different doses of S-adenosyl-L-methionine on paracetamol hepatotoxicity in a mouse model. Carrasco, R; Caturla, J; Esteban, A; Gutiérrez, A; Mayol, MJ; Ortiz, P; Pérez-Mateo, M, 2000)	0.31
" The dosage of NAC should therefore be modified to avoid these disadvantages."	( Influence of N-acetylcysteine on hepatic amino acid metabolism in patients undergoing orthotopic liver transplantation. Babylon, A; Breitkreutz, R; Dröge, W; Martin, E; Taut, FJ; Thies, JC; Zapletal, CM, 2001)	0.31
" We have examined prospectively in routine clinical practice the concentrations of intravenous infusions of a drug (acetylcysteine) which is given according to a complicated dosing schedule."	( Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Anton, C; Bateman, DN; Ferner, RE; Hutchings, A; Langford, NJ; Routledge, PA, 2001)	0.31
"Our data suggest that there is large random variation in administered dosage of intravenous infusions."	( Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Anton, C; Bateman, DN; Ferner, RE; Hutchings, A; Langford, NJ; Routledge, PA, 2001)	0.31
"03 micromol/L could inhibit neural cell variability and differentiation by 50%, respectively, both in a significant dose-response pattern."	( [Toxicity to neural cell development of lead and its relation to glutathione]. Fu, S; Li, H, 2000)	0.31
" Thiamphenicol is present as glycinate hydrochloride (TG) and glycinate acetylcysteinate (TGA) esters in the parenteral and aerosol dosage form."	( Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. De Benedetto, F; Grassi, C, 2002)	0.31
" SNAC reduced the medium arterial pressure in a dose-response manner in both normotensive and hypertensive animals."	( Characterization of the hypotensive effect of S-nitroso-N-acetylcysteine in normotensive and hypertensive conscious rats. de Oliveira, MG; Krieger, MH; Ricardo, KF; Shishido, SM, 2002)	0.31
" We measured cysteinyl adducts of these metabolites in hemoglobin (Hb) and albumin (Alb) from F344 rats dosed with 100-800 mg naphthalene per kg body weight."	( Measurement of hemoglobin and albumin adducts of naphthalene-1,2-oxide, 1,2-naphthoquinone and 1,4-naphthoquinone after administration of naphthalene to F344 rats. Lindstrom, AB; Rappaport, SM; Troester, MA; Waidyanatha, S, 2002)	0.31
" In addition to the lack of studies on efficacy, no studies on the dose-response relationship were available, leading to suggested dose regimens in the French license of acetylcystein ranging from 44."	( [Mucolytic agents for acute respiratory tract infections in infants: a pharmacoepidemiologic problem?]. Assathiany, R; Bavoux, F; Bréart, G; Chalumeau, M; Chéron, G; Moulin, F; Pons, G, 2002)	0.31
" Both oxidative stress and apoptosis exhibited a dose-response relationship with CSE concentrations."	( Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts. Barale, R; Carnevali, S; Celi, A; Cipollini, M; Giuntini, C; Longoni, B; Paggiaro, P; Petruzzelli, S; Scatena, F; Vanacore, R, 2003)	0.32
" at a dosage of 1000 mg kg-1 day-1 for more than 1 wk before mating were assessed morphologically by stereomicroscopy."	( Infertility observed in reproductive toxicity study of N-acetyl-L-cysteine in rats. Furuhashi, T; Harada, M; Hiraoka, I; Kawaguchi, Y; Kishimoto, K; Naito, K; Nakashima, Y, 2003)	0.32
"The currently recommended dosing scheme for treating acetaminophen overdose in the United States consists of a loading dose of oral N-acetylcysteine 140 mg/kg, followed by 70 mg/kg every 4 hours for 17 doses, for a total of 72 hours of oral N-acetylcysteine therapy."	( Acetaminophen intoxication and length of treatment: how long is long enough? Kociancic, T; Reed, MD, 2003)	0.32
"Acetaminophen, a safe analgesic when dosed properly but hepatotoxic at overdoses, has been reported to induce DNA strand breaks but it is unclear whether this event preceeds hepatocyte toxicity or is only obvious in case of overt cytotoxicity."	( Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity. El-Bahay, C; Hanelt, S; Kahl, R; Lewerenz, V; Nastevska, C; Röhrdanz, E, 2003)	0.32
" Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3)."	( N-acetylcysteine in severe falciparum malaria in Thailand. Brittenham, G; Carroll, J; Krudsood, S; Kuhn, WF; Looareesuwan, S; Maek-A-Nantawat, W; Saengnetswang, T; Tosukhowong, T; Treeprasertsuk, S; Vannaphan, S, 2003)	0.32
" One of the diastereoisomeric forms of the methyl ester of the mercapturic acid is identical with the ester of the mercapturic acid excreted by rats dosed with the epoxide or by rats and rabbits dosed with phenanthrene."	( METABOLISM OF POLYCYCLIC COMPOUNDS. THE METABOLISM OF 9,10-EPOXY-9,10-DIHYDROPHENANTHRENE IN RATS. BOYLAND, E; SIMS, P, 1965)	0.24
" We therefore propose a reconsideration of the individual effective dose or individual tolerance concept postulated by Gaddum 50 years ago for the log-normal dose-response relationship."	( Fish tolerance to organophosphate-induced oxidative stress is dependent on the glutathione metabolism and enhanced by N-acetylcysteine. Ferrando, MD; Peña, JB; Peña-Llopis, S, 2003)	0.32
"We previously reported infertility in female rats that received N-acetyl-L-cysteine (NAC) intravenously at a dosage of 1000 mg/kg/day."	( Infertility observed in female rats treated with N-acetyl-L-cysteine: Histopathological examination of ovarian follicles and recovery of fertility. Hagiwara, R; Harada, M; Kawaguchi, Y; Kishimoto, K; Kurisu, K; Nakashima, Y, 2003)	0.32
" Of seven prospective studies using various dosing regimens of N-acetylcysteine, four revealed beneficial results."	( Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Brokering, KL; Theobald, JC; Walker, PD, 2003)	0.32
" All showed close dose-response relationship."	( [A study on biomarkers of styrene]. Cheng, H; Shao, H; Shi, YK; Wang, XY; Zhang, MP, 2003)	0.32
" However, the impact of long-term oral dosing on tissue pathology has not been determined."	( Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology. Arfsten, D; Bausman, T; Bobb, A; Eggers, J; Johnson, E; Jung, A; Lohrke, S; Thitoff, A; Wilfong, E, )	0.13
"Although there are controversies on dosing and timing, the use of acetylcysteine together with hydration should be considered to protect patients from radiographic contrast media-induced nephropathy."	( N-Acetylcysteine in nephrology; contrast nephropathy and beyond. Tepel, M; Zidek, W, 2004)	0.32
" We observed in our present study that DDC induced not only apoptosis but also necrosis depending on its dosage in HL60 premyelocytic leukemia cells."	( Diethyldithiocarbamate can induce two different type of death: apoptosis and necrosis mediating the differential MAP kinase activation and redox regulation in HL60 cells. Kimoto-Kinoshita, S; Nishida, S; Tomura, TT, 2004)	0.32
" Additional studies aimed at long-term analysis and investigation of injury severity--or dosage dependency are needed."	( Acute effects of N-acetylcysteine on skeletal muscle microcirculation following closed soft tissue trauma in rats. Bail, HJ; Haas, NP; Melcher, I; Mittlmeier, T; Schaser, KD; Schewior, L; Stover, JF, 2005)	0.33
" Trials varied in patient demographic characteristics, inclusion criteria, dosing regimens, and trial quality."	( Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Bates, ER; Hofer, TP; Humes, HD; Moscucci, M; Nallamothu, BK; Saint, S; Shojania, KG, 2004)	0.32
" The clinical value of this treatment regimen is probably restricted, both due to the unfavourable post-traumatic internal environment and imposed dosing limitations."	( N-Acetylcysteine administered as part of the immediate post-traumatic resuscitation regimen does not significantly influence initiation of inflammatory responses or subsequent endotoxin hyporesponsiveness. Gundersen, Y; Opstad, PK; Sterri, SH; Thrane, I; Vaagenes, P, 2005)	0.33
" The treatment consisted of either 600 mg NAC bid, 500 mg Vitamin C bid, a combination of those two substances using the same dosage or a placebo-preparation."	( [Antioxidant treatment with N-acetylcysteine and vitamin C in patients with chronic bronchitis]. Gillissen, A; Lukas, R; Schärling, B; Schultze-Werninghaus, G, 2005)	0.33
" While N-acetylcysteine is inexpensive and nontoxic, undeviating insistence for dosing at least 12 hours in advance of contrast exposure may delay diagnostic and therapeutic procedures."	( N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. Bent, S; Ix, J; Liu, R; Moore, DH; Nair, D, 2005)	0.33
"Two conflicting phenomena, bystander effect and adaptive response, are important in determining the biological responses at low doses of radiation and have the potential to impact the shape of the dose-response relationship."	( Radiation-induced bystander effect and adaptive response in mammalian cells. Hei, TK; Randers-Pehrson, G; Waldren, CA; Zhou, H, 2004)	0.32
" Urine samples before dosing and within 46 h after the dose were analysed for d(3)-AAMA and d(3)-GAMA by LC-ESI-MS/MS."	( Excretion of mercapturic acids of acrylamide and glycidamide in human urine after single oral administration of deuterium-labelled acrylamide. Angerer, J; Boettcher, MI; Bolt, HM; Drexler, H, 2006)	0.33
" The variability in study results may reflect differences in baseline risks in study patients, hydration regimens, choice of contrast agent, definition of RCIN, and the oral dosage formulation of N-acetylcysteine used."	( N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Humphries, KH; Levin, A; Pate, GE; Shalansky, SJ; Vu, T; Webb, JG, 2005)	0.33
" Various dosing solutions containing a penetration enhancer in the absence or in the presence of NAC were directly administered into the exposed rat jejunum, and the bioavailability of FD-4 up to 2 h was determined."	( Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Horikiri, Y; Kitazawa, T; Morita, T; Takatsuka, S; Yoshino, H, 2006)	0.33
" Data extraction included patient characteristics, intravenous fluid regimen, type and dose of contrast media, dosing regimen, creatinine at baseline and 48 hours and CIN requiring dialysis."	( N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Azadpour, M; Hennekens, CH; Mercado, C; Zagler, A, 2006)	0.33
" The treatment duration was 5 days at usual recommended dosage regimens."	( [Efficacy of Derinox assessed with one PNIF (Peak Nasal Inspiratory Flow) in patients suffering from common cold]. Bruhwyler, J; Concas, V; Dessanges, JF; Peynegre, R, 2005)	0.33
" It was concluded that under controlled study conditions: (1) 1-OHP, S-PMA and t,t-MA are useful biomarkers that could differentiate exposure between smoking conventional and EHCSS cigarettes or between smoking conventional cigarettes and no smoking; between S-PMA and t,t-MA, the former appeared to be more sensitive; (2) 3-MeAd could only differentiate between smoking conventional cigarettes and no smoking; the results for 3-EtAd were not conclusive because contradictory results were observed; (3) 8-OHdG had a questionable association with smoking and therefore the utility of this biomarker for smoking-related exposure could not be established; and (4) urinary excretion of thioethers as a biomarker lacked sensitivity to demonstrate a clear dose-response relationship in conventional cigarette smokers, although it could differentiate the excretion levels between those subjects who smoked a conventional cigarette and those who stopped smoking."	( Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2'-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke. Engl, J; Feng, S; Jin, Y; Kinser, R; Liang, Q; Riedel, K; Roethig, HJ; Scherer, G; Urban, M, )	0.13
" Dosing solutions containing these agents were administered directly into the rat jejunum, and the bioavailability of SCT up to 2 h was determined."	( Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant. Horikiri, Y; Koguchi, A; Morita, T; Takatsuka, S; Yamahara, H; Yoshino, H, 2006)	0.33
" The determination of total SPMA allows the standardization of the preanalyticalfactors and the dosage with analytical methods less sensitive than HPLC/MS/MS."	( [Determination of free and total S-phenylmercapturic acid in the biologic monitoring of exposure to benzene]. Cialdella, A; Faranda, P; Paci, E; Pigini, D; Tranfo, G, )	0.13
"This patient with multiple risk factors and severe hepatotoxicity after therapeutic dosage of acetaminophen was successfully treated with N-acetylcysteine."	( Severe hepatotoxicity after therapeutic doses of acetaminophen. Cairon, E; Mian, P; Moling, O; Pristerá, R; Rimenti, G; Rizza, F, 2006)	0.33
" Although supportive care is sufficient in many cases, a specific antidote can significantly reduce morbidity and mortality in a number of poisoning scenarios, and so the pediatric emergency medicine practitioner must be familiar with its indications for use, dosage and administration, and contraindications."	( New and novel antidotes in pediatrics. Calello, DP; Henretig, FM; Osterhoudt, KC, 2006)	0.33
" In contrast to the protective effects of L-NAC against noise-induced hearing loss, the lack of protective effect in this study may be due to (i) the dosage level; (ii) the duration of treatment; (iii) the biochemical mechanisms underlying age-induced hearing loss; or (iv) how the mouse metabolizes L-NAC."	( N-Acetyl L-cysteine does not protect against premature age-related hearing loss in C57BL/6J mice: a pilot study. Alagramam, KN; Canlon, B; Davis, RR; Krieg, E; Kuo, MW; Stanton, SG, 2007)	0.34
" Animals were sacrificed 24h after the last dosing for various biochemical parameters."	( Co-administration of zinc and n-acetylcysteine prevents arsenic-induced tissue oxidative stress in male rats. Flora, SJ; Kannan, GM; Kaul, RK; Modi, M, 2006)	0.33
" LPS was intraperitoneally injected at a dosage of 20mg/kg."	( Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine. Demiralay, R; Erdem, H; Gürsan, N, 2006)	0.33
" The group which showed the best protection was that which received a total dosage of 1500 mg/kg of L-N-acetyl-cysteine."	( Noise-induced hearing loss: a study on the pharmacological protection in the Sprague Dawley rat with N-acetyl-cysteine. Giordano, P; Hatzopoulos, S; Lorito, G; Martini, A; Prosser, S, 2006)	0.33
" Although initial response to all pediatric poisonings begins with basic stabilization, knowledge of specific antidotes, their mechanisms of action, safety profile in pediatrics, and dosing regimens can be life-saving for pediatric victims of nerve gas exposure, acetaminophen toxicity, methanol and ethylene glycol ingestion, and snakebites."	( Update on antidotes for pediatric poisoning. Liebelt, EL; White, ML, 2006)	0.33
" Concentrations of AA and AAMA correlated significantly with average AUC values determined previously for AA in groups of rats and mice similarly dosed with AA."	( Urinary excretion of acrylamide and metabolites in Fischer 344 rats and B6C3F(1) mice administered a single dose of acrylamide. Angerer, J; Boettcher, MI; Doerge, DR; McDaniel, LP; Twaddle, NC, 2007)	0.34
" Dosing solutions containing these agents were administered into various mucosal sites including the nose, the lung and the large intestine, and the bioavailabilities were determined."	( Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant. Horikiri, Y; Morita, T; Saji, H; Takatsuka, S; Yamahara, H, 2007)	0.34
"With similar intravenous hydration protocols, 20 patients received N-acetylcysteine (treatment group) and 20 patients received placebo (control group) in a twice per day dosing regimen with one dose before and three doses after contrast media exposure."	( Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Ferguson, IA; Jensen, LA; Seyon, RA; Williams, RG, )	0.13
" Repeated dosing was administered intraperitoneally every 4 to 6 hours for 48 hours."	( Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model. Betten, DP; Clark, RF; Favata, M; Hernandez, M; Richardson, WH; Riffenburgh, RH; Tanen, DA; Tong, TC, 2007)	0.34
" This study assessed the ability of doctors and nurses to calculate correct doses using manual calculation skills and a weight-based NAC dosing chart when prescribing and preparing NAC infusions."	( Weight-based N-acetylcysteine dosing chart to minimise the risk of calculation errors in prescribing and preparing N-acetylcysteine infusions for adults presenting with paracetamol overdose in the emergency department. Calvert, SH; Cavell, G; Glucksman, E; Gonzalez, J; Kerins, M; Selvan, VA, 2007)	0.34
" dosing of 3 mg/kg."	( Metabolic profile of [(14)C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. Chovan, JP; Li, F; Ring, SC; Yu, E, 2007)	0.34
" Trials varied in patient demographic characteristics, inclusion criteria, dosing regimens, and trial quality."	( [Prophylaxis of contrast-induced nephropathy with N-acetylcysteine]. Brunkwall, J; Gawenda, M; Möller, A; Wassmer, G, 2007)	0.34
"The distribution of radio-labeled N-Acetyl-L-Cysteine (NAC) and its impact on glutathione (GSH) metabolism was studied in Sprague-Dawley rats following single and multiple dosing with NAC by oral gavage."	( Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage. Arfsten, DP; Bobb, AJ; Johnson, EW; Jung, AE; Wilfong, ER, 2007)	0.34
" Various dosing solutions were administered into rat jejunum, and the bioavailability of FD-4 was determined."	( Influence of various combinations of mucolytic agent and non-ionic surfactant on intestinal absorption of poorly absorbed hydrophilic compounds. Horikiri, Y; Morita, T; Saji, H; Takatsuka, S; Yamahara, H, 2008)	0.35
"5 or 2% NAC using standard dosing schemes."	( N-Acetylcysteine as an adjunct for refractory ear infections. Choe, WT; Murray, MT; Roberson, JB; Stidham, KR, 2007)	0.34
" This study examines the dose-response relationship of NAC in preventing neuronal death."	( Analysis of the dose-response of N-acetylcysteine in the prevention of sensory neuronal loss after peripheral nerve injury. Hart, AM; Terenghi, G; West, CA; Wiberg, M, 2007)	0.34
" Significant neuronal loss was observed in the 1 mg/kg/day dosage group (18."	( Analysis of the dose-response of N-acetylcysteine in the prevention of sensory neuronal loss after peripheral nerve injury. Hart, AM; Terenghi, G; West, CA; Wiberg, M, 2007)	0.34
" First, the efficacy of the acivicin treatment was established from a dose-response investigation in which urinary gamma-GT was measured daily in rats exposed to 1750 ppm toluene, 6 h per day for five days."	( Toluene-induced hearing loss in acivicin-treated rats. Campo, P; Cosnier, F; Cossec, B; Ferrari, L; Grossman, S; Waniusiow, D, )	0.13
" The dosing regimen is complex, consisting of a loading dose followed by 2 maintenance doses, each with different infusion rates."	( Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Doyon, S; Hayes, BD; Klein-Schwartz, W, 2008)	0.35
"To analyze the frequency of medication errors related to the complex dosing regimen for intravenous acetylcysteine."	( Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Doyon, S; Hayes, BD; Klein-Schwartz, W, 2008)	0.35
" Then the optimal dosage and incubation time of NAC intervention in apoptosis were ascertained, and the differences between induction and intervention of apoptosis, including the percentage of apoptosis, the expression of apoptotic protein (GRP78, Caspase-12, PARP) and the production of reactive oxygen species (ROS) were compared."	( [The effect of N-acetyl-L-cysteine on endoplasmic reticulum stress mediated apoptosis of HepG2 cells]. Guo, Q; Jiang, S; Lin, LY; Liu, YY; Wang, H; Xie, Q; Yu, H; Zhou, XQ, 2008)	0.35
" The single injection dosage was 375 mg/kg; the controls received an equal volume of saline solution."	( Different strategies in treating noiseinduced hearing loss with N-acetylcysteine. Giordano, P; Hatzopoulos, S; Lorito, G; Martini, A; Petruccelli, J, 2008)	0.35
" The multivariate analysis showed that the dosage of NAC is inversely correlated with Scr independent of baseline Scr and dosage of contrast media."	( Preventive effect of N-acetylcysteine on contrast-induced nephropathy following coronary angiography and angioplasty. Asano, R; Hamada, H; Kamiyama, N; Ogawa, R; Ohno, T; Umemura, J; Yoshida, H, 2008)	0.35
" Rats (10/group) were dosed with 0-100mg/kg allyl acetate, 0-25mg/kg allyl alcohol, or 0-10mg/kg acrolein."	( A comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein. Auerbach, SS; Irwin, RD; Mahler, J; Travlos, GS, 2008)	0.35
" This case suggests that individualized dosing of antidotal therapy may be needed for preparations of acetaminophen that result in delayed absorption or after massive overdose."	( Development of hepatic failure despite use of intravenous acetylcysteine after a massive ingestion of acetaminophen and diphenhydramine. Hayes, BD; Sarmiento, KF; Schwartz, EA, 2009)	0.35
" The results obtained suggest that in a pathophysiological condition, such as PE, the deleterious effect of reactive oxygen species may be counteract by an antioxidant therapy, and there is the need to investigate the optimum dosing and timing of antioxidants administration, since an inappropriate antioxidant treatment in pregnant women may have deleterious consequences, reducing placental cells proliferation until to cell death."	( Effects of vitamin E and C on placental oxidative stress: an in vitro evidence for the potential therapeutic or prophylactic treatment of preeclampsia. Capasso, A; Fiore, G, 2008)	0.35
" There is a need for delivery of NAC which can enhance its efficacy, reduce dosage and prevent it from binding plasma proteins."	( Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Kannan, RM; Kannan, S; Kurtoglu, YE; Navath, RS; Romero, R; Wang, B, 2009)	0.35
" According to pharmacokinetic data, parenteral administration of ascorbate decreased the growth rate of a murine hepatoma, whereas oral administration of the same dosage did not."	( Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Calderon, PB; Verrax, J, 2009)	0.35
" Patients were randomized to treatment with thiamphenicol glycinate acetylcysteinate, dosage 250 mg/day in 2 administrations plus beclomethasone with a dosage of 400 microg/day in 2 administrations, or no treatment, control group, unless required."	( Aerosol antibiotic therapy in children with chronic upper airway infections: a potential alternative to surgery. Castelnuovo, P; Macchi, A, )	0.13
" For in vivo studies, adult cycling CD-1 mice were dosed with MXC or vehicle for 20 days."	( Methoxychlor inhibits growth of antral follicles by altering cell cycle regulators. Flaws, JA; Gupta, RK; Hernández-Ochoa, I; Meachum, S; Peretz, J; Yao, HH, 2009)	0.35
"N-Acetylcysteine (NAC) is a frequently used "antioxidant" in vitro, but the concentrations applied rarely correlate with those encountered with oral dosing in vivo."	( Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. Barrett, F; Gibson, KR; MacRury, SM; Megson, IL; Neilson, IL; Sharma, S; Winterburn, TJ, 2009)	0.35
" Current intravenous dosing regimens may not provide enough N-acetylcysteine to effectively metabolise paracetamol to non-toxic adducts."	( Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. Chan, B; Graudins, A; Naidoo, D; Pham, HN; Salonikas, C, 2009)	0.35
" Additional groups of mice were dosed once with BPQ or BP-7,8-diol each at 30 mg/kg and tissues harvested 48 and 72 h later, or with B[a]P (50mg/kg, a tumorigenic dose) and tissues harvested 72 h later."	( Lack of contribution of covalent benzo[a]pyrene-7,8-quinone-DNA adducts in benzo[a]pyrene-induced mouse lung tumorigenesis. Adams, LD; George, MH; King, LC; Moore, T; Nelson, G; Nesnow, S; Padgett, WT; Ross, JA, 2010)	0.36
" For reasons of safety and efficacy, the pure enantiomer is usually preferred over the racemate in many marketed dosage forms."	( Chiral self assembled monolayers as resolving auxiliaries in the crystallization of valine. Myerson, AS; Singh, A, 2010)	0.36
"Some medication dosing protocols are logistically complex for traditional physician ordering."	( Computerized N-acetylcysteine physician order entry by template protocol for acetaminophen toxicity. Blackwood, L; Leikin, JB; Lu, JJ; Thompson, TM, )	0.13
"001), and although PTS was reduced in the 25 and 75 mg/kg SAL dosage groups compared to the saline group, only the 75 mg/kg SAL group was significantly different at all but 2 kHz frequency."	( Dosing study on the effectiveness of salicylate/N-acetylcysteine for prevention of noise-induced hearing loss. Coleman, J; Huang, X; Jackson, R; Kopke, R; Liu, J, )	0.13
" When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein."	( N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Chiang, CK; Chien, CT; Hsu, SP; Yang, SY, 2010)	0.36
" Dosing periods were separated by a washout period of 2 weeks."	( N-Acetyl-cysteine against noise-induced temporary threshold shift in male workers. Guo, YL; Lin, CY; Ma, MC; Shih, TS; Sun, YM; Tsai, PJ; Wu, JL, 2010)	0.36
"Though, oxidative stress has been implicated in silica nanoparticles induced toxicity both in vitro and in vivo, but no similarities exist regarding dose-response relationship."	( Nanotoxicity of pure silica mediated through oxidant generation rather than glutathione depletion in human lung epithelial cells. Ahamed, M; Ahmad, I; Akhtar, MJ; Ashquin, M; Kumar, S; Patil, G; Siddiqui, H, 2010)	0.36
"Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats."	( Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats. Abdel Baki, SG; Bergold, PJ; Fenton, AA; Haber, M; Schwab, B, 2010)	0.36
" Recent studies in large animals using both realistic time frames and dosing regimens have improved our knowledge, but clinical guidance remains based on incomplete data."	( Management of phosgene-induced acute lung injury. Grainge, C; Rice, P, 2010)	0.36
" Future experimental work should ensure that potential treatments are tested in a large animal model using realistic dosing regimens and clinically relevant timings, such as those that might be found in a mass casualty situation."	( Management of phosgene-induced acute lung injury. Grainge, C; Rice, P, 2010)	0.36
" Although the lower dosage of NAC (300 mg/kg) resulted in a decrease in the incidence of ocular defects in both the left and right eyes, this reduction was not statistically significant."	( Reduction of ethanol-induced ocular abnormalities in mice through dietary administration of N-acetylcysteine. Chen, SY; Dehart, DB; Parnell, SE; Sulik, KK, )	0.13
" Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen."	( Intravenous acetylcysteine for the treatment of acetaminophen overdose. Doyon, S; Klein-Schwartz, W, 2011)	0.37
" Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concentrations may be persistently elevated at the end of the infusion or in late presenters."	( Intravenous acetylcysteine for the treatment of acetaminophen overdose. Doyon, S; Klein-Schwartz, W, 2011)	0.37
" Nevertheless, we conclude that the formation of this reactive species might not be a safety concern for oxymetazoline nasal products because of the typical low-dose and brief dosage regimen limited to nasal delivery."	( In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Daniels, JS; Gan, LS; LeDuc, BW; Mahajan, MK; Uttamsingh, V; Williams, DA, 2011)	0.37
" dosing can cause symptomatic hyponatraemia in children."	( Using 0.45% saline solution and a modified dosing regimen for infusing N-acetylcysteine in children with paracetamol poisoning. Deasy, C; Oakley, E; Robinson, J, 2011)	0.37
"45% saline plus 5% dextrose, and a novel two-stage dosing regimen between January 2003 and July 2006 were undertaken."	( Using 0.45% saline solution and a modified dosing regimen for infusing N-acetylcysteine in children with paracetamol poisoning. Deasy, C; Oakley, E; Robinson, J, 2011)	0.37
" In cases of massive acetaminophen overdose, standard acetylcysteine dosing may not be adequate."	( Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose. Bagdure, D; Heard, K; Monte, A; Wang, GS, 2011)	0.37
" The labeled dosing regimen for Acetadote, the only intravenous N-acetylcysteine (IV-NAC) product approved by the Food and Drug Administration (FDA) for treatment of acetaminophen toxicity, is a complex 3-step process that produces frequent medication errors."	( Evaluation of a simplified N-acetylcysteine dosing regimen for the treatment of acetaminophen toxicity. Halcomb, SE; Johnson, MT; McCammon, CA; Mullins, ME, 2011)	0.37
" Charts were reviewed for prescribing practices, dosing errors, and clinical outcomes."	( Evaluation of a simplified N-acetylcysteine dosing regimen for the treatment of acetaminophen toxicity. Halcomb, SE; Johnson, MT; McCammon, CA; Mullins, ME, 2011)	0.37
" While dosing errors are common, in most cases, overdoses produce minimal clinical effects."	( Massive acetylcysteine overdose associated with cerebral edema and seizures. Heard, K; Schaeffer, TH, 2011)	0.37
" The mixture of D-methionine and N-acetyl-L-cysteine administered at levels less than 10% of standard dosing has not been previously reported."	( Low-dose D-methionine and N-acetyl-L-cysteine for protection from permanent noise-induced hearing loss in chinchillas. Balough, BJ; Clifford, RE; Coleman, JK; Jackson, RL; Kopke, RD; Liu, J, 2011)	0.37
" Intranasal dosing of NAC prior to CK(30)PEG(10k)/DNA nanoparticles enhanced gene expression by up to ~12-fold compared to saline control, reaching levels observed in the lungs of mice without LPS challenge."	( N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Boylan, NJ; Boyle, MP; Cooper, MJ; Hanes, J; Lai, SK; Lin, JM; Schneider, CS; Suk, JS; Tang, BC; Trehan, K; Zeitlin, PL, 2011)	0.37
" This may result in dosing errors, a delay in treatment, or possibly more adverse effects - due to the use of a high dose rate for the first infusion when treatment is initiated."	( A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Coulter, CV; Duffull, SB; Isbister, GK; Shen, F, 2011)	0.37
"Our aim was to investigate a novel dosing regimen for the immediate administration of NAC on admission at a lower infusion rate."	( A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Coulter, CV; Duffull, SB; Isbister, GK; Shen, F, 2011)	0.37
" We investigated an NAC infusion using a lower dosing rate initiated immediately on presentation."	( A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Coulter, CV; Duffull, SB; Isbister, GK; Shen, F, 2011)	0.37
"Lower dosing rates of NAC initiated immediately resulted in a similar exposure to NAC."	( A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Coulter, CV; Duffull, SB; Isbister, GK; Shen, F, 2011)	0.37
"The novel dosing regimen allowed immediate treatment of a patient using a lower dosing rate."	( A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Coulter, CV; Duffull, SB; Isbister, GK; Shen, F, 2011)	0.37
" The average lengths of treatment and stay for IV dosing were 23."	( Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review. Blackford, MG; Felter, T; Gothard, MD; Reed, MD, 2011)	0.37
"Based on our review, the majority of patients received recommended dosing of NAC therapy; however, 3 patients received extended NAC therapy."	( Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review. Blackford, MG; Felter, T; Gothard, MD; Reed, MD, 2011)	0.37
" However, the complicated dosing regimen is prone to errors in preparation and administration."	( Hemolysis and hemolytic uremic syndrome following five-fold N-acetylcysteine overdose. Mullins, ME; Vitkovitsky, IV, 2011)	0.37
" In this study, we retrospectively investigated data from SSc patients who had undergone therapy with high-dose intravenous N-acetylcysteine (NAC) at a dosage of 15 mg/Kg/h for 5 consecutive hours every 14 days."	( Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Giovannetti, A; Molinaro, I; Pisarri, S; Rosato, E; Rossi, C; Salsano, F, )	0.13
" Both forms of chromium induced DNA deletions albeit with different dose-response curves."	( Intracellular and extracellular factors influencing Cr(VI) and Cr(III) genotoxicity. Schiestl, RH; Sobol, Z, 2012)	0.38
" A ten-fold IV paracetamol dosing error ocurred, with delayed recognition and treatment resulting in transient hepatotoxicity, with a peak alanine transaminase (ALT) of 1378 IU/L in a 3-year-old child."	( Intravenous paracetamol toxicity in a malnourished child. Anscombe, M; Berling, I; Isbister, GK, 2012)	0.38
" Additional studies are required to further clarify the efficiency of this treatment and determine the optimal dosage and protocol."	( Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Amarantidis, K; Chamalidou, E; Chelis, L; Danielides, V; Dimopoulos, P; Kakolyris, S; Papadopoulos, S; Riga, MG; Stathakidou, S; Xenidis, N, 2013)	0.39
" Etoposide was administered at a dosage of 30 or 60 mg/kg."	( Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study. Attia, SM, 2012)	0.38
" Experience from Europe indicates that serious dosing errors are likely to occur."	( Intravenous acetaminophen in the United States: iatrogenic dosing errors. Dart, RC; Rumack, BH, 2012)	0.38
" This commentary addresses the reasons for this, and the background to choice of dose of acetylcysteine utilized in the oral and IV dosing regimens."	( Acetaminophen and acetylcysteine dose and duration: past, present and future. Bateman, DN; Rumack, BH, 2012)	0.38
" The patient worsened over the course of one week despite broad-spectrum antimicrobial therapy, but subsequently improved promptly with augmentation of prednisone dosed to 50 mg daily and addition of N-acetylcysteine."	( Acute exacerbation of pulmonary fibrosis following single lung transplantation. Bai, C; Khalil, N; Levy, RD; Wilcox, PG; Wilson, JM; Yang, D; Yee, J, )	0.13
" Two weeks after treatment (day 15), rats in the control group and three test groups exhibited no clinical signs of toxicity during the dosing period or during the 14-day post-treatment period."	( Acute toxicity study of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol, and γ-tocopherol in rats. Alipour, M; Pucaj, K; Smith, MG; Suntres, ZE, 2012)	0.38
" The 1,8-cineole dosage relative to humans only accelerated the mucociliary clearance in vivo without having an effect on the CBF."	( Effect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters. Begrow, F; Böckenholt, C; Ehmen, M; Verspohl, EJ; Wittig, T, 2012)	0.38
"5-fold shift in the dose-response curve generated by ADPR, the intracellular agonist for TRPM2."	( Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons. Belrose, JC; Gierszewski, LJ; Jackson, MF; MacDonald, JF; Xie, YF, 2012)	0.38
" In one case, we found that the use of estimated APAP dosage alone led to inappropriate NAC medication."	( [Study of the serum concentrations of acetaminophen overdose]. Hosoya, J; Iseki, K; Shiraishi, T; Suzuki, T; Takahashi, N; Tominaga, A; Toyoguchi, T, 2012)	0.38
" We further showed that apigenin downregulates telomerase activity in caspase-dependent apoptosis and observed that apigenin dosing results in downregulation of telomerase activity by suppression of c-Myc-mediated telomerase reverse transcriptase (hTERT) expression."	( Apigenin decreases cell viability and telomerase activity in human leukemia cell lines. Chang, WY; Choi, YH; Hyun, JW; Jayasooriya, RG; Kang, CH; Kang, SH; Kim, GY; Moon, DO, 2012)	0.38
" Urinary CEMA levels show a clear dose-response relationship with daily cigarette consumption and urinary cotinine."	( A column-switching liquid chromatography-tandem mass spectrometry method for quantitation of 2-cyanoethylmercapturic acid and 2-hydroxyethylmercapturic acid in Chinese smokers. Gao, N; Hou, H; Hu, Q; Tang, G; Xiong, W; Zhang, X, 2012)	0.38
" In addition, acute NAC administration showed a nonsignificant trend in attenuating nicotine self-administration under a progressive-ratio schedule that was similar to the dose-response function under the fixed-ratio schedule."	( N-acetylcysteine decreased nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking. D'Souza, MS; Markou, A; Ramirez-Niño, AM, 2013)	0.39
"The aim of this study was to determine whether oral dosing with N-acetylcysteine (NAC) increases intraplatelet levels of the antioxidant, glutathione (GSH), and reduces platelet-monocyte conjugation in blood from patients with type 2 diabetes."	( N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Barr, C; Barrett, F; Dransfield, I; Mackenzie, I; MacRury, SM; Megson, IL; Rushworth, GF; Treweeke, AT; Winterburn, TJ, 2012)	0.38
"In this placebo-controlled randomised crossover study, the effect of oral NAC dosing on platelet-monocyte conjugation and intraplatelet GSH was investigated in patients with type 2 diabetes (eligibility criteria: men or post-menopausal women with well-controlled diabetes (HbA(1c) < 10%), not on aspirin or statins)."	( N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Barr, C; Barrett, F; Dransfield, I; Mackenzie, I; MacRury, SM; Megson, IL; Rushworth, GF; Treweeke, AT; Winterburn, TJ, 2012)	0.38
" After 24h, cells were dosed with the IL-6-like cytokine, leukemia inhibitory factor (LIF)."	( Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes. Aon, MA; Booz, GW; Duhé, RJ; Kurdi, M; Paolocci, N; Sivakumaran, V, 2012)	0.38
"N-Acetylcysteine (NAC) dosing for acetaminophen (APAP) overdose is weight based (150 mg/kg intravenous or 140-mg/kg oral loading dose) and, in the United States, the dosing protocol recommends using a maximum patient weight of 100 and 110 kg, respectively."	( Acetylcysteine for acetaminophen overdose in patients who weigh >100 kg. Buchanan, JA; Heard, K; Kokko, J; Varney, SM, )	0.13
" Finally, the analysis of hepatic glutathione conjugates and urinary N-acetylcysteine conjugates from mice dosed with capsaicin confirmed the formation of glutathione conjugates of O-demethylated quinone methide and 5-OH-capsaicin in vivo."	( Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes. Bugni, TS; Ethirajan, M; Henion, F; Pramanik, KC; Reilly, CA; Srivastava, SK; Stockmann, C; Yost, GS, 2013)	0.39
"N-Acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NA-DCVC) has been detected in the urine of humans exposed to trichloroethylene and its related sulfoxide, N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine sulfoxide (NA-DCVCS), has been detected as hemoglobin adducts in blood of rats dosed with S-(1,2-dichlorovinyl)-L-cysteine (DCVC) or S-(1,2-dichlorovinyl)-L-cysteine sulfoxide (DCVCS)."	( Characterization of the chemical reactivity and nephrotoxicity of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine sulfoxide, a potential reactive metabolite of trichloroethylene. Elfarra, AA; Irving, RM; Pinkerton, ME, 2013)	0.39
" This study evaluated the effect of a weight-based dosing chart (WBDC) introduced to decrease NAC prescription errors."	( Introduction of an N-acetylcysteine weight-based dosing chart reduces prescription errors in the treatment of paracetamol poisoning. Greene, S; McD Taylor, D; McIntyre, S, 2013)	0.39
"001), NAC dosage (13."	( Introduction of an N-acetylcysteine weight-based dosing chart reduces prescription errors in the treatment of paracetamol poisoning. Greene, S; McD Taylor, D; McIntyre, S, 2013)	0.39
" Trials varied in patient demographic characteristics, inclusion criteria, dosing regimens, and trial quality."	( Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. Cao, L; Cheng, L; Fu, Q; Jin, W; Li, Z; Sun, Z, 2013)	0.39
" The dogs in the control group (EL) and three test groups exhibited no signs of toxicity during the dosing period or day 15 post treatment."	( Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol or γ-tocopherol in beagle dogs. Alipour, M; Bolger, G; Mitsopoulos, P; Pucaj, K; Smith, MG; Suntres, ZE, 2013)	0.39
" Complications include frequent nausea and vomiting, anaphylactoid reactions and dosing errors."	( Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP). Bateman, DN; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, S; Sandilands, EA; Thanacoody, HK; Thomas, SH; Webb, DJ, 2013)	0.39
" N-acetylcysteine (NAC) is the antidote of choice for the treatment of APAP toxicity; however, due to its short-half-life repeated dosing of NAC is required."	( Therapeutic effect of liposomal-N-acetylcysteine against acetaminophen-induced hepatotoxicity. Alipour, M; Buonocore, C; Omri, A; Pucaj, K; Suntres, ZE; Szabo, M, 2013)	0.39
" A 5-point (1-5 mM) dose-response curve of NAC clearly indicated no adverse effect on astroglial cell viability."	( Attenuating effect of N-acetyl-L-cysteine against acute cocaine toxicity in rat C6 astroglial cells. Badisa, RB; Fitch-Pye, CA; Goodman, CB, 2013)	0.39
" This work shows the potential utility of MRS monitoring, which could assist in determining dosing regimens for clinical trials of this potentially useful antioxidant therapy for PD disease, GD, and other neurodegenerative disorders."	( N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Ahlskog, M; Cloyd, JC; Coles, LD; Holmay, MJ; Mishra, U; Öz, G; Terpstra, M; Tuite, PJ, )	0.13
" In conclusion, adjunctive therapy with N-acetyl-l-cysteine at a dosage of 300 mg/kg of body weight intraperitoneally for 4 days reduced hearing loss but not other neurologic deficits after pneumococcal meningitis in mice."	( Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis. Angele, B; Demel, C; Giese, A; Högen, T; Klein, M; Koedel, U; Pfister, HW, 2013)	0.39
" No clear dose-response relationship existed between the quantity of paracetamol ingested and the observed concentrations of 5-oxoproline."	( What is the clinical significance of 5-oxoproline (pyroglutamic acid) in high anion gap metabolic acidosis following paracetamol (acetaminophen) exposure? Liss, DB; Mullins, ME; Paden, MS; Schwarz, ES, 2013)	0.39
" However, the optimal dose, volume, and dosing time for the premedication regimen are still unclear."	( Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy. Chang, WK; Chen, HW; Hsu, HC; Hu, MK; Yeh, MK, 2014)	0.4
" Despite many years of intense research, the precise mechanisms of paracetamol-induced liver injury in humans are still not defined, and few studies have examined the optimal dosing regimen for clinical NAC use."	( Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Antoine, DJ; Dear, JW, 2014)	0.4
"hy926 EC following irradiation with doses < 1 Gy that may contribute to a discontinuous dose-response relationship of residual γH2AX foci detection."	( A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. Fournier, C; Hehlgans, S; Large, M; Reichert, S; Rödel, C; Rödel, F, 2014)	0.4
"A total of 10 TEN patients were enrolled to be treated at admission in burn units with the antioxidant N-acetylcysteine [NAC, 150mg/kg in a 20-h intravenous (IV) administration], or the combination of the same IV NAC perfusion with the anti-TNFα antibody infliximab (Remicade(®)), administered at a 5mg/kg dosage as a single 2-h IV administration."	( Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Delvenne, P; Jennes, S; Libon, F; Paquet, P; Piérard, GE; Rousseau, AF, 2014)	0.4
" For synaptic and non-synaptic mitochondria, only 300mg/kg NACA dosage showed efficacy."	( N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma. Eldahan, KC; Goldstein, GA; Magnuson, DS; Morehouse, J; Pandya, JD; Patel, SP; Rabchevsky, AG; Sullivan, PG; VanRooyen, JL; Yonutas, HM, 2014)	0.4
" This study explored the dose-response relationship between ingested acetaminophen and hepatotoxicity, the early biochemical and clinical predictors of hepatotoxicity, the impact of early N-acetylcysteine treatment on hepatotoxicity and the incidence of nephrotoxicity."	( Early predictors of severe acetaminophen-induced hepatotoxicity in a paediatric population referred to a tertiary paediatric department. Andersen, J; Askbo, N; Hedeland, RL; Iskandar, A; Jørgensen, MH, 2014)	0.4
" Thus, the methods were suitable to quantify flupirtine absorption and metabolic disposition in man after single intravenous and oral dosing (100mg) and repeated oral administration (400mg once daily)."	( Quantitative LC-MS/MS determination of flupirtine, its N-acetylated and two mercapturic acid derivatives in man. Bednarski, PJ; Methling, K; Oswald, S; Scheuch, E; Siegmund, W, 2015)	0.42
" We observed a time and dosage dependent reduction of cellular viability after ZnO NP exposure."	( Genotoxic effects of zinc oxide nanoparticles. Brieger, J; Brochhausen, C; Felder, E; Heim, J; Heinrich, UR; Kaltbeitzel, A; Mailänder, V; Tahir, MN; Tremel, W, 2015)	0.42
" Together with these new biomarkers of hepatotoxicity, a 12-hour acetylcysteine protocol offers clinicians and patients the possibility for better targeting of therapy, fewer adverse effects, a simpler dosing regimen, and shorter hospital stay."	( Changing the Management of Paracetamol Poisoning. Bateman, DN, 2015)	0.42
" Thus, we conclude that concomitant oral dosing with APAP and NAC can provide a convenient and effective way of preventing toxicity associated with large dosage of APAP."	( Co-administration of N-Acetylcysteine and Acetaminophen Efficiently Blocks Acetaminophen Toxicity. Andrus, JP; Herzenberg, LA; Owumi, SE, 2015)	0.42
"Further research involving NAC for OCD may require larger samples to detect moderate or small effect sizes, involve dosage or formulation differences, use in concert with exposure therapy, or an additional post-study observational period to mitigate study withdrawal."	( N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. Berk, M; Blair-West, S; Camfield, DA; Dean, OM; Dowling, N; Menon, R; Murphy, J; Ng, CH; Oliver, G; Sarris, J; Smith, DJ, 2015)	0.42
" Although antidote, acetylcysteine, is potentially extracted by renal replacement therapies, pharmacokinetic data are lacking to guide potential dosing alterations."	( The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Hernandez, SH; Hoffman, RS; Howland, M; Schiano, TD, 2015)	0.42
" Treatment with 20% acetylcysteine oral solution was initiated at a dosage of 600 mg twice daily as an adjunct to quetiapine therapy."	( Acetylcysteine for treatment of autism spectrum disorder symptoms. Dopheide, J; Stutzman, D, 2015)	0.42
" NAC prevents COPD exacerbations at high dosage (≥1200 mg daily), while a regular treatment with 600 mg daily is enough in chronic bronchitis."	( Oxidation pathway and exacerbations in COPD: the role of NAC. Calzetta, L; Cazzola, M; Matera, MG, 2016)	0.43
" NAC dosing in humans can then be calibrated to achieve these NAC levels in human CSF."	( Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Brennan-Minnella, AM; Cittolin-Santos, GF; Glass, GA; Katz, M; Kim, JE; Reyes, RC; Swanson, RA; Won, SJ, 2016)	0.43
"Multiparticulate dosage forms are a recent strategy to meet the special needs of children, elderly people and patients suffering from dysphagia."	( Advanced stable lipid-based formulations for a patient-centric product design. Becker, K; Haack, D; Kienberger, D; Köberle, M; Lochmann, D; Lopes, D; Salar-Behzadi, S; Saurugger, EM; Stehr, M; Zimmer, A, 2016)	0.43
" Mice were then dosed orally eight times over 3 days with additional paracetamol (250 mg/kg) or saline, followed by either one or two doses of oral NAC (1200 mg/kg) or saline."	( N-Acetyl cysteine does not prevent liver toxicity from chronic low-dose plus subacute high-dose paracetamol exposure in young or old mice. Cogger, V; de Cabo, R; Hilmer, SN; Huizer-Pajkos, A; Jones, B; Kane, AE; Le Couteur, DG; Mach, J; McKenzie, C; Mitchell, SJ, 2016)	0.43
" However, its low thermal stability precludes the preparation of stable dosage forms based on presynthesized SNAC."	( Intratablet S-nitrosation: A New Approach for the Oral Administration of S-nitrosothiols as Nitric Oxide Donors. de Oliveira, MG; de Souza, GF, 2016)	0.43
" This study defined the dosage of L-NAC, Mannitol, and Dex for the survival of 50% protection of hair cells in vitro."	( A novel combination of drug therapy to protect residual hearing post cochlear implant surgery. Bas, E; Bauer, B; Eshraghi, AA; Guardiola, M; Mittal, J; Rivera, I; Roell, J; Shaikh, N; Telischi, FF; Van De Water, T, 2016)	0.43
"6) were positively associated with the 3-HPMA, CEMA and ∑Acrolein with evidence of a dose-response relationship (p<0."	( Acrolein metabolites, diabetes and insulin resistance. Attanasio, R; Feroe, AG; Scinicariello, F, 2016)	0.43
" Oral administration of 6 in mice increased the plasma exposure of the active parent compound 20-fold compared to when 1 was dosed orally."	( Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. Bjartell, A; Canesin, G; Escobar, Z; Evans-Axelsson, S; Hellsten, R; Johansson, MH; Sterner, O, 2016)	0.43
" Concentrations required for effective simvastatin- or resveratrol-induced inhibition of mitochondrial respiration were found much higher than concentrations achieved under standard dosing of these drugs."	( Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration. Fišar, Z; Hroudová, J; Kopřivová, A; Macečková, D; Singh, N, 2016)	0.43
" In 2012, the UK Commission on Human Medicines made recommendations for the management of paracetamol overdose, including provision of weight-based acetylcysteine dosing tables."	( An assessment of the variation in the concentration of acetylcysteine in infusions for the treatment of paracetamol overdose. Archer, JR; Bailey, GP; Dargan, PI; Flanagan, RJ; Rab, E; Wood, DM, 2017)	0.46
" The effects of antioxidants thus reveal an inverted U-shaped dose-response relationship between ROS levels and lifespan."	( Antioxidants reveal an inverted U-shaped dose-response relationship between reactive oxygen species levels and the rate of aging in Caenorhabditis elegans. Bernard, K; Breton, L; Cacho-Valadez, B; Desjardins, D; Hekimi, S; Khaki, A; Liu, JL; Wang, Y; Yee, C, 2017)	0.46
" At the end of reperfusion, blood was collected for enzyme dosage (alanine aminotransferase [ALT], aspartate aminotransferase [AST], lactate dehydrogenase [LDH], alkaline phosphatase [ALP]), and the terminal ileum was resected to study mucosal morphology by optical microscopy, computerized histomorphometry, and immunohistochemical assessment of apoptosis with caspase 3."	( N-Acetylcysteine Use in Hepatic Ischemia/Reperfusion in Rats Minimizing Bowel Injury. de Oliveira Menezes, A; Frasson de Souza Montero, E; Lauz Medeiros, SH; Zogbi, L, 2016)	0.43
" This suggests that the application of NAC by nebulization at a high dosage may be beneficial for patients with airway conditions associated with bacterial infections."	( Effects of N-acetyl-L-cysteine on the membrane vesicle release and growth of respiratory pathogens. Benedikter, BJ; Grauls, GE; Hellebrand, PHM; Savelkoul, PHM; Stassen, FRM; Volgers, C, 2017)	0.46
" Intraperitoneal administration of 4-pentenoic acid was performed once daily during seven days, the used dosage was 20mg/kg."	( [ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE SYNDROME IN RATS]. Antelava, N; Ghonghadze, M; Liluashvili, K; Okujava, M; Pachkoria, K, 2017)	0.46
" We also simulated extended duration acetylcysteine regimens and other increased dosing strategies that have been recommended in specific paracetamol poisoning scenarios."	( Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning. Graudins, A; Landersdorfer, C; Wong, A, 2017)	0.46
"The drug plasma profile after oral administration of immediate release dosage forms can be affected by the human gastrointestinal physiology, the formulation, and the drug itself."	( Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus. Jedamzik, P; Koziolek, M; Sager, M; Schneider, F; Schremmer, E; Weitschies, W; Wiedmann, M, 2017)	0.46
" Following a completed dose-response curve, responding for methamphetamine self-administration was extinguished and the effects of N-acetylcysteine or bupropion on methamphetamine-triggered reinstatement was evaluated in separate experiments."	( The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine-triggered reinstatement of female rats. Bevins, RA; Charntikov, S; Pittenger, ST; Pudiak, CM, 2018)	0.48
"Nephrotoxicity is the main limitation to the dosage and anticancer efficacy of cisplatin."	( N-acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity. Fuentes-Calvo, I; López-Hernández, FJ; López-Novoa, JM; Martínez-Salgado, C; Morales, AI; Prieto, M; Prieto-García, L; Sancho-Martínez, SM, 2018)	0.48
" Myelin content is restored by minocycline (MINO) plus n-acetylcysteine (NAC) or MINO alone when first dosed at 12 h after CHI."	( Minocycline plus N-acetylcysteine protect oligodendrocytes when first dosed 12 hours after closed head injury in mice. Bergold, PJ; Nikulina, E; Sangobowale, M, 2018)	0.48
"The current study revealed that ML and NAC are potent antioxidants with similar efficacy in terms of reducing CABG related cardiac injury and oxidative stress with the dosage employed for the intervention."	( Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial. Akbarzadeh, S; Anvaripour, A; Bahtoei, M; Iranpour, D; Movahed, A; Netticadan, T; Ostovar, A; Raj, P; Shafiei, E; Shahryari, H; Tahmasebi, R, 2018)	0.48
" Current evidence supports its use as an adjunctive therapy clinically for psychiatric conditions, administered concomitantly with existing medications, with a recommended dosage between 2000 and 2400 mg/day."	( N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. Green, R; Ooi, SL; Pak, SC, 2018)	0.48
" In the present paper, we advocate to lower intravenous ascorbate dosage along with monothiol N-acetylcysteine pretreatment due to anticipation of the same therapeutic effect but less or none of side effects."	( On infusion of high-dose ascorbate in treating cancer: Is it time for N-acetylcysteine pretreatment to enhance susceptibility and to lower side effects? Juránek, I; Rapta, P; Šoltés, L; Valachová, K; Valent, I, 2019)	0.51
" A total of 24 patients will be assigned into one of three dosing cohorts of eight patients (n = 6 for PP100-01 and NAC; n = 2 for NAC alone)."	( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi Dear, J, 2019)	0.51
" Aggressive dosing of these therapies is significantly hampered by side effects due to normal tissue toxicity."	( Methylseleninic Acid Induces Lipid Peroxidation and Radiation Sensitivity in Head and Neck Cancer Cells. Buettner, GR; Goswami, PC; Kalen, AL; Lafin, JT; Sarsour, EH; Wagner, BA, 2019)	0.51
" A pivotal factor affecting the therapeutic potency of NAC in sepsis is timing and dosing of its infusion."	( Clinical Trial Assessment of Intermittent and Continuous Infusion Dose of N-Acetylcysteine on Redox Status of the Body in Patients with Sepsis Admitted to the ICU. Boroumand, N; Hashemy, SI; Peivandi Yazdi, A; Razavi, M; Salehi, M; Sheikh, S, 2020)	0.56
" Data on study design, dosing regimens, comorbidities, concurrent treatment, and side effects were extracted from the included articles."	( A review of N-acetylcysteine in the treatment of grooming disorders. Braun, TL; DeBord, LC; Patel, V; Rosen, T, 2019)	0.51
" Dosing of oral NAC ranged from 450 to 2,400 mg per day, and treatment periods lasted from 1 to 8 months."	( A review of N-acetylcysteine in the treatment of grooming disorders. Braun, TL; DeBord, LC; Patel, V; Rosen, T, 2019)	0.51
" Challenges include timing, dosing and administration route for each neuroprotectant."	( Novel interventions to reduce oxidative-stress related brain injury in neonatal asphyxia. Cheung, PY; Schmölzer, GM; Solevåg, AL, 2019)	0.51
" Plasma samples were collected at 17 hr after dosing (during the manifestation of symptoms) and at one month (after recovery) and were subjected to LC-MS analysis of NAPQI-adducts."	( LC-MS analyses of N-acetyl-p-benzoquinone imine-adducts of glutathione, cysteine, N-acetylcysteine, and albumin in a plasma sample: A case study from a patient with a rare acetaminophen-induced acute swelling rash. Kubo, T; Lee, SH; Oe, T; Ozawa, M, 2019)	0.51
" A regular treatment of low dosage (< 1200 mg per day) and a duration of at least 3 months seems to be effective."	( Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis. Han, J; Pang, CS; Wei, J; Yan, H, 2019)	0.51
" Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing."	( Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020)	0.56
"The dose-response curve revealed U-shaped nonlinear relationships of SPMA with hematocrit (HCT) and mean corpuscular hemoglobin concentration (MCHC) (P-overall < 0."	( Influence of benzene exposure, fat content, and their interactions on erythroid-related hematologic parameters in petrochemical workers: a cross-sectional study. Chen, L; Chen, W; Dang, S; Deng, Q; Guo, H; He, Z; Huang, M; Li, J; Ma, X; Peng, J; Wang, H; Wu, D; Xiao, Y; Xing, X; Yang, B; Zhang, X; Zhang, Z; Zhu, Y, 2020)	0.56
" We found significantly negative dose-response relationships of all urinary acrylamide metabolites and TGF-β1 with all six HRV indices after adjusting for potential confounders (all P < 0."	( Exposure to acrylamide and reduced heart rate variability: The mediating role of transforming growth factor-β. Cen, X; Chen, A; Chen, W; Cheng, M; Guo, Y; He, H; Li, W; Ma, J; Mu, G; Qiu, W; Wang, B; Wang, D; Wang, X; Xiao, L; Yang, M; Yang, S; Zhang, X; Zhou, M; Zhou, Y; Zhu, C, 2020)	0.56
" Further adequately powered prospective researches with more emphasis on dosing parameters are warranted for better quantification in different settings and for clinical implementation."	( Survival Benefits of N-Acetylcysteine in Rodenticide Poisoning: Retrospective Evidence from an Indian Tertiary Care Setting. Chandran, VP; Hyder, S; Mark, K; Nair, S; Rashid, M; Seshadri, S; Thunga, G, 2021)	0.62
"N-Acetylcysteine (NAC) is an effective antidote for the treatment of acetaminophen (APAP) poisoning; however, due to its low stability and bioavailability, repeated dosing of NAC is needed."	( Improvement of therapeutic potential N-acetylcysteine in acetaminophen hepatotoxicity by encapsulation in PEGylated nano-niosomes. Azandaryani, MT; Firozian, F; Karami, S; Nili-Ahmadabadi, A; Ranjbar, A, 2020)	0.56
" The 3 pillars of prevention are identification of high-risk patients, appropriate hydration before and after contrast exposure, eGFR-based contrast dosing and use of ultra-low contrast volume in high-risk patients."	( A Practical Approach to Preventing Renal Complications in the Catheterization Laboratory. Aggarwal, D; Gurm, HS, 2020)	0.56
" Rats were divided into five groups of eight rats each as follows: Group I: No treatment; Group II: 10/mg/kg/day dosage of intraperitoneal (i."	( The effects of specific and non-specific phosphodiesterase inhibitors and N-acetylcysteine on oxidative stress and remote organ injury in two-hit trauma model. Özer, Ö; Şen, M; Topal, U, 2020)	0.56
"In this randomized clinical trial of 65 women and their infants, maternal intravenous NAC employing the FDA-approved dosing protocol resulted in lower composite neonatal morbidity independent of gestational age, race, sex, and birthweight."	( Antenatal N-acetylcysteine to improve outcomes of premature infants with intra-amniotic infection and inflammation (Triple I): randomized clinical trial. Abdelghany, O; Bahtiyar, MO; Bhandari, V; Buhimschi, CS; Buhimschi, IA; Dulay, AT; Lipkind, HS; Mieth, S; Razeq, SA; Rogers, L; Schneider, L; Zhao, G, 2021)	0.62
" The use of NSAIDs together with an overall reduction of their dosage and time of assumption has been reduced as well."	( Effectiveness of the integration of quercetin, turmeric, and N-acetylcysteine in reducing inflammation and pain associated with endometriosis. In-vitro and in-vivo studies. Accardi, M; Baietti, MG; Fadin, M; Fratter, A; Nicoletti, MC; Pellizzato, M, 2020)	0.56
" Subgroup analyses suggested that the administration of NAC had greater benefits in patients with renal dysfunction and in those receiving oral administration and higher dosage of NAC."	( Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials. Chen, JY; Chen, S; Guo, Z; Huang, H; Lei, L; Lin, Y; Liu, J; Liu, L; Liu, Y; Tao, J; Wu, K; Xu, Q; Xue, Y; Zhang, L, 2020)	0.56
" N-Acetylcysteine should be given according to specific regimens through weight-based dosing tables."	( Paracetamol overdose in the newborn and infant: a life-threatening event. Antonucci, R; Capobianco, G; Cuzzolin, L; Locci, C, 2021)	0.62
" Additionally, dosing with N-acetylcysteine (NAC) effectively mitigated bone loss and normalized expression of ALP, Runx2, and OPN."	( The Dual Effects of Reactive Oxygen Species on the Mandibular Alveolar Bone Formation in SOD1 Knockout Mice: Promotion or Inhibition. Chen, G; Guo, Q; Guo, W; Tian, W; Xu, M; Xu, Y; Yang, Y; Zhang, Y; Zheng, J, 2021)	0.62
"Recent recognition of "massive" acetaminophen (APAP) overdoses has led to the question of whether standard dosing of N-acetylcysteine (NAC) is adequate to prevent hepatoxicity in these patients."	( Clinical outcome of massive acetaminophen overdose treated with standard-dose N-acetylcysteine. Cumpston, KL; Downs, JW; Kershner, EK; Rose, SR; Troendle, MM; Wills, BK, 2021)	0.62
" Equimolar Glu + NA + NAC dosing in a zebrafish vertebrate model of rotenone-based complex I inhibition synergistically rescued larval activity, brain death, lactate, ATP and glutathione levels."	( Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease. Bennett, M; Falk, MJ; Guha, S; Konkwo, C; Kwon, YJ; Mathew, ND; Nakamaru-Ogiso, E; Ostrovsky, J; Polyak, E; Seiler, C; Xiao, R; Zhang, Z, 2021)	0.62
" We performed a retrospective, multi-center analysis to determine if a capped NAC dosing scheme is similar to a non-capped dosing scheme in patients weighing over 100 kg."	( Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used? Akpunonu, P; Bailey, AM; Baum, RA; Geraghty, L; Howell, MM; Mohan, S; Su, MK; Weant, KA; Webb, AN; Woolum, JA, 2021)	0.62
" A capped NAC dosing scheme resulted in no difference in hepatic injury when compared to a non-capped regimen (49."	( Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used? Akpunonu, P; Bailey, AM; Baum, RA; Geraghty, L; Howell, MM; Mohan, S; Su, MK; Weant, KA; Webb, AN; Woolum, JA, 2021)	0.62
"A capped NAC dosing scheme was not associated with higher rates of hepatic injury or hepatotoxicity in obese patients in the setting of acetaminophen poisoning when compared to a non-capped regimen."	( Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used? Akpunonu, P; Bailey, AM; Baum, RA; Geraghty, L; Howell, MM; Mohan, S; Su, MK; Weant, KA; Webb, AN; Woolum, JA, 2021)	0.62
" We have previously examined the human metabolism of MI and MCI after oral dosage of isotope-labelled analogues in human volunteers and confirmed N-methylmalonamic acid to be a major, but presumably unspecific human urinary metabolite."	( New data on the metabolism of chloromethylisothiazolinone and methylisothiazolinone in human volunteers after oral dosage: excretion kinetics of a urinary mercapturic acid metabolite ("M-12"). Bertram, J; Kraus, T; Schettgen, T, 2021)	0.62
" Several novel approaches to the management of acetaminophen overdose have been suggested to improve patient safety by reducing adverse drug reactions and dosing errors."	( A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose. Burnham, K; Knight, S; Smith, H; Yang, T, 2021)	0.62
" Many of these dosing regimens have supporting safety data but most lack robust data."	( A review of alternative intravenous acetylcysteine regimens for acetaminophen overdose. Burnham, K; Knight, S; Smith, H; Yang, T, 2021)	0.62
" However, an understanding of the pharmacokinetic characteristics of intravenous NAC dosing in these patients is limited."	( Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. Basso, LM; Brundage, RC; Cloyd, JC; Coles, LD; Kartha, RV; Mishra, U; Ng, M; Orchard, PJ; Sahasrabudhe, SA, 2021)	0.62
" These data show that in addition to the structural integrity of the dendritic arbor, spine and synapse density can be successfully targeted with drugs first dosed days after injury."	( Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury. Alexis, A; Bergold, PJ; Nikulina, E; Rahman, SN; Whitney, K, 2021)	0.62
" Similarly, OTA-derived mercapturic acids were not detected in urine of rats repeatedly dosed with OTA, while indirect analysis using enzymatic hydrolysis of the urine samples prior to LC-MS/MS established a linear relationship between urinary glucuronide excretion and OTA exposure."	( In Vitro and In Vivo Analysis of Ochratoxin A-Derived Glucuronides and Mercapturic Acids as Biomarkers of Exposure. Adaku Chilaka, C; Dekant, R; Langer, M; Lupp, M; Mally, A, 2021)	0.62
" Further studies on this dosage and duration of administration should be conducted to best elucidate the effect of administering NAC."	( N-Acetylcysteine's Renoprotective Effect in Cardiac Surgery: A Systematic Review and Meta-Analysis. Kang, GS; Kofidis, T; Luo, H; Tan, YK; Teoh, KL, 2022)	0.72
"036) significantly increased risk of dyslexia, with a dose-response relationship (P-trend = 0."	( Association between urinary propylene oxide metabolite and the risk of dyslexia. Feng, Y; Jiang, Q; Liu, Q; Meng, H; Song, R; Wan, Y; Wu, X; Xiang, Z; Xiao, P; Xie, X; Zhang, J; Zhu, B; Zhu, K, 2022)	0.72
" Clinical trial evidence supporting shorter NAC dosing now allows the possibility for intensifying treatment without the risk of very high rates of ADRs."	( Large paracetamol overdose-Higher dose acetylcysteine is required. Bateman, DN, 2023)	0.91
" The standard oral or intravenous dosing regimen of NAC is highly effective for patients with moderate overdoses who present within 8 h of APAP ingestion."	( Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose. Akakpo, JY; Curry, SC; Jaeschke, H; Ramachandran, A; Rumack, BH, 2022)	0.72
" Other advancements include individualized acetylcysteine dosing regimens for acetaminophen toxicity and carnitine supplementation in valproic acid toxicity."	( The Roles of Antidotes in Emergency Situations. Dart, RC; Kaiser, SK, 2022)	0.72
" Adult evidence demonstrates that alternative dosing regimens decrease NAARs and medication errors (MEs)."	( Comparison of Two-Bag Versus Three-Bag N-Acetylcysteine Regimens for Pediatric Acetaminophen Toxicity. Camarena-Michel, A; Hoyte, C; Leonard, J; Pennington, S; Sudanagunta, S; Wang, GS, 2023)	0.91
" Most importantly, the dose-response effects and time course of APAP accumulation and metabolism agree well with those of the liver injury development."	( Metabolic Competency of Larval Zebrafish in Drug-Induced Liver Injury: A Case Study of Acetaminophen Poisoning. Chen, Y; Ge, W; Song, W; Yan, R, 2022)	0.72
" This diagnosis was confirmed by an organic acid dosage in the urine."	( [A case of pyroglutamic metabolic acidosis after cotreatment by flucloxacillin and paracetamol]. Desgranges, A; Hu, K; Monney Chaubert, C, 2022)	0.72
" Although the clinical efficacy and dosing regimens of NAC have been evaluated in the clinical setting with small series of patients, the results are promising."	( N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions. Izquierdo-Alonso, JL; Peces-Barba, G; Pérez-Rial, S; Rivera, CG, 2022)	0.72
"Although N-acetyl-cysteine (NAC) has long been used for the treatment of acetaminophen poisoning/overdose, the optimal NAC dosing regimen for varying patterns or severity of the poisoning/overdose is still unknown."	( Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens. Janković, SM, 2022)	0.72
" In several trials, cells dosed with NAC and cisplatin demonstrated a 22."	( Designing a Prolonged Method of Therapeutic Delivery to Support Rehabilitation From Ototoxic Damage in a Schwann Cell Model. Echanique, KA; Hoffman, LF; Hong, MK; Kita, AE, 2023)	0.91
"When dosed at their respective therapeutic ranges, cisplatin is more likely than gentamicin to induce damage to the Schwann cell model."	( Designing a Prolonged Method of Therapeutic Delivery to Support Rehabilitation From Ototoxic Damage in a Schwann Cell Model. Echanique, KA; Hoffman, LF; Hong, MK; Kita, AE, 2023)	0.91
" A significant reduction in ICU stay was observed but need more optimal dosing schedule and precise outcome targets are required to clarify the clinical impacts of antioxidants in these patients."	( Efficacy of Acetylcysteine and Selenium in Aneurysmal Subarachnoid Hemorrhage Patients: A Prospective, Multicenter, Single Blind Randomized Controlled Trial. Ahn, JS; Chung, Y; Jeon, H; Kim, M; Lee, S; Lee, SU; Park, JC; Park, W, 2023)	0.91

Product Category	Products
Professional Supplements	11
Active Lifestyle & Fitness	3
Vitamins & Supplements	34
Pet Supplies	2

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Allergy Research Group NAC -- 120 Tablets	Allergy Research Group	Professional Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Allergy Research Group NAC Enhanced Antioxidant Formula -- 90 Tablets	Allergy Research Group	Professional Supplements	N-Acetyl Cysteine, Trimethylglycine, Trimethylglycine, Alpha-Lipoic Acid	2024-11-29 10:47:42
ALLMAX Nutrition Liver D-Tox Ultimate Liver Protection -- 42 Capsules	ALLMAX Nutrition	Active Lifestyle & Fitness	NAC, Vitamin C, Vitamin E, Vitamin E, Selenium	2024-11-29 10:47:42
Amazing Nutrition Amazing Formulas NAC -- 1200 mg - 250 Capsules	Amazing Nutrition	Vitamins & Supplements	N-Acetyl-L-Cysteine	2024-11-29 10:47:42
Amy Myers MD Microb-Clear -- 120 Capsules	Amy Myers MD	Professional Supplements	N-Acetyl Cysteine, Caprylic Acid	2024-11-29 10:47:42
Amy Myers MD NeuroLive -- 120 Capsules	Amy Myers MD	Professional Supplements	N-Acetyl-Cysteine, Vitamin B6, Vitamin B6	2024-11-29 10:47:42
Bark & Whiskers Detox Liver & Kidney Support Powder for Cats & Dogs -- 1.7 oz	Bark & Whiskers	Pet Supplies	N-Acetyl L-Cysteine, Glycine, Taurine	2024-11-29 10:47:42
Best Naturals NAC N-Acetyl Cysteine -- 600 mg - 250 Capsules	Best Naturals	Vitamins & Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
Bluebonnet Nutrition NAC -- 500 mg - 90 Vegetable Capsules	Bluebonnet Nutrition	Vitamins & Supplements	NAC	2024-11-29 10:47:42
Carlson NAC N-Acetyl Cysteine -- 500 mg - 60 Capsules	Carlson	Vitamins & Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
Country Life Aller-Max™ -- 100 Vegetarian Capsules	Country Life	Vitamins & Supplements	N-Acetyl Cysteine, Vitamin C, calcium ascorbate, L-Histidine, Pantothenic Acid, Quercetin, Vitamin A	2024-11-29 10:47:42
Country Life NAC N-Acetyl Cysteine -- 750 mg - 60 Vegetarian Capsules	Country Life	Vitamins & Supplements	NAC	2024-11-29 10:47:42
DaVinci Laboratories N-Acetyl-Cysteine -- 500 mg - 90 Capsules	DaVinci Laboratories	Professional Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
Douglas Laboratories N-Acetyl-L-Cysteine -- 900 mg - 90 Vegetarian Capsules	Douglas Laboratories	Professional Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Dr. Mercola NAC with Milk Thistle -- 500 mg - 180 Capsules	Dr. Mercola	Professional Supplements	N-Acetyl-Cysteine	2024-11-29 10:47:42
Dr. Mercola NAC with Milk Thistle -- 500 mg - 60 Capsules	Dr. Mercola	Professional Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
Emerald Labs NAC Vegan N-Acetyl Cysteine -- 600 mg - 60 Vegetable Caps	Emerald Labs	Vitamins & Supplements	N-Acetyl-L-Cysteine	2024-11-29 10:47:42
Force Factor NAC N-Acetyl-L-Cysteine -- 600 mg - 200 Vegetable Capsules	Force Factor	Vitamins & Supplements	N-Acetyl-L-Cysteine	2024-11-29 10:47:42
Integrative Therapeutics NAC N-Acetyl L-Cysteine -- 60 Capsules	Integrative Therapeutics	Professional Supplements	N-Acetyl L-Cysteine, cellulose	2024-11-29 10:47:42
Irwin Naturals 2-In-1 Kidney & Liver Super Cleanse™ -- 60 Liquid Softgels	Irwin Naturals	Vitamins & Supplements	N-Acetyl Cysteine, annatto, Vitamin C, dextrin, glycerin, maltodextrin, Vitamin B6, Selenium, titanium dioxide, Vitamin B12, Vitamin B6	2024-11-29 10:47:42
Jarrow Formulas Vegan N-A-C Sustain -- 600 mg - 60 Tablets	Jarrow Formulas	Vitamins & Supplements	N-Acetyl-Cysteine, Carbomer, microcrystalline cellulose, stearic acid, calcium phosphate	2024-11-29 10:47:42
Kal NAC+ -- 600 mg - 60 Tablets	KAL	Vitamins & Supplements	N-Acetyl Cysteine, Cellulose, Molybdenum, Riboflavin, stearic acid	2024-11-29 10:47:42
Life Extension N-Acetyl-L-Cysteine -- 600 mg - 60 Vegetarian Capsules	Life Extension	Vitamins & Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Mason Natural Marine Collagen Powder Pomegranate Blueberry -- 14 Packs	Mason Natural	Vitamins & Supplements	citric acid, N-Acetyl L-Cysteine, Vitamin C, Biotin, citric acid, Vitamin E, Vitamin E, Malic acid, Niacin	2024-11-29 10:47:42
MRM Cardio Chelate™ with EDTA -- 180 Vegetarian Capsules	MRM	Vitamins & Supplements	NAC, Vitamin C	2024-11-29 10:47:42
MRM NAC N-Acetyl-L-Cysteine -- 600 mg - 60 Vegan Capsules	MRM	Active Lifestyle & Fitness	N-Acetyl-L-Cysteine	2024-11-29 10:47:42
Natural Balance Metal And Toxin Clenz™ -- 60 Vegetarian Capsules	Natural Balance	Vitamins & Supplements	N-Acetyl Cysteine, cellulose, Glycine, IP-6, Vitamin B6, Selenium, Vitamin B6	2024-11-29 10:47:42
Natural Dog Company Liver & Kidney Supplement For Dogs -- 90 Soft Chews	Natural Dog Company	Pet Supplies	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Natural Factors Lung Bronchial & Sinus Health -- 90 Tablets	Natural Factors	Vitamins & Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Natural Factors NAC N-Acetyl-L-Cysteine -- 500 mg - 90 Vegetarian Capsules	Natural Factors	Vitamins & Supplements	N-Acetyl-L-Cysteine	2024-11-29 10:47:42
NutraBio Immune -- 90 Veggie Caps	NutraBio	Vitamins & Supplements	N-Acetyl Cysteine, Vitamin C, Vitamin D3, Selenium	2024-11-29 10:47:42
NutraBio N-Acetyl-Cysteine NAC -- 600 mg - 90 Veggie Capsules	NutraBio	Vitamins & Supplements	NAC	2024-11-29 10:47:42
NutraBio NAC N-Acetyl Cysteine Powder -- 5.3 oz	NutraBio	Vitamins & Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
Nutri NAC N-Acetyl Cysteine -- 600 mg - 60 Vegetable Capsules	Nutri	Vitamins & Supplements	N-Acetyl Cysteine	2024-11-29 10:47:42
NutriCology NAC N-Acetyl-Cysteine -- 500 mg - 120 Tablets	NutriCology	Vitamins & Supplements	N-Acetyl-L-Cysteine, Dicalcium phosphate, stearic acid	2024-11-29 10:47:42
NutriCology Ocudyne II -- 200 Capsules	NutriCology	Vitamins & Supplements	N-Acetyl L-Cysteine, Vitamin C, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Glycine, microcrystalline cellulose, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin	2024-11-29 10:47:42
Nutricost NAC N-Acetyl L-Cysteine Capsules -- 600 mg - 120 Capsules	Nutricost	Vitamins & Supplements	N-Acetyl L-Cysteine, cellulose, stearic acid	2024-11-29 10:47:42
Nutricost NAC N-Acetyl L-Cysteine Capsules -- 600 mg - 180 Capsules	Nutricost	Vitamins & Supplements	N-Acetyl L-Cysteine, cellulose, stearic acid	2024-11-29 10:47:42
Source Naturals Life Force™ Multiple No Iron -- 180 Capsules	Source Naturals	Vitamins & Supplements	N-Acetyl L-Cysteine, Vitamin C, Astaxanthin, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, DMAE, Folate, Vitamin E, microcrystalline cellulose, Inositol, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, N-Acetyl-L-Tyrosine, Niacin, Pantethine, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K1	2024-11-29 10:47:42
Thorne Research NAC N-Acetylcysteine -- 500 mg - 90 Capsules	Thorne Research	Professional Supplements	N-Acetyl Cysteine, leucine	2024-11-29 10:47:42
Twinlab OcuGuard® Plus -- 60 Veggie Caps	Twinlab	Vitamins & Supplements	N-Acetyl L-Cysteine, Vitamin C, Chromium, Vitamin E, eriocitrin, Vitamin E, Lutein, naringin, Quercetin Dihydrate, Vitamin A, Riboflavin, Rutin, Selenium, Taurine, Zeaxanthin	2024-11-29 10:47:42
Vibrant Health Metabolic Vibrance -- 90 Capsules	Vibrant Health	Vitamins & Supplements	Ascorbyl Palmitate, Acetyl L-Carnitine, N-Acetyl Cysteine, Vitamin C, Vitamin D3, Chromium, Iodine, Manganese, Taurine, Alpha-Lipoic Acid, Vanadium, Vanadyl sulfate	2024-11-29 10:47:42
Vitacost N-Acetyl L-Cysteine -- 600 mg - 120 Capsules	Vitacost Brand	Vitamins & Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Vitacost N-Acetyl L-Cysteine -- 600 mg - 240 Capsules	Vitacost Brand	Vitamins & Supplements	N-Acetyl L-Cysteine	2024-11-29 10:47:42
Vitacost-Synergy Eye Defense Formula† -- 120 Capsules	Vitacost-Synergy	Vitamins & Supplements	N-Acetyl L-Cysteine, Vitamin C, Chromium, Vitamin E, Vitamin E, Lutein, Quercetin Dihydrate, Vitamin A, Riboflavin, Rutin, Selenium, Taurine, Zeaxanthin	2024-11-29 10:47:42
Vitacost-Synergy Super Milk Thistle Complex - Advanced Formula -- 60 Capsules	Vitacost-Synergy	Active Lifestyle & Fitness	N-Acetyl-L-Cysteine, Vitamin C, Vitamin A, Alpha Lipoic Acid	2024-11-29 10:47:42
Vital Nutrients NAC N-Acetyl Cysteine - Antioxidant Support -- 600 mg - 200 Vegan Capsules	Vital Nutrients	Professional Supplements	N-Acetyl-L-Cysteine, leucine, magnesium citrate	2024-11-29 10:47:42
Viteyes Complete Eye & Total Body Health Multivitamin -- 180 Capsules	Viteyes	Vitamins & Supplements	N-Acetyl Cysteine, Vitamin C, Biotin, Boron, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin	2024-11-29 10:47:42
Viteyes Optic Nerve Support -- 90 Tablets	Viteyes	Vitamins & Supplements	N-Acetyl Cysteine, Vitamin C, Dicalcium phosphate, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Quercetin Dihydrate, stearic acid, Taurine, Alpha-Lipoic Acid, Vitamin B12	2024-11-29 10:47:42
Wholesome Story NAC N-Acetyl-L-Cysteine -- 600 mg - 120 Vegetarian Capsules	Wholesome Story	Vitamins & Supplements	N-Acetyl-L-Cysteine	2024-11-29 10:47:42

Role	Description
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
antioxidant	A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
antidote to paracetamol poisoning	A role borne by a molecule that acts to counteract or neutralize the deleterious effects of paracetamol (acetaminophen).
vulnerary	A drug used in treating and healing of wounds.
mucolytic	A compound that alters the structure of mucus so as to decrease its viscosity and thereby facilitate its removal by ciliary action and expectoration. Compare with antitussives, which suppress the cough reflex, and expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing.
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
radical scavenger	A role played by a substance that can react readily with, and thereby eliminate, radicals.
ferroptosis inhibitor	Any substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
geroprotector	Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
acetylcysteine
N-acetyl-L-amino acid	An L-amino acid having an N-acetyl substituent.
L-cysteine derivative	A proteinogenic amino acid derivative resulting from the formal reaction of L-cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of L-cysteine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	89.1251	0.6310	35.7641	100.0000	AID504339
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	25.1189	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	1.4125	0.1259	19.1169	125.8920	AID2353
acetylcholinesterase	Homo sapiens (human)	Potency	31.6538	0.0025	41.7960	15,848.9004	AID1347399
dopamine D1 receptor	Homo sapiens (human)	Potency	0.0206	0.0052	1.3022	8.1995	AID624455
15-lipoxygenase, partial	Homo sapiens (human)	Potency	0.0251	0.0126	10.6917	88.5700	AID887
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	31.6228	0.0251	27.9203	501.1870	AID651751
phosphopantetheinyl transferase	Bacillus subtilis	Potency	35.4813	0.1413	37.9142	100.0000	AID1490
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	13.3332	0.0060	38.0041	19,952.5996	AID1159521
USP1 protein, partial	Homo sapiens (human)	Potency	39.8107	0.0316	37.5844	354.8130	AID743255
NFKB1 protein, partial	Homo sapiens (human)	Potency	4.4668	0.0282	7.0559	15.8489	AID895; AID928
Microtubule-associated protein tau	Homo sapiens (human)	Potency	24.7028	0.1800	13.5574	39.8107	AID1460
Thrombopoietin	Homo sapiens (human)	Potency	31.6228	0.0251	7.3048	31.6228	AID917; AID918
AR protein	Homo sapiens (human)	Potency	6.3632	0.0002	21.2231	8,912.5098	AID1259243; AID1259247
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	0.2376	0.5318	15.4358	37.6858	AID504845
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0028	0.0002	14.3764	60.0339	AID588532
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	36.0271	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	9.2111	0.0008	17.5051	59.3239	AID1159531
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	28.1838	0.3758	27.4851	61.6524	AID588527
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	26.6032	0.0002	29.3054	16,493.5996	AID743079
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	1.1220	0.0237	23.2282	63.5986	AID588543
arylsulfatase A	Homo sapiens (human)	Potency	37.9330	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	11.6561	0.0355	20.9770	89.1251	AID504332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	1.0000	0.5406	17.6392	96.1227	AID2364; AID2528
D(1A) dopamine receptor	Homo sapiens (human)	Potency	5.8045	0.0224	5.9449	22.3872	AID488982
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	0.5623	0.0100	39.5371	1,122.0200	AID1479
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	21.6458	0.0003	23.4451	159.6830	AID743065
heat shock protein beta-1	Homo sapiens (human)	Potency	33.4889	0.0420	27.3789	61.6448	AID743210
flap endonuclease 1	Homo sapiens (human)	Potency	26.6795	0.1337	25.4129	89.1251	AID588795
geminin	Homo sapiens (human)	Potency	0.2593	0.0046	11.3741	33.4983	AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	40.5334	0.0056	12.3677	36.1254	AID624032
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	1.5849	0.1259	12.2344	35.4813	AID1458
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	12.5893	0.0010	6.0009	35.4813	AID944
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	50.1187	1.9953	25.5327	50.1187	AID624288
Ataxin-2	Homo sapiens (human)	Potency	11.2202	0.0119	12.2221	68.7989	AID588378
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	26.8545	0.0601	10.7453	37.9330	AID485367
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0019	0.0013	10.1577	42.8575	AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 3	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0004	0.6196	10.0000	AID1271568
Solute carrier family 22 member 6	Rattus norvegicus (Norway rat)	Ki	2,000.0000	1.6000	5.7440	10.0000	AID680341
Histone deacetylase 4	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0006	1.0526	10.0000	AID1271568
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0001	0.5543	9.9000	AID1271568
Histone deacetylase 7	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0007	1.0260	9.9000	AID1271568
Histone deacetylase 2	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0001	0.7221	9.9700	AID1271568
Polyamine deacetylase HDAC10	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0005	0.7245	9.9000	AID1271568
Histone deacetylase 11	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0003	0.9298	9.9000	AID1271568
Histone deacetylase 8	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0007	0.9947	9.9000	AID1271568
Histone deacetylase 6	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0000	0.5376	9.9000	AID1271568
Histone deacetylase 9	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0005	0.9413	9.9000	AID1271568
Histone deacetylase 5	Homo sapiens (human)	IC50 (µMol)	3,160.0000	0.0007	0.9610	10.0000	AID1271568
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of myotube differentiation	Histone deacetylase 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
establishment of mitotic spindle orientation	Histone deacetylase 3	Homo sapiens (human)
in utero embryonic development	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein phosphorylation	Histone deacetylase 3	Homo sapiens (human)
chromatin organization	Histone deacetylase 3	Homo sapiens (human)
transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
protein deacetylation	Histone deacetylase 3	Homo sapiens (human)
regulation of mitotic cell cycle	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein ubiquitination	Histone deacetylase 3	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 3	Homo sapiens (human)
positive regulation of TOR signaling	Histone deacetylase 3	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
regulation of multicellular organism growth	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein import into nucleus	Histone deacetylase 3	Homo sapiens (human)
regulation of circadian rhythm	Histone deacetylase 3	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 3	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
negative regulation of JNK cascade	Histone deacetylase 3	Homo sapiens (human)
spindle assembly	Histone deacetylase 3	Homo sapiens (human)
establishment of skin barrier	Histone deacetylase 3	Homo sapiens (human)
cellular response to fluid shear stress	Histone deacetylase 3	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Histone deacetylase 3	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Histone deacetylase 3	Homo sapiens (human)
cornified envelope assembly	Histone deacetylase 3	Homo sapiens (human)
negative regulation of cardiac muscle cell differentiation	Histone deacetylase 3	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 4	Homo sapiens (human)
protein deacetylation	Histone deacetylase 4	Homo sapiens (human)
inflammatory response	Histone deacetylase 4	Homo sapiens (human)
nervous system development	Histone deacetylase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 4	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Histone deacetylase 4	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Histone deacetylase 4	Homo sapiens (human)
protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
B cell differentiation	Histone deacetylase 4	Homo sapiens (human)
positive regulation of protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 4	Homo sapiens (human)
B cell activation	Histone deacetylase 4	Homo sapiens (human)
regulation of protein binding	Histone deacetylase 4	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 4	Homo sapiens (human)
negative regulation of glycolytic process	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
type I interferon-mediated signaling pathway	Histone deacetylase 4	Homo sapiens (human)
response to interleukin-1	Histone deacetylase 4	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
chromatin organization	Histone deacetylase 1	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
protein deacetylation	Histone deacetylase 1	Homo sapiens (human)
endoderm development	Histone deacetylase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 1	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
hippocampus development	Histone deacetylase 1	Homo sapiens (human)
neuron differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Histone deacetylase 1	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 1	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 1	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Histone deacetylase 1	Homo sapiens (human)
negative regulation by host of viral transcription	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Histone deacetylase 1	Homo sapiens (human)
oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 1	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 1	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Histone deacetylase 1	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Histone deacetylase 1	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 7	Homo sapiens (human)
vasculogenesis	Histone deacetylase 7	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 7	Homo sapiens (human)
protein deacetylation	Histone deacetylase 7	Homo sapiens (human)
cell-cell junction assembly	Histone deacetylase 7	Homo sapiens (human)
protein sumoylation	Histone deacetylase 7	Homo sapiens (human)
negative regulation of interleukin-2 production	Histone deacetylase 7	Homo sapiens (human)
negative regulation of osteoblast differentiation	Histone deacetylase 7	Homo sapiens (human)
regulation of mRNA processing	Histone deacetylase 7	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 7	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Histone deacetylase 7	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
response to amphetamine	Histone deacetylase 2	Homo sapiens (human)
cardiac muscle hypertrophy	Histone deacetylase 2	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 2	Homo sapiens (human)
response to xenobiotic stimulus	Histone deacetylase 2	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 2	Homo sapiens (human)
negative regulation of neuron projection development	Histone deacetylase 2	Homo sapiens (human)
dendrite development	Histone deacetylase 2	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 2	Homo sapiens (human)
response to caffeine	Histone deacetylase 2	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 2	Homo sapiens (human)
response to lipopolysaccharide	Histone deacetylase 2	Homo sapiens (human)
positive regulation of interleukin-1 production	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Histone deacetylase 2	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 2	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
cellular response to heat	Histone deacetylase 2	Homo sapiens (human)
response to nicotine	Histone deacetylase 2	Homo sapiens (human)
protein modification process	Histone deacetylase 2	Homo sapiens (human)
response to cocaine	Histone deacetylase 2	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Histone deacetylase 2	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 2	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of MHC class II biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
positive regulation of proteolysis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
behavioral response to ethanol	Histone deacetylase 2	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 2	Homo sapiens (human)
response to hyperoxia	Histone deacetylase 2	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of dendritic spine development	Histone deacetylase 2	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 2	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 2	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone deacetylase 2	Homo sapiens (human)
cellular response to retinoic acid	Histone deacetylase 2	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Histone deacetylase 2	Homo sapiens (human)
positive regulation of male mating behavior	Histone deacetylase 2	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
cellular response to dopamine	Histone deacetylase 2	Homo sapiens (human)
response to amyloid-beta	Histone deacetylase 2	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of peptidyl-lysine acetylation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Polyamine deacetylase HDAC10	Homo sapiens (human)
DNA repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Polyamine deacetylase HDAC10	Homo sapiens (human)
regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
macroautophagy	Polyamine deacetylase HDAC10	Homo sapiens (human)
positive regulation of mismatch repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
homologous recombination	Polyamine deacetylase HDAC10	Homo sapiens (human)
negative regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
polyamine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
spermidine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
epigenetic regulation of gene expression	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Histone deacetylase 11	Homo sapiens (human)
oligodendrocyte development	Histone deacetylase 11	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 11	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 8	Homo sapiens (human)
chromatin organization	Histone deacetylase 8	Homo sapiens (human)
mitotic sister chromatid cohesion	Histone deacetylase 8	Homo sapiens (human)
negative regulation of protein ubiquitination	Histone deacetylase 8	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 8	Homo sapiens (human)
regulation of telomere maintenance	Histone deacetylase 8	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 8	Homo sapiens (human)
polyamine deacetylation	Histone deacetylase 6	Homo sapiens (human)
spermidine deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 6	Homo sapiens (human)
protein polyubiquitination	Histone deacetylase 6	Homo sapiens (human)
response to amphetamine	Histone deacetylase 6	Homo sapiens (human)
protein deacetylation	Histone deacetylase 6	Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteins	Histone deacetylase 6	Homo sapiens (human)
intracellular protein transport	Histone deacetylase 6	Homo sapiens (human)
autophagy	Histone deacetylase 6	Homo sapiens (human)
actin filament organization	Histone deacetylase 6	Homo sapiens (human)
negative regulation of microtubule depolymerization	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy	Histone deacetylase 6	Homo sapiens (human)
positive regulation of epithelial cell migration	Histone deacetylase 6	Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic process	Histone deacetylase 6	Homo sapiens (human)
regulation of macroautophagy	Histone deacetylase 6	Homo sapiens (human)
axonal transport of mitochondrion	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Histone deacetylase 6	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 6	Homo sapiens (human)
protein destabilization	Histone deacetylase 6	Homo sapiens (human)
lysosome localization	Histone deacetylase 6	Homo sapiens (human)
protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Histone deacetylase 6	Homo sapiens (human)
cellular response to heat	Histone deacetylase 6	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 6	Homo sapiens (human)
response to immobilization stress	Histone deacetylase 6	Homo sapiens (human)
cellular response to topologically incorrect protein	Histone deacetylase 6	Homo sapiens (human)
erythrocyte enucleation	Histone deacetylase 6	Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
regulation of fat cell differentiation	Histone deacetylase 6	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 6	Homo sapiens (human)
negative regulation of proteolysis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 6	Homo sapiens (human)
collateral sprouting	Histone deacetylase 6	Homo sapiens (human)
negative regulation of axon extension involved in axon guidance	Histone deacetylase 6	Homo sapiens (human)
positive regulation of dendrite morphogenesis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of oxidoreductase activity	Histone deacetylase 6	Homo sapiens (human)
response to corticosterone	Histone deacetylase 6	Homo sapiens (human)
response to misfolded protein	Histone deacetylase 6	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Histone deacetylase 6	Homo sapiens (human)
cilium assembly	Histone deacetylase 6	Homo sapiens (human)
regulation of microtubule-based movement	Histone deacetylase 6	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Histone deacetylase 6	Homo sapiens (human)
dendritic spine morphogenesis	Histone deacetylase 6	Homo sapiens (human)
cilium disassembly	Histone deacetylase 6	Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization	Histone deacetylase 6	Homo sapiens (human)
regulation of establishment of protein localization	Histone deacetylase 6	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone deacetylase 6	Homo sapiens (human)
aggresome assembly	Histone deacetylase 6	Homo sapiens (human)
polyubiquitinated misfolded protein transport	Histone deacetylase 6	Homo sapiens (human)
response to growth factor	Histone deacetylase 6	Homo sapiens (human)
cellular response to misfolded protein	Histone deacetylase 6	Homo sapiens (human)
cellular response to parathyroid hormone stimulus	Histone deacetylase 6	Homo sapiens (human)
response to dexamethasone	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of tubulin deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of cellular response to oxidative stress	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein acetylation	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy of mitochondrion	Histone deacetylase 6	Homo sapiens (human)
positive regulation of cholangiocyte proliferation	Histone deacetylase 6	Homo sapiens (human)
negative regulation of aggrephagy	Histone deacetylase 6	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 6	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 9	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 9	Homo sapiens (human)
negative regulation of cytokine production	Histone deacetylase 9	Homo sapiens (human)
response to amphetamine	Histone deacetylase 9	Homo sapiens (human)
inflammatory response	Histone deacetylase 9	Homo sapiens (human)
heart development	Histone deacetylase 9	Homo sapiens (human)
neuron differentiation	Histone deacetylase 9	Homo sapiens (human)
B cell differentiation	Histone deacetylase 9	Homo sapiens (human)
cellular response to insulin stimulus	Histone deacetylase 9	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 9	Homo sapiens (human)
B cell activation	Histone deacetylase 9	Homo sapiens (human)
cholesterol homeostasis	Histone deacetylase 9	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 9	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 9	Homo sapiens (human)
regulation of skeletal muscle fiber development	Histone deacetylase 9	Homo sapiens (human)
regulation of striated muscle cell differentiation	Histone deacetylase 9	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 9	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
inflammatory response	Histone deacetylase 5	Homo sapiens (human)
response to xenobiotic stimulus	Histone deacetylase 5	Homo sapiens (human)
regulation of myotube differentiation	Histone deacetylase 5	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 5	Homo sapiens (human)
response to activity	Histone deacetylase 5	Homo sapiens (human)
neuron differentiation	Histone deacetylase 5	Homo sapiens (human)
B cell differentiation	Histone deacetylase 5	Homo sapiens (human)
cellular response to insulin stimulus	Histone deacetylase 5	Homo sapiens (human)
B cell activation	Histone deacetylase 5	Homo sapiens (human)
response to cocaine	Histone deacetylase 5	Homo sapiens (human)
regulation of protein binding	Histone deacetylase 5	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 5	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 5	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Histone deacetylase 5	Homo sapiens (human)
cellular response to lipopolysaccharide	Histone deacetylase 5	Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription corepressor binding	Histone deacetylase 3	Homo sapiens (human)
chromatin binding	Histone deacetylase 3	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
protein binding	Histone deacetylase 3	Homo sapiens (human)
enzyme binding	Histone deacetylase 3	Homo sapiens (human)
cyclin binding	Histone deacetylase 3	Homo sapiens (human)
chromatin DNA binding	Histone deacetylase 3	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 3	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 3	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 3	Homo sapiens (human)
protein decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 3	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 4	Homo sapiens (human)
histone binding	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
protein binding	Histone deacetylase 4	Homo sapiens (human)
zinc ion binding	Histone deacetylase 4	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 4	Homo sapiens (human)
potassium ion binding	Histone deacetylase 4	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
identical protein binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 4	Homo sapiens (human)
molecular adaptor activity	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 1	Homo sapiens (human)
p53 binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
protein binding	Histone deacetylase 1	Homo sapiens (human)
enzyme binding	Histone deacetylase 1	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
Krueppel-associated box domain binding	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 1	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
E-box binding	Histone deacetylase 1	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 1	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 1	Homo sapiens (human)
chromatin binding	Histone deacetylase 7	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 7	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 7	Homo sapiens (human)
protein binding	Histone deacetylase 7	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase binding	Histone deacetylase 7	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
metal ion binding	Histone deacetylase 7	Homo sapiens (human)
14-3-3 protein binding	Histone deacetylase 7	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 7	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 2	Homo sapiens (human)
chromatin binding	Histone deacetylase 2	Homo sapiens (human)
RNA binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
protein binding	Histone deacetylase 2	Homo sapiens (human)
enzyme binding	Histone deacetylase 2	Homo sapiens (human)
heat shock protein binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
histone binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 2	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 2	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 2	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 2	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 2	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
zinc ion binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
enzyme binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylputrescine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylspermidine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 11	Homo sapiens (human)
protein binding	Histone deacetylase 11	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 11	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
protein binding	Histone deacetylase 8	Homo sapiens (human)
Hsp70 protein binding	Histone deacetylase 8	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
metal ion binding	Histone deacetylase 8	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 8	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 8	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 8	Homo sapiens (human)
acetylspermidine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 6	Homo sapiens (human)
actin binding	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-catenin binding	Histone deacetylase 6	Homo sapiens (human)
microtubule binding	Histone deacetylase 6	Homo sapiens (human)
zinc ion binding	Histone deacetylase 6	Homo sapiens (human)
enzyme binding	Histone deacetylase 6	Homo sapiens (human)
polyubiquitin modification-dependent protein binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin protein ligase binding	Histone deacetylase 6	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
alpha-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin binding	Histone deacetylase 6	Homo sapiens (human)
tau protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
misfolded protein binding	Histone deacetylase 6	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 6	Homo sapiens (human)
dynein complex binding	Histone deacetylase 6	Homo sapiens (human)
transcription factor binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 9	Homo sapiens (human)
protein binding	Histone deacetylase 9	Homo sapiens (human)
histone H3K14 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H3K9 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H4K16 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 9	Homo sapiens (human)
metal ion binding	Histone deacetylase 9	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 5	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 5	Homo sapiens (human)
chromatin binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 5	Homo sapiens (human)
protein binding	Histone deacetylase 5	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
identical protein binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 5	Homo sapiens (human)
metal ion binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Histone deacetylase 3	Homo sapiens (human)
nucleoplasm	Histone deacetylase 3	Homo sapiens (human)
cytoplasm	Histone deacetylase 3	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 3	Homo sapiens (human)
cytosol	Histone deacetylase 3	Homo sapiens (human)
plasma membrane	Histone deacetylase 3	Homo sapiens (human)
mitotic spindle	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 3	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 3	Homo sapiens (human)
nucleus	Histone deacetylase 3	Homo sapiens (human)
nucleus	Histone deacetylase 4	Homo sapiens (human)
nucleoplasm	Histone deacetylase 4	Homo sapiens (human)
cytoplasm	Histone deacetylase 4	Homo sapiens (human)
cytosol	Histone deacetylase 4	Homo sapiens (human)
nuclear speck	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 4	Homo sapiens (human)
chromatin	Histone deacetylase 4	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 4	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 7	Homo sapiens (human)
nucleoplasm	Histone deacetylase 7	Homo sapiens (human)
cytoplasm	Histone deacetylase 7	Homo sapiens (human)
cytosol	Histone deacetylase 7	Homo sapiens (human)
chromosome, telomeric region	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleoplasm	Histone deacetylase 2	Homo sapiens (human)
cytoplasm	Histone deacetylase 2	Homo sapiens (human)
NuRD complex	Histone deacetylase 2	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 2	Homo sapiens (human)
chromatin	Histone deacetylase 2	Homo sapiens (human)
protein-containing complex	Histone deacetylase 2	Homo sapiens (human)
ESC/E(Z) complex	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleus	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytosol	Polyamine deacetylase HDAC10	Homo sapiens (human)
intracellular membrane-bounded organelle	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase complex	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleus	Histone deacetylase 11	Homo sapiens (human)
plasma membrane	Histone deacetylase 11	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 11	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear chromosome	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleoplasm	Histone deacetylase 8	Homo sapiens (human)
cytoplasm	Histone deacetylase 8	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 6	Homo sapiens (human)
nucleoplasm	Histone deacetylase 6	Homo sapiens (human)
cytoplasm	Histone deacetylase 6	Homo sapiens (human)
multivesicular body	Histone deacetylase 6	Homo sapiens (human)
centrosome	Histone deacetylase 6	Homo sapiens (human)
cytosol	Histone deacetylase 6	Homo sapiens (human)
microtubule	Histone deacetylase 6	Homo sapiens (human)
caveola	Histone deacetylase 6	Homo sapiens (human)
inclusion body	Histone deacetylase 6	Homo sapiens (human)
aggresome	Histone deacetylase 6	Homo sapiens (human)
axon	Histone deacetylase 6	Homo sapiens (human)
dendrite	Histone deacetylase 6	Homo sapiens (human)
cell leading edge	Histone deacetylase 6	Homo sapiens (human)
ciliary basal body	Histone deacetylase 6	Homo sapiens (human)
perikaryon	Histone deacetylase 6	Homo sapiens (human)
perinuclear region of cytoplasm	Histone deacetylase 6	Homo sapiens (human)
axon cytoplasm	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 6	Homo sapiens (human)
microtubule associated complex	Histone deacetylase 6	Homo sapiens (human)
nucleus	Histone deacetylase 9	Homo sapiens (human)
nucleoplasm	Histone deacetylase 9	Homo sapiens (human)
cytoplasm	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 9	Homo sapiens (human)
transcription regulator complex	Histone deacetylase 9	Homo sapiens (human)
histone methyltransferase complex	Histone deacetylase 9	Homo sapiens (human)
nucleus	Histone deacetylase 5	Homo sapiens (human)
nucleoplasm	Histone deacetylase 5	Homo sapiens (human)
cytoplasm	Histone deacetylase 5	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 5	Homo sapiens (human)
cytosol	Histone deacetylase 5	Homo sapiens (human)
nuclear speck	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID608193	Cell cycle arrest in human NTUB1 cells assessed as accumulation at G1 phase at 1 mM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 50.64%)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells.
AID1416864	Oral bioavailability in human	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID106125	Effect on intracellular GSH content at 250 uM in human macrophage-derived monocytes (MDMs)	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	NAC/MEA conjugate: a new potent antioxidant which increases the GSH level in various cell lines.
AID1705128	Induction of apoptosis in human EC-109 cells assessed as apoptotic rate at 5 mM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.8 %)	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis and in vitro and in vivo biological evaluation of novel derivatives of flexicaulin A as antiproliferative agents.
AID608194	Cell cycle arrest in human NTUB1 cells assessed as accumulation at S phase at 1 mM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 20.37%)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1488685	Hepatoprotective activity against APAP-induced cell injury in human HL-7702 cells assessed as survival rate at 10 uM pre-incubated for 24 hrs before APAP addition and measured 6 hrs post APAP challenge by MTT assay (Rvb = 60.49 +/- 0.28%)	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Discovery and structure-activity relationship of auriculatone: A potent hepatoprotective agent against acetaminophen-induced liver injury.
AID1488676	Effect on APAP-induced depletion of GSH levels in human HL-7702 cells assessed as GSH level at 10 uM by colorimetric method (Rvb = 59.68 +/- 1.16 au)	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Discovery and structure-activity relationship of auriculatone: A potent hepatoprotective agent against acetaminophen-induced liver injury.
AID1205932	Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205932	Antibacterial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID695876	Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID736271	Neuroprotective activity against H2O2-induced toxicity in rat PC12 cells assessed as cell viability at 100 uM incubated for 2 hrs prior to H2O2-challenge measured after 24 hrs by MTT assay relative to control	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	(M)- and (P)-bicelaphanol A, dimeric trinorditerpenes with promising neuroprotective activity from Celastrus orbiculatus.
AID1287165	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 5 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.4%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	3,3'-OH curcumin causes apoptosis in HepG2 cells through ROS-mediated pathway.
AID1193494	Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID118995	Protection of mice against acetaminophen-induced Hepatotoxicity	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1424234	Antioxidant activity assessed as singlet oxygen scavenging activity by measuring rate constant using VIS irradiation by ESR spin trapping method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID1451748	Antibacterial activity against non-pigmented Staphylococcus aureus Newman assessed as H2O2-induced bacterial death by measuring survival rate at 1 uM preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method (Rvb =	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
AID1472678	Inhibition of CrtN in methicillin-resistant Staphylococcus aureus LAC USA300 assessed as increase in H2O2-induced bacterial death by measuring survival rate preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
AID1762611	Neuroprotection against H202-induced oxidative stress in human SH-SY5Y cells assessed as cell protection at 1 mM preincubated for 2 hr before H202 challenge and measured after 24 hrs by MTT assay
AID1647281	Neuroprotective activity against H2O2-induced cytotoxicity in human SH-SY5Y cells assessed as cell viability at 1 mM pretreated for 2 hrs followed by H2O2 challenge and measured after MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Design, synthesis and evaluation of diosgenin carbamate derivatives as multitarget anti-Alzheimer's disease agents.
AID1126623	Antioxidant activity in human SH-SY5Y cells assessed as inhibition of t-BuOOH-induced intracellular ROS formation at 500 uM after 30 mins by dihydroethidium-based spectrofluorometric analysis relative to control	2014	European journal of medicinal chemistry, May-06, Volume: 78	Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1281763	Induction of apoptosis in Bax deficient human HCT116 cells assessed as late apoptotic cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.56%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID606798	Induction of Nrf2-mediated GCLM gene expression in human BEAS2B cells at 10 mM after 24 hrs by RT-PCR analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells.
AID1281736	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.73%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1451795	Inhibition of CrtN in Staphylococcus aureus USA400 MW2 assessed as H2O2-induced bacterial death by measuring survival rate at 1 uM preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method (Rvb = 26.3%)	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
AID1193499	Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1370893	Cell cycle arrest in human HL60 cells assessed as accumulation at G0/G1 phase at 5 mM after 48 hrs by propidium iodide staining based assay (Rvb = 50.88%)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
AID1654174	Antioxidant activity in human Gingival fibroblast assessed as reduction in H202-induced intracellular ROS level by measuring ROS production at 1 mM after 72 hrs by H2DCFDA staining based fluorescence method (Rvb = 181.9 +/- 7.4%)	2020	Journal of natural products, 03-27, Volume: 83, Issue:3	Antioxidant Activity of Compounds Isolated from
AID285164	Antimicrobial activity against catheter-associated biofilm of methicillin-resistant Staphylococcus epidermidis	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID715275	Inhibition of H2O2-induced cytotoxicity in HUVEC cells assessed as cell viability at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs by MTT assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	The synthesis and biological evaluation of novel Danshensu-cysteine analog conjugates as cardiovascular-protective agents.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID122864	Compound was evaluated for its protective activity against acetaminophen (750 mg (4.97 mol) /kg) toxicity, given intraperitoneally in mice and the number of animals with liver necrosis was determined after 1 hr	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicity.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID616405	Cytotoxicity against human NTUB1 cells assessed as cell viability at 1 mM after 72 hrs by MTT assay relative to control	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Anthraquinone derivatives induce G2/M cell cycle arrest and apoptosis in NTUB1 cells.
AID1273638	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 1 mM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.1%)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1901284	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS generation at 5 mM preincubated for 3 hrs followed by LPS stimulation and measured after 12 hrs by DCFH-DA probe based flow cytometry	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis of lathyrane diterpenoid nitrogen-containing heterocyclic derivatives and evaluation of their anti-inflammatory activities.
AID1698073	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
AID1546323	Cardioprotective activity in Swiss mouse model of isoproterenol-induced myocardial infarction assessed as reduction in creatine kinase myocardial band at 1200 mg/kg administered 30 mins post isoproterenol stimulation	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1393003	Effect on total STAT3 protein level in human DU145 cells assessed as ratio of ERK1/2 protein level to GAPDH protein level at 2 mM after 1 hr by Western blot analysis (Rvb = 1 No_unit)	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.
AID1367957	Neuroprotective activity against glutamate-induced cell death in mouse HT22 cells assessed as increase in cell viability at 5 mM after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Protective effect of casuarinin against glutamate-induced apoptosis in HT22 cells through inhibition of oxidative stress-mediated MAPK phosphorylation.
AID1756331	Inhibition of salsolinol-induced mitochondrial depolarization in human SH-SY5Y cells assessed as mitochondrial membrane potential at 100 uM measured after 24 hrs by JC-1 staining based flow cytometry (Rvb = 45.3 +/-2.09%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID695851	Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1437794	Antioxidant activity of the compound assessed as DPPH radical scavenging activity after 30 mins	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
AID551415	Neuroprotective activity against rotenone/oligomycin-A-induced death in human SH-SY5Y cells assessed as protective effect at 1 mM after 2 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2	Synthesis, structure, theoretical and experimental in vitro antioxidant/pharmacological properties of α-aryl, N-alkyl nitrones, as potential agents for the treatment of cerebral ischemia.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1395985	Bactericidal activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 planktonic cells after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID710227	Prevention of apoptosis in rat H9c2 cells assessed as reduction in fall of mitochondrial membrane potential at 100 nM after 1 hr	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
AID1205925	Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205925	Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1416863	Drug excretion in iv dosed human	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1273629	Induction of reactive oxygen species in human HCT116 cells at 1 mM after 48 hrs by DCFH-DA staining-based flow cytometric analysis (Rvb = 5.1%)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
AID1756282	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 10 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1287164	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 5 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.8%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	3,3'-OH curcumin causes apoptosis in HepG2 cells through ROS-mediated pathway.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1281760	Induction of apoptosis in Bax deficient human HCT116 cells assessed as early apoptotic cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.85%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID1193493	Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1395986	Induction of biofilm eradication of methicillin-resistant Staphylococcus epidermidis ATCC 35984 after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1451794	Inhibition of CrtN in Staphylococcus aureus USA300 LAC assessed as H2O2-induced bacterial death by measuring survival rate at 1 uM preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method (Rvb = 24%)	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
AID1756328	Inhibition of Salsolinol-induced oxidative stress in human SH-SY5Y cells assessed as reduction in superoxide radical formation at 1000 uM measured after 24 hrs by DHE staining based fluorescence microscopy	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1319625	Protection against H2O2-induced apoptosis in rat MC3T3-E1 cells assessed as late apoptotic cells pretreated with compound for 48 hrs followed by H2O2 treatment for 24 hrs by annexin V-FITC/PI staining based flow cytometry (Rvb = 57.8%)	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Wnt/β-catenin signaling plays an important role in the protective effects of FDP-Sr against oxidative stress induced apoptosis in MC3T3-E1 cell.
AID497827	Protection against fragile X syndrome phenotypes in Fmr1 null mutant Drosophila Fmr1'3/TM6C assessed as embryo viability at 40 uM at 25 degC by flow cytometry relative to untreated homozygous embryos	2008	Nature chemical biology, Apr, Volume: 4, Issue:4	Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.
AID1304831	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 assessed as biofilm eradication incubated for 24 hrs by CBD assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1416855	Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 1.5 hrs by LC-MS/MS analysis	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1488673	Hepatoprotective activity against APAP-induced cell injury in human HL-7702 cells assessed as increase in survival rate at 10 uM pre-incubated for 24 hrs before APAP addition and measured 6 hrs post APAP challenge by MTT assay	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Discovery and structure-activity relationship of auriculatone: A potent hepatoprotective agent against acetaminophen-induced liver injury.
AID1756291	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell death at 100 uM measured after 24 hrs by PI staining based analysis (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1395988	Induction of biofilm eradication of vancomycin-resistant Enterococcus faecium ATCC 700221 after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1424233	Antioxidant activity assessed as hydroxyl radical scavenging activity by measuring rate constant using UV irradiation by ESR spin trapping method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID127495	The compound was tested for antiviral activity against HIV-1/Ba-L-infected monocyte-derived macrophages in human at a concentration of 2 mM	1999	Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23	Synthesis and in vitro anti-HIV activity in human monocyte-derived macrophages of 2-oxothiazolidine-4(R)-carboxylic acid derivatives.
AID1594772	Increase in live cell area in human HepG2 cells measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID1546318	Cardioprotective activity in Swiss mouse model of isoproterenol-induced myocardial infarction assessed as reduction in myocardial infarct size at 1200 mg/kg administered 30 mins post isoproterenol stimulation by TTC staining based assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID295045	Inhibition of horseradish peroxidase	2007	Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9	Quercinol, an anti-inflammatory chromene from the wood-rotting fungus Daedalea quercina (Oak Mazegill).
AID1205938	Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205938	Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2301 expressing NDM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1654194	Protection against H202-induced cell cycle blockade in human Gingival fibroblast assessed as accumulation at G0/G1 phase after 72 hrs by flow cytometry (Rvb = 42.2%)	2020	Journal of natural products, 03-27, Volume: 83, Issue:3	Antioxidant Activity of Compounds Isolated from
AID1557168	Neuroprotective activity against H2O2-induced oxidative stress in human SH-SY5Y cells assessed as cell viability at 1 mM preincubated for 2 hrs followed by H2O2 stimulation for 30 mins followed by further incubation for 24 hrs by MTT assay relative to con	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and biological evaluation of 3-carbamate smilagenin derivatives as potential neuroprotective agents.
AID1370895	Cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at 5 mM after 48 hrs by propidium iodide staining based assay (Rvb = 2.68%)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
AID120748	Percentage survival of mice after 48 hr.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID561440	Inhibition of amphotericin B-induced renal tubular apoptosis in Sprague-Dawley rat assessed as apoptotic index at 120 mg/kg, ip BID measured post last dose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.
AID1326426	Induction of apoptosis in human PC3 cells assessed as externalization of phosphatidylserine on cell surface by measuring early apoptotic cells at 5 uM after 6 hrs by Annexin-V/FITC/PI staining by flow cytometry (Rvb = 0.93 +/- 0.05%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1135695	Half life of the compound in phosphate buffer with 350 ml/min oxygen flow assessed as oxidation at 0.27 mM by Ellman's method	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Mercaptoimidazolylpropionic acid hydrobromide. Inhibition of tadpole collagenase and related properties.
AID1264245	Neuroprotective activity against nutrient deprivation-induced neuronal cell death in Sprague-Dawley rat CGN cells at 10 mM preincubated for 24 hrs followed by induction of nutrient deprivation measured after 24 hrs relative to control	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1700042	Neuroprotective activity against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 1 mM by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID1281733	Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.2%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID1546311	Cardioprotective activity in Swiss mouse model of isoproterenol-induced myocardial Infarction assessed as abnormal ST-segment at 1200 mg/kg administered 30 mins post isoproterenol stimulation and measured for 5 mins by electrocardiographic analysis (Rvb =	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1370920	Neuroprotective activity against glutamate induced cell death in mouse HT22 cells assessed as increase in cell viability at 1 to 5 uM after 24 hrs by MTT assay
AID737020	Neuroprotective activity in H2O2-stimulated human SH-SY5Y cells assessed as downregulation of Bcl2 expression at 5 mM incubated for 4 hrs prior to H2O2 challenge measured after 12 hrs by Western blotting analysis	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1205934	Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205934	Antibacterial activity against Pseudomonas aeruginosa T2226 expressing IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID91056	Percent viscosity reduction after 15 min was tested for in vitro mucolytic activity using pooled human sputum adjusted to pH 7.5 and compared with saline by 0.03 M solution of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	N-[[(Mercaptoacetyl)amino]benzoyl]glycines as mucolytic agents.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1205924	Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205924	Inhibition of hexahistidine-tagged NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID681809	TP_TRANSPORTER: inhibition of DNP-NAC uptake (DNP-NAC: 1 uM, NAC: 1000 uM) in Xenopus laevis oocytes	2001	Molecular pharmacology, Nov, Volume: 60, Issue:5	Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1.
AID1193496	Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID197252	In vitro increased GSH content of rat hepatocytes when incubated with compound after 4 hr	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1205942	Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205942	Ratio of imipenim MIC to imipenim MIC in presence of compound for Klebsiella pneumoniae T2216 expressing VIM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1546314	Cardioprotective activity in Swiss mouse model of myocardial infarction assessed as reversal of isoproterenol-induced increase in QTc interval at 1200 mg/kg administered 30 mins post isoproterenol stimulation and measured for 5 mins by electrocardiographi	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1762594	Neuroprotection against Abeta-induced oxidative stress in human SH-SY5Y cells assessed as cell protection at 1 mM incubated for 2 hr before before Abeta(1-42) challenge and measured after 24 hrs by MTT assay
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147029	Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-treated rat assessed as reduction of blood acetaldehyde level at 8 mmol/kg, po administered 24 hrs prior to ethanol treatment measured after 1 hr by head space gas chrom	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID1472676	Inhibition of CrtN in methicillin-resistant Staphylococcus aureus USA400 MW2 assessed as increase in H2O2-induced bacterial death by measuring survival rate preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID285165	Antimicrobial activity against catheter-associated biofilm of Klebsiella pneumoniae	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID1762612	Neuroprotection against 6-OHDA-induced oxidative stress in human SH-SY5Y cells assessed as cell protection at 1 mM preincubated for 2 hr before 6-OHDA challenge and measured after 24 hrs by MTT assay
AID118275	Number of mice with necrosis was measured for compound along with acetaminophen and number of animals showing necrosis rating of 0 was reported.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1304843	Antibiofilm activity against methicillin-resistant Enterococcus faecium ATCC 700221 assessed as biofilm eradication incubated for 24 hrs by CBD assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1756317	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 1000 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID616396	Induction of ROS production in human NTUB1 cells using H2DCFDA staining at 1 mM after 24 hrs by flow cytometry analysis	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Anthraquinone derivatives induce G2/M cell cycle arrest and apoptosis in NTUB1 cells.
AID1576116	Neuroprotective activity against H2O2-induced neurotoxicity in Sprague-Dawley rat hippocampal neuron assessed as cell survival rate at 1 uM incubated for 24 hrs in presence of 150 uM H2O2 by MTT assay (Rvb = 41.6 to 43.2 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	The synthesis and biological evaluation of novel gardenamide A derivatives as multifunctional neuroprotective agents.
AID710228	Cytotoxicity against rat H9c2 cells assessed as cell viability in absence of H2O2	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
AID1511942	Inhibition of PMA-induced NETosis in human neutrophils at 0.5 to 4 mM preincubated for 30 mins followed by PMA stimulation and measured after 3.5 hrs by Hoechst 33242 staining based fluorescence microscopic analysis	2019	ACS medicinal chemistry letters, Sep-12, Volume: 10, Issue:9	Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.
AID1205941	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205941	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring VIM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1703579	Antioxidant activity assessed as radical scavenging activity measured after 30 mins by microplate reader based DPPH assay	2020	European journal of medicinal chemistry, Oct-01, Volume: 203	Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
AID1370807	Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition by spectrophotometric analysis	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	New butenolide derivatives from the marine sponge-derived fungus Aspergillus terreus.
AID123981	Compound was evaluated for its protective activity against acetaminophen (750 mg (4.97 mol) /kg) toxicity, given intraperitoneally in mice and the survival of the mice was determined at 48 h; 17/17	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicity.
AID1768307	Protection against cisplatin-induced nephrotoxicity in pig LLC-PK1 cells assessed as increase in cell viability at 50 to 1000 uM measured after 24 hrs in presence of cisplatin	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Necrostatins regulate apoptosis, necroptosis, and inflammation in cisplatin-induced nephrotoxicity in LLC-PK1 cells.
AID1756324	Inhibition of Salsolinol-induced oxidative stress in human SH-SY5Y cells assessed as reduction in superoxide radical formation measured after 24 hrs by DHE staining based fluorescence spectrophotometry	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1654196	Protection against H202-induced cell cycle blockade in human Gingival fibroblast assessed as accumulation at G2/M phase after 72 hrs by flow cytometry (Rvb = 39.3%)	2020	Journal of natural products, 03-27, Volume: 83, Issue:3	Antioxidant Activity of Compounds Isolated from
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1756336	Inhibition of salsolinol-induced apoptosis in human SH-SY5Y cells assessed as appearance of necrotic cells along with early and late apoptotic cells at 1000 uM measured after 24 hrs by AO/PIstaining based fluorescence microscopy	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1573712	Neuroprotective activity against glutamate-induced neuronal cell death in mouse HT22 cells assessed as increase in cell viability at 0.5 to 5 uM after 24 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Sanguiin H-11 from Sanguisorbae radix protects HT22 murine hippocampal cells against glutamate-induced death.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID613906	Antioxidant activity in human SH-SY5Y cells assessed as decrease of tert-butyl hydroperoxide-induced ROS production at 20 uM after 24 hrs using DCFH-DA by fluorescence assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease.
AID1576115	Neuroprotective activity against H2O2-induced neurotoxicity in Sprague-Dawley rat hippocampal neuron assessed as cell survival rate at 0.1 uM incubated for 24 hrs in presence of 150 uM H2O2 by MTT assay (Rvb = 41.6 to 43.2 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	The synthesis and biological evaluation of novel gardenamide A derivatives as multifunctional neuroprotective agents.
AID695877	Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1768308	Protection against cisplatin-induced nephrotoxicity in pig LLC-PK1 cells assessed as cell viability at 1000 uM measured after 24 hrs in presence of cisplatin	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Necrostatins regulate apoptosis, necroptosis, and inflammation in cisplatin-induced nephrotoxicity in LLC-PK1 cells.
AID1700041	Neuroprotection against H202-induced oxidative stress in human SH-SY5Y cells assessed as increase in cell viability at 1 mM by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents.
AID513610	Inhibition of NO production in BAEC assessed as inhibition of Ca2+ influx at 10 mM	2006	Nature chemical biology, Nov, Volume: 2, Issue:11	Nitric oxide activates TRP channels by cysteine S-nitrosylation.
AID1304827	Antibiofilm activity against methicillin-resistant Staphylococcus aureus isolate 2 assessed as biofilm eradication incubated for 24 hrs by CBD assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID715278	Antioxidant activity in HUVEC cells assessed as reduction in H2O2-induced GSH activity at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs	2012	European journal of medicinal chemistry, Sep, Volume: 55	The synthesis and biological evaluation of novel Danshensu-cysteine analog conjugates as cardiovascular-protective agents.
AID1273637	Induction of apoptosis in human HCT116 cells assessed as viable cells at 1 mM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 87.4%)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
AID1754201	Neuroprotective activity against oxygen glucose-deprivation induced toxicity in human SH-SY5Y cells at 1 mM relative to control	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID577800	Potentiation of Angeli's salt induced- vasodilatory activity in Sprague-Dawley rat thoracic aorta at 1 mM	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties.
AID1205935	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205935	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1374851	Neuroprotective activity against tetracycline removal-induced cytotoxicity in human MC65 cells assessed as reduction in oxidative stress at 8 mM after 48 hrs by DCFH-DA dye based fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6	Design and characterization of bivalent compounds as potential neuroprotectants for Alzheimer's disease: Impact of the spacer on biological activity.
AID608130	Decrease in ROS generation in human NTUB1 cells at 1 mM after 24 hrs by H2DCFDA staining based flow cytometeric analysis relative to control	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells.
AID1472680	Inhibition of CrtN in methicillin-resistant Staphylococcus aureus Mu50 assessed as increase in H2O2-induced bacterial death by measuring survival rate at preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method (R	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
AID1756283	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell viability at 100 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis (Rvb = 70.49 +/-0.51%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1205931	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205931	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring NDM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1135694	Half life of the compound in phosphate buffer with 200 ml/min oxygen flow assessed as oxidation at 0.28 mM by Ellman's method	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Mercaptoimidazolylpropionic acid hydrobromide. Inhibition of tadpole collagenase and related properties.
AID1514853	Neuroprotection against H2O2-induced cell death in human SH-SY5Y cells preincubated for 6 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of clovamide analogues with catechol functionality as potent Parkinson's disease agents in vitro and in vivo.
AID527151	Increase of lipid peroxidation in gastrocnemius muscle of C57BL/6 mouse tail suspension model assessed as decrease of thiobarbituric acid-reactive substance level at 2.5 pmol administered in gastrocnemius muscle qd for 10 days by RT-PCR analysis	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Quercetin prevents unloading-derived disused muscle atrophy by attenuating the induction of ubiquitin ligases in tail-suspension mice.
AID1756329	Inhibition of salsolinol-induced apoptosis in human SH-SY5Y cells assessed as caspase 3/7 activity at 1000 uM incubated for 24 hrs using Ac-DEVD-AMC as substrate by fluorescence analysis (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID577803	Potentiation of MahmaNonoate induced- vasodilatory activity in Sprague-Dawley rat thoracic aorta at 1 mM	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1281730	Induction of apoptosis in human HCT116 cells assessed as viable cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 93.64%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID1659276	Neuroprotection against glutamate-induced oxidative stress in mouse HT22 cells assessed as increase in cell viability pretreated with glutamate for 24 hrs followed by compound addition by calcein AM and PI staining based assay	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Synthesis and biological evaluation of isoliquiritigenin derivatives as a neuroprotective agent against glutamate mediated neurotoxicity in HT22 cells.
AID606800	Induction of Nrf2-mediated HO1 gene expression in human BEAS2B cells at 10 mM after 24 hrs by RT-PCR analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID122863	Compound was evaluated for its protective activity against acetaminophen (750 mg (4.97 mol) /kg) toxicity, given intraperitoneally in mice and the number of animals with liver necrosis was determined after 0h	1984	Journal of medicinal chemistry, May, Volume: 27, Issue:5	2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicity.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193498	Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1546343	Cardioprotective activity against isoproterenol-induced apoptosis in Swiss mouse model of myocardial infarction assessed as reduction in Bax/Bcl2 expression ratio in at 1200 mg/kg administered 30 mins post isoproterenol stimulation by Western blot analysi	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1424235	Antioxidant activity assessed as alkoxyl radical scavenging activity by measuring rate constant by ESR spin trapping method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID1205936	Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205936	Antibacterial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID715277	Antioxidant activity against H2O2-induced lipid accumulation in HUVEC cells assessed as reduction in MDA level at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs	2012	European journal of medicinal chemistry, Sep, Volume: 55	The synthesis and biological evaluation of novel Danshensu-cysteine analog conjugates as cardiovascular-protective agents.
AID715276	Inhibition of H2O2-induced cytotoxicity in HUVEC cells assessed as LDH release at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs by LDH assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	The synthesis and biological evaluation of novel Danshensu-cysteine analog conjugates as cardiovascular-protective agents.
AID1654171	Protective activity against H202-induced cell death in human Gingival fibroblast assessed as cell proliferation after 72 hrs by MTS assay (Rvb = 50.9 +/- 4%)	2020	Journal of natural products, 03-27, Volume: 83, Issue:3	Antioxidant Activity of Compounds Isolated from
AID26336	pKa value was determined	2001	Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3	Equilibrium and kinetics studies of transnitrosation between S-nitrosothiols and thiols.
AID1576117	Neuroprotective activity against H2O2-induced neurotoxicity in Sprague-Dawley rat hippocampal neuron assessed as cell survival rate at 10 uM incubated for 24 hrs in presence of 150 uM H2O2 by MTT assay (Rvb = 41.6 to 43.2 %)	2019	MedChemComm, Jul-01, Volume: 10, Issue:7	The synthesis and biological evaluation of novel gardenamide A derivatives as multifunctional neuroprotective agents.
AID1452237	Antioxidant activity in human HaCaT cells assessed as inhibition of TBHP-induced ROS accumulation by measuring ROS level preincubated with cells followed by TBHP addition by CM-H2DCFDA dye-based fluorescence assay relative to control	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Effect of natural and semi-synthetic cadinanes from Heterotheca inuloides on NF-κB, Nrf2 and STAT3 signaling pathways and evaluation of their in vitro cytotoxicity in human cancer cell lines.
AID1273636	Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 1 mM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.2%)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
AID710226	Prevention of apoptosis in rat H9c2 cells assessed as protection against oxidative stress-induced cytotoxicity at 100 nM pM by Alamar blue assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
AID118277	Number of mice with necrosis was measured for compound along with acetaminophen and number of animals showing necrosis rating of 2+ was reported.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1205939	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205939	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring IMP-7 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1705127	Induction of apoptosis in human EC-109 cells assessed as apoptotic rate at 5 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.7 %)	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis and in vitro and in vivo biological evaluation of novel derivatives of flexicaulin A as antiproliferative agents.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1176229	Neuroprotective activity in human SH-SY5Y cells assessed as inhibition H2O2-induced damage measured as cell viability at 100 uM measured after 24 hrs	2015	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2	Synthesis and biological evaluation of novel marine-derived indole-based 1,2,4-oxadiazoles derivatives as multifunctional neuroprotective agents.
AID1273635	Induction of apoptosis in human HCT116 cells assessed as dead cells at 1 mM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 4.2%)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells.
AID285163	Antimicrobial activity against catheter-associated biofilm of methicillin-resistant Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.
AID577802	Potentiation of 1-Nitrosocyclohexyl acetate induced- vasodilatory activity in Sprague-Dawley rat thoracic aorta at 1 mM	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties.
AID1451735	Inhibition of CrtN in Staphylococcus aureus Mu50 assessed as H2O2-induced bacterial death by measuring survival rate at 1 uM preincubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method (Rvb = 24.3%)	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1705123	Induction of apoptosis in human EC109 cells assessed as increase in intracellular ROS level at 5 mM incubated for 24 hrs by DCFH-DA staining based flow cytometry analysis (Rvb = 0.6 %)	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis and in vitro and in vivo biological evaluation of novel derivatives of flexicaulin A as antiproliferative agents.
AID1472674	Chemo-sensitization activity in non-pigmented Staphylococcus aureus Newman assessed as increase in H2O2-induced bacterial death by measuring survival rate pre-incubated for 24 hrs followed by H2O2 addition measured after 30 mins by serial dilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
AID737019	Neuroprotective activity in H2O2-stimulated human SH-SY5Y cells assessed as upregulation of Bax expression at 5 mM incubated for 4 hrs prior to H2O2 challenge measured after 12 hrs by Western blotting analysis	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells.
AID197254	In vitro increased GSH content of rat hepatocytes when incubated with compound after 4 hr at 2.5 mM concentration.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID680341	TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes	2002	Molecular pharmacology, Oct, Volume: 62, Issue:4	Identification of a mechanism by which the methylmercury antidotes N-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1.
AID197241	GSH level related to controls	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1416856	Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 1.5 hrs by LC-MS/MS analysis	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1271568	Inhibition of HDAC in human LoVo/DX cells using Boc-Lys(Ac)-AMC as substrate assessed as release of AMC pre-incubated for 15 mins followed by substrate addition measured after 3 hrs by indirect spectrofluorometric assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.
AID1205928	Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205928	Binding affinity to hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as change in melting temperature at 500 uM by thermal shift assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID90925	Percent viscosity reduction after 10 min was tested for in vitro mucolytic activity using pooled human sputum adjusted to pH 7.5 and compared with saline by 0.03 M solution of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	N-[[(Mercaptoacetyl)amino]benzoyl]glycines as mucolytic agents.
AID111462	Tested for 17 animals(mice) and the deaths were observed after the 48 hours due to liver necrosis	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Prodrugs of L-cysteine as liver-protective agents. 2(RS)-Methylthiazolidine-4(R)-carboxylic acid, a latent cysteine.
AID1756332	Inhibition of salsolinol-induced mitochondrial depolarization in human SH-SY5Y cells assessed as mitochondrial membrane potential at 1000 uM measured after 24 hrs by JC-1 staining based flow cytometry (Rvb = 45.3 +/-2.09%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID118410	Tested for Protection from Acetaminophen-Induced Liver Necrosis in Mice, Number of animals(mice) with liver necrosis was determined after 1 hr	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Prodrugs of L-cysteine as liver-protective agents. 2(RS)-Methylthiazolidine-4(R)-carboxylic acid, a latent cysteine.
AID1319606	Cytotoxicity against rat MC3T3-E1 cells assessed as effect on cell number at 1 mM after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Wnt/β-catenin signaling plays an important role in the protective effects of FDP-Sr against oxidative stress induced apoptosis in MC3T3-E1 cell.
AID1326427	Induction of apoptosis in human PC3 cells assessed as externalization of phosphatidylserine on cell surface by measuring late apoptotic cells at 5 uM after 6 hrs by Annexin-V/FITC/PI staining by flow cytometry (Rvb = 0%)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1705124	Induction of mitochondrial depolarization in human EC-109 cells assessed as depolarized cell population at 5 mM measured after 24 hrs by JC1 dye based flow cytometry (Rvb = 4.2 %)	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis and in vitro and in vivo biological evaluation of novel derivatives of flexicaulin A as antiproliferative agents.
AID1654195	Protection against H202-induced cell cycle blockade in human Gingival fibroblast assessed as accumulation at S phase after 72 hrs by flow cytometry (Rvb = 11.6%)	2020	Journal of natural products, 03-27, Volume: 83, Issue:3	Antioxidant Activity of Compounds Isolated from
AID1416854	Cytoprotection against APAP induced cytotoxicity in human LO2 cells assessed as decrease in MDA level at 100 mmol after 15 mins by lipid oxidation assay	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID118278	Number of mice with necrosis was measured for compound along with acetaminophen and number of animals showing necrosis rating of 3+ was reported.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1546341	Cardioprotective activity against isoproterenol-induced apoptosis in Swiss mouse model of myocardial infarction assessed as increase in Bcl2 expression at 1200 mg/kg administered 30 mins post isoproterenol stimulation by Western blot analysis	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1594771	Protection against AfB1-induced toxicity in human HepG2 cells assessed as increase in live cell area measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID1756284	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell viability at 1000 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis (Rvb = 70.49 +/-0.51%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1205926	Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205926	Inhibition of hexahistidine-tagged VIM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1405423	Neuroprotective activity against H2O2-induced cytotoxicity in rat PC12 cells assessed as cell viability at 1 mM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1205937	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205937	Ratio of imipenim MIC to imipenim MIC in presence of compound for Escherichia coli BL21(DE3) cells harboring NDM-1 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1135700	Inhibition of Rana catesbeiana tadpole collagenase using lathyritic rat skin collagen as substrate after 41 hrs by radial diffusion assay	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Mercaptoimidazolylpropionic acid hydrobromide. Inhibition of tadpole collagenase and related properties.
AID360670	Inhibition of 6-hydroxydopamine induced cytotoxicity in rat PC12 cells pretreated for 24 hrs assessed as elevation of intracellular glutathione level	2007	The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7	Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID1546345	Cardioprotective activity against isoproterenol-induced apoptosis in Swiss mouse model of myocardial infarction assessed as reduction in Bax expression at 1200 mg/kg administered 30 mins post isoproterenol stimulation by Western blot analysis	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1433725	Neuroprotective activity against H2O2-induced cytotoxicity in rat PC12 cells assessed as cell viability at 1 mM preincubated for 2 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay (Rvb = 18.9 +/- 2.2%)	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and SAR study of novel sarsasapogenin derivatives as potent neuroprotective agents and NO production inhibitors.
AID1546316	Cardioprotective activity in Swiss mouse model of myocardial infarction assessed as reversal of isoproterenol-induced increase in heart rate at 1200 mg/kg administered 30 mins post isoproterenol stimulation and measured for 5 mins by electrocardiographic	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID1307954	Cytoprotective activity in NHBE cells assessed as inhibition of tBHP-induced GSH depletion at 1 mM preincubated for 18 hrs followed by tBHP addition for 4 hrs by thiostar dye based fluorescence assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
AID1281740	Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 1 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.44%)	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Identification of a new cyathane diterpene that induces mitochondrial and autophagy-dependent apoptosis and shows a potent in vivo anti-colorectal cancer activity.
AID763017	Neuroprotective activity in human SH-SY5Y cells assessed as protection against H2O2-induced reduction of cell viability at 100 uM treated 2 hrs before H2O2 addition measured after 24 hrs by MTT assay relative to H2O2 treated control	2013	Journal of natural products, Aug-23, Volume: 76, Issue:8	Casuarinines A-J, lycodine-type alkaloids from Lycopodiastrum casuarinoides.
AID1193497	Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID608195	Cell cycle arrest in human NTUB1 cells assessed as accumulation at G2/M phase at 1 mM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 20.37%)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193492	Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID91057	Percent viscosity reduction after 5 min was tested for in vitro mucolytic activity using pooled human sputum adjusted to pH 7.5 and compared with saline by 0.03 M solution of the compound	1985	Journal of medicinal chemistry, Jul, Volume: 28, Issue:7	N-[[(Mercaptoacetyl)amino]benzoyl]glycines as mucolytic agents.
AID118279	Number of mice with necrosis was measured for compound along with acetaminophen and number of animals showing necrosis rating of 4+ was reported.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1367960	Neuroprotective activity against glutamate-induced cell death in mouse HT22 cells assessed as reduction in apoptotic cells at 50 uM after 10 to 12 hrs by Annexin V-alexa 488/propidium iodide staining based flow cytometry	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Protective effect of casuarinin against glutamate-induced apoptosis in HT22 cells through inhibition of oxidative stress-mediated MAPK phosphorylation.
AID561438	Inhibition of amphotericin B-induced renal tubular apoptosis in Sprague-Dawley rat assessed as apoptotic index at 30 mg/kg, ip BID measured post last dose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1756292	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell death at 1000 uM measured after 24 hrs by PI staining based analysis (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1546331	Cardioprotective activity against isoproterenol-induced oxidative stress in Swiss mouse model of myocardial infarction assessed as reduction in ROS generation at 1200 mg/kg administered 30 mins post isoproterenol stimulation by DHE staining based fluoresc	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1393001	Inhibition of STAT3 phosphorylation in human DU145 cells assessed as ratio of phosphorylated STAT3 protein level to GAPDH protein level at 2 mM after 1 hr by Western blot analysis (Rvb = 1 No_unit)	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.
AID458686	Antioxidant activity against ABTS radicals assessed as trolox equivalents in phosphate buffer of pH 7.4 at 6.08 uM by ABTS assay	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Exploring a synthetic organoselenium compound for antioxidant pharmacotherapy--toxicity and effects on ROS-production.
AID1319624	Protection against H2O2-induced apoptosis in rat MC3T3-E1 cells assessed as early apoptotic cells pretreated with compound for 48 hrs followed by H2O2 treatment for 24 hrs by annexin V-FITC/PI staining based flow cytometry (Rvb = 5.68%)	2016	Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19	Wnt/β-catenin signaling plays an important role in the protective effects of FDP-Sr against oxidative stress induced apoptosis in MC3T3-E1 cell.
AID1367961	Neuroprotective activity against glutamate-induced apoptosis in mouse HT22 cells assessed as apoptotic cells at 50 uM after 10 to 12 hrs by Annexin V-alexa 488/propidium iodide staining based flow cytometry (Rvb = 57%)	2017	Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23	Protective effect of casuarinin against glutamate-induced apoptosis in HT22 cells through inhibition of oxidative stress-mediated MAPK phosphorylation.
AID1370894	Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 5 mM after 48 hrs by propidium iodide staining based assay (Rvb = 46.44%)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
AID1264243	Neuroprotective activity against nutrient deprivation-induced neuronal cell death in Sprague-Dawley rat CGN cells assessed as cell viability at 10 mM preincubated for 24 hrs followed by induction of nutrient deprivation measured after 24 hrs by MTT assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1416853	Cytoprotection against H2O2 induced cytotoxicity in human LO2 cells assessed as decrease in MDA level at 100 mmol after 15 mins by lipid oxidation assay	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID1193495	Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1756316	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 100 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1395982	Induction of biofilm eradication of methicillin-resistant Staphylococcus aureus 2 after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1205933	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205933	Antibacterial activity against Escherichia coli BL21(DE3) cells harboring IMP-7 assessed as growth inhibition at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1546322	Cardioprotective activity in Swiss mouse model of isoproterenol-induced myocardial infarction assessed as reduction in lactate dehydrogenase at 1200 mg/kg administered 30 mins post isoproterenol stimulation	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	d-Limonene Ameliorates Myocardial Infarction Injury by Reducing Reactive Oxygen Species and Cell Apoptosis in a Murine Model.
AID551412	Neuroprotective activity against rotenone/oligomycin-A-induced death in human SH-SY5Y cells assessed as increase of cell viability at 1 mM after 2 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2	Synthesis, structure, theoretical and experimental in vitro antioxidant/pharmacological properties of α-aryl, N-alkyl nitrones, as potential agents for the treatment of cerebral ischemia.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1395987	Bactericidal activity against vancomycin-resistant Enterococcus faecium ATCC 700221 planktonic cells after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1424232	Antioxidant activity assessed as superoxide anion free radical scavenging activity by measuring rate constant using UV irradiation by ESR spin trapping method	2017	European journal of medicinal chemistry, Jun-16, Volume: 133	Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID118409	Tested for Protection from Acetaminophen-Induced Liver Necrosis in Mice, Number of animals(mice) with liver necrosis was determined after 0 hour	1982	Journal of medicinal chemistry, May, Volume: 25, Issue:5	Prodrugs of L-cysteine as liver-protective agents. 2(RS)-Methylthiazolidine-4(R)-carboxylic acid, a latent cysteine.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1351981	Antibacterial activity against wild type Staphylococcus aureus Newman assessed as bacterial survival at 1 uM after 24 hrs by H2O2 killing assay (Rvb = 26.67%)	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1395981	Bactericidal activity against methicillin-resistant Staphylococcus aureus 2 planktonic cells after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID1307955	Increase in glutathione level in NHBE cells at 1 mM incubated for 18 hrs by thiostar dye based fluorescence assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
AID482867	Neuroprotective activity in human SH-SY5Y cells assessed as protection against rotenone/oligomycin A-induced cell death at 1 uM after 24 hrs by LDH release assay	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID561439	Inhibition of amphotericin B-induced renal tubular apoptosis in Sprague-Dawley rat assessed as apoptotic index at 60 mg/kg, ip BID measured post last dose	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.
AID1370892	Induction of apoptosis in human HL60 cells assessed as late apoptotic cells at 5 mM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.23%)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
AID577801	Potentiation of 1-Nitrosocyclohexyl trifluoroacetate induced- vasodilatory activity in Sprague-Dawley rat thoracic aorta at 1 mM	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties.
AID118276	Number of mice with necrosis was measured for compound along with acetaminophen and number of animals showing necrosis rating of 1+ was reported.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.
AID552793	Neuroprotection against rotenone/oligomycin-A-indced human SH-SY5Y cell death assessed as protective effect at 1 uM after 2 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles.
AID606799	Induction of Nrf2-mediated NQO1 gene expression in human BEAS2B cells at 10 mM after 24 hrs by RT-PCR analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells.
AID1147033	Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2-methylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 7.4 mmol/kg, po administered 1 hr prior	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID1370891	Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 5 mM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.13%)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
AID1205940	Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8	Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1205940	Ratio of imipenim MIC to imipenim MIC in presence of compound for Pseudomonas aeruginosa T2226 expressing IMP-7 at 128 mg/l by broth microdilution assay	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Correction to Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
AID1126624	Antioxidant activity in human SH-SY5Y cells assessed as inhibition of amyloid beta (25 to 35)-induced intracellular ROS formation at 500 uM after 3 hrs by dihydroethidium-based fluorescence microscopic analysis relative to control	2014	European journal of medicinal chemistry, May-06, Volume: 78	Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease.
AID763019	Neuroprotective activity in human SH-SY5Y cells assessed as protection against H2O2-induced reduction of cell viability at 100 uM treated 2 hrs before H2O2 addition measured after 24 hrs by MTT assay relative to control	2013	Journal of natural products, Aug-23, Volume: 76, Issue:8	Casuarinines A-J, lycodine-type alkaloids from Lycopodiastrum casuarinoides.
AID1287166	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 5 mM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.6%)	2016	European journal of medicinal chemistry, Apr-13, Volume: 112	3,3'-OH curcumin causes apoptosis in HepG2 cells through ROS-mediated pathway.
AID527148	Reduction of gastrocnemius muscle weight loss in C57BL/6 mouse tail suspension model at 2.5 pmol administered in gastrocnemius muscle qd for 10 days relative to whole body weight	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Quercetin prevents unloading-derived disused muscle atrophy by attenuating the induction of ubiquitin ligases in tail-suspension mice.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID608192	Cell cycle arrest in human NTUB1 cells assessed as accumulation at subG1 phase at 1mM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 6.68%)	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1756335	Inhibition of salsolinol-induced mPTP opening in human SH-SY5Y cells assessed as fold change in fluorescence intensity at 1000 uM measured after 24 hrs by calcein AM/CoCl2 based fluorescence microscopic analysis (Rvb = 0.49 +/-0.02 No_unit)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID360671	Inhibition of hydrogen peroxide induced cytotoxicity in rat PC12 cells pretreated for 24 hrs assessed as elevation of intracellular glutathione level	2007	The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7	Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID1416862	Terminal half life in iv dosed human plasma	2017	MedChemComm, Dec-01, Volume: 8, Issue:12	Identification of novel
AID1756296	Inhibition of Salsolinol-induced oxidative stress in human SH-SY5Y cells assessed as superoxide radical formation at 1000 uM measured after 24 hrs by DHE staining based fluorescence spectrophotometry (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1330 (9.56)	18.7374
1990's	1864 (13.39)	18.2507
2000's	4220 (30.32)	29.6817
2010's	5111 (36.73)	24.3611
2020's	1391 (10.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,046 (7.17%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	987 (6.77%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	490 (3.36%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	29 (0.20%)	0.25%
Observational	0 (0.00%)	0.25%
Other	12,028 (82.50%)	84.16%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (462)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial [NCT03759158]		100 participants (Actual)	Interventional	2018-12-01	Completed
Multimodal Prevention of First Psychotic Episode - a 2x2-Factorial Randomized Trial Investigating the Efficacy of Acetylcysteine and Integrated Preventive Psychological Intervention in Subjects Clinically at High Risk for Psychosis [NCT03149107]	Phase 3	48 participants (Actual)	Interventional	2016-09-01	Terminated(stopped due to Recruitment not sufficient)
[NCT01131572]	Phase 2/Phase 3	11 participants (Actual)	Interventional	2010-02-28	Terminated
Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital [NCT03879356]	Phase 4	44 participants (Actual)	Interventional	2016-01-01	Completed
N-AcetylCysteine as a Potential Treatment of Methamphetamine Dependence [NCT01063205]	Phase 1	10 participants (Actual)	Interventional	2010-03-31	Completed
Effect of N-Acetyl Cysteine on Expression of HOXA Cluster Genes in Endometrium of Women With Recurrent Implantation Failure (RIF) During Implantation Window: a Double-blinded Randomized Research [NCT03862586]	Phase 3	40 participants (Actual)	Interventional	2015-02-01	Completed
Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness [NCT01187108]	Phase 1/Phase 2	85 participants (Actual)	Interventional	2013-06-30	Completed
N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study [NCT01111734]	Phase 1	67 participants (Actual)	Interventional	2011-03-31	Completed
A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis [NCT01111422]	Phase 4	66 participants (Anticipated)	Interventional	2010-03-31	Recruiting
The Evaluation of the Protective Effect of N-Acetylcysteine Against Drug Induced Ototoxicity in Peritoneal Dialysis Patients [NCT01131468]	Phase 2	60 participants (Actual)	Interventional	2008-02-29	Completed
Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine [NCT01138956]		40 participants (Anticipated)	Interventional	2010-04-30	Recruiting
Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis [NCT05122559]	Phase 2	98 participants (Anticipated)	Interventional	2022-02-16	Recruiting
Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1 [NCT04481048]	Phase 2	58 participants (Anticipated)	Interventional	2020-12-15	Recruiting
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) [NCT01381354]	Phase 1	38 participants (Actual)	Interventional	2010-10-31	Completed
Effect of N-acetyl Cysteine on Oxidative Stress Biochemical Factors and IVF/ICSI Outcomes in Women With Endometrioma: A Randomized, Double-blinded, Phase III Clinical Trial [NCT05460858]	Phase 3	140 participants (Anticipated)	Interventional	2021-04-13	Recruiting
Antioxidants for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization [NCT03755700]	Phase 3	1,000 participants (Anticipated)	Interventional	2018-11-01	Recruiting
Effect of N-acetylcysteine on the Acute Cognitive Effects of Delta-9-Tetrahydrocannabinol [NCT02335060]	Early Phase 1	5 participants (Actual)	Interventional	2014-05-02	Terminated(stopped due to Feasibility pilot was completed)
Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients [NCT01082445]	Phase 3	100 participants (Actual)	Interventional	2009-08-31	Completed
Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study With [11C]PBR-28 and N-Acetyl Cysteine (NAC) Antidepressant Treatment [NCT03730064]	Early Phase 1	3 participants (Actual)	Interventional	2018-11-01	Completed
Acetaminophen in Combination With N-Acetylcysteine (NAC) vs. Placebo in the Treatment of Fever: A Double-Blind, Randomized Control Study [NCT01137591]		0 participants (Actual)	Interventional	2009-04-30	Withdrawn(stopped due to Unable to recruit sufficient participants due to lack of funding; PI has left the institution.)
Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer [NCT01138137]	Phase 1	0 participants (Actual)	Interventional	2010-06-30	Withdrawn(stopped due to No funding was available for the cost of the IV N-acetylcysteine (NAC).)
Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis [NCT03708458]	Phase 4	250 participants (Anticipated)	Interventional	2017-04-01	Recruiting
Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial [NCT01354132]	Phase 2	20 participants (Actual)	Interventional	2011-05-31	Completed
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease: A 2x2 Factorial Randomized Phase II Trial Testing N-Acetyl Cysteine and Dexamethasone [NCT05986318]	Phase 2	98 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
The Effect of N_acetylcystein as an Antioxidant on Iron Overload and Frequency of Blood Transfusion in β-thalassemia Major Patients at Assiut Childern Hospital University [NCT05777733]	Phase 1	100 participants (Anticipated)	Interventional	2024-03-23	Not yet recruiting
Macrophage Activation, Assessed by Macrophage Markers Soluble CD163 and Soluble CD206, as Indication of Early Liver Cell Damage in Paracetamol Overdose [NCT03679442]	Phase 1	16 participants (Actual)	Interventional	2014-09-08	Completed
Prospective Randomized, Double-blind Controlled Clinical Study of N-acetylcysteine for Treatment of Dryness Symptoms Due to Primary Sjogren's Syndrome [NCT04793646]		60 participants (Anticipated)	Interventional	2021-04-30	Active, not recruiting
Effect of a Multi-ingredient of L-Histidine, L-Serine, L-Carnosine and N-Acetylcysteine on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity. Randomized, Parallel, Placebo Controlled, Triple Blind Study. [NCT05807204]		20 participants (Actual)	Interventional	2023-05-01	Active, not recruiting
Effect of N-acetyl Cysteine on Non Alcoholic Fatty Liver Disease in Obese Children [NCT02117700]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2015-04-30	Completed
A Prospective Randomized Controlled Trial of Adjunctive N-acetylcysteine (NAC) in Adult Patients With Pulmonary Tuberculosis: a Sub-study of TB Sequel [NCT03702738]	Phase 2	110 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Comparative Evaluation of the Effect of Theophylline Plus N-acetylcysteine, Theophylline Alone, and N-acetylcysteine Alone in Preventing Contrast-induced Nephropathy in Patients With Moderate to High Risk Undergoing Coronary Angiographic Procedures [NCT02088502]	Phase 2/Phase 3	96 participants (Anticipated)	Interventional	2013-09-30	Recruiting
The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate [NCT01210456]	Phase 3	458 participants (Anticipated)	Interventional	2009-10-31	Enrolling by invitation
Cardioprotection of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Angioplasty Through a Combined Antioxidant Therapy. A Phase I, Randomized Clinical Trial. [NCT05215743]	Phase 1	18 participants (Anticipated)	Interventional	2022-02-15	Recruiting
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: A Randomized Controlled Trial [NCT04627922]	Phase 4	60 participants (Anticipated)	Interventional	2021-08-25	Recruiting
Intratumoral Bromelain + N-acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei. Phase I Single-arm Trial [NCT04982146]	Phase 1	10 participants (Anticipated)	Interventional	2021-09-13	Active, not recruiting
A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis [NCT02804594]	Phase 2	15 participants (Actual)	Interventional	2016-10-01	Completed
The Effects of N-Acetylcysteine on Oxidative Stress Markers in Chronic Obstructive Pulmonary Disease (COPD) [NCT03956888]	Phase 3	30 participants (Anticipated)	Interventional	2019-06-01	Not yet recruiting
A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis [NCT02182167]	Phase 2/Phase 3	102 participants (Actual)	Interventional	2014-05-31	Completed
Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease [NCT02476526]	Phase 4	50 participants (Actual)	Interventional	2008-09-30	Completed
Oxidative Stress and Surgical Recovery [NCT04732000]	Phase 2	21 participants (Actual)	Interventional	2021-07-01	Active, not recruiting
Efficacy and Safety of N-acetylcysteine (NAC) in Patients With Mild Vascular Cognitive Impairment [NCT03306979]	Phase 2	60 participants (Anticipated)	Interventional	2018-04-30	Recruiting
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease: a Phase 1 Study [NCT05258682]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy [NCT04440280]	Phase 2	45 participants (Anticipated)	Interventional	2020-09-16	Recruiting
N-Acetyl-Cysteine for Healing of Amputation Stumps in the Setting of Diabetes [NCT03253328]		50 participants (Anticipated)	Interventional	2016-12-15	Suspended(stopped due to No one is currently receiving treatment and enrollment is of course on hold. Subjects being unblinded to perform interim analysis.)
A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei [NCT03976973]	Phase 2	62 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone [NCT02707640]	Phase 2	123 participants (Actual)	Interventional	2013-08-31	Completed
Glial Regulators for Treating Comorbid Posttraumatic Stress Disorder and Substance Use Disorders [NCT02911285]	Phase 2	90 participants (Actual)	Interventional	2016-10-31	Completed
Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19 [NCT04455243]	Phase 3	1,180 participants (Anticipated)	Interventional	2020-08-01	Not yet recruiting
ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE [NCT02206178]	Phase 1	24 participants (Actual)	Interventional	2013-09-30	Completed
Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis. [NCT02080182]	Phase 2	70 participants (Actual)	Interventional	2014-01-31	Completed
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine (NAC) (SNAC) [NCT00775476]	Phase 2	290 participants (Anticipated)	Interventional	2022-03-31	Recruiting
Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators in Mechanically Ventilated Intensive Care Patients' [NCT02159196]		950 participants (Actual)	Interventional	2014-07-31	Completed
Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI) [NCT04987775]	Early Phase 1	170 participants (Anticipated)	Interventional	2023-11-30	Recruiting
N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT02239107]	Phase 4	70 participants (Actual)	Interventional	2012-01-31	Completed
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease [NCT04740580]	Early Phase 1	52 participants (Anticipated)	Interventional	2022-02-15	Recruiting
A Pilot Study of N-acetylcysteine for Alcohol Use Disorder [NCT04964843]	Phase 2	0 participants (Actual)	Interventional	2023-04-30	Withdrawn(stopped due to Null results were posted from a neurometabolite study and a recent trial for AUD. Study may resume if more positive data emerge.)
Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment [NCT04945096]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Evaluating N-acetylcysteine as a Pharmacotherapy for Tobacco Use Disorder [NCT02737358]	Phase 2	114 participants (Actual)	Interventional	2016-08-30	Completed
TOLERANCE STUDY OF N-ACETYLCYSTEINE FOR THROMBOLYSIS IN THE ACUTE PHASE OF ISCHEMIC STROKE / ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L'INFARCTUS CEREBRAL [NCT04920448]	Phase 2	19 participants (Anticipated)	Interventional	2021-06-07	Not yet recruiting
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold: a Prospective, Randomized, Double-blind, Controlled Trial [NCT05070650]	Phase 3	1,002 participants (Anticipated)	Interventional	2024-09-20	Not yet recruiting
Pilot Study of N-acetyl Cysteine for Refractory Generalized Epilepsy in Children With Autism [NCT02054949]		0 participants (Actual)	Interventional	2013-04-30	Withdrawn(stopped due to no eligible subjects located)
Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson's Disease [NCT04459052]	Phase 2	50 participants (Anticipated)	Interventional	2020-04-30	Recruiting
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [NCT03460808]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2018-03-10	Not yet recruiting
Randomized Controlled Clinical Trial of Antioxidant Therapy in Critically Ill Patients With Septic Shock: Analysis Before and After Treatment of the Oxidative Stress [NCT03557229]	Phase 3	131 participants (Anticipated)	Interventional	2018-07-23	Active, not recruiting
Evaluation of N-Acetylcysteine Efficacy to Reduce the Craving and to Prolong THE Abstinence Time of Coca Paste [NCT03556371]	Phase 2	140 participants (Actual)	Interventional	2018-04-09	Completed
A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer [NCT02094625]	Phase 1	52 participants (Actual)	Interventional	2016-03-31	Completed
The Efficacy of N-acetylcysteine as a Cessation Treatment for Tobacco Smoking and Oxidative Stress Reduction [NCT02124525]	Phase 3	32 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine in Patients With Primary Immune Thrombocytopenia Resistant to Steroid Treatment or in Relapse: An Exploratory Clinical Trial [NCT05551624]	Early Phase 1	15 participants (Actual)	Interventional	2018-07-04	Completed
A Prospective Randomized Controlled Study for Intervention of Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation: N-acetyl-L-cysteine (NAC) Versus Supportive Therapy [NCT03391856]	Phase 2/Phase 3	15 participants (Actual)	Interventional	2018-03-01	Terminated(stopped due to protocol changed)
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine [NCT03354572]	Phase 4	60 participants (Actual)	Interventional	2017-10-20	Completed
A Randomized Controlled Trial of N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection Performed Under Ischemic Preconditioning and Intermittent Portal Triad Clamping [NCT01223326]	Phase 4	46 participants (Actual)	Interventional	2003-01-31	Completed
A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A) [NCT02269540]	Early Phase 1	10 participants (Actual)	Interventional	2014-10-31	Completed
Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity [NCT04226456]	Phase 4	19 participants (Actual)	Interventional	2021-07-10	Terminated(stopped due to poor recruitment)
Neurocircuit Strategy to Decrease Cocaine Cue Reactivity [NCT04155632]	Phase 2	96 participants (Anticipated)	Interventional	2020-12-18	Recruiting
Role of HIV on Glutathione Synthesis and Oxidative Stress [NCT01355198]	Phase 1	10 participants (Actual)	Interventional	2010-08-31	Completed
Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease [NCT01232257]	Phase 3	28 participants (Actual)	Interventional	2011-07-31	Completed
N-acetylcysteine to Prevent Renal Failure in Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Surgery [NCT01359722]		50 participants (Anticipated)	Interventional	2010-03-31	Recruiting
Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis [NCT03720483]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2022-01-31	Withdrawn(stopped due to The study encountered challenges during startup due to the COVID-19 epidemic and was withdrawn.)
The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome [NCT05309070]		60 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft [NCT01394419]	Phase 4	115 participants (Actual)	Interventional	2010-09-30	Completed
Ability of N-acetylcysteine to Prevent Deterioration in Renal Functioning in CKD Patients Undergoing Major Surgery Under General Anesthesia [NCT01251029]	Phase 1	0 participants	Interventional	2011-01-31	Not yet recruiting
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: a Prospective, Randomized, Double-blind, Placebo-controlled Trial [NCT04123405]	Phase 3	944 participants (Actual)	Interventional	2020-10-22	Completed
Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction [NCT01160627]		720 participants (Actual)	Interventional	2010-04-30	Completed
Early N-Acetyl Cysteine Treatment for Head Trauma-induced Anosmia [NCT03680911]	Phase 3	7 participants (Actual)	Interventional	2018-10-12	Terminated(stopped due to Poor participant compliance)
Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration [NCT01188005]		30 participants (Anticipated)	Interventional	2010-08-31	Recruiting
Effect of N-acetylcysteine Versus Calcium Hydroxide Used as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Levels of MMP -9 in Periapical Fluids in Patients With Necrotic Pulp: A Randomized Clinical Trial [NCT05666089]	Early Phase 1	30 participants (Anticipated)	Interventional	2023-02-01	Not yet recruiting
A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder [NCT03216954]	Early Phase 1	14 participants (Actual)	Interventional	2017-09-15	Completed
N-acetylcysteine Supplementation in Individuals With Low Glutathione Levels: the Effects on Physical Performance and Redox Homeostasis [NCT03121222]	Phase 2	36 participants (Actual)	Interventional	2015-11-01	Completed
A Randomized Controlled Trial of N-Acetylcysteine for Alcohol Use Disorder and Comorbid Post Traumatic Stress Disorder [NCT02966873]	Phase 2	182 participants (Actual)	Interventional	2016-10-01	Completed
A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder [NCT00539188]	Phase 2	6 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Study terminated due to poor subject compliance.)
Overcoming Membrane Transporters to Improve CNS Drug Delivery [NCT01322009]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2011-03-31	Completed
Double-Blind, Placebo-Controlled Trial of N-acetylcysteine for the Treatment of Pediatric Trichotillomania [NCT00993265]	Phase 2	39 participants (Actual)	Interventional	2009-10-31	Completed
Cardiac Arrhythmia Catheter Ablation Procedures Guided by x-Ray Imaging: N-Acetylcysteine Protection Against Radiation Induced Cellular damagE (CARAPACE Study) [NCT04154982]	Phase 2	550 participants (Anticipated)	Interventional	2020-09-02	Recruiting
An Open-Label Study of N-Acetyl Cysteine in Autism [NCT00676195]	Phase 2	24 participants (Actual)	Interventional	2008-06-30	Completed
N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Balloon Angioplasty and Pulmonary Endarterectomy. [NCT04081012]		34 participants (Anticipated)	Interventional	2019-05-21	Recruiting
Effect of Oral N-Acetyl Cysteine on Pregnancy Outcome After Cervical Cerclage: a Randomized Controlled Trial [NCT00787813]		100 participants (Anticipated)	Interventional	2008-06-30	Completed
N-acetylcysteine in the Treatment of Depressive Symptoms in Youth at High-risk for Bipolar Disorder: a Functional Connectivity Study [NCT02865629]		22 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine [NCT00975689]	Phase 1/Phase 2	35 participants (Actual)	Interventional	2009-08-31	Completed
Efficacy of N-Acetylcysteine in Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization in Patients With Diabetes Mellitus and Chronic Kidney Disease: A Randomized Clinical Trial [NCT00808795]	Phase 3	90 participants (Actual)	Interventional	2006-04-30	Completed
A Open Label, Multi-Dose, Multi-Period Exploratory Clinical Trial to Test Immune Diversity Response to Oral Dosing of Approved Nutritional Health Products at Approved Doses to Healthy Volunteers [NCT05242718]		32 participants (Actual)	Interventional	2021-01-10	Completed
N-acetylcysteine for Attenuation of COVID Symptomatology [NCT05074121]	Phase 2	200 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study. [NCT00863785]	Phase 3	174 participants (Actual)	Interventional	2004-04-30	Completed
Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure [NCT00870883]	Phase 2	81 participants (Actual)	Interventional	2009-03-31	Completed
Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects [NCT02259595]	Phase 1	32 participants (Actual)	Interventional	2014-10-31	Completed
N-Acetylcysteine Versus L-carnitine in Clomiphene Citrate Resistant Pcos Women. a Randomized Controlled Trial [NCT03164421]	Phase 2	164 participants (Actual)	Interventional	2017-01-31	Completed
Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk [NCT01550432]		78 participants (Actual)	Interventional	2011-06-30	Completed
Pharmacological Treatment of a Rare Genetic Disease: Pilot Trial Phase II-III With N-acetylcysteine in Myopathy Associated SEPN1-RM (Selenoprotein N-related Myopathy) [NCT02505087]	Phase 2/Phase 3	7 participants (Actual)	Interventional	2015-09-30	Terminated
Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene [NCT02493933]	Phase 1	240 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia [NCT02481609]	Early Phase 1	29 participants (Actual)	Interventional	2014-07-31	Completed
Clinical Study Evaluating the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy [NCT05485558]	Phase 2	45 participants (Anticipated)	Interventional	2022-09-15	Recruiting
Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder [NCT02252341]	Phase 4	130 participants (Anticipated)	Interventional	2014-09-30	Enrolling by invitation
[NCT02124941]	Phase 1	6 participants (Actual)	Interventional	2014-02-28	Completed
The Impact of N-Acetylcysteine on Volumetric Retention of Autologous Fat Graft for Breast Asymmetry Correction [NCT03197103]	Phase 4	15 participants (Actual)	Interventional	2017-07-04	Active, not recruiting
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users: A Pilot Test of Glutamatergic Modulation [NCT03154580]	Phase 1	21 participants (Actual)	Interventional	2017-05-01	Active, not recruiting
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 [NCT05371288]	Early Phase 1	50 participants (Anticipated)	Interventional	2024-06-30	Not yet recruiting
Effects of Oral N- Acetylcysteine on Macular Function in Retinitis Pigmentosa; a Phase 2 Randomized Controlled Trial [NCT04864496]	Phase 2	30 participants (Anticipated)	Interventional	2021-04-17	Active, not recruiting
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study [NCT06165068]	Phase 3	174 participants (Anticipated)	Interventional	2023-12-31	Recruiting
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia [NCT04013555]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2020-01-20	Recruiting
Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial [NCT06105060]	Early Phase 1	160 participants (Anticipated)	Interventional	2023-12-17	Not yet recruiting
The Effect of Acetylcysteine and Ascorbic Acid on the Prevention of Radiographic-contrast-agent Induced Reduction in Renal Function in ICU Patients. [NCT01017796]	Early Phase 1	100 participants (Anticipated)	Interventional	2009-01-31	Active, not recruiting
N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media [NCT00956748]	Phase 4	0 participants (Actual)	Interventional	2019-11-29	Withdrawn(stopped due to Lack of staff, time, and resources)
Investigation of the Efficacy of N-acetylcysteine (NAC) to Protect Against Hepato-renal Ischemia-reperfusion Injury in Patients Undergoing Orthotopic Liver Transplantation [NCT00736541]		100 participants (Actual)	Interventional	2004-07-31	Completed
A Double-Blind Randomized Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease [NCT05706402]	Phase 3	80 participants (Anticipated)	Interventional	2023-09-18	Recruiting
[NCT01015209]	Phase 1	30 participants (Actual)	Interventional	2010-09-30	Completed
N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial [NCT00962442]	Phase 3	44 participants (Actual)	Interventional	2000-09-30	Completed
Effect of N-acetyl Cysteine on Markers of Oxidative Stress and Insulin Resistance in Patients With Non-alcoholic Fatty Liver Disease [NCT05589584]	Phase 3	60 participants (Anticipated)	Interventional	2022-10-31	Recruiting
Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function [NCT00998972]	Phase 3	236 participants (Actual)	Interventional	2006-09-30	Completed
The Use of Anti-oxidants to Reduce Sequela of Mild TBI (mTBI) After Blast Exposure [NCT00822263]		150 participants (Anticipated)	Interventional	2008-11-30	Completed
Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection [NCT04374461]	Phase 2	48 participants (Actual)	Interventional	2020-05-01	Active, not recruiting
Risk Stratification-directed N-acetyl-L-cysteine for Prevention of Poor Hematopoietic Reconstitution After Unmanipulated Haploidentical Stem Cell Transplantation--an Open-label, Randomized, Controlled, Clinical Trial [NCT03967665]	Phase 3	130 participants (Actual)	Interventional	2018-10-01	Active, not recruiting
ROS Signaling in Endothelial Function [NCT01037465]		72 participants (Actual)	Interventional	2008-09-30	Completed
Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea [NCT04557215]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2020-11-13	Completed
A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression [NCT02719392]	Phase 4	40 participants (Anticipated)	Interventional	2017-08-09	Suspended(stopped due to Due to limited study staff and the COVID-19 pandemic, enrollment has been paused as staff hours for this project have been reduced and reallocated to other projects.)
Prevention of Cartilage Cell Death Following a Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC) [NCT03652753]	Phase 4	30 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Effect of N-Acetylcysteine on Autologous Fat Graft Survival [NCT02788292]	Phase 4	14 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial [NCT02775734]	Phase 2/Phase 3	144 participants (Actual)	Interventional	2016-05-31	Completed
Application of LiveSpo Navax® in the Treatment Support of Acute Rhinosinusitis and Acute Otitis Media [NCT05804123]		120 participants (Anticipated)	Interventional	2021-10-28	Recruiting
Intratympanic N-Acetylcysteine (NAC) Injections for Prevention of Cisplatin-induced Ototoxicity in Head and Neck Cancer Patients: A Multi-centre Phase II Randomized Controlled Trial. [NCT04291209]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2020-02-26	Recruiting
The Effect of Substrate Supply on Modulating Plasma GSH Levels in Treated HIV+ Patients [NCT00910442]	Phase 2	32 participants (Actual)	Interventional	2002-02-28	Completed
A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia With the Use of Standard Laboratory Measures and Novel Biomarkers [NCT02761577]	Phase 4	90 participants (Actual)	Interventional	2012-06-30	Completed
Effect on Migraine Frequency of Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT Study [NCT02629536]	Phase 3	90 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study [NCT01564303]		80 participants (Anticipated)	Interventional	2012-05-31	Not yet recruiting
[NCT01033149]	Phase 3	11 participants (Actual)	Interventional	2009-12-31	Terminated
A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination With N-Acetylcysteine Amid (NACA) and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma [NCT06169280]	Phase 1	20 participants (Anticipated)	Interventional	2024-01-02	Not yet recruiting
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa [NCT05537220]	Phase 3	438 participants (Anticipated)	Interventional	2023-10-11	Recruiting
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications [NCT02583672]	Phase 2	50 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study [NCT04381897]	Phase 2	10 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis [NCT01020708]	Phase 1	9 participants (Anticipated)	Interventional	2009-11-30	Completed
A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders [NCT00453180]	Phase 2	31 participants (Actual)	Interventional	2007-03-31	Completed
A Double-Blind Study of N-Acetylcysteine Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder and Depression [NCT00539513]	Phase 2	10 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Researchers terminated study due to limited enrollment.)
Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury: A Prospective Randomized Controlled Trial [NCT02686385]		4 participants (Actual)	Interventional	2016-03-01	Terminated(stopped due to Steroids were given for 2 patients who had biopsy proven Drug induced Liver Injury and both have them developed sepsis.)
A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking [NCT01063348]	Phase 2	66 participants (Actual)	Interventional	2012-09-30	Completed
Pre-medication With N-acetylcysteine and Simethicone to Improve Mucosal Visibility During Gastroduodenoscopy: A Double Blind, Randomized Controlled Trial. [NCT05951712]		800 participants (Actual)	Interventional	2022-06-16	Completed
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy. [NCT00915200]	Phase 2	114 participants (Actual)	Interventional	2009-10-31	Completed
Functional Consequences and Therapeutic Intervention in Hampered Production of Cysteine, Glutathione and Taurine in Classical Homocystinuria [NCT04015557]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2022-02-11	Suspended(stopped due to Study was interrupted due to COVID-19 pandemic)
A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients [NCT00809094]	Phase 2	70 participants (Actual)	Interventional	2008-11-30	Completed
[NCT00716001]	Phase 4	0 participants	Interventional	2008-07-31	Not yet recruiting
The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease [NCT00498342]		0 participants	Interventional	2007-06-30	Completed
A Randomized Controlled Trial of Oral N-acetylcysteine for Smoking Reduction: a Pilot Study [NCT00751257]	Phase 2	33 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Open-Label, Two-Period, Crossover Bioequivalence Study in Healthy Adult Subjects After Single Oral Dosing of a NCH-GSK Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil® Acetylcysteine 2% Oral Solution [NCT02688361]	Phase 1	46 participants (Actual)	Interventional	2016-02-22	Completed
Randomized Study on N-acetylcysteine Treatment and Outcomes in Patients With Advanced Atherosclerotic Heart Diseases and Diabetes Mellitus (RENEWAL) [NCT05908513]	Phase 1	0 participants (Actual)	Interventional	2021-10-15	Withdrawn(stopped due to Lack of available resources needed to conduct study.)
The Efficiency and Safety of N-acetylcysteine for Prevention of Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation [NCT05907486]	Phase 3	260 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Evaluation of the Effect of Acetylcysteine and Vitamin E on Psoriasis Vulgaris Patients During The Active Phase [NCT05906498]	Phase 3	60 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients [NCT05658549]	Phase 1/Phase 2	120 participants (Actual)	Interventional	2021-05-01	Completed
A Randomized, Double Blind, Placebo Controlled Trial of Intravenous N-acetylcysteine and Oseltamivir Versus Intravenous 5% Dextrose and Oseltamivir in Adults Hospitalized With Influenza Complicated by Lower Respiratory Tract Infection. [NCT03900988]	Phase 3	160 participants (Anticipated)	Interventional	2023-05-08	Recruiting
A Pragmatic Randomized Clinical Trial Evaluating the Effect of Acetylcysteine for Contrast-induced Nephropathy [NCT00736866]	Phase 3	2,300 participants (Anticipated)	Interventional	2008-08-31	Completed
Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF [NCT00650091]	Phase 3	264 participants (Actual)	Interventional	2009-10-31	Completed
Double-blind , Randomized, Placebo Controlled Study of N-Acetyl Cysteine in Autism. [NCT00627705]	Phase 2	43 participants (Actual)	Interventional	2008-02-29	Completed
Evaluation of Aerosolized Drugs Deposition Delivered Through a Mechanical Ventilator [NCT02818270]		30 participants (Actual)	Interventional	2016-06-30	Completed
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy [NCT02882477]	Phase 2/Phase 3	20 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography: A Randomized Trial [NCT00830193]	Phase 2/Phase 3	45 participants (Actual)	Interventional	2002-08-31	Completed
The Effect of Redox Potential on the Regulation of Satellite Cells and Skeletal Muscle Healing Following Exercise-Induced Muscle Damage [NCT03711838]		45 participants (Actual)	Interventional	2019-07-22	Completed
Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity [NCT00564642]		60 participants (Actual)	Interventional	2007-11-30	Completed
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI) [NCT04520139]	Phase 1/Phase 2	102 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II. [NCT01394497]	Phase 2	140 participants (Actual)	Interventional	2006-12-31	Completed
Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant [NCT00994305]		74 participants (Anticipated)	Interventional	2005-04-30	Active, not recruiting
Double Blind, Randomized, Placebo-controlled, Two-way Crossover, Pilot Study to Assess the Effect of High Dose N-acetylcysteine on Small Airways and on Inflammation and Oxidative Stress in COPD Patients. [NCT00969904]	Phase 4	12 participants (Actual)	Interventional	2009-03-31	Completed
Postoperative Nasal Irrigation Using Mucolytic Agents in Patients Undergoing Endoscopic Sinus Surgery [NCT01582555]		44 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania [NCT00354770]	Phase 2	50 participants (Actual)	Interventional	2006-07-31	Completed
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major [NCT04260516]	Phase 1	100 participants (Actual)	Interventional	2019-06-03	Completed
How do Glutathione Levels Affect Compulsivity? A Double-blind, Placebo-controlled Study [NCT02794389]		23 participants (Actual)	Interventional	2016-03-31	Completed
The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function. [NCT00996424]	Phase 4	19 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to Insufficient recruitment.)
N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome [NCT01008046]		192 participants (Actual)	Interventional	2007-04-30	Completed
The Prevalence of Insulin Resistance and the Potential Modulation of Insulin Resistance by N-acetylcysteine (NAC) in Patients Chronically Infected by the Hepatitis C Virus [NCT00614757]		121 participants (Actual)	Interventional	2005-05-31	Suspended
Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation [NCT01866644]	Phase 3	214 participants (Actual)	Interventional	2011-09-30	Completed
RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia [NCT02040818]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-11-30	Withdrawn(stopped due to no enrollment)
Modulation of Lung Injury Complicating Lung Resection [NCT00655928]	Phase 2	52 participants (Actual)	Interventional	2007-08-31	Completed
The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724]		60 participants (Anticipated)	Interventional	2009-06-30	Active, not recruiting
A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning [NCT01050270]	Phase 4	222 participants (Actual)	Interventional	2010-09-30	Completed
A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. [NCT00248625]	Phase 3	184 participants (Actual)	Interventional	2000-01-31	Completed
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: A Randomized, Controlled Trial [NCT05664789]	Phase 2/Phase 3	48 participants (Anticipated)	Interventional	2023-04-26	Recruiting
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension [NCT05494398]	Phase 2/Phase 3	48 participants (Anticipated)	Interventional	2022-11-15	Enrolling by invitation
Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: a Single-dose Challenge Study [NCT04278898]	Phase 2	24 participants (Anticipated)	Interventional	2021-02-12	Recruiting
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics [NCT03220776]	Phase 2	54 participants (Actual)	Interventional	2017-08-07	Completed
[NCT01021163]	Phase 4	48 participants (Actual)	Interventional		Completed
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome [NCT00467831]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to insufficient enrollment)
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer [NCT01878695]	Phase 1	13 participants (Actual)	Interventional	2012-07-26	Completed
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia [NCT01885338]	Phase 1	26 participants (Actual)	Interventional	2013-06-30	Completed
A Phase 2 Study of the Efficacy of Antioxidant Therapy Compared With Enalapril in Slowing the Progression of Sickle Nephropathy in Children [NCT01891292]		30 participants (Anticipated)	Interventional	2013-07-31	Not yet recruiting
The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow Under Hypoxic and Normoxic Conditions [NCT01905696]	Early Phase 1	10 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to Lack of funding)
Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress [NCT01907061]		30 participants (Actual)	Interventional	2007-07-31	Completed
A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) [NCT00203099]	Phase 2	18 participants (Actual)	Interventional	2004-12-31	Completed
Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors [NCT00238173]	Phase 1	2 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to OHSU IRB closed study to further enrollment 2/17/2006)
Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy [NCT00556465]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2007-01-31	Completed
N-Acetylcysteine and Vitamin D in Infants With Hypoxic Ischemic Encephalopathy Treated With Hypothermia [NCT04643821]	Early Phase 1	30 participants (Actual)	Interventional	2015-01-01	Completed
RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine A Randomized, Double-blind, Placebo-controlled, Cross-over Trial [NCT03636932]	Phase 2	40 participants (Actual)	Interventional	2019-04-30	Completed
The Role of N-acetylcysteine as a Novel Adjuvant Treatment in Acute Organophosphorus.A Randomized, Clinical Trial in Poison Control Center -Ain Shams University Hospitals [NCT05927259]	Early Phase 1	40 participants (Actual)	Interventional	2022-01-01	Completed
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers [NCT00967005]	Phase 2	28 participants (Actual)	Interventional	2009-09-30	Completed
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia [NCT01232790]		28 participants (Actual)	Interventional	2010-02-28	Completed
TO COMPARE THE EFFICACY OF N -ACETYLCYSTEINE AND STANDARD THERAPY VERSUS STANDARD THERAPY IN THE PREVENTION OF ISCHEMIC HEPATITIS AND SURVIVAL POST UPPER GI BLEED [NCT02015403]		220 participants (Actual)	Interventional	2013-12-31	Completed
Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour [NCT00568113]	Phase 4	120 participants (Actual)	Interventional	2007-07-31	Completed
Effects of Arginine and N-Acetylcysteine Administration on Nitric Oxide Production and Arterial Blood Pressure in Hypertensive Diabetic Patients. [NCT00569465]	Phase 4	24 participants (Actual)	Interventional	2005-01-31	Terminated(stopped due to End of the study)
The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patientswith Chronic Kidney Disease-Placebo Controlled, Randomized,Open, Cross-Over Study [NCT00572663]		0 participants	Interventional	2005-01-31	Completed
Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia [NCT04570254]		110 participants (Actual)	Interventional	2020-08-19	Completed
A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization [NCT00579995]		41 participants (Actual)	Interventional	2005-05-01	Terminated(stopped due to Technical measurement problems led to unreliable or uninterpretable data.)
Possible Ameliorating Effect of N- Acetylcysteine on Type-II Diabetes Induced Nephropathy [NCT04531163]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2019-10-01	Active, not recruiting
Experimentally Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder [NCT05340504]	Phase 2	12 participants (Actual)	Interventional	2022-05-13	Completed
Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Pediatric Obsessive-Compulsive Disorder [NCT01172275]	Phase 2	11 participants (Actual)	Interventional	2012-07-31	Completed
The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00866866]	Phase 4	60 participants (Anticipated)	Interventional	2009-03-31	Recruiting
Assessment of the Effect of Atorvastatin and N-acetyl Cysteine on Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary Angiography CIN [NCT06139952]	Phase 4	120 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Open Label, Randomized, Two-Arm, Single-Dose, Two-Period, Crossover Study to Determine the Relative Bioavailability of AR10 (Acetylcysteine Effervescent Tablets) Compared to Reference Product in Healthy, Adult Subjects, Fasting [NCT02723669]	Phase 1	30 participants (Actual)	Interventional	2014-04-30	Completed
Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity [NCT02760901]	Phase 2	52 participants (Actual)	Interventional	2013-11-30	Completed
High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial [NCT02718079]		40 participants (Actual)	Interventional	2016-12-30	Completed
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome and on the Degree of Mucositis Developed in Response to Concurrent Chemotherapy and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck [NCT03982537]	Phase 2	0 participants (Actual)	Interventional	2020-06-18	Withdrawn(stopped due to Concept is withdrawn and a different concept will be submitted the near future.)
Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients [NCT04291066]	Phase 2	92 participants (Actual)	Interventional	2019-09-01	Completed
Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth [NCT03596125]	Phase 2/Phase 3	39 participants (Actual)	Interventional	2018-11-05	Terminated(stopped due to difficulty of recruitment)
N-acetylcysteine as Treatment in Cocaine Addiction [NCT00136825]	Phase 1	17 participants (Actual)	Interventional	2003-03-31	Completed
A Multi-center, Double-blind, Randomized, Controlled Study to Determine the Efficacy and Safety of a New Formulation of Acetylcysteine Injection [NCT01118663]	Phase 3	17 participants (Actual)	Interventional	2010-09-30	Terminated
Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) [NCT00639496]	Phase 3	184 participants (Actual)	Interventional	2000-03-31	Completed
Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome [NCT01172288]	Phase 2	31 participants (Actual)	Interventional	2010-07-31	Completed
A Multiple Ascending Phase 1 Dose Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels [NCT05241262]	Phase 1	18 participants (Anticipated)	Interventional	2023-04-30	Recruiting
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial [NCT04300920]	Phase 3	200 participants (Anticipated)	Interventional	2020-12-17	Recruiting
N-Acetyl Cysteine Helps Pulp Stem Cells Differentiate During Endodontic Revascularization [NCT03451435]	Early Phase 1	14 participants (Anticipated)	Interventional	2018-06-15	Recruiting
An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) [NCT03757585]	Phase 4	60 participants (Anticipated)	Interventional	2019-05-20	Recruiting
Adding Antioxidants Into Human Embryo Culture Media [NCT02971878]		128 participants (Actual)	Interventional	2016-11-30	Completed
N-acetyl Cysteine: the Effectiveness and Safety in a Cohort of Pediatric Patients With Chronic Kidney Disease [NCT04916080]	Phase 2	50 participants (Actual)	Interventional	2021-11-01	Completed
Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation [NCT04712435]	Phase 2	80 participants (Anticipated)	Interventional	2021-04-30	Not yet recruiting
Oxidative Stress and Postoperatory Renal Function in Deceased Kidney Transplantation [NCT00851708]		0 participants	Interventional		Completed
Anti-microbial Role of Non-antibiotic Agents Against Cutibacterium Acnes in Patients With Acne Vulgaris [NCT06179056]		24 participants (Actual)	Observational	2023-03-01	Completed
Dose Escalation Study Of I.V. And Intra-Aortic N-Acetylcysteine For The Prevention Of Contrast Induced Nephropathy In Patients With Stage 3 Renal Failure Undergoing Contrast Imaging Studies: A Phase I Trial [NCT00575419]	Phase 1	6 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to Low accrual)
The PRIME (Perioperative Renal Insufficiency Management) Study: A Randomized, Double-blinded, Placebo-controlled Trial of N-acetylcysteine for Preventing Renal Injury After Cardiac Surgery. [NCT00188630]	Phase 3	176 participants (Actual)	Interventional	2003-07-31	Completed
N-Acetylcysteine Protects Against Acute Renal Insult in Patients With Abnormal Renal Function Undergoing Cardiopulmonary Bypass. [NCT00190034]	Phase 4	60 participants (Anticipated)	Interventional	2005-01-31	Suspended(stopped due to opposite result)
Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma [NCT06115408]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Randomized, Double-Blind, Controlled Trial of Combined Amiodarone and N-Acetylcysteine Versus Amiodarone Plus Placebo for the Prevention of Atrial Fibrillation in High Risk Patients Undergoing Thoracic Surgery [NCT02750319]	Phase 3	184 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain [NCT01849016]	Phase 3	96 participants (Actual)	Interventional	2013-04-30	Completed
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32) [NCT05294744]		390 participants (Anticipated)	Interventional	2022-04-30	Not yet recruiting
Acetylcystein Vid Stapedotomi [NCT00525551]	Phase 4	152 participants (Actual)	Interventional	2007-09-30	Completed
EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS [NCT02241876]	Phase 4	60 participants (Anticipated)	Interventional	2014-10-31	Not yet recruiting
A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E [NCT01495260]	Phase 2	13 participants (Actual)	Interventional	2011-09-30	Completed
An Open Labelled Randomized Multi-center Study of COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Incidence of Contrast Induced Nephropathy [NCT00497328]	Phase 2/Phase 3	477 participants (Actual)	Interventional	2007-08-31	Completed
[NCT00592618]		0 participants	Interventional		Not yet recruiting
Use of Mucomyst (NAC) to Ameliorate Oxidant Stress in Diabetic Patients as Measurable by Surrogate Serum Markers [NCT00493727]		15 participants (Actual)	Interventional	2006-09-30	Completed
Defining Neurobiological Signatures for Chronic Traumatic Brain Injury Using PET-MRI Technology [NCT03241732]		150 participants (Anticipated)	Interventional	2017-06-07	Enrolling by invitation
Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer. A Multicenter, Prospective, Randomised Double Blind, Placebo-controlled Study [NCT00512265]	Phase 4	29 participants (Actual)	Interventional	2006-01-31	Completed
Evidence of a Redox-dependent Regulation of Immune Responses to Exercise-Induced Inflammation [NCT02930031]		10 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine (NAC) As A Renal Protective Agent for Prevention of Renal Dysfunction Following Cardiopulmonary Bypass (CPB) [NCT00187330]	Phase 2	104 participants	Interventional	2004-03-31	Completed
Randomised Control Pilot Trial of n-Acetylcysteine in the Treatment of Chronic Heart Failure With Coexistent Chronic Renal Failure. [NCT00532688]	Phase 2/Phase 3	10 participants (Anticipated)	Interventional	2007-09-30	Recruiting
Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy [NCT01265563]	Phase 2	108 participants (Actual)	Interventional	2011-01-31	Completed
The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms [NCT04405193]	Phase 2/Phase 3	66 participants (Actual)	Interventional	2019-10-01	Completed
Comparison of G-Series Media System With Antioxidants Versus Standard G-Series Media System [NCT02999958]		128 participants (Actual)	Interventional	2016-12-31	Completed
Phase 3 Study of Protective Effect of N-acetylcysteine Against From Ototoxicity [NCT01271088]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2010-06-30	Completed
[NCT00247507]	Phase 4	0 participants	Interventional	2005-09-30	Active, not recruiting
Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans - the Role of Oxidative Stress [NCT00434005]		24 participants (Actual)	Interventional	2008-07-31	Completed
Effects of N-acetylcysteine on Muscle Fatigue in ESRD [NCT00440869]	Phase 1	30 participants (Anticipated)	Interventional	2007-03-31	Completed
N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery. [NCT00122018]	Phase 2	80 participants	Interventional	2002-05-31	Completed
Randomized Controlled Trial Examining the Effect of N-Acetylcysteine on Serum Creatinine in Patients With Stage 3 Chronic Kidney Disease [NCT00506506]	Phase 3	60 participants (Actual)	Interventional	2007-10-31	Completed
[NCT00507052]		0 participants	Interventional		Not yet recruiting
Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults [NCT04005053]	Phase 2	44 participants (Actual)	Interventional	2019-08-01	Completed
Attenuation of Myocardial Dysfunction by N-Acetylcysteine in Infants Undergoing Arterial Switch Procedure [NCT00374088]	Phase 2	21 participants (Actual)	Interventional	2005-02-28	Completed
Antioxidation Medication for Noise-induced Hearing Loss [NCT00552786]	Phase 2	53 participants (Actual)	Interventional	2007-11-30	Completed
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in Patients Undergoing Pharmaco-invasive Reperfusion Early After an ST-segment Elevation Myocardial Infarction [NCT04023266]	Phase 2	44 participants (Actual)	Interventional	2019-09-20	Completed
Randomized Trial of Supplementing Glycine and N-acetylcysteine vs. Placebo in COVID-19 [NCT04703036]	Early Phase 1	64 participants (Anticipated)	Interventional	2021-01-11	Active, not recruiting
A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents [NCT01005810]	Phase 2	116 participants (Actual)	Interventional	2009-09-30	Completed
N-acetyl-L-cysteine for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy--a Prospective Single-arm Clinical Study [NCT06024031]	Phase 2	30 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations [NCT01537926]	Phase 1	42 participants (Actual)	Interventional	2012-01-31	Completed
A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice [NCT00184977]	Phase 4	270 participants	Interventional	1998-12-31	Completed
Glutathione in Mild Cognitive Impairment [NCT03493178]	Early Phase 1	60 participants (Anticipated)	Interventional	2018-04-14	Recruiting
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material [NCT00558142]	Phase 4	90 participants (Actual)	Interventional	2008-02-29	Completed
Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure [NCT00211653]	Phase 1/Phase 2	102 participants (Actual)	Interventional	2003-04-30	Completed
The Relation Between Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation in Diabetic Patients Suffering From Foot Ulcers [NCT00463671]		50 participants	Interventional	2003-12-31	Completed
Systemic Vascular Dysfunction in COPD Patients With Mild-to-moderate Airflow Obstruction: Pharmacological Treatment With N-acetylcysteine [NCT02579772]	Phase 4	13 participants (Actual)	Interventional	2015-07-31	Completed
Homocystinuria: Treatment With N-Acetylcysteine [NCT00483314]	Phase 2	5 participants (Actual)	Interventional	2007-11-30	Completed
Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy: A Placebo Controlled Randomized Study [NCT00492518]	Phase 4	254 participants (Actual)	Interventional	2002-02-28	Completed
Use of Mucomyst (NAC) to Ameliorate Oxidant Stress as Measured by Surrogate Serum in Patients With Hepatitis C [NCT00493610]		5 participants (Anticipated)	Interventional	2006-11-30	Suspended(stopped due to Collaborator no longer interested, short of funds)
A Trial Evaluating the Impact of N-acetylcysteine on Opioid Use in Patients Undergoing a Hysterectomy Procedure [NCT06039566]	Phase 3	240 participants (Anticipated)	Interventional	2023-11-30	Recruiting
Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study [NCT01515839]		100 participants (Actual)	Interventional	2009-05-31	Completed
Serotonin Reuptake Inhibitor Augmentation With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder: a Double-blind, Randomized and Controlled Study [NCT01555970]	Phase 2	40 participants (Actual)	Interventional	2012-03-31	Completed
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia: A Single Blind, Randomized Controlled Trial [NCT05611086]	Phase 4	16 participants (Actual)	Interventional	2019-08-29	Terminated(stopped due to The study stopped because the study period already ended)
Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia: Double-blind and Crossover Study [NCT01506765]	Phase 1	13 participants (Actual)	Interventional	2003-08-31	Completed
Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis [NCT02971306]	Phase 4	60 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Effect of N-acetylcysteine in Preventing Adverse Neonatal Outcomes in Women With Intra-amniotic Infection/Inflammation [NCT00397735]	Phase 1/Phase 2	68 participants (Actual)	Interventional	2006-10-01	Completed
A Randomized Factorial Trial of N-Acetylcysteine and Continuous Veno-Venous Hemo(Dia)Filtration for Rhabdomyolysis [NCT00391911]	Phase 2	3 participants (Actual)	Interventional	2006-11-30	Completed
Improved Estimation of Glomerular Filtration Rate by Serum Cystatin C in Preventing Contrast Induced Nephropathy by N-Acetylcysteine or Zinc [NCT00399256]		60 participants	Interventional	2004-03-31	Terminated
[NCT00396396]		35 participants	Interventional	2006-10-31	Recruiting
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease? [NCT03104725]	Phase 1	6 participants (Actual)	Interventional	2017-09-25	Terminated(stopped due to Difficulty with recruitment and participant accrual due to study eligibility criteria and required study procedures (e.g., multiple lumbar punctures).)
A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder [NCT05408247]	Phase 4	280 participants (Anticipated)	Interventional	2023-02-16	Recruiting
Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit: A Randomized, Double Blind, Controlled Trial [NCT00131521]		260 participants (Anticipated)	Interventional	2005-01-31	Completed
Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis [NCT02141620]	Early Phase 1	15 participants (Actual)	Interventional	2014-05-31	Completed
[NCT00188773]	Phase 4	15 participants (Anticipated)	Interventional	2004-01-31	Completed
Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study) [NCT00196885]	Phase 2	60 participants	Interventional	2003-12-31	Completed
N-acetylcysteine in Alcohol Dependence [NCT00568087]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2007-12-31	Completed
N-acetylcysteine and NMDA Antagonist Interactions [NCT00611897]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2006-01-31	Completed
Efficacy of N-acetylcysteine for the Prevention and Relief of Paclitaxel-induced Peripheral Neuropathy in Women With Ovarian, Tubal, and Peritoneal Cancer: an Open-label, Randomized Controlled Trial [NCT05539053]		60 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence [NCT02994875]	Early Phase 1	21 participants (Actual)	Interventional	2016-05-31	Completed
Glutathione and Function in HIV Patients [NCT02348775]	Phase 1	16 participants (Actual)	Interventional	2014-11-30	Completed
An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents [NCT00542750]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2008-01-31	Completed
Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections. [NCT01726465]	Phase 2	50 participants (Actual)	Interventional	2012-11-30	Terminated(stopped due to The first phase was completed)
Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity [NCT06019520]		70 participants (Anticipated)	Interventional	2023-08-09	Active, not recruiting
N-acetylcysteine Plus Transcutaneous Vagus Nerve Stimulation in Infants of Diabetic Mothers Who Fail Oral Feeding [NCT04632069]	Early Phase 1	10 participants (Actual)	Interventional	2021-08-12	Active, not recruiting
[NCT00267384]	Phase 2/Phase 3	0 participants	Interventional	2006-03-31	Completed
[NCT00237614]	Phase 2/Phase 3	300 participants	Interventional	2003-02-28	Completed
Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18 [NCT01403506]	Phase 3	60 participants (Anticipated)	Interventional	2011-04-30	Recruiting
An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling [NCT00273702]	Phase 1	36 participants (Actual)	Interventional	2006-01-31	Completed
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty [NCT06083480]	Phase 4	148 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
High-Dose N-Acetylcysteine in Cardiac Surgery Patients at High-Risk of Postoperative Renal Dysfunction. [NCT00332631]	Phase 2	60 participants	Interventional	2004-08-31	Completed
Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma [NCT00003346]	Phase 2	80 participants (Anticipated)	Interventional	1997-11-30	Completed
Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2 [NCT04755972]		175 participants (Actual)	Interventional	2020-10-01	Completed
Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. [NCT01653171]	Phase 4	230 participants (Actual)	Interventional	2012-07-31	Completed
Elucidation of Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder: An 8-week Multimodal Neuroimaging and Neurocognitive Study [NCT01664260]	Phase 2	0 participants (Actual)	Interventional	2012-11-01	Withdrawn(stopped due to The research project has been cancelled before any participants were enrolled.)
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3 [NCT05264584]		120 participants (Actual)	Interventional	2020-12-01	Completed
Supplementation of N-acetylcysteine and Arachonic Acid in Type 1 Diabetes to Determine Changes in Oxidative Stress [NCT03056014]	Early Phase 1	8 participants (Actual)	Interventional	2018-11-01	Terminated(stopped due to COVID)
Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury [NCT01098032]	Phase 3	294 participants (Actual)	Interventional	2009-01-31	Completed
Pilot Studies Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli [NCT05287724]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-06-19	Recruiting
Effects of Diesel Exhaust on Airways [NCT01699204]		26 participants (Actual)	Interventional	2007-09-30	Completed
Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome [NCT01501110]	Phase 4	83 participants (Actual)	Interventional	2011-11-30	Completed
N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement. [NCT01704482]	Phase 2	60 participants (Actual)	Interventional	2011-02-28	Completed
A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery. [NCT04562597]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2021-01-20	Completed
Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses [NCT01747616]	Phase 1	48 participants (Actual)	Interventional	2011-07-31	Completed
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma [NCT05081479]	Phase 1	32 participants (Anticipated)	Interventional	2021-12-08	Recruiting
[NCT01753752]	Phase 2	32 participants (Actual)	Interventional	2012-09-30	Completed
Effects of NAC Supplementation on Skeletal Muscle Performance Following Aseptic Injury Induced by Exercise [NCT01778309]		20 participants (Actual)	Interventional	2010-01-31	Completed
Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention [NCT01878669]	Phase 3	390 participants (Anticipated)	Interventional	2013-01-31	Active, not recruiting
A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease [NCT01800526]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2013-03-31	Completed
A Pilot Study of N-acetylcysteine in Suspected Thrombotic Thrombocytopenia Purpura [NCT01808521]	Early Phase 1	3 participants (Actual)	Interventional	2013-05-31	Completed
Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis [NCT01841411]	Phase 4	90 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Mechanisms of Improving Cognition and Negative Symptoms in Schizophrenia With N-Acetylcysteine: a Magnetic Resonance Spectroscopy Study of Glutamate and Glutathione [NCT02505477]	Phase 4	51 participants (Actual)	Interventional	2017-02-06	Completed
A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009) [NCT01797575]	Phase 2	38 participants (Actual)	Interventional	2013-01-31	Completed
Effect of Anti-oxidants on Beta-cell Function in Humans [NCT01394510]		13 participants (Actual)	Interventional	2011-06-30	Completed
A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. [NCT03510741]	Phase 2	64 participants (Actual)	Interventional	2019-01-01	Completed
A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder [NCT03008889]	Phase 2	8 participants (Actual)	Interventional	2018-07-05	Completed
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial [NCT05738681]	Phase 2/Phase 3	82 participants (Anticipated)	Interventional	2022-09-09	Recruiting
Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial [NCT02249546]	Phase 4	654 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Comparative Bioavailability Study of N-acetyl-cysteine (NAC) 600 mg Uncoated Tablets vs. NAC 600 mg Film-coated Tablets in Healthy Male and Female Volunteers [NCT02265224]	Phase 1	48 participants (Actual)	Interventional	2014-09-30	Completed
Phase I Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple i.v. Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers [NCT03881163]	Phase 1	24 participants (Actual)	Interventional	2019-11-11	Completed
A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study [NCT00896025]	Phase 4	255 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to This observational study was stopped after 140 patients were enrolled, no more funds available to continue.)
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization - Randomized Controlled Trial. [NCT06039280]		150 participants (Anticipated)	Interventional	2023-09-15	Not yet recruiting
Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction [NCT03423667]	Phase 2	80 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections [NCT04792021]	Phase 3	60 participants (Actual)	Interventional	2021-03-09	Completed
A Pilot Pre-Phase 1 Clinical Trial to Study How Administering Sublingual Nitric Oxide Donor S-nitroso-N-acetylcysteine Affects the Systemic Blood Pressure in Healthy Human Volunteers. [NCT05798481]	Early Phase 1	14 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients. [NCT00421785]		20 participants (Anticipated)	Interventional	2007-02-28	Recruiting
Translational Neuropsychopharmacology Research of Nicotine Addiction [NCT02723162]	Phase 2	67 participants (Actual)	Interventional	2016-05-04	Completed
Efficacy and Safety of N-acetyl Cysteine for the Prevention of Oral Mucositis After High-dose Chemotherapy and Autologous Hematopoietic Cell Transplantation: a Phase III, Randomized, Open Label, Multi-center Study. [NCT04756622]	Phase 3	116 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease [NCT02212678]	Phase 2	8 participants (Actual)	Interventional	2014-09-30	Completed
N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence [NCT01214083]	Phase 2	111 participants (Actual)	Interventional	2010-10-15	Completed
Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly [NCT01384591]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-07-31	Completed
PILOT: The Effects of Short Term Administration of a Novel Glutathione Precursor (FT061452), on Serum and Intracellular Glutathione Levels [NCT01251315]	Phase 1	24 participants (Actual)	Interventional	2010-12-31	Completed
A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence [NCT00332605]	Phase 2	45 participants (Actual)	Interventional	2006-06-30	Completed
Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease [NCT01427517]	Phase 1	9 participants (Actual)	Interventional	2011-07-31	Completed
Clinical Trial of NAC in Asthma [NCT02605824]	Phase 4	1 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to The study was closed after we determined that this albuterol/NAC regimen may be associated with excessive bronchoconstriction.)
N-Acetylcysteine for Neuroprotection in Parkinson's Disease [NCT01470027]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2012-01-31	Completed
Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage [NCT00585559]	Phase 3	120 participants (Anticipated)	Interventional	2007-04-30	Active, not recruiting
A Phase II Placebo-controlled Intervention Trial of Oral N-acetylcysteine (NAC) for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo [NCT01612221]	Phase 2	100 participants (Actual)	Interventional	2012-09-30	Completed
A Controlled Trial of N-Acetylcysteine (NAC) for Cocaine Dependence [NCT00218491]	Phase 2	111 participants (Actual)	Interventional	2005-11-30	Completed
The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers in Patients With Tobacco Use Disorders and Bipolar Disorders .. [NCT02420418]		72 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study [NCT04900129]	Phase 1	43 participants (Actual)	Interventional	2020-12-01	Completed
Antioxidant Therapy in RYR1-Related Congenital Myopathy [NCT02362425]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2015-02-12	Completed
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms [NCT05123365]	Phase 1/Phase 2	27 participants (Anticipated)	Interventional	2022-01-03	Active, not recruiting
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers [NCT05509153]	Phase 2	160 participants (Anticipated)	Interventional	2022-11-01	Not yet recruiting
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer. A Randomized, Placebo Controlled Clinical Trial [NCT03400709]		45 participants (Actual)	Interventional	2015-11-30	Completed
An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth [NCT03911414]	Phase 4	60 participants (Anticipated)	Interventional	2019-06-18	Recruiting
Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. [NCT01572597]	Phase 4	120 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients [NCT01597765]		60 participants (Actual)	Interventional	2009-06-30	Completed
The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy: a Prospective, Non-inferiority, Randomized Controlled Trial [NCT04764643]		140 participants (Actual)	Interventional	2020-02-01	Completed
Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1 [NCT01599884]		65 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients [NCT01614431]	Phase 4	23 participants (Actual)	Interventional	2011-03-31	Completed
Effect of N-acetylcysteine on Exacerbations of Bronchiectasis (BENE): a Randomized Controlled Trial [NCT02088216]		161 participants (Actual)	Interventional	2014-04-01	Completed
Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement [NCT03440268]	Phase 4	154 participants (Anticipated)	Interventional	2018-03-15	Not yet recruiting
Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine in Patients Undergoing Cardiac Catheterization [NCT00353340]		250 participants (Anticipated)	Interventional	2005-01-31	Completed
Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis [NCT00428883]	Phase 2/Phase 3	45 participants	Interventional	2007-01-31	Recruiting
Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis [NCT03032601]		55 participants (Anticipated)	Interventional	2017-01-05	Enrolling by invitation
[NCT01339858]	Phase 4	60 participants (Actual)	Interventional	2011-05-31	Completed
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC [NCT06152653]	Phase 4	20 participants (Anticipated)	Interventional	2023-11-21	Recruiting
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain [NCT01840345]	Phase 2	11 participants (Actual)	Interventional	2014-01-31	Completed
A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia [NCT01993849]	Phase 3	23 participants (Actual)	Interventional	2013-10-31	Completed
A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy [NCT01962961]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2013-10-31	Completed
A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial) [NCT03177395]	Phase 1	24 participants (Actual)	Interventional	2017-06-08	Completed
Drug Nephrotoxicity Amelioration in Cancer Patients by N-acetylcysteine [NCT06122311]		30 participants (Anticipated)	Interventional	2023-02-20	Recruiting
The Effect of NAC on Lung Function and CT Mucus Score [NCT03822637]	Phase 4	30 participants (Anticipated)	Interventional	2019-02-20	Recruiting
A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy [NCT03499249]	Phase 2	16 participants (Anticipated)	Interventional	2018-05-18	Active, not recruiting
[NCT00004467]	Phase 3	173 participants (Actual)	Interventional	1998-06-30	Completed
Use of NAC in Alleviation of Hangover Symptoms [NCT02541422]		62 participants (Actual)	Interventional	2015-08-31	Completed
A Randomized Double Blinded Study to Examine the Use of N-Acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes [NCT02206152]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2015-02-28	Completed
N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI [NCT02791945]	Phase 2	30 participants (Actual)	Interventional	2016-08-31	Completed
Inpatient Clinical Trial of NAC [NCT03581084]	Phase 4	1 participants (Actual)	Interventional	2018-07-06	Terminated(stopped due to The study was redesigned to be conducted in an outpatient setting.)
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 [NCT04481035]	Phase 2	5 participants (Actual)	Interventional	2019-01-15	Active, not recruiting
Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke [NCT04918719]	Phase 2	118 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms [NCT03221231]	Phase 4	75 participants (Anticipated)	Interventional	2016-05-15	Recruiting
Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial [NCT02357303]	Phase 4	300 participants (Actual)	Interventional	2015-04-30	Completed
Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19 [NCT05736887]	Phase 2	80 participants (Anticipated)	Interventional	2022-05-24	Active, not recruiting
Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) [NCT01675661]	Phase 3	302 participants (Actual)	Interventional	2014-01-31	Completed
N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking [NCT05911282]		40 participants (Actual)	Interventional	2021-06-01	Completed
Effectiveness of N-Acetylcysteine in Motivational Enhancement Therapy for Nicotine Addiction: Study on the Dopaminergic Pathways, Changes in Functional Connectivity of fMRI Bold, and Changes in Smoking Abstinence [NCT05903014]	Phase 4	88 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Neuroscience-Informed Treatment Development for Adolescent Alcohol Use [NCT03238300]	Phase 2	57 participants (Actual)	Interventional	2017-10-16	Completed
The Efficacy and Safety of N-acetyl-L-cysteine (NAC) as Adjuvant Therapy in Acute on Chronic Liver Failure (ACLF) A Randomized Double Blind Placebo Controlled Pilot Trial [NCT05089981]		100 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients [NCT04370288]	Phase 1	20 participants (Anticipated)	Interventional	2020-04-19	Recruiting
The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. [NCT03018236]	Phase 4	100 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Sperm DNA Damage in β-thalassemia Major: Is There a Role for Antioxidants? [NCT03014882]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2015-02-28	Active, not recruiting
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma [NCT02569957]	Phase 2	1 participants (Actual)	Interventional	2015-10-02	Terminated(stopped due to The trial was halted prematurely due to slow accrual.)
A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies [NCT02123511]	Phase 2	34 participants (Actual)	Interventional	2014-04-30	Completed
Assessment of the Impact of N-acetylcysteine Supplementation on Physical Performance Depending on the Polymorphism of Genes Related to Folate Metabolism [NCT05604586]		100 participants (Anticipated)	Interventional	2022-05-01	Recruiting
N-Acetyl Cysteine add-on to Antidepressant Medication in Therapy Refractory Major Depressive Disorder Patients With Increased Inflammatory Activity [NCT02972398]		200 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple-Dose, Proof-of-Concept Study to Evaluate the Efficacy of N-acetylcysteine Capsules in the Treatment of the Common Cold (Viral URTI) Associated With Cough in an Adult Population [NCT02379637]	Phase 2	70 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized Double-blind Study of N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy in Patients Treated for (Non)Small Cell Lung Cancer and Malignant Mesothelioma [NCT00637624]		69 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Unable to recruit enough patients)
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder [NCT03707951]	Phase 2	120 participants (Anticipated)	Interventional	2019-02-27	Active, not recruiting
N-Acetylcysteine for Youth Cannabis Use Disorder [NCT03055377]	Phase 2/Phase 3	192 participants (Anticipated)	Interventional	2017-08-03	Active, not recruiting
Effects of N-acetylcysteine on Psychosis-like Symptoms and a Neurophysiological Biomarker of the Clinical High Risk for Schizophrenia [NCT05142735]		90 participants (Anticipated)	Interventional	2023-01-13	Recruiting
Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe Chronic Obstructive Pulmonary Disease (COPD) [NCT03388853]	Phase 4	68 participants (Actual)	Interventional	2018-02-20	Completed
Effect of Dietary Glycemic Index on Beta-cell Function [NCT01386645]		56 participants (Actual)	Interventional	2011-07-31	Completed
Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers [NCT01278784]	Phase 1	24 participants (Actual)	Interventional	2011-03-31	Completed
Safety of N-acetylcysteine in Maternal Chorioamnionitis [NCT00724594]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2008-08-31	Completed
The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed Immune Thrombocytopenia: A Single-arm, Open-label Trial [NCT04368598]	Phase 2	44 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Glutathione and Fuel Oxidation in Aging [NCT01870193]	Early Phase 1	36 participants (Anticipated)	Interventional	2013-04-23	Completed
Clinical, Control, Double-blind, Randomized Experimentation With N-acetylcysteine and Bromhexine for COVID-19 [NCT04928495]	Phase 3	219 participants (Anticipated)	Interventional	2021-07-15	Not yet recruiting
Use of N-acetyl Cysteine (NAC) in Alleviation or Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol [NCT03104959]		200 participants (Anticipated)	Interventional	2016-01-31	Terminated(stopped due to unable to enroll sufficient number of participants)
Glutamatergic Mechanisms in Opioid and Cocaine Co-Use [NCT05610072]	Early Phase 1	24 participants (Anticipated)	Interventional	2022-12-15	Recruiting
Impact of Combining N-acetylcysteine Intravenous Infusion and Intralipid Emulsion Infusion Versus Intralipid Infusion Alone on Myocardial Injury in Aluminum Phosphide Toxicity [NCT05370729]		58 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection [NCT04545008]	Phase 1	2 participants (Actual)	Interventional	2020-10-20	Terminated(stopped due to Study was stopped due to poor accrual.)
A Phase III, Multi-centre, Randomized, Rater- and Patient-blind, Placebo- and Active-controlled, Parallel Group Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily (Active Test Tre [NCT03843541]	Phase 3	333 participants (Actual)	Interventional	2019-06-25	Completed
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients [NCT00780962]	Phase 2	399 participants (Actual)	Interventional	2007-10-16	Completed
Energetics and Function in Older Humans [NCT02348762]	Phase 1	16 participants (Actual)	Interventional	2014-11-30	Completed
Clinical Trial of Oral Medication for CTD-ILD Treatment [NCT01424033]	Phase 2/Phase 3	5 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Departure of study team)
CSP #578 - Prevention of Serious Adverse Events Following Angiography (PRESERVE) [NCT01467466]	Phase 3	5,177 participants (Actual)	Interventional	2013-10-07	Completed
A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study) [NCT03063021]	Phase 1	30 participants (Actual)	Interventional	2017-02-15	Completed
The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis [NCT01587001]		17 participants (Actual)	Interventional	2011-11-30	Completed
Comparative Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Acute Aluminium Phosphide Poisoning: A Clinical Trial [NCT04509258]	Phase 4	100 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial [NCT03364218]	Phase 4	106 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder [NCT03120468]	Early Phase 1	16 participants (Anticipated)	Interventional	2017-05-01	Active, not recruiting
A Randomised Controlled Double Blind Crossover Study of the Effect of a Single Dose of N-acetylcysteine Versus Placebo on Brain Glutamate in Patients With Psychotic Disorders [NCT02483130]		20 participants (Actual)	Observational	2015-06-30	Completed
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease [NCT02445651]		51 participants (Actual)	Interventional	2014-03-31	Completed
Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3 [NCT01739790]		51 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to PI discretion)
Safety and Efficacy of Adding Intravenous N-acetyl Cysteine to Parenteral L-alanyl L-glutamine in Hospitalized Patients Undergoing Colon Surgeries [NCT03589495]	Phase 4	60 participants (Actual)	Interventional	2015-07-30	Completed
The Use of N-acetylcysteine Supplementation in Addition to Night Splinting for Treatment of Mild to Moderate Carpal Tunnel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial [NCT04460521]	Phase 4	240 participants (Anticipated)	Interventional	2021-08-01	Recruiting
A Randomized Controlled Study to Evaluate the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose [NCT05517668]	Phase 2	40 participants (Anticipated)	Interventional	2022-09-12	Recruiting
The Effect of N-acetylcysteine in Decreasing the Incidence of Linezolid-induced Thrombocytopenia in Critically Ill Patients [NCT05944458]	Phase 4	112 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression - A Double Blind Randomized Placebo-controlled Trial With Follow up [NCT02294591]	Phase 2	80 participants (Actual)	Interventional	2014-11-30	Completed
Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial [NCT03494387]	Phase 4	600 participants (Actual)	Interventional	2018-04-06	Completed
Evaluation of The Effect of N-AcetylCysteine in The Prevention of Paclitaxel-Induced Peripheral Neuropathy in Cancer Patients [NCT03492047]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2018-04-01	Completed
A Safety and Efficacy Study of N-acetylcysteine in Patients With Transplant-Associated Thrombotic Microangiopathy [NCT03252925]	Phase 3	170 participants (Actual)	Interventional	2017-11-01	Completed
N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome [NCT03346681]	Early Phase 1	0 participants (Actual)	Interventional	2018-02-01	Withdrawn(stopped due to no patients enrolled)
A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients [NCT05994534]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2023-10-29	Recruiting
The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis [NCT03069300]	Phase 3	42 participants (Anticipated)	Interventional	2015-10-01	Recruiting
Effect of N-acetylcysteine as Add on Therapy With Selective Serotonin Reuptake Inhibitors in Moderate to Severe Obsessive Compulsive Disorder Patients [NCT04904952]		60 participants (Anticipated)	Interventional	2020-03-13	Recruiting
Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT) [NCT05126004]	Phase 2	100 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient [NCT02168387]	Phase 4	39 participants (Actual)	Interventional	2010-12-31	Completed
A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM) [NCT05686356]	Phase 2/Phase 3	352 participants (Anticipated)	Interventional	2023-07-28	Recruiting
N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial [NCT02483143]	Phase 4	231 participants (Actual)	Interventional	2014-02-28	Completed
Glial Regulators for Treating Comorbid Posttraumatic Stress and Substance Abuse Disorders [NCT02499029]	Phase 2	35 participants (Actual)	Interventional	2013-02-28	Completed
Effects of NAC Supplementation on Immune Function, Inflammatory and Performance Responses of Elite Soccer Players Participated in Three Repetitive Games. [NCT04523675]		40 participants (Actual)	Interventional	2016-04-30	Completed
Open-Label Study of N-Acetylcysteine in Children and Adolescents Ages 5-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder [NCT02357290]	Phase 4	40 participants (Actual)	Interventional	2014-01-31	Completed
Effect of the Prophylactic Intervention of N-acetyl-L-cysteine (NAC) on the Incidence of Poor Graft Function and Prolonged Isolated Thrombocytopenia in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation [NCT03236220]	Phase 2	35 participants (Actual)	Interventional	2017-08-01	Completed
Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease [NCT04419025]	Phase 2	165 participants (Actual)	Interventional	2020-09-23	Completed
Effect of High-Dose N-acetyl Cysteine (NAC) on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy (DPN) [NCT04766450]	Phase 4	30 participants (Anticipated)	Interventional	2021-12-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00218491 (1) [back to overview]	Number of Participants That Achieved Study Compliance
NCT00248625 (8) [back to overview]	Survival
NCT00248625 (8) [back to overview]	Categorized Length of ICU Stay
NCT00248625 (8) [back to overview]	Highest Coma Grade of Hepatic Encephalopathy
NCT00248625 (8) [back to overview]	Number of Organ Systems Failing
NCT00248625 (8) [back to overview]	Length of Hospital Stay
NCT00248625 (8) [back to overview]	Infectious Complication
NCT00248625 (8) [back to overview]	Cumulative Percent Incidence of Transplantation by 1 Year
NCT00248625 (8) [back to overview]	Spontaneous Recovery
NCT00332605 (1) [back to overview]	Penn Craving Scale
NCT00354770 (1) [back to overview]	Massachusetts General Hospital Hairpulling Scale
NCT00374088 (3) [back to overview]	Urine Output
NCT00374088 (3) [back to overview]	Maximum Decline in Measured Cardiac Output
NCT00374088 (3) [back to overview]	Max Creatinine
NCT00453180 (3) [back to overview]	Vineland Adaptive Behavior Scales-II (VABS-II)
NCT00453180 (3) [back to overview]	Aberrant Behavior Checklist
NCT00453180 (3) [back to overview]	Social Responsiveness Scale
NCT00467831 (1) [back to overview]	Survival at 2 Years
NCT00539188 (4) [back to overview]	Self-Harm Inventory (SHI) Score at 6 Weeks
NCT00539188 (4) [back to overview]	Self-Harm Inventory (SHI) Score at Baseline
NCT00539188 (4) [back to overview]	Hamilton Depression Rating Scale (HAM-D) at 6 Weeks
NCT00539188 (4) [back to overview]	Hamilton Depression Rating Scale (HAM-D) at Baseline
NCT00539513 (4) [back to overview]	Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at 12 Weeks
NCT00539513 (4) [back to overview]	The Hamilton Depression Inventory (HAM-D)at 12 Weeks
NCT00539513 (4) [back to overview]	The Hamilton Depression Inventory (HAM-D)at Baseline
NCT00539513 (4) [back to overview]	Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at Baseline
NCT00542750 (1) [back to overview]	Feasibility of Recruitment, Measured by Number of Participants Recruited and Retained During Study Period
NCT00552786 (2) [back to overview]	Temporary Threshold Shift Measurement by Pure Tone Audiometry (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)
NCT00552786 (2) [back to overview]	Temporary Threshold Changes Measurement by Distortion Product Otoacoustic Emissions (DPOAE) (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)
NCT00568087 (4) [back to overview]	Alcohol Consumption (Percentage of Heavy Drinking Days)
NCT00568087 (4) [back to overview]	The Obsessive Compulsive Drinking Scale
NCT00568087 (4) [back to overview]	Liver Function Tests
NCT00568087 (4) [back to overview]	The Penn Alcohol Craving Scale
NCT00579995 (1) [back to overview]	Compare the Effectiveness of Two Medications for Prevention of Contrast-induced Nephropathy
NCT00611897 (5) [back to overview]	Mismatch Negativity (MMN) Duration
NCT00611897 (5) [back to overview]	Novel P300
NCT00611897 (5) [back to overview]	Mismatch Negativity (MMN) Intensity
NCT00611897 (5) [back to overview]	Mismatch Negativity (MMN) Frequency
NCT00611897 (5) [back to overview]	Target P300
NCT00627705 (4) [back to overview]	Irritability Subscale of the Aberrant Behavior Checklist (ABC)
NCT00627705 (4) [back to overview]	Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES)
NCT00627705 (4) [back to overview]	Social Responsiveness Scale (SRS)
NCT00627705 (4) [back to overview]	The Clinical Global Rating Scale (CGRS) Improvement Subscale Score
NCT00650091 (6) [back to overview]	Disease Progression
NCT00650091 (6) [back to overview]	Overall Change in Forced Vital Capacity
NCT00650091 (6) [back to overview]	Respiratory Infections
NCT00650091 (6) [back to overview]	Change in Forced Vital Capacity
NCT00650091 (6) [back to overview]	Number of Participants With Maintained Forced Vital Capacity Response
NCT00650091 (6) [back to overview]	Acute Exacerbations
NCT00655928 (1) [back to overview]	Post-operative Plasma IL-6
NCT00676195 (1) [back to overview]	Number of Participants With Adverse Events Reported on the Dosage Record and Treatment Emergent Symptom Scale (DOTES)
NCT00724594 (10) [back to overview]	NAC Volume of Distribution
NCT00724594 (10) [back to overview]	NAC Terminal Elimination Half-life
NCT00724594 (10) [back to overview]	Maternal and Infant Mean Blood Pressure Change
NCT00724594 (10) [back to overview]	Magnetic Resonance Spectroscopy of Infants
NCT00724594 (10) [back to overview]	NAC Total Body Clearance
NCT00724594 (10) [back to overview]	Prothrombin Time
NCT00724594 (10) [back to overview]	NAC Concentrations
NCT00724594 (10) [back to overview]	Placental Transfer Ratio
NCT00724594 (10) [back to overview]	Cerebral Blood Flow
NCT00724594 (10) [back to overview]	Cytokine Level IL-1Ra in Plasma
NCT00780962 (1) [back to overview]	Number of Participants With Contrast-induced Nephropathy
NCT00809094 (7) [back to overview]	FEV1 (L)
NCT00809094 (7) [back to overview]	Change in ECHO Tricuspid Regurgitation (mm Hg) Over Time by Treatment Group
NCT00809094 (7) [back to overview]	Change in FEV1 (Percent of Predicted for Age)
NCT00809094 (7) [back to overview]	Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum
NCT00809094 (7) [back to overview]	FEF 25-75% (L/Sec)
NCT00809094 (7) [back to overview]	Change in DLCO (ml/Min/mmHg) Over Time by Treatment Group
NCT00809094 (7) [back to overview]	FEF 25-75% (Percent of Predicted)
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale
NCT00967005 (24) [back to overview]	Hamilton Anxiety Rating Scale Total Score
NCT00967005 (24) [back to overview]	Fagerstrom Test for Nicotine Dependence Total Score
NCT00967005 (24) [back to overview]	Fagerstrom Test for Nicotine Dependence Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale
NCT00967005 (24) [back to overview]	Fagerstrom Test for Nicotine Dependence Total Score
NCT00967005 (24) [back to overview]	Fagerstrom Test for Nicotine Dependence Total Score
NCT00967005 (24) [back to overview]	Hamilton Anxiety Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Anxiety Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Anxiety Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Depression Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Depression Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Depression Rating Scale Total Score
NCT00967005 (24) [back to overview]	Hamilton Depression Rating Scale Total Score
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale
NCT00967005 (24) [back to overview]	Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale
NCT00975689 (1) [back to overview]	Oxysterol Levels
NCT00993265 (7) [back to overview]	Trichotillomania Scale for Children - Child Version
NCT00993265 (7) [back to overview]	Trichotillomania Scale for Children - Parent Version
NCT00993265 (7) [back to overview]	The Milwaukee Inventory for Styles of Trichotillomania-Child Version
NCT00993265 (7) [back to overview]	Children's Depression Inventory
NCT00993265 (7) [back to overview]	Massachusetts General Hospital Hair Pulling Scale (MGH-HPS)
NCT00993265 (7) [back to overview]	Multidimensional Anxiety Scale for Children (MASC)
NCT00993265 (7) [back to overview]	National Institute of Mental Health -Trichotillomania Severity Scale (NIMH-TSS)
NCT01005810 (1) [back to overview]	Percentage of Negative Urine Cannabinoid Tests During Treatment
NCT01063348 (2) [back to overview]	Skin Picking Self Assessment Scale (SP-SAS)
NCT01063348 (2) [back to overview]	Yale Brown Obsessive Compulsive Scale (YBOCS) Modified for PSP (NE-YBOCS)
NCT01098032 (1) [back to overview]	Number of Participants With Contrast-induced Acute Kidney Injury
NCT01118663 (2) [back to overview]	To Evaluate the Incidence of Treatment Emergent Adverse Events
NCT01118663 (2) [back to overview]	To Evaluate the Incidence of Anaphylactoid Reaction.
NCT01172275 (2) [back to overview]	OCD Severity at 12 Weeks
NCT01172275 (2) [back to overview]	Overall Improvement at 12 Weeks
NCT01172288 (5) [back to overview]	Number of Participants With Adverse Effects
NCT01172288 (5) [back to overview]	Overall Improvement
NCT01172288 (5) [back to overview]	Improvement of Premonitory Urges
NCT01172288 (5) [back to overview]	Improvement in Tic Severity
NCT01172288 (5) [back to overview]	Improvement in OCD Severity
NCT01214083 (9) [back to overview]	Percentage of Drinking Days
NCT01214083 (9) [back to overview]	Liver Function Tests (ALT)
NCT01214083 (9) [back to overview]	Liver Function Tests (AST)
NCT01214083 (9) [back to overview]	Obsessive Compulsive Drinking Scale (OCDS)
NCT01214083 (9) [back to overview]	Penn Alcohol Craving Scale (PACS)
NCT01214083 (9) [back to overview]	Percentage of Heavy Drinking Days
NCT01214083 (9) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT01214083 (9) [back to overview]	Drinks Per Drinking Days
NCT01214083 (9) [back to overview]	Clinical Global Impression (CGI)
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Visuospatial Memory Test (BVMT) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Psychiatric Rating Scale (BPRS)Total Score
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	Brief Psychiatric Rating Scale (BPRS)Total Score
NCT01232790 (24) [back to overview]	Brief Psychiatric Rating Scale (BPRS)Total Score
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01232790 (24) [back to overview]	BACS Composite RAW Score
NCT01251315 (2) [back to overview]	Intracellular Glutathione Level
NCT01251315 (2) [back to overview]	Augmentation Index
NCT01265563 (2) [back to overview]	Change From Baseline in Urinary Albumin Excretion
NCT01265563 (2) [back to overview]	Change From Baseline in Hemoglobin-A1c
NCT01322009 (2) [back to overview]	Number of Participants Who Experienced Adverse Events
NCT01322009 (2) [back to overview]	Antioxidant Reserve
NCT01339858 (10) [back to overview]	Cognitive Functioning
NCT01339858 (10) [back to overview]	Cortical Thickness
NCT01339858 (10) [back to overview]	Functional Status
NCT01339858 (10) [back to overview]	Symptoms of a Psychotic Disorder
NCT01339858 (10) [back to overview]	Working Memory
NCT01339858 (10) [back to overview]	Cortical Volume
NCT01339858 (10) [back to overview]	Mismatch Negativity Voltage Differences
NCT01339858 (10) [back to overview]	Number of Participants With Glutamine/Glutamate Level Changes
NCT01339858 (10) [back to overview]	Symptoms of a Psychotic Disorder
NCT01339858 (10) [back to overview]	Attention Measures
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Speed of Processing
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Reasoning and Problem Solving
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Attention and Vigilance
NCT01354132 (21) [back to overview]	Change in Blood Level of Glutathione
NCT01354132 (21) [back to overview]	Social and Occupational Functioning Assessment Scale (SOFAS)
NCT01354132 (21) [back to overview]	Myo-Inositol Brain Level for the NAC Group
NCT01354132 (21) [back to overview]	Myo-Inositol Brain Level for Placebo Group
NCT01354132 (21) [back to overview]	GPxbc Glutathione Peroxidase Activity in Blood Cells
NCT01354132 (21) [back to overview]	Glutathione Brain Level for Placebo Group
NCT01354132 (21) [back to overview]	Glutathione Brain Level for NAC Group
NCT01354132 (21) [back to overview]	Glutamine Brain Level for Placebo Group
NCT01354132 (21) [back to overview]	Global Assessment of Functioning (GAF)
NCT01354132 (21) [back to overview]	Glutamine Brain Level for NAC Group
NCT01354132 (21) [back to overview]	Glutamate Brain Level for Placebo Group
NCT01354132 (21) [back to overview]	Glutamate Brain Level for NAC Group
NCT01354132 (21) [back to overview]	Change in Positive Symptoms (PANSS)
NCT01354132 (21) [back to overview]	Change in Negative Symptoms of Schizophrenia as Measured on the PANSS
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Working Memory
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Visual Learning
NCT01354132 (21) [back to overview]	Change in Cognition and Working Memory (MATRICS) Verbal Learning
NCT01354132 (21) [back to overview]	Blood Plasma Level of Cysteine
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry at Baseline
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry at Baseline
NCT01384591 (41) [back to overview]	Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory After Study Invention
NCT01384591 (41) [back to overview]	Global Fatigue Score as Measured by Brief Fatigue Inventory at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue at Baseline
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.
NCT01384591 (41) [back to overview]	Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue at Baseline
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01384591 (41) [back to overview]	Leg Blood Flow as Measured by Doppler Ultrasound
NCT01386645 (3) [back to overview]	Urine F2alpha Isoprostanes
NCT01386645 (3) [back to overview]	Disposition Index
NCT01386645 (3) [back to overview]	Glycemic Variability
NCT01394510 (3) [back to overview]	Area Under the Curve for Glucose (AUCg)
NCT01394510 (3) [back to overview]	Fasting Urine F2 Alpha Isoprostane Levels
NCT01394510 (3) [back to overview]	Oral Disposition Index
NCT01424033 (1) [back to overview]	Pulmonary Function Tests
NCT01427517 (1) [back to overview]	Brain GSH
NCT01467466 (2) [back to overview]	Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.
NCT01467466 (2) [back to overview]	Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.
NCT01470027 (8) [back to overview]	Hamilton Depression Rating Scale (HAM-D)
NCT01470027 (8) [back to overview]	Mini Mental State Examination (MMSE)
NCT01470027 (8) [back to overview]	Parkinson's Disease Quality of Life Questionnaire (PDQLQ)
NCT01470027 (8) [back to overview]	Beck Anxiety Inventory
NCT01470027 (8) [back to overview]	10-Meter Walk Test
NCT01470027 (8) [back to overview]	9-Hole Peg Board Test (9-HPT)
NCT01470027 (8) [back to overview]	Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy
NCT01470027 (8) [back to overview]	Unified Parkinson's Disease Rating Scale (UPDRS) Parts I-V (Total Score Reported)
NCT01501110 (1) [back to overview]	Serum T3 Levels at 48 Hours
NCT01537926 (10) [back to overview]	Interventricular Septal Thickness (IVST) as Assessed by Echocardiography
NCT01537926 (10) [back to overview]	Compliance as Assessed by Percentage of Pills Taken by Participant
NCT01537926 (10) [back to overview]	Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography
NCT01537926 (10) [back to overview]	Left Ventricular Mass (LVM) as Assessed by Echocardiography
NCT01537926 (10) [back to overview]	Left Ventricular Mass (LVM) as Assessed by Echocardiography
NCT01537926 (10) [back to overview]	Number of Participants With Side Effects Attributable to the Intervention
NCT01537926 (10) [back to overview]	Recruitment as Assessed by Number of Participants Who Enrolled to the Study
NCT01537926 (10) [back to overview]	Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography
NCT01537926 (10) [back to overview]	Retention as Assessed by Number of Participants Who Completed the Study
NCT01537926 (10) [back to overview]	Interventricular Septal Thickness (IVST) as Assessed by Echocardiography
NCT01587001 (2) [back to overview]	Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels
NCT01587001 (2) [back to overview]	Bronchoalveolar Lavage (BAL) Cell Glutathione (GSH) Levels
NCT01612221 (2) [back to overview]	Transcriptional Markers of UV-induced Oxidative Stress in Nevi
NCT01612221 (2) [back to overview]	UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi
NCT01675661 (1) [back to overview]	The Odds of Negative Urine Cannabinoid Tests During Treatment.
NCT01739790 (1) [back to overview]	Changes in the Saint George's Respiratory Questionnaire
NCT01797575 (6) [back to overview]	Number of Patients Demonstrating a > 30% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT01797575 (6) [back to overview]	Number of Patients Demonstrating a > 30% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT01797575 (6) [back to overview]	Number of Patients Demonstrating a > 50% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT01797575 (6) [back to overview]	Number of Patients Demonstrating a > 50% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT01797575 (6) [back to overview]	Inflammation as Indicated by C-reactive Protein (CRP) Levels
NCT01797575 (6) [back to overview]	Inflammation as Indicated by Interleukin 6 (IL-6) Levels
NCT01840345 (4) [back to overview]	Pain
NCT01840345 (4) [back to overview]	Stress
NCT01840345 (4) [back to overview]	Mood
NCT01840345 (4) [back to overview]	Opioid Use
NCT01962961 (3) [back to overview]	Change in Circulating F2-isoprostane Levels
NCT01962961 (3) [back to overview]	Change in Circulating Malondialdehyde Levels
NCT01962961 (3) [back to overview]	Change in Flow-mediated Dilation (FMD) of the Brachial Artery
NCT01993849 (2) [back to overview]	Measurement of Nail Length
NCT01993849 (2) [back to overview]	Number of Participants Enrolled Within One Year
NCT02088216 (11) [back to overview]	Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines
NCT02088216 (11) [back to overview]	Change of Forced Vital Capacity (FVC) From Baselines
NCT02088216 (11) [back to overview]	Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa
NCT02088216 (11) [back to overview]	Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up.
NCT02088216 (11) [back to overview]	Median Number of Exacerbations
NCT02088216 (11) [back to overview]	Nature of Sputum (Number of Patients With Yellow Purulent)
NCT02088216 (11) [back to overview]	Time to Recurrent Exacerbations
NCT02088216 (11) [back to overview]	Time to the First Exacerbation
NCT02088216 (11) [back to overview]	Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines
NCT02088216 (11) [back to overview]	Adverse Events (AEs) (Elevation of Liver Enzymes)
NCT02088216 (11) [back to overview]	Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines
NCT02123511 (10) [back to overview]	EORTC Quality of Life Questionnaire (QLQ) H&N Sticky Saliva AUC
NCT02123511 (10) [back to overview]	EORTC Quality of Life Questionnaire (QLQ) Swallowing
NCT02123511 (10) [back to overview]	GRIX Xerostiomia Total Score AUC
NCT02123511 (10) [back to overview]	GRIX Xerostomia Daytime AUC
NCT02123511 (10) [back to overview]	GRIX Xerostomia Nighttime AUC
NCT02123511 (10) [back to overview]	Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Daytime Area Under the Curve (AUC)
NCT02123511 (10) [back to overview]	Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Nighttime Area Under the Curve (AUC).
NCT02123511 (10) [back to overview]	Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC)
NCT02123511 (10) [back to overview]	Adverse Event, as Measured by the Number of Patients With a Maximum Grade of Any Adverse Event
NCT02123511 (10) [back to overview]	EORTC Quality of Life Questionnaire (QLQ) H&N Pain AUC
NCT02141620 (27) [back to overview]	"Peak Ratings of Nervous/Anxious on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Nauseous on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Like Drug on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Irregular/Racing Heartbeat on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of High on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Good Effects on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Euphoric on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Bad Effects on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Any Effect on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Stimulated on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Talkative/Friendly on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Willing to Pay For on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Willing to Take Again on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
NCT02141620 (27) [back to overview]	Peak Diastolic Blood Pressure
NCT02141620 (27) [back to overview]	Peak Heart Rate
NCT02141620 (27) [back to overview]	Peak Score on Sedative Subscale of the Adjective Rating Scale
NCT02141620 (27) [back to overview]	Peak Score on Stimulant Subscale of the Adjective Rating Scale
NCT02141620 (27) [back to overview]	Peak Systolic Blood Pressure
NCT02141620 (27) [back to overview]	Peak Temperature
NCT02141620 (27) [back to overview]	"Peak Ratings of Shaky/Jittery on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Rush on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Restless on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Performance Improved on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Performance Impaired on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Sluggish/Fatigued/Lazy on the Visual Analog Scale"
NCT02141620 (27) [back to overview]	"Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale"
NCT02168387 (2) [back to overview]	Change in Capnography (Vd/Vt)
NCT02168387 (2) [back to overview]	Improvement of Atelectasis
NCT02206152 (1) [back to overview]	Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions
NCT02212678 (1) [back to overview]	Glutathione (GSH) Brain Levels
NCT02265224 (7) [back to overview]	AUC0-t of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	Cmax of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	Frel of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	Lambda Zeta of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	t1/2 of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	Tmax of NAC After Single Dose Administration of Test and Reference
NCT02265224 (7) [back to overview]	AUC0-∞ of NAC After Single Dose Administration of Test and Reference
NCT02348775 (1) [back to overview]	Muscle Glutathione Concentration
NCT02357290 (2) [back to overview]	Mean Change in the Young Mania Rating Scale (YMRS) Score
NCT02357290 (2) [back to overview]	Mean Change in the Children's Depression Rating Scale (CDRS) Score
NCT02362425 (56) [back to overview]	Adult Quality of Life in Neurological Disorders (NeuroQoL) Fatigue
NCT02362425 (56) [back to overview]	Peak Torque Flexion
NCT02362425 (56) [back to overview]	Peak Torque Flexion Pre-Intervention
NCT02362425 (56) [back to overview]	Pediatric Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score
NCT02362425 (56) [back to overview]	Pediatric Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score Pre-Intervention
NCT02362425 (56) [back to overview]	Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue
NCT02362425 (56) [back to overview]	Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Pre-Intervention
NCT02362425 (56) [back to overview]	Pediatric Quality of Life in Neurological Disorders (NeuroQoL) Fatigue
NCT02362425 (56) [back to overview]	Pediatric Quality of Life in Neurological Disorders (NeuroQoL) Fatigue Pre-Intervention
NCT02362425 (56) [back to overview]	Six Minute Walk Test (6MWT)
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 2 (D2) Pre-Intervention
NCT02362425 (56) [back to overview]	Six Minute Walk Test (6MWT) Pre-Intervention
NCT02362425 (56) [back to overview]	Supine to Stand Pre-Intervention
NCT02362425 (56) [back to overview]	Time to Ascend Steps (Seconds)
NCT02362425 (56) [back to overview]	Time to Ascend Steps (Seconds) Pre-Intervention
NCT02362425 (56) [back to overview]	Urine 15-F2t Isoprostane Concentration
NCT02362425 (56) [back to overview]	Urine 15-F2t Isoprostane Concentration Pre-Intervention
NCT02362425 (56) [back to overview]	Walk/Run 10 Meters
NCT02362425 (56) [back to overview]	Walk/Run 10 Meters Pre-Intervention
NCT02362425 (56) [back to overview]	Supine to Stand
NCT02362425 (56) [back to overview]	Adult Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue
NCT02362425 (56) [back to overview]	Adult Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Mental Fatigue Score
NCT02362425 (56) [back to overview]	Adult Quality of Life in Neurological Disorders (NeuroQoL) Fatigue Pre-Intervention
NCT02362425 (56) [back to overview]	Blood Glutathione Reduced (GSH):Oxidized (GSSG) Ratio
NCT02362425 (56) [back to overview]	DCF-fluorescence Intensity (AU)
NCT02362425 (56) [back to overview]	DCF-fluorescence Intensity (AU) Pre-Intervention
NCT02362425 (56) [back to overview]	Descend Steps
NCT02362425 (56) [back to overview]	Descend Steps Pre-Intervention
NCT02362425 (56) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score
NCT02362425 (56) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score Pre-Intervention
NCT02362425 (56) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Trial Outcome Index
NCT02362425 (56) [back to overview]	Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Trial Outcome Index Pre-Intervention
NCT02362425 (56) [back to overview]	Hand Grip Strength
NCT02362425 (56) [back to overview]	Hand Grip Strength Pre-Intervention
NCT02362425 (56) [back to overview]	Hand Pinch Strength
NCT02362425 (56) [back to overview]	Hand Pinch Strength Pre-Intervention
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 1 (D1)
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 1 (D1) Pre-Intervention
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 2 (D2)
NCT02362425 (56) [back to overview]	Urine 15-F2t Isoprostane Concentration at Baseline
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 3 (D3)
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Domain 3 (D3) Pre-Intervention
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Total Score
NCT02362425 (56) [back to overview]	Motor Function Measure-32 (MFM-32) Total Score Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory - 20 (MFI-20) General Fatigue Score
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory - 20 (MFI-20) General Fatigue Score Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Mental Fatigue Score Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Physical Fatigue Score
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Physical Fatigue Score Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Reduced Activity Score
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Reduced Activity Score Pre-Intervention
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Reduced Motivation Score
NCT02362425 (56) [back to overview]	Multidimensional Fatigue Inventory-20 (MFI-20) Reduced Motivation Score Pre-Intervention
NCT02362425 (56) [back to overview]	Peak Torque Extension
NCT02362425 (56) [back to overview]	Peak Torque Extension Pre-Intervention
NCT02379637 (2) [back to overview]	Safety of Daily Dose of NAC (Number of Patients With Adverse Advents)
NCT02379637 (2) [back to overview]	Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)
NCT02499029 (4) [back to overview]	Craving
NCT02499029 (4) [back to overview]	PTSD Symptoms
NCT02499029 (4) [back to overview]	PTSD Symptoms
NCT02499029 (4) [back to overview]	Depression
NCT02541422 (1) [back to overview]	Hangover Symptom Scale
NCT02579772 (7) [back to overview]	Change in Central Cardiovascular Function - Cardiac Output
NCT02579772 (7) [back to overview]	Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time)
NCT02579772 (7) [back to overview]	Change in Pulmonary Ventilation - Minute Ventilation (VE)
NCT02579772 (7) [back to overview]	Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time)
NCT02579772 (7) [back to overview]	Exercise Capacity - Time to Exhaustion
NCT02579772 (7) [back to overview]	Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time)
NCT02579772 (7) [back to overview]	Plasma Redox Status - Circulating Glutathione
NCT02707640 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
NCT02707640 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Deaths of All Causes
NCT02707640 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events That Led to Dose Reduction or Temporary Discontinuation of Study Treatment
NCT02707640 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events Resulting in Permanent Discontinuation of Study Treatment
NCT02707640 (7) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02707640 (7) [back to overview]	Percentage of Participants With Early Treatment Discontinuations
NCT02707640 (7) [back to overview]	Percentage of Participants With Dose Reductions
NCT02723162 (3) [back to overview]	Number of Cigarettes Smoked Per Day
NCT02723162 (3) [back to overview]	Percent Change in Blood Oxygen Level Dependent (BOLD) Signal Response
NCT02723162 (3) [back to overview]	rZ Change Score in Resting State Functional Connectivity From Baseline
NCT02737358 (3) [back to overview]	Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol.
NCT02737358 (3) [back to overview]	Number of Participants With 7-day Point Prevalence Abstinence at the 8-week End-of-treatment Visit
NCT02737358 (3) [back to overview]	Days to Relapse to Smoking Among Abstinent Participants
NCT02791945 (3) [back to overview]	Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB)
NCT02791945 (3) [back to overview]	Change in TBI Symptoms as Assessed by the Neurobehavioral Symptom Inventory (NSI)
NCT02791945 (3) [back to overview]	Change in Number of Standard Drinks Per Week as Assessed by the Timeline Followback (TLFB)
NCT02804594 (3) [back to overview]	Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine.
NCT02804594 (3) [back to overview]	Change in Level of Blood Markers From Baseline
NCT02804594 (3) [back to overview]	Change in Fatigue Score on Questionnaires From Baseline
NCT02911285 (4) [back to overview]	Change in Alcohol Use Disorder Severity
NCT02911285 (4) [back to overview]	Change in Post Traumatic Stress Disorder Severity
NCT02911285 (4) [back to overview]	Change in Post Traumatic Stress Disorder Severity
NCT02911285 (4) [back to overview]	Change in Alcohol Craving
NCT02966873 (6) [back to overview]	Change in Alcohol Use Severity
NCT02966873 (6) [back to overview]	Change in Alcohol Craving - Compulsive Subscale
NCT02966873 (6) [back to overview]	Change in Alcohol Craving - Obsessive Subscale
NCT02966873 (6) [back to overview]	Change in Alcohol Use Severity - Percent Days Abstinent
NCT02966873 (6) [back to overview]	Change in Post Traumatic Stress Disorder Symptom Severity - Clinician Rated
NCT02966873 (6) [back to overview]	Change in Post Traumatic Stress Disorder Symptom Severity - Self Report
NCT03008889 (9) [back to overview]	Study Medication Compliance
NCT03008889 (9) [back to overview]	Aberrant Behavior Checklist Irritability Subscale Score at Baseline and 9 Weeks Post-intervention
NCT03008889 (9) [back to overview]	Successful Collection of Outcome Measures
NCT03008889 (9) [back to overview]	Percentage of Participants Randomized
NCT03008889 (9) [back to overview]	Parent Satisfaction Rating
NCT03008889 (9) [back to overview]	Change in Clinical Global Impression (CGI-I) Scale at 9 Weeks Post-intervention
NCT03008889 (9) [back to overview]	Attrition Rate
NCT03008889 (9) [back to overview]	Positive Predictive Value of Screening Method of Classifying Self-injurious Behavior (SIB) by Type.
NCT03008889 (9) [back to overview]	Number of Self-Injurious Behavior Events
NCT03104725 (3) [back to overview]	Mean Ratio of Cys-DA/DOPAC Pre and Post-treatment Lumbar Puncture With and Without N-acetylcysteine (NAC)
NCT03104725 (3) [back to overview]	The Mean Percent Change in Cerebrospinal Fluid (CSF) Concentration of 5-S-cysteinyl-dopamine (Cys-DA) Pre and Post-N-acetylcysteine (NAC) Treatment
NCT03104725 (3) [back to overview]	Mean Percent Change in Cys-DA/DOPAC Between Pre and Post-treatment Lumbar Puncture With and Without N-acetylcysteine (NAC)
NCT03177395 (24) [back to overview]	ccK18 (U/L)
NCT03177395 (24) [back to overview]	ccK18 (U/L)
NCT03177395 (24) [back to overview]	INR
NCT03177395 (24) [back to overview]	ALT(U/L)
NCT03177395 (24) [back to overview]	INR
NCT03177395 (24) [back to overview]	INR
NCT03177395 (24) [back to overview]	K18 (U/L)
NCT03177395 (24) [back to overview]	K18 (U/L)
NCT03177395 (24) [back to overview]	K18 (U/L)
NCT03177395 (24) [back to overview]	K18(U/L)
NCT03177395 (24) [back to overview]	miR-122 (Copies/mcL)
NCT03177395 (24) [back to overview]	miR-122 (Copies/mcL)
NCT03177395 (24) [back to overview]	miR-122 (Copies/mcL)
NCT03177395 (24) [back to overview]	miR-122 (Delta Count)
NCT03177395 (24) [back to overview]	miR-122 (Delta Count)
NCT03177395 (24) [back to overview]	miR-122 (Delta Count)
NCT03177395 (24) [back to overview]	miR-122(Copies/mcL)
NCT03177395 (24) [back to overview]	Additional NAC Infusion
NCT03177395 (24) [back to overview]	Safety Events
NCT03177395 (24) [back to overview]	INR
NCT03177395 (24) [back to overview]	ALT(U/L)
NCT03177395 (24) [back to overview]	ALT(U/L)
NCT03177395 (24) [back to overview]	ccK18 (U/L)
NCT03177395 (24) [back to overview]	ccK18 (U/L)
NCT03216954 (1) [back to overview]	Number of Alcohol Drinks Chosen
NCT03220776 (2) [back to overview]	Prefrontal Glx Concentrations
NCT03220776 (2) [back to overview]	Prefrontal GABA+ Concentrations
NCT03238300 (2) [back to overview]	Quantifying the Difference in Glutamate Levels (mmol/kg) During N-Acetylcysteine Versus Placebo in the Anterior Cingulate Brain Region.
NCT03238300 (2) [back to overview]	Change in Neural Reactivity (as Measured by BOLD: Blood Oxygen Level-Dependent Response) in Reward Regions During Alcohol-cue Reactivity Task.
NCT03252925 (2) [back to overview]	The Level of TNF-α
NCT03252925 (2) [back to overview]	The Incidence of TA-TMA.
NCT03581084 (1) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Measurement
NCT03843541 (15) [back to overview]	Number of Participants With Adverse Events
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Cough Severity Score of Ambroxol Hydrochloride and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 in Mean Expectoration Difficulty Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 in Mean Sputum Viscosity Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 7 in Mean Expectoration Difficulty Score of NAC and Ambroxol Hydrochloride
NCT03843541 (15) [back to overview]	Change From Baseline to Day 7 in Mean Sputum Viscosity Score of NAC and Ambroxol Hydrochloride
NCT03843541 (15) [back to overview]	Change From Baseline to Day 7 of Mean Sputum Viscosity Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 7 Treatment of Mean Expectoration Difficulty Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Cough Severity Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Expectoration Difficulty Score of Ambroxol Hydrochloride and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Sputum Color Score of Ambroxol Hydrochloride and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Sputum Color Score of NAC and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Sputum Viscosity Score of Ambroxol Hydrochloride and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 in Mean Sputum Volume of Ambroxol Hydrochloride and Placebo
NCT03843541 (15) [back to overview]	Change From Baseline to Day 3 and to Day 7 of Mean Sputum Volume of NAC and Placebo
NCT03881163 (18) [back to overview]	Total Amount of NAC Excreted in Urine From the Last Multiple Dose to 32 h at Steady-state [Aess(0-32)]
NCT03881163 (18) [back to overview]	Percentage of the AUC(0-inf) Obtained by Extrapolation (%AUCextra)
NCT03881163 (18) [back to overview]	Renal Clearance (CLr) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Terminal Elimination Rate Constant (Kel) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Time to Achieve Cmax (Tmax) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Accumulation Ratio After Multiple Doses of NAC
NCT03881163 (18) [back to overview]	Degree of Fluctuation Over One Dosing Interval at Steady-state (DF%) After Multiple Dose of NAC
NCT03881163 (18) [back to overview]	Time to Achieve Css_max (tss_max) After Multiple Doses of NAC
NCT03881163 (18) [back to overview]	Total Fraction of NAC Dose Excreted in Urine [Fe(0-t)] After Single Dose of NAC
NCT03881163 (18) [back to overview]	Total Amount of NAC Excreted in Urine [Ae(0-t)] After Single Dose of NAC
NCT03881163 (18) [back to overview]	Plasma Concentration at Steady-state After Multiple Doses of NAC
NCT03881163 (18) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT03881163 (18) [back to overview]	Area Under the Concentration-time Curve at Steady State After Multiple Doses of NAC
NCT03881163 (18) [back to overview]	Area Under the Concentration-time Curve (AUC) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Volume of Distribution (Vd) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Half-life (t1/2) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Total Body Clearance (CLt) After Single Dose of NAC
NCT03881163 (18) [back to overview]	Peak Drug Concentration (Cmax) After Single Dose of NAC
NCT04005053 (3) [back to overview]	Percent Increase in Glutathione (GSH) Concentrations in the ACC
NCT04005053 (3) [back to overview]	Change in Glutamate Concentrations
NCT04005053 (3) [back to overview]	Change in GSH Reduced-to-oxidized Ratio
NCT04123405 (12) [back to overview]	Time to Onset of Action, Per-Protocol Set
NCT04123405 (12) [back to overview]	Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Per Protocol Set
NCT04123405 (12) [back to overview]	Major Symptom Score (MSS) Development Over the Course of the Study, Full Analysis Set
NCT04123405 (12) [back to overview]	Number of Responders and Non-responders to Treatment, Full Analysis Set
NCT04123405 (12) [back to overview]	Sino-Nasal Outcome Test (SNOT-22) by Visit, Per Protocol Set
NCT04123405 (12) [back to overview]	Sino-Nasal Outcome Test (SNOT-22) by Visit, Full Analysis Set
NCT04123405 (12) [back to overview]	Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set
NCT04123405 (12) [back to overview]	Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Per-Protocol Set
NCT04123405 (12) [back to overview]	Sino-Nasal Outcome Test (SNOT-22) by Change to Baseline, Full Analysis Set
NCT04123405 (12) [back to overview]	Major Symptom Score (MSS) Development Over the Course of the Study, Per-protocol Set
NCT04123405 (12) [back to overview]	Time to Onset of Action, Full Analysis Set
NCT04123405 (12) [back to overview]	Number of Responders and Non-responders to Treatment, Per-Protocol Set
NCT04481035 (3) [back to overview]	Transcranial Magnetic Stimulation (TMS) - Cortical Silent Period
NCT04481035 (3) [back to overview]	Change From Baseline in ADHD Symptoms as Reported Via Parent/Teacher Surveys
NCT04481035 (3) [back to overview]	Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS)
NCT04545008 (3) [back to overview]	Time to Symptom Resolution
NCT04545008 (3) [back to overview]	Rate of Hospitalization
NCT04545008 (3) [back to overview]	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0
NCT04557215 (3) [back to overview]	Change in Abdominal Pain
NCT04557215 (3) [back to overview]	Change in Stool Form
NCT04557215 (3) [back to overview]	Change in Stool Frequency
NCT04562597 (2) [back to overview]	Opioid Consumption Every 6 Hours Post Operative
NCT04562597 (2) [back to overview]	Opioid Consumption 12 Hours Post Operative

Number of Participants That Achieved Study Compliance

Drug and placebo compliance were measured by urine riboflavin levels. Study compliance was defined as 80% or greater weekly urine riboflavin levels equal to or greater than 1500 ng/ml (NCT00218491)
Timeframe: 8 weeks

Intervention	Participants (Count of Participants)
1200mg N-Acetylcysteine	22
2400mg N-Acetylcysteine	15
Matching Placebo	18

Intervention	participants (Number)
	0 days	1 day	2 days	3 days	4 days	5 days	6 days	7 days	underwent LTx w/i 7 days of randomization	died w/o LTx w/i 7 days of randomization
N-acetylcysteine (NAC)	29	3	3	2	1	4	5	9	28	8
Placebo	34	4	4	0	3	3	3	14	22	5

Intervention	units on a scale (Mean)
	MGH-HPS Baseline	MGH-HPS Final Visit After 12 Weeks
N-Acetyl Cysteine	17.6	10.4
Placebo	16.7	16.0

Intervention	units on a scale (Mean)
	Communication	Daily Living Skills	Socialization	Adaptive Behavior Composite
N-acetylcysteine	88.5	99.0	71.7	62.9
Placebo	95.0	98.6	75.9	60.5

Intervention	units on a scale (Mean)
	Irritablity	Lethargy	Stereotypy	Hyperactivity	Inappropriate Speech
N-acetylcysteine	14.9	10.0	3.9	17.4	4.1
Placebo	12.0	7.9	5.8	15.1	5.14

Intervention	percentage of heavy drinking days (Mean)
	Percentage of heavy drinking days at week 1	Percentage of heavy drinking days at week 9
N-acetylcysteine	70.2	20.2
Placebo	58.4	14.7

Intervention	score on a scale (Mean)
	Obsessive Compulsive Drinking Scale at week 1	Obsessive Compulsive Drinking Scale at week 9
N-acetylcysteine	29.0	13.8
Placebo	27.6	17.0

Intervention	U/L (Mean)
	AST at week 0	AST at week 9
N-acetylcysteine	40.89	26.13
Placebo	35.85	31.53

Intervention	score on a scale (Mean)
	Penn Alcohol Craving Scale at week 1	Penn Alcohol Craving Scale at week 9
N-acetylcysteine	18.1	7.2
Placebo	18.0	11.5

Intervention	microvolts (Least Squares Mean)
	Fz	Cz	Pz
NAC+Ketamine	-2.8	-2.8	-2.1
NAC+Saline	-3.2	-3.3	-2.4
Placebo+Ketamine	-3.1	-3.1	-2.3
Placebo+Saline	-3.2	-3.1	-2.4

Intervention	microvolts (Least Squares Mean)
	Fz	Cz	Pz
NAC+Ketamine	-2.6	-2.6	-2.1
NAC+Saline	-3.4	-3.4	-2.4
Placebo+Ketamine	-2.7	-2.5	-2.0
Placebo+Saline	-3.5	-3.2	-2.1

Intervention	microvolts (Least Squares Mean)
	Fz	Cz	Pz
NAC+Ketamine	-2.9	-2.9	-1.9
NAC+Saline	-3.1	-3.1	-1.8
Placebo+Ketamine	-2.7	-2.7	-1.7
Placebo+Saline	-3.3	-3.3	-2.3

Intervention	microvolts (Least Squares Mean)
	Fz	Cz	Pz
NAC+Ketamine	3.4	5.4	8.2
NAC+Saline	5.2	9.9	12.6
Placebo+Ketamine	3.2	5.5	8.1
Placebo+Saline	2.5	7.7	11.8

Intervention	Score (range 0-45) (Mean)
	Baseline ABC-I Score	Week 12 ABC-I Score
N-Acetyl Cysteine	16.9	7.2
Sugar Pill	14.8	13.1

Intervention	participants (Number)
	Total Number of Subjects with GI adverse Events	Constipation	Nausea/Vomiting	Diarrhea	Increased Appetite	Decreased Appetite	Akathisia	Excitement/Agitation	Increased Motor Activity	Tremor	Syncope/Dizziness	Depressive Affect	Nasal Congestion	Increased Salivation	Sweating
N-Acetyl Cysteine	11	3	6	3	2	2	1	2	2	0	0	1	4	0	0
Sugar Pill	7	2	3	1	0	3	0	3	3	1	1	0	6	2	1

Intervention	SRS total score (range 0-195) (Mean)
	Baseline SRS Total Score	Week 12 SRS Total Score
N-Acetyl Cysteine	111.9	93.8
Sugar Pill	104.7	98.5

Intervention	liters (Mean)
	15 week	30 week	45 week	60 week
N-Acetylcysteine	-0.07	-0.07	-0.15	-0.16
Placebo	-0.04	-0.08	-0.15	-0.15

Intervention	mmHg (Mean)
NAC Infants	-1.2
Control Infants	2.1
NAC Maternal	1
Control Maternal	2

Intervention	seconds (Mean)
NAC Infant	19.5
Control Infant	19.0
NAC Maternal	14.2
Control Maternal	14.4

Intervention	micromol/L (Mean)
	Peak NAC concentration in plasma	NAC cord concentration
NAC Maternal	1222	NA
NAC Preterm Infants	49.0	370.7
NAC Term Infants	92.3	639.7

Intervention	units on a scale (Mean)
NAC Term Infants	0.93
Control Term Infants	0.89
NAC Preterm Infants	0.92
Control Preterm Infants	0.89

acetylcysteine

Description

Cross-References

Synonyms (282)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (50 Product(s))

Product Categories

Products

Roles (10)

Drug Classes (3)

Protein Targets (49)

Potency Measurements

Inhibition Measurements

Biological Processes (195)

Molecular Functions (62)

Ceullar Components (40)

Bioassays (410)

Research

Studies (13,916)

Market Indicators

Research Demand Index: 88.72

Study Types

Clinical Trials (462)

Trial Overview

Trial Outcomes

Number of Participants That Achieved Study Compliance

Survival

Categorized Length of ICU Stay

Highest Coma Grade of Hepatic Encephalopathy

Number of Organ Systems Failing

Length of Hospital Stay

Infectious Complication

Cumulative Percent Incidence of Transplantation by 1 Year

Spontaneous Recovery

Penn Craving Scale

Massachusetts General Hospital Hairpulling Scale

Urine Output

Maximum Decline in Measured Cardiac Output

Max Creatinine

Vineland Adaptive Behavior Scales-II (VABS-II)

Aberrant Behavior Checklist

Social Responsiveness Scale

Survival at 2 Years

Self-Harm Inventory (SHI) Score at 6 Weeks

Self-Harm Inventory (SHI) Score at Baseline

Hamilton Depression Rating Scale (HAM-D) at 6 Weeks

Hamilton Depression Rating Scale (HAM-D) at Baseline

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at 12 Weeks

The Hamilton Depression Inventory (HAM-D)at 12 Weeks

The Hamilton Depression Inventory (HAM-D)at Baseline

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at Baseline

Feasibility of Recruitment, Measured by Number of Participants Recruited and Retained During Study Period

Temporary Threshold Shift Measurement by Pure Tone Audiometry (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)

Temporary Threshold Changes Measurement by Distortion Product Otoacoustic Emissions (DPOAE) (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and Post-shift, and the 14th Day Pre- and Post-shift)

Alcohol Consumption (Percentage of Heavy Drinking Days)

The Obsessive Compulsive Drinking Scale

Liver Function Tests

The Penn Alcohol Craving Scale

Compare the Effectiveness of Two Medications for Prevention of Contrast-induced Nephropathy

Mismatch Negativity (MMN) Duration

Novel P300

Mismatch Negativity (MMN) Intensity

Mismatch Negativity (MMN) Frequency

Target P300

Irritability Subscale of the Aberrant Behavior Checklist (ABC)

Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES)

Social Responsiveness Scale (SRS)

The Clinical Global Rating Scale (CGRS) Improvement Subscale Score

Disease Progression

Overall Change in Forced Vital Capacity

Respiratory Infections

Change in Forced Vital Capacity

Number of Participants With Maintained Forced Vital Capacity Response

Acute Exacerbations

Post-operative Plasma IL-6

Intervention	units on a scale (Mean)
	"Week 12 MIST-C Automatic Subscale"	"Week 12 MIST-C Focused Subscale"
N-acetylcysteine (NAC)	13.24	90.8
Placebo	13.16	79.6

Intervention	units on a scale (Mean)
	Baseline	Week 3	Week 6	Week 9	Week 12
N-Acetyl Cysteine	28.6	24.8	21.9	21.5	19.4
Placebo	28.6	25.5	25.0	24.2	24.5

Intervention	participants (Number)
	Irritability	Sadness or depressed mood	Fatigue	Insomnia	Decreased appetite	Chest pain	Syncope	Stomach ache	Nausea	Vomiting	Headache
N-Acetylcysteine	0	0	0	0	0	0	0	0	0	0	1
Placebo	0	1	0	0	0	0	0	2	3	0	1

Intervention	percentage of drinking days (Mean)
	percentage of drinking days at week 1	percentage of drinking days at week 13
High-dose Naltrexone (150 mg) Alone	63.8	24.5
Low-dose Naltrexone (50 mg) Alone	55.3	18.2
N-acetylcysteine + High-dose Naltrexone (150 mg)	64.6	21.1

Intervention	units/liter (Mean)
	Liver Function Tests (ALT) at week 0	Liver Function Tests (ALT) at week 13
High-dose Naltrexone (150 mg) Alone	36.5	40.1
Low-dose Naltrexone (50 mg) Alone	34.7	31.3
N-acetylcysteine + High-dose Naltrexone (150 mg)	49.4	27.6

Intervention	units/liter (Mean)
	Liver function tests (AST) at week 0	Liver function tests (AST) at week 13
High-dose Naltrexone (150 mg) Alone	29.0	32.1
Low-dose Naltrexone (50 mg) Alone	30.0	22.2
N-acetylcysteine + High-dose Naltrexone (150 mg)	34.7	27.3

Intervention	units on a scale (Mean)
	Penn Alcohol Craving Scale at week 1	Penn Alcohol Craving Scale at week 13
High-dose Naltrexone (150 mg) Alone	18.4	8.3
Low-dose Naltrexone (50 mg) Alone	16.1	6.3
N-acetylcysteine + High-dose Naltrexone (150 mg)	18.0	7.2

Intervention	units on a scale (Mean)
	Q-LES-Q at week 1	Q-LES-Q at week 13
High-dose Naltrexone (150 mg) Alone	53.8	59.6
Low-dose Naltrexone (50 mg) Alone	55.1	63.9
N-acetylcysteine + High-dose Naltrexone (150 mg)	53.2	61.6

Intervention	drinks/drinking day (Mean)
	drinks per drinking days at week 1	drinks per drinking days at week 13
High-dose Naltrexone (150 mg) Alone	5.9	1.2
Low-dose Naltrexone (50 mg) Alone	7.3	1.0
N-acetylcysteine + High-dose Naltrexone (150 mg)	7.3	1.1

Intervention	units on a scale (Mean)
	Clinical Global Impression at week 1	Clinical Global Impression at week 13
High-dose Naltrexone (150 mg) Alone	3.7	1.7
Low-dose Naltrexone (50 mg) Alone	3.6	1.4
N-acetylcysteine + High-dose Naltrexone (150 mg)	3.7	1.5